data_5vj8_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 5vj8 _Structure_validation_residue.Date_analyzed 2017-05-12 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 120.998 0.428 . . . . 0.0 110.789 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.93 178.05 48.43 Favored Glycine 0 CA--C 1.492 -1.37 0 N-CA-C 106.805 -2.518 . . . . 0.0 106.805 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 99.7 mt-10 -130.22 145.65 51.76 Favored 'General case' 0 N--CA 1.438 -1.055 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 62.9 m -129.78 157.81 41.17 Favored 'General case' 0 CA--C 1.496 -1.131 0 N-CA-C 106.763 -1.569 . . . . 0.0 106.763 -179.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 35.6 t -136.37 141.46 43.71 Favored 'General case' 0 CA--C 1.497 -1.061 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 -179.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 85.5 mt -121.26 130.68 74.42 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.998 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 44.1 t -128.63 137.58 51.74 Favored 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 107.205 -1.405 . . . . 0.0 107.205 -179.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 47.4 pt -127.13 157.82 38.45 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.059 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -166.28 -179.55 39.73 Favored Glycine 0 CA--C 1.492 -1.371 0 N-CA-C 108.184 -1.966 . . . . 0.0 108.184 -179.71 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -127.85 149.05 50.46 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 -179.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -74.16 143.09 45.42 Favored 'General case' 0 N--CA 1.44 -0.967 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -122.28 152.11 40.41 Favored 'General case' 0 CA--C 1.499 -1.003 0 N-CA-C 106.877 -1.527 . . . . 0.0 106.877 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 37.8 t -144.63 150.39 37.33 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 106.567 -1.642 . . . . 0.0 106.567 -179.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -72.07 129.36 38.32 Favored 'General case' 0 N--CA 1.44 -0.945 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 -179.478 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 31.5 m -133.53 159.75 42.58 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.004 0 N-CA-C 106.604 -1.628 . . . . 0.0 106.604 179.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -111.93 138.01 49.13 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 107.273 -1.38 . . . . 0.0 107.273 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 79.4 mm-40 -124.78 125.14 43.56 Favored 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -109.58 20.65 17.92 Favored 'General case' 0 CA--C 1.503 -0.841 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.35 -6.44 71.63 Favored Glycine 0 C--N 1.352 1.463 0 N-CA-C 107.494 -2.242 . . . . 0.0 107.494 -179.14 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -128.31 152.03 48.62 Favored 'General case' 0 N--CA 1.436 -1.136 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 179.675 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 61.9 mtpt -81.6 63.09 5.73 Favored 'General case' 0 CA--C 1.504 -0.808 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -179.121 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 87.6 mt -70.26 -38.18 75.05 Favored 'General case' 0 N--CA 1.442 -0.845 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 179.23 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -98.58 137.96 36.47 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 107.602 -1.258 . . . . 0.0 107.602 -179.597 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -85.11 151.75 23.9 Favored 'General case' 0 N--CA 1.441 -0.902 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 179.246 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 97.2 m-20 -71.95 147.0 90.99 Favored Pre-proline 0 N--CA 1.443 -0.814 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 -179.276 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -78.37 160.94 28.95 Favored 'Trans proline' 0 CA--C 1.499 -1.233 0 C-N-CA 122.437 2.092 . . . . 0.0 112.632 179.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 95.2 mtm-85 -125.56 129.51 49.84 Favored 'General case' 0 CA--C 1.5 -0.971 0 N-CA-C 107.451 -1.314 . . . . 0.0 107.451 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -178.68 167.16 37.4 Favored Glycine 0 C--N 1.35 1.317 0 N-CA-C 106.995 -2.442 . . . . 0.0 106.995 179.597 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 54.9 p90 -157.23 164.57 37.58 Favored 'General case' 0 CA--C 1.5 -0.951 0 N-CA-C 107.418 -1.327 . . . . 0.0 107.418 -179.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 12.7 p30 -151.42 156.62 41.04 Favored 'General case' 0 N--CA 1.438 -1.07 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 179.613 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -145.39 137.64 25.73 Favored 'General case' 0 N--CA 1.437 -1.087 0 N-CA-C 106.444 -1.687 . . . . 0.0 106.444 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -128.82 144.36 51.15 Favored 'General case' 0 N--CA 1.44 -0.955 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 -179.65 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -127.39 138.71 53.07 Favored 'General case' 0 CA--C 1.499 -1.003 0 N-CA-C 106.806 -1.553 . . . . 0.0 106.806 179.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 48.3 ttp180 -112.36 128.16 56.21 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 107.069 -1.456 . . . . 0.0 107.069 179.661 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 10.7 t80 -117.95 129.43 55.61 Favored 'General case' 0 N--CA 1.439 -1.002 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 179.618 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -96.08 126.63 41.45 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 -178.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 74.8 m-85 -120.99 161.1 22.2 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 106.124 -1.806 . . . . 0.0 106.124 178.491 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 66.0 t30 -80.29 95.32 6.3 Favored 'General case' 0 N--CA 1.439 -1.006 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -165.32 -178.84 5.22 Favored 'General case' 0 N--CA 1.434 -1.267 0 N-CA-C 106.047 -1.835 . . . . 0.0 106.047 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -83.64 -16.76 43.9 Favored 'General case' 0 N--CA 1.441 -0.882 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 -179.311 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 53.3 m95 -133.95 151.24 51.41 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 -179.366 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -100.19 -175.59 30.3 Favored Glycine 0 C--N 1.354 1.551 0 N-CA-C 107.842 -2.103 . . . . 0.0 107.842 -179.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 10.1 p -143.11 146.14 21.93 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.895 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 43.4 pt -130.16 161.63 39.52 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.053 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 -179.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -125.15 137.44 10.39 Favored Glycine 0 CA--C 1.492 -1.375 0 N-CA-C 105.202 -3.159 . . . . 0.0 105.202 178.119 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 53.3 m -130.89 145.75 52.11 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 -178.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 88.6 t80 -131.77 132.19 43.59 Favored 'General case' 0 CA--C 1.498 -1.023 0 N-CA-C 105.695 -1.965 . . . . 0.0 105.695 178.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -138.44 143.98 39.93 Favored 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 -179.339 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 59.7 tt0 -142.01 136.3 30.13 Favored 'General case' 0 N--CA 1.437 -1.107 0 N-CA-C 106.278 -1.749 . . . . 0.0 106.278 179.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 15.2 t -145.42 152.22 39.48 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 79.2 ttt-85 -103.51 130.97 50.99 Favored 'General case' 0 N--CA 1.438 -1.036 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 4.7 tmt_? -112.77 130.38 56.09 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 -178.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -169.5 174.03 43.82 Favored Glycine 0 CA--C 1.491 -1.45 0 N-CA-C 106.486 -2.645 . . . . 0.0 106.486 179.756 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -88.03 96.14 10.4 Favored 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 106.352 -1.722 . . . . 0.0 106.352 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 72.9 mm-40 -95.79 2.59 53.91 Favored 'General case' 0 CA--C 1.504 -0.817 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 -178.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -91.16 149.81 21.64 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 -179.704 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 45.4 m -98.49 132.37 43.98 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 179.131 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 78.6 t -64.67 -47.41 88.96 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.754 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -179.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 62.4 m-20 -129.78 -51.45 1.14 Allowed 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 107.042 -1.466 . . . . 0.0 107.042 179.448 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 170.88 122.79 0.66 Allowed Glycine 0 CA--C 1.492 -1.398 0 N-CA-C 106.746 -2.542 . . . . 0.0 106.746 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 94.8 m-85 62.48 31.19 17.18 Favored 'General case' 0 C--N 1.356 0.85 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 17.3 tppt? -144.36 126.15 15.23 Favored 'General case' 0 CA--C 1.495 -1.151 0 N-CA-C 106.411 -1.7 . . . . 0.0 106.411 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -157.38 173.94 16.17 Favored 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 -179.101 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 83.7 mt -97.1 122.56 48.77 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.023 0 N-CA-C 106.558 -1.645 . . . . 0.0 106.558 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -82.19 132.45 35.24 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 -179.242 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -168.17 159.05 32.13 Favored Glycine 0 CA--C 1.491 -1.413 0 N-CA-C 106.253 -2.739 . . . . 0.0 106.253 179.373 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 63.7 m-20 -132.83 129.28 38.28 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 9.2 t80 -158.15 133.98 9.11 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 106.273 -1.751 . . . . 0.0 106.273 178.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 57.3 mtmt -127.95 142.96 51.1 Favored 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 107.602 -1.258 . . . . 0.0 107.602 -179.276 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -117.09 133.02 56.52 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 179.359 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -114.09 127.53 55.97 Favored 'General case' 0 CA--C 1.495 -1.146 0 N-CA-C 105.227 -2.138 . . . . 0.0 105.227 178.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 70.1 m -132.86 140.51 47.96 Favored 'General case' 0 CA--C 1.493 -1.231 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 -179.338 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 61.6 t -128.61 135.18 63.04 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.242 0 N-CA-C 105.097 -2.186 . . . . 0.0 105.097 178.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 68.0 p -140.26 160.66 39.46 Favored 'General case' 0 CA--C 1.495 -1.153 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 -179.425 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -153.7 155.69 36.44 Favored 'General case' 0 N--CA 1.433 -1.275 0 N-CA-C 106.108 -1.812 . . . . 0.0 106.108 179.272 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -178.83 171.64 43.81 Favored Glycine 0 N--CA 1.435 -1.388 0 N-CA-C 107.949 -2.06 . . . . 0.0 107.949 179.554 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_endo -81.8 165.18 17.88 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 122.734 2.289 . . . . 0.0 113.361 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 8.3 p -121.43 132.65 70.16 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.989 0 N-CA-C 106.181 -1.785 . . . . 0.0 106.181 178.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -115.41 124.81 52.13 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 -178.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 56.3 ttp180 -112.15 132.44 54.88 Favored 'General case' 0 CA--C 1.498 -1.04 0 N-CA-C 106.131 -1.803 . . . . 0.0 106.131 179.253 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 97.1 mt -71.97 -63.95 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.912 0 N-CA-C 106.981 -1.488 . . . . 0.0 106.981 179.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 65.8 t30 -175.25 93.89 0.07 Allowed 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 177.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 39.69 44.13 1.23 Allowed 'General case' 0 C--N 1.357 0.905 0 C-N-CA 123.103 0.561 . . . . 0.0 112.21 177.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -141.62 -46.26 0.37 Allowed 'General case' 0 CA--C 1.501 -0.93 0 C-N-CA 118.824 -1.15 . . . . 0.0 109.022 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 22.1 m -149.02 158.08 6.6 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.149 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 64.2 m -133.95 142.93 47.89 Favored 'General case' 0 CA--C 1.496 -1.109 0 N-CA-C 106.622 -1.622 . . . . 0.0 106.622 178.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 89.9 mt -117.05 139.72 50.36 Favored 'General case' 0 CA--C 1.497 -1.079 0 N-CA-C 107.16 -1.422 . . . . 0.0 107.16 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 64.3 m-85 -116.57 142.83 46.38 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 -179.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -114.66 138.35 14.75 Favored Glycine 0 C--N 1.35 1.341 0 N-CA-C 105.727 -2.949 . . . . 0.0 105.727 178.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 8.7 mp -117.77 133.2 56.18 Favored 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 -179.136 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.3 tt -150.33 133.51 16.25 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 106.194 -1.78 . . . . 0.0 106.194 178.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 179.01 -151.24 10.09 Favored Glycine 0 CA--C 1.493 -1.332 0 N-CA-C 108.016 -2.034 . . . . 0.0 108.016 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -143.67 160.15 41.21 Favored 'General case' 0 N--CA 1.437 -1.124 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 -179.071 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -131.69 155.77 21.56 Favored Glycine 0 CA--C 1.493 -1.3 0 N-CA-C 107.751 -2.14 . . . . 0.0 107.751 -179.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 60.3 t-80 -151.57 141.67 22.2 Favored 'General case' 0 N--CA 1.437 -1.102 0 N-CA-C 106.952 -1.499 . . . . 0.0 106.952 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -147.44 140.5 8.56 Favored Glycine 0 CA--C 1.492 -1.39 0 N-CA-C 107.032 -2.427 . . . . 0.0 107.032 179.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -157.33 134.92 10.62 Favored 'General case' 0 N--CA 1.436 -1.126 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -143.68 52.54 1.32 Allowed 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 107.359 -1.348 . . . . 0.0 107.359 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -125.47 139.88 53.25 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 107.097 -1.445 . . . . 0.0 107.097 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -132.57 147.46 52.35 Favored 'General case' 0 CA--C 1.498 -1.056 0 N-CA-C 106.835 -1.543 . . . . 0.0 106.835 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 32.6 t -147.37 -72.19 0.22 Allowed 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 37.2 t -155.1 149.57 26.24 Favored 'General case' 0 N--CA 1.437 -1.103 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 45.5 pt -96.83 -3.19 10.19 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.869 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 88.5 t80 -138.57 124.2 19.65 Favored 'General case' 0 N--CA 1.439 -1.016 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 159.88 -175.52 36.7 Favored Glycine 0 CA--C 1.491 -1.414 0 N-CA-C 107.107 -2.397 . . . . 0.0 107.107 179.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 64.7 tt0 -135.42 120.31 18.55 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 106.666 -1.605 . . . . 0.0 106.666 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 36.7 t -160.31 151.24 18.92 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 63.0 mt-10 -74.22 141.15 45.44 Favored 'General case' 0 N--CA 1.44 -0.942 0 N-CA-C 107.022 -1.473 . . . . 0.0 107.022 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 68.0 m -129.77 151.14 50.68 Favored 'General case' 0 CA--C 1.494 -1.179 0 N-CA-C 107.577 -1.268 . . . . 0.0 107.577 -179.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -128.68 150.83 50.09 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 38.4 t -148.26 147.9 29.87 Favored 'General case' 0 CA--C 1.497 -1.096 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 -179.397 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 65.3 mttp -125.39 148.69 48.68 Favored 'General case' 0 CA--C 1.497 -1.061 0 N-CA-C 106.803 -1.555 . . . . 0.0 106.803 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 93.0 m -110.2 128.46 55.5 Favored 'General case' 0 CA--C 1.495 -1.148 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 -179.762 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 51.1 m -88.56 144.06 26.56 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 -179.575 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 63.6 tp -94.95 123.5 38.46 Favored 'General case' 0 CA--C 1.498 -1.044 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 179.671 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -114.9 130.57 56.93 Favored 'General case' 0 N--CA 1.438 -1.051 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -178.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 55.5 p90 -149.87 161.28 42.58 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 106.48 -1.674 . . . . 0.0 106.48 179.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 179.36 -169.43 40.56 Favored Glycine 0 CA--C 1.491 -1.423 0 N-CA-C 108.056 -2.018 . . . . 0.0 108.056 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -153.13 159.37 42.73 Favored 'General case' 0 CA--C 1.495 -1.158 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 -179.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -144.07 154.2 25.51 Favored Glycine 0 CA--C 1.491 -1.442 0 N-CA-C 108.496 -1.842 . . . . 0.0 108.496 -179.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 3.9 mp -121.63 140.59 52.07 Favored 'General case' 0 N--CA 1.437 -1.119 0 N-CA-C 106.543 -1.651 . . . . 0.0 106.543 179.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 38.5 tt0 -116.65 131.88 56.83 Favored 'General case' 0 CA--C 1.495 -1.167 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 -179.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -122.57 140.66 52.55 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 106.188 -1.782 . . . . 0.0 106.188 179.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 7.5 m120 -127.69 79.14 73.99 Favored Pre-proline 0 CA--C 1.502 -0.893 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 -179.054 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.08 -25.36 27.18 Favored 'Trans proline' 0 CA--C 1.499 -1.23 0 C-N-CA 121.665 1.577 . . . . 0.0 112.156 179.15 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 78.7 m80 -135.8 152.19 75.47 Favored Pre-proline 0 N--CA 1.437 -1.115 0 N-CA-C 105.849 -1.908 . . . . 0.0 105.849 179.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.11 -20.97 37.18 Favored 'Trans proline' 0 C--N 1.31 -1.477 0 C-N-CA 121.719 1.613 . . . . 0.0 113.637 -179.645 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -109.45 14.54 23.54 Favored 'General case' 0 N--CA 1.444 -0.766 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 -179.028 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 50.3 t80 -142.44 121.44 12.85 Favored 'General case' 0 CA--C 1.5 -0.967 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 59.7 t -119.39 129.49 75.22 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.972 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 -179.27 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 85.4 mt -101.61 126.2 55.54 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.026 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -119.59 112.78 19.76 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 -179.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -118.44 132.69 56.24 Favored 'General case' 0 CA--C 1.498 -1.054 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 178.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 97.7 p -156.2 170.81 21.36 Favored 'General case' 0 CA--C 1.497 -1.085 0 C-N-CA 119.384 -0.926 . . . . 0.0 108.683 -178.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 54.4 p90 -142.28 155.81 45.24 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 179.406 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -137.0 133.53 35.64 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 87.5 t80 -118.33 129.31 55.37 Favored 'General case' 0 N--CA 1.438 -1.043 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 47.9 t -103.98 121.8 43.91 Favored 'General case' 0 CA--C 1.497 -1.068 0 N-CA-C 106.14 -1.8 . . . . 0.0 106.14 179.501 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 60.3 tptt -93.38 119.79 32.91 Favored 'General case' 0 N--CA 1.439 -1.021 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 -178.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -152.97 126.87 8.95 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 105.282 -2.118 . . . . 0.0 105.282 178.623 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -64.76 -39.54 93.78 Favored 'General case' 0 N--CA 1.445 -0.694 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.129 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -63.17 -47.87 80.79 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 120.53 -0.468 . . . . 0.0 110.581 -178.268 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 58.6 t -142.21 128.2 18.23 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.004 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 -179.098 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -91.21 127.71 36.75 Favored 'General case' 0 CA--C 1.501 -0.937 0 N-CA-C 106.036 -1.839 . . . . 0.0 106.036 178.7 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 81.5 t -126.75 127.1 69.74 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.013 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -178.733 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -117.28 134.16 11.03 Favored Glycine 0 C--N 1.351 1.416 0 N-CA-C 105.671 -2.972 . . . . 0.0 105.671 178.341 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 88.8 m -129.87 135.3 48.22 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 -178.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 92.9 m95 -107.66 140.56 40.5 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 105.314 -2.106 . . . . 0.0 105.314 178.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 78.7 mtm -125.32 132.74 52.8 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 -178.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -133.53 138.4 46.05 Favored 'General case' 0 CA--C 1.495 -1.157 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 179.563 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -170.58 -168.75 32.81 Favored Glycine 0 N--CA 1.434 -1.436 0 N-CA-C 108.374 -1.89 . . . . 0.0 108.374 -179.55 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -139.19 160.86 38.81 Favored 'General case' 0 N--CA 1.435 -1.197 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 -179.293 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -133.78 165.26 24.27 Favored Glycine 0 CA--C 1.491 -1.447 0 N-CA-C 108.183 -1.967 . . . . 0.0 108.183 -179.311 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 88.2 t80 -132.21 135.18 46.13 Favored 'General case' 0 N--CA 1.435 -1.179 0 N-CA-C 106.49 -1.671 . . . . 0.0 106.49 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 6.8 tmm_? -136.94 139.68 41.7 Favored 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 -179.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 31.7 t80 . . . . . 0 C--O 1.263 1.815 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 179.826 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 80.3 mm-40 . . . . . 0 N--CA 1.488 1.461 0 CA-C-O 120.886 0.374 . . . . 0.0 110.549 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 179.41 -179.81 48.82 Favored Glycine 0 N--CA 1.436 -1.351 0 N-CA-C 107.224 -2.351 . . . . 0.0 107.224 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 24.1 pt-20 -154.59 156.04 35.84 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 55.8 m -116.05 -60.49 1.86 Allowed 'General case' 0 CA--C 1.498 -1.033 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 38.7 t -154.51 145.96 23.08 Favored 'General case' 0 CA--C 1.498 -1.037 0 N-CA-C 107.413 -1.329 . . . . 0.0 107.413 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 47.4 pt -129.01 149.5 33.75 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.097 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 179.278 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.454 ' HB2' ' HB2' ' A' ' 32' ' ' LYS . 63.6 m -138.75 149.32 44.91 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 -179.498 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 46.5 pt -131.94 157.09 43.06 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.057 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 179.216 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -176.83 -168.3 36.59 Favored Glycine 0 CA--C 1.492 -1.394 0 N-CA-C 108.19 -1.964 . . . . 0.0 108.19 -179.703 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -127.54 149.21 50.25 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 -179.492 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -111.68 134.06 53.51 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 107.375 -1.342 . . . . 0.0 107.375 -179.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 84.2 mt-30 -123.23 136.31 54.67 Favored 'General case' 0 CA--C 1.495 -1.149 0 N-CA-C 106.681 -1.599 . . . . 0.0 106.681 179.508 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 66.6 m -120.73 145.77 47.16 Favored 'General case' 0 CA--C 1.493 -1.226 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -142.05 153.19 44.03 Favored 'General case' 0 N--CA 1.437 -1.103 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 -179.761 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.2 p -143.81 142.7 24.56 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.166 0 N-CA-C 106.42 -1.696 . . . . 0.0 106.42 179.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 75.5 mmtt -109.19 124.89 51.57 Favored 'General case' 0 CA--C 1.497 -1.091 0 N-CA-C 106.984 -1.488 . . . . 0.0 106.984 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -153.27 140.56 19.56 Favored 'General case' 0 N--CA 1.435 -1.201 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 -179.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -65.01 136.99 57.43 Favored 'General case' 0 N--CA 1.442 -0.868 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 -179.765 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 104.35 -16.29 49.17 Favored Glycine 0 C--N 1.352 1.452 0 N-CA-C 108.365 -1.894 . . . . 0.0 108.365 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 88.8 m-85 -115.19 128.83 56.43 Favored 'General case' 0 CA--C 1.497 -1.065 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 179.446 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 60.8 tptt -110.49 -58.04 2.14 Favored 'General case' 0 CA--C 1.501 -0.915 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 -179.494 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.515 ' HG ' ' H ' ' A' ' 24' ' ' LYS . 58.3 tp -120.77 121.77 38.9 Favored 'General case' 0 N--CA 1.44 -0.954 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 -179.04 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 97.5 m-20 -98.3 6.33 47.46 Favored 'General case' 0 C--N 1.356 0.891 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 -179.474 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.515 ' H ' ' HG ' ' A' ' 22' ' ' LEU . 48.3 mmtm 69.98 -147.67 0.1 Allowed 'General case' 0 C--N 1.355 0.818 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 47.3 t30 -130.69 116.69 17.24 Favored Pre-proline 0 N--CA 1.439 -0.982 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 -179.751 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -74.05 156.43 47.34 Favored 'Trans proline' 0 CA--C 1.499 -1.253 0 C-N-CA 121.758 1.639 . . . . 0.0 112.495 179.583 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -94.78 122.04 37.0 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -152.1 156.2 26.56 Favored Glycine 0 C--N 1.351 1.399 0 N-CA-C 107.942 -2.063 . . . . 0.0 107.942 -179.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -131.82 151.72 51.48 Favored 'General case' 0 CA--C 1.498 -1.021 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 -179.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 -137.25 125.25 22.79 Favored 'General case' 0 N--CA 1.441 -0.909 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 -179.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 89.7 mt -119.64 135.47 54.8 Favored 'General case' 0 CA--C 1.499 -1.006 0 N-CA-C 106.153 -1.795 . . . . 0.0 106.153 178.714 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.454 ' HB2' ' HB2' ' A' ' 7' ' ' SER . 37.8 mtmm -133.36 144.68 49.76 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 107.859 -1.163 . . . . 0.0 107.859 -179.483 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 92.3 m-85 -132.19 136.78 47.29 Favored 'General case' 0 CA--C 1.498 -1.042 0 N-CA-C 106.764 -1.569 . . . . 0.0 106.764 179.577 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 79.2 ttt180 -119.22 132.33 55.92 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 98.4 m-85 -117.57 130.2 56.25 Favored 'General case' 0 N--CA 1.438 -1.061 0 N-CA-C 106.346 -1.724 . . . . 0.0 106.346 179.148 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -109.2 127.07 53.93 Favored 'General case' 0 CA--C 1.498 -1.036 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 -179.381 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 -127.99 147.68 50.5 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 179.646 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -86.65 72.92 10.14 Favored 'General case' 0 N--CA 1.441 -0.893 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 -179.375 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 31.9 m120 -124.13 -54.96 1.69 Allowed 'General case' 0 CA--C 1.499 -1.017 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 178.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -178.45 -55.22 0.01 OUTLIER 'General case' 0 N--CA 1.439 -0.987 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 35.7 m0 -125.25 149.47 47.98 Favored 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 -178.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -87.32 -179.48 48.29 Favored Glycine 0 C--N 1.351 1.41 0 N-CA-C 107.716 -2.154 . . . . 0.0 107.716 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.9 p -138.68 143.05 33.09 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.891 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.3 tt -131.96 141.19 46.17 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.951 0 N-CA-C 107.37 -1.344 . . . . 0.0 107.37 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -118.91 145.91 18.29 Favored Glycine 0 CA--C 1.492 -1.359 0 N-CA-C 106.459 -2.656 . . . . 0.0 106.459 179.56 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 45.3 t -138.66 136.67 36.11 Favored 'General case' 0 CA--C 1.499 -0.995 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 -179.205 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 91.2 t80 -131.02 130.42 43.3 Favored 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 105.765 -1.939 . . . . 0.0 105.765 179.248 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -146.86 152.89 39.46 Favored 'General case' 0 N--CA 1.436 -1.126 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 -179.314 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 20.6 pt20 -150.96 152.25 33.3 Favored 'General case' 0 N--CA 1.433 -1.287 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 179.398 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 10.1 t -146.38 152.11 38.55 Favored 'General case' 0 CA--C 1.499 -1.003 0 N-CA-C 107.215 -1.402 . . . . 0.0 107.215 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 5.6 tmm_? -132.84 129.62 38.7 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 107.004 -1.48 . . . . 0.0 107.004 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 72.3 ttp85 -133.71 127.02 31.98 Favored 'General case' 0 CA--C 1.495 -1.156 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 179.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -173.57 160.39 30.64 Favored Glycine 0 CA--C 1.489 -1.583 0 N-CA-C 108.1 -2.0 . . . . 0.0 108.1 179.795 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 95.7 m-85 -135.96 152.38 50.9 Favored 'General case' 0 N--CA 1.437 -1.106 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 179.723 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -63.93 -39.87 95.16 Favored 'General case' 0 CA--C 1.505 -0.787 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 -179.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -138.81 132.7 31.02 Favored 'General case' 0 N--CA 1.439 -0.999 0 N-CA-C 106.753 -1.573 . . . . 0.0 106.753 179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 69.3 m -128.03 142.01 51.35 Favored 'General case' 0 CA--C 1.496 -1.113 0 N-CA-C 107.224 -1.398 . . . . 0.0 107.224 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 76.6 t -65.55 -45.57 92.16 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.826 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 179.294 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 61.2 t0 -152.36 100.98 2.64 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 106.302 -1.74 . . . . 0.0 106.302 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -150.6 43.95 0.7 Allowed Glycine 0 CA--C 1.491 -1.413 0 N-CA-C 107.427 -2.269 . . . . 0.0 107.427 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 6.5 t80 79.58 -54.43 0.41 Allowed 'General case' 0 C--N 1.358 0.966 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -117.31 137.33 52.5 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 179.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 87.8 mt -67.11 -40.09 86.79 Favored 'General case' 0 CA--C 1.505 -0.786 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 -179.628 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 45.5 pt -133.67 157.8 42.38 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.086 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 -179.517 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 59.04 41.42 20.8 Favored 'General case' 0 C--N 1.358 0.962 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 179.548 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -92.36 85.55 1.19 Allowed Glycine 0 C--N 1.35 1.36 0 N-CA-C 107.555 -2.218 . . . . 0.0 107.555 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -112.25 135.38 53.01 Favored 'General case' 0 CA--C 1.499 -0.996 0 N-CA-C 107.397 -1.335 . . . . 0.0 107.397 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -127.33 125.4 40.73 Favored 'General case' 0 N--CA 1.439 -0.986 0 N-CA-C 106.708 -1.59 . . . . 0.0 106.708 179.739 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 65.0 mttp -109.11 140.63 42.42 Favored 'General case' 0 CA--C 1.496 -1.1 0 N-CA-C 106.733 -1.58 . . . . 0.0 106.733 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 49.9 t80 -136.29 127.36 27.88 Favored 'General case' 0 N--CA 1.438 -1.058 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -120.29 140.76 50.76 Favored 'General case' 0 CA--C 1.495 -1.137 0 N-CA-C 106.813 -1.551 . . . . 0.0 106.813 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 67.9 m -132.33 136.15 46.68 Favored 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 108.015 -1.105 . . . . 0.0 108.015 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 61.1 t -129.12 136.39 59.71 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.211 0 N-CA-C 105.013 -2.217 . . . . 0.0 105.013 178.572 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.41 ' HG1' ' C ' ' A' ' 91' ' ' LEU . 11.2 t -159.08 154.84 26.28 Favored 'General case' 0 N--CA 1.436 -1.137 0 C-N-CA 119.152 -1.019 . . . . 0.0 108.609 -179.086 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -156.52 159.43 38.58 Favored 'General case' 0 N--CA 1.435 -1.182 0 N-CA-C 106.119 -1.808 . . . . 0.0 106.119 179.447 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -174.33 175.46 46.7 Favored Glycine 0 C--N 1.348 1.233 0 N-CA-C 108.208 -1.957 . . . . 0.0 108.208 179.759 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -77.68 155.49 31.27 Favored 'Trans proline' 0 C--N 1.312 -1.394 0 C-N-CA 122.547 2.165 . . . . 0.0 113.239 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 65.8 t -115.26 128.31 72.5 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.995 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 94.8 m-85 -113.79 130.4 56.46 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 -179.191 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 54.2 ttp180 -112.64 134.58 54.09 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 179.163 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 51.2 mm -73.16 -64.26 0.85 Allowed 'Isoleucine or valine' 0 CA--C 1.503 -0.841 0 N-CA-C 106.972 -1.492 . . . . 0.0 106.972 179.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 65.7 t30 -176.75 93.59 0.04 OUTLIER 'General case' 0 N--CA 1.441 -0.911 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 177.655 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 70.8 tt0 36.48 46.72 0.45 Allowed 'General case' 0 C--N 1.359 0.984 0 C-N-CA 123.378 0.671 . . . . 0.0 111.365 178.337 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 18.2 t80 -142.57 -45.96 0.32 Allowed 'General case' 0 CA--C 1.501 -0.922 0 C-N-CA 118.823 -1.151 . . . . 0.0 108.641 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 16.6 m -148.85 157.89 6.97 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.159 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 179.618 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 66.3 m -132.09 145.96 51.74 Favored 'General case' 0 CA--C 1.497 -1.079 0 N-CA-C 106.52 -1.659 . . . . 0.0 106.52 178.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 1.1 pp -142.47 159.63 41.86 Favored 'General case' 0 CA--C 1.493 -1.226 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 23.7 p90 -152.64 158.76 42.88 Favored 'General case' 0 N--CA 1.435 -1.175 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 -179.566 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -109.05 151.22 17.15 Favored Glycine 0 CA--C 1.491 -1.447 0 N-CA-C 107.059 -2.416 . . . . 0.0 107.059 -179.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 92.0 mt -115.88 133.52 55.94 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 -179.473 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.41 ' C ' ' HG1' ' A' ' 74' ' ' THR . 64.5 tp -137.42 128.08 26.93 Favored 'General case' 0 N--CA 1.437 -1.092 0 N-CA-C 105.312 -2.107 . . . . 0.0 105.312 178.599 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -178.71 -158.26 20.9 Favored Glycine 0 CA--C 1.491 -1.431 0 N-CA-C 108.518 -1.833 . . . . 0.0 108.518 -179.319 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -146.66 158.37 43.89 Favored 'General case' 0 N--CA 1.434 -1.246 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 -179.206 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -117.49 150.67 18.33 Favored Glycine 0 CA--C 1.493 -1.342 0 N-CA-C 107.166 -2.374 . . . . 0.0 107.166 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 96.8 m-70 -126.56 137.36 53.33 Favored 'General case' 0 CA--C 1.497 -1.086 0 N-CA-C 107.164 -1.421 . . . . 0.0 107.164 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -113.15 141.28 16.84 Favored Glycine 0 C--N 1.35 1.358 0 N-CA-C 107.313 -2.315 . . . . 0.0 107.313 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 17.9 tppt? -137.6 128.91 27.9 Favored 'General case' 0 CA--C 1.5 -0.973 0 N-CA-C 107.443 -1.317 . . . . 0.0 107.443 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -155.04 33.02 0.39 Allowed 'General case' 0 N--CA 1.44 -0.97 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 179.58 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 40.0 ttpt -147.86 137.47 22.5 Favored 'General case' 0 N--CA 1.436 -1.131 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 -179.535 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -97.74 134.27 41.14 Favored 'General case' 0 CA--C 1.497 -1.072 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 31.2 t -152.82 153.92 34.09 Favored 'General case' 0 N--CA 1.438 -1.054 0 N-CA-C 106.666 -1.605 . . . . 0.0 106.666 -179.52 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 44.3 t -66.86 142.31 57.37 Favored 'General case' 0 CA--C 1.504 -0.823 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 93.8 mt -62.09 -44.58 99.19 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.828 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -102.63 115.46 30.63 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 106.53 -1.655 . . . . 0.0 106.53 179.54 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 166.58 -167.8 39.75 Favored Glycine 0 CA--C 1.492 -1.383 0 N-CA-C 106.782 -2.527 . . . . 0.0 106.782 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 54.3 tt0 -104.36 119.39 38.85 Favored 'General case' 0 N--CA 1.439 -0.992 0 N-CA-C 107.004 -1.48 . . . . 0.0 107.004 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 70.9 m -132.48 148.84 52.4 Favored 'General case' 0 CA--C 1.495 -1.149 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 179.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -131.93 144.28 50.72 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 107.154 -1.425 . . . . 0.0 107.154 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 66.4 m -133.21 139.83 47.21 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 179.599 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 60.8 ttp180 -84.18 -52.19 6.46 Favored 'General case' 0 CA--C 1.503 -0.863 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.2 m -168.29 80.27 0.16 Allowed 'General case' 0 CA--C 1.497 -1.068 0 N-CA-C 107.305 -1.368 . . . . 0.0 107.305 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -98.73 1.4 46.04 Favored 'General case' 0 CA--C 1.502 -0.88 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 89.2 m -115.09 129.08 56.6 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 106.83 -1.545 . . . . 0.0 106.83 -179.592 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 63.8 m -128.66 148.28 50.8 Favored 'General case' 0 CA--C 1.496 -1.098 0 N-CA-C 107.359 -1.349 . . . . 0.0 107.359 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 92.1 mt -79.72 149.62 31.11 Favored 'General case' 0 CA--C 1.499 -0.998 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -136.01 144.89 45.55 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 -179.548 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -134.04 152.05 51.68 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 106.396 -1.705 . . . . 0.0 106.396 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -174.39 -175.69 42.16 Favored Glycine 0 CA--C 1.491 -1.431 0 N-CA-C 108.612 -1.795 . . . . 0.0 108.612 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -154.78 159.98 40.99 Favored 'General case' 0 N--CA 1.435 -1.199 0 N-CA-C 106.129 -1.804 . . . . 0.0 106.129 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -142.65 152.68 24.04 Favored Glycine 0 CA--C 1.491 -1.427 0 N-CA-C 108.477 -1.849 . . . . 0.0 108.477 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 89.0 mt -120.36 142.62 48.99 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 106.384 -1.71 . . . . 0.0 106.384 179.76 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 51.8 tt0 -125.02 126.92 46.17 Favored 'General case' 0 N--CA 1.437 -1.112 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -114.77 120.27 39.49 Favored 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 106.467 -1.679 . . . . 0.0 106.467 179.651 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 12.7 p-10 -133.36 75.17 70.63 Favored Pre-proline 0 N--CA 1.439 -0.996 0 N-CA-C 108.401 -0.962 . . . . 0.0 108.401 -179.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -67.54 -22.49 44.6 Favored 'Trans proline' 0 CA--C 1.499 -1.274 0 C-N-CA 121.761 1.641 . . . . 0.0 111.914 179.202 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 4.3 p80 -152.51 152.8 29.61 Favored Pre-proline 0 N--CA 1.433 -1.282 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 179.037 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -72.05 -15.03 29.2 Favored 'Trans proline' 0 C--N 1.31 -1.456 0 C-N-CA 122.004 1.802 . . . . 0.0 114.074 -179.049 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 27.1 m120 -62.93 -41.83 99.61 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 -178.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -139.5 140.8 37.31 Favored 'General case' 0 CA--C 1.498 -1.04 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 -179.658 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 75.7 t -124.77 129.73 73.52 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.006 0 N-CA-C 106.16 -1.793 . . . . 0.0 106.16 179.21 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 84.6 mt -101.16 125.62 55.09 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.995 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 -179.064 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 45.3 m-20 -119.26 134.13 55.38 Favored 'General case' 0 N--CA 1.44 -0.931 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -139.7 128.68 23.57 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 106.089 -1.819 . . . . 0.0 106.089 178.721 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 63.6 m -136.46 150.1 48.55 Favored 'General case' 0 CA--C 1.494 -1.196 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -179.214 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -126.73 134.78 50.57 Favored 'General case' 0 N--CA 1.438 -1.055 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 179.348 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -137.06 133.27 35.24 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 -179.751 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -130.96 150.07 52.29 Favored 'General case' 0 CA--C 1.498 -1.053 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 -179.593 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 47.1 t -134.65 135.15 41.88 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 179.751 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -112.89 124.9 53.66 Favored 'General case' 0 CA--C 1.498 -1.037 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 -178.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . 0.4 ' HG ' ' H ' ' A' ' 142' ' ' ASP . 52.8 tp -138.81 142.74 38.7 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 104.946 -2.242 . . . . 0.0 104.946 178.861 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -61.46 -38.62 87.9 Favored 'General case' 0 CA--C 1.508 -0.658 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 -178.487 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . 0.4 ' H ' ' HG ' ' A' ' 140' ' ' LEU . 98.6 m-20 -62.98 -41.87 99.68 Favored 'General case' 0 C--N 1.352 0.711 0 C-N-CA 120.604 -0.438 . . . . 0.0 110.113 -178.842 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 13.8 p -166.49 144.5 1.36 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.79 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 -179.461 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 57.5 mtmt -107.53 135.92 48.17 Favored 'General case' 0 CA--C 1.498 -1.038 0 N-CA-C 106.18 -1.785 . . . . 0.0 106.18 179.145 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 35.2 m -133.83 157.98 42.28 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.06 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 -179.019 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -128.17 140.07 11.52 Favored Glycine 0 C--N 1.352 1.423 0 N-CA-C 106.702 -2.559 . . . . 0.0 106.702 179.284 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 92.1 m -126.65 129.66 48.92 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 -179.614 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 54.1 m0 -113.64 138.84 49.63 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 106.216 -1.772 . . . . 0.0 106.216 179.519 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 64.5 mtt -126.37 126.48 43.94 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 -179.321 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 89.9 mt -126.88 142.66 51.49 Favored 'General case' 0 CA--C 1.494 -1.177 0 N-CA-C 105.998 -1.853 . . . . 0.0 105.998 179.293 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -172.72 -171.89 37.91 Favored Glycine 0 CA--C 1.492 -1.389 0 N-CA-C 108.737 -1.745 . . . . 0.0 108.737 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -143.67 160.18 41.16 Favored 'General case' 0 N--CA 1.434 -1.242 0 N-CA-C 106.508 -1.664 . . . . 0.0 106.508 -179.376 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -142.46 -178.16 18.18 Favored Glycine 0 CA--C 1.49 -1.481 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -179.116 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 93.5 t80 -143.2 143.4 31.76 Favored 'General case' 0 N--CA 1.436 -1.14 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 -179.579 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 17.7 ptm180 -145.67 159.85 42.56 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 36.1 t80 . . . . . 0 C--O 1.264 1.832 0 N-CA-C 108.134 -1.062 . . . . 0.0 108.134 -179.995 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 . . . . . 0 N--CA 1.489 1.501 0 CA-C-O 120.865 0.364 . . . . 0.0 110.564 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 179.67 -176.42 47.57 Favored Glycine 0 CA--C 1.492 -1.377 0 N-CA-C 107.162 -2.375 . . . . 0.0 107.162 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -129.38 146.35 51.26 Favored 'General case' 0 CA--C 1.497 -1.072 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 13.2 m -120.96 -88.28 0.63 Allowed 'General case' 0 CA--C 1.5 -0.946 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 -179.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 64.0 m -139.7 150.99 45.52 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 107.902 -1.148 . . . . 0.0 107.902 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 20.1 tt -133.43 138.96 50.08 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.996 0 N-CA-C 106.208 -1.775 . . . . 0.0 106.208 179.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.459 ' HB2' ' HB2' ' A' ' 32' ' ' LYS . 49.7 m -131.57 148.55 52.63 Favored 'General case' 0 CA--C 1.497 -1.079 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 -179.156 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 45.6 pt -131.6 158.24 43.27 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.106 0 N-CA-C 106.311 -1.737 . . . . 0.0 106.311 179.205 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -167.19 -176.05 37.74 Favored Glycine 0 CA--C 1.493 -1.329 0 N-CA-C 108.506 -1.837 . . . . 0.0 108.506 -179.547 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -125.38 150.77 46.93 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 106.849 -1.538 . . . . 0.0 106.849 -179.43 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -100.62 135.44 42.06 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 -179.469 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 7.5 tp-100 -117.69 129.17 55.56 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 179.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 43.8 m -122.04 -3.11 9.1 Favored 'General case' 0 CA--C 1.502 -0.892 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 -179.27 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 79.6 ttt180 -134.46 127.59 31.77 Favored 'General case' 0 CA--C 1.497 -1.072 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 -179.02 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 64.9 t -122.44 118.13 54.28 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.013 0 N-CA-C 106.174 -1.787 . . . . 0.0 106.174 178.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 65.8 tttm -161.49 141.42 10.5 Favored 'General case' 0 CA--C 1.497 -1.069 0 N-CA-C 106.803 -1.555 . . . . 0.0 106.803 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 89.1 tt0 -91.07 109.17 20.41 Favored 'General case' 0 N--CA 1.438 -1.035 0 N-CA-C 107.006 -1.479 . . . . 0.0 107.006 179.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -158.44 97.05 1.45 Allowed 'General case' 0 N--CA 1.436 -1.153 0 N-CA-C 106.667 -1.605 . . . . 0.0 106.667 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -102.1 1.17 51.07 Favored Glycine 0 C--N 1.35 1.361 0 N-CA-C 108.514 -1.834 . . . . 0.0 108.514 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -71.09 -40.06 71.77 Favored 'General case' 0 CA--C 1.503 -0.843 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 -179.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 39.9 ttmt -157.56 137.66 12.58 Favored 'General case' 0 N--CA 1.437 -1.083 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 88.9 mt -108.99 123.42 49.09 Favored 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 179.549 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 19.9 t0 -167.62 155.88 9.23 Favored 'General case' 0 N--CA 1.435 -1.192 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 57.0 mtmt 58.85 43.93 17.5 Favored 'General case' 0 C--N 1.357 0.932 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 179.503 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 36.2 m120 -106.42 147.53 35.1 Favored Pre-proline 0 N--CA 1.441 -0.916 0 N-CA-C 107.059 -1.459 . . . . 0.0 107.059 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -75.65 155.59 39.98 Favored 'Trans proline' 0 CA--C 1.497 -1.328 0 C-N-CA 122.224 1.95 . . . . 0.0 112.88 179.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 16.0 mtm180 -136.57 129.76 31.35 Favored 'General case' 0 N--CA 1.438 -1.039 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -159.21 160.03 30.91 Favored Glycine 0 CA--C 1.492 -1.367 0 N-CA-C 107.595 -2.202 . . . . 0.0 107.595 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -130.16 145.71 51.74 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 107.045 -1.465 . . . . 0.0 107.045 -179.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 85.0 m-20 -125.06 136.8 54.03 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 7.0 mp -124.69 129.85 51.29 Favored 'General case' 0 CA--C 1.497 -1.081 0 N-CA-C 105.682 -1.97 . . . . 0.0 105.682 178.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.459 ' HB2' ' HB2' ' A' ' 7' ' ' SER . 97.4 mttt -128.37 142.53 51.09 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 -179.044 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -127.13 137.28 52.95 Favored 'General case' 0 CA--C 1.495 -1.135 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 179.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 78.5 ttt180 -117.86 129.24 55.53 Favored 'General case' 0 CA--C 1.495 -1.147 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 -179.496 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -110.88 127.38 55.42 Favored 'General case' 0 N--CA 1.438 -1.048 0 N-CA-C 106.153 -1.795 . . . . 0.0 106.153 179.007 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 50.1 mt-10 -105.8 139.56 40.19 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 108.007 -1.108 . . . . 0.0 108.007 -179.167 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -132.18 164.82 25.49 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 66.9 t30 -79.62 77.79 6.21 Favored 'General case' 0 N--CA 1.443 -0.806 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 9.3 t-20 -165.94 175.98 8.18 Favored 'General case' 0 N--CA 1.433 -1.277 0 N-CA-C 106.056 -1.831 . . . . 0.0 106.056 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -91.11 -0.17 57.66 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 93.7 m95 -115.52 139.47 50.04 Favored 'General case' 0 CA--C 1.498 -1.036 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -124.85 174.43 17.19 Favored Glycine 0 C--N 1.35 1.307 0 N-CA-C 107.265 -2.334 . . . . 0.0 107.265 179.704 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 92.6 t -127.5 131.94 69.75 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.997 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 19.8 tt -127.24 138.05 55.97 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.878 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -120.76 140.03 13.93 Favored Glycine 0 CA--C 1.489 -1.532 0 N-CA-C 106.12 -2.792 . . . . 0.0 106.12 179.297 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 54.8 m -133.04 139.51 47.23 Favored 'General case' 0 CA--C 1.497 -1.071 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 -179.021 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -123.5 133.21 54.05 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 105.814 -1.921 . . . . 0.0 105.814 178.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -128.96 130.14 46.32 Favored 'General case' 0 CA--C 1.496 -1.099 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 -179.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 71.5 mt-30 -129.78 127.52 40.52 Favored 'General case' 0 CA--C 1.497 -1.085 0 N-CA-C 106.447 -1.686 . . . . 0.0 106.447 179.353 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 88.0 m -121.77 121.7 37.84 Favored 'General case' 0 CA--C 1.498 -1.051 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 71.7 ttp85 -70.12 -43.19 71.48 Favored 'General case' 0 CA--C 1.502 -0.889 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 -179.521 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 76.0 ttt180 -151.07 135.25 16.78 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -120.62 149.67 17.5 Favored Glycine 0 C--N 1.352 1.418 0 N-CA-C 107.04 -2.424 . . . . 0.0 107.04 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 89.9 t80 -137.94 130.17 29.01 Favored 'General case' 0 N--CA 1.438 -1.032 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 -179.653 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -98.47 139.25 34.49 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 106.851 -1.537 . . . . 0.0 106.851 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 36.3 mp0 -73.1 102.83 3.66 Favored 'General case' 0 CA--C 1.501 -0.91 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 -179.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 34.8 t -159.89 152.54 21.29 Favored 'General case' 0 N--CA 1.435 -1.18 0 N-CA-C 105.909 -1.886 . . . . 0.0 105.909 179.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 58.8 t -85.66 95.29 4.43 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.968 0 N-CA-C 106.827 -1.546 . . . . 0.0 106.827 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -158.74 110.76 2.2 Favored 'General case' 0 N--CA 1.434 -1.243 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -168.5 173.17 43.18 Favored Glycine 0 CA--C 1.492 -1.376 0 N-CA-C 107.429 -2.268 . . . . 0.0 107.429 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 18.8 t80 77.83 -70.31 0.12 Allowed 'General case' 0 C--N 1.356 0.864 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 179.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -66.14 -39.81 90.11 Favored 'General case' 0 CA--C 1.504 -0.813 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -124.87 144.52 50.27 Favored 'General case' 0 CA--C 1.497 -1.077 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 -179.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 46.6 mm -66.32 -45.1 90.48 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.759 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 179.599 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 33.7 t0 58.83 50.01 9.17 Favored 'General case' 0 C--N 1.359 1.02 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.556 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 176.58 -167.67 39.28 Favored Glycine 0 CA--C 1.491 -1.412 0 N-CA-C 107.131 -2.387 . . . . 0.0 107.131 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 33.3 t0 62.19 48.26 5.04 Favored 'General case' 0 C--N 1.355 0.83 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 33.9 t80 -135.86 125.82 25.92 Favored 'General case' 0 N--CA 1.438 -1.052 0 N-CA-C 106.034 -1.839 . . . . 0.0 106.034 179.718 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 8.0 mptt -89.69 141.9 28.18 Favored 'General case' 0 CA--C 1.501 -0.942 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 -179.096 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -126.34 134.66 51.03 Favored 'General case' 0 CA--C 1.499 -1.007 0 N-CA-C 106.957 -1.497 . . . . 0.0 106.957 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -130.64 136.49 48.89 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 179.228 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 70.9 m -145.02 142.76 30.04 Favored 'General case' 0 CA--C 1.493 -1.234 0 N-CA-C 108.106 -1.072 . . . . 0.0 108.106 179.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 71.2 t -128.7 135.55 62.05 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.246 0 N-CA-C 105.271 -2.122 . . . . 0.0 105.271 178.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 67.5 p -140.19 159.95 41.04 Favored 'General case' 0 CA--C 1.499 -1.007 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 -179.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -156.94 156.63 33.37 Favored 'General case' 0 N--CA 1.436 -1.17 0 N-CA-C 106.19 -1.781 . . . . 0.0 106.19 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -177.12 177.16 48.28 Favored Glycine 0 N--CA 1.436 -1.328 0 N-CA-C 108.355 -1.898 . . . . 0.0 108.355 179.618 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 69.5 Cg_endo -82.45 157.76 16.84 Favored 'Trans proline' 0 C--N 1.309 -1.501 0 C-N-CA 122.754 2.303 . . . . 0.0 113.836 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 66.4 t -119.74 130.09 74.57 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.017 0 N-CA-C 105.641 -1.985 . . . . 0.0 105.641 178.733 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 86.9 t80 -124.96 131.5 53.41 Favored 'General case' 0 N--CA 1.441 -0.917 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 -179.077 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 41.6 ptt180 -112.17 142.89 44.08 Favored 'General case' 0 CA--C 1.5 -0.969 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 179.689 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 49.1 mm -75.07 -63.28 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.502 -0.885 0 N-CA-C 106.787 -1.56 . . . . 0.0 106.787 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.2 p30 -174.8 92.82 0.07 Allowed 'General case' 0 N--CA 1.442 -0.865 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 177.508 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 38.93 41.45 0.54 Allowed 'General case' 0 C--N 1.357 0.898 0 CA-C-N 115.596 -0.729 . . . . 0.0 112.136 177.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 19.8 t80 -142.19 -45.62 0.34 Allowed 'General case' 0 CA--C 1.501 -0.93 0 C-N-CA 118.749 -1.18 . . . . 0.0 108.655 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 27.8 m -144.74 155.48 14.41 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.184 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 66.0 m -136.26 147.1 47.38 Favored 'General case' 0 CA--C 1.496 -1.132 0 N-CA-C 106.908 -1.516 . . . . 0.0 106.908 178.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 1.1 pp -134.54 158.79 43.05 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -151.46 158.93 44.31 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 -179.47 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -123.16 147.58 16.7 Favored Glycine 0 CA--C 1.489 -1.574 0 N-CA-C 106.356 -2.698 . . . . 0.0 106.356 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 94.8 mt -123.85 140.05 53.37 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 -179.36 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -148.72 149.01 30.68 Favored 'General case' 0 N--CA 1.436 -1.157 0 N-CA-C 106.078 -1.823 . . . . 0.0 106.078 178.602 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 175.6 -147.28 8.7 Favored Glycine 0 CA--C 1.491 -1.423 0 N-CA-C 107.704 -2.158 . . . . 0.0 107.704 -179.46 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -140.78 155.77 46.32 Favored 'General case' 0 N--CA 1.438 -1.052 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 -178.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -119.72 142.83 16.6 Favored Glycine 0 C--N 1.351 1.404 0 N-CA-C 107.118 -2.393 . . . . 0.0 107.118 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . 0.496 ' HE1' ' HE2' ' A' ' 97' ' ' LYS . 58.8 t-80 -151.67 136.45 17.15 Favored 'General case' 0 N--CA 1.438 -1.026 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 -179.504 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -154.82 152.83 24.34 Favored Glycine 0 CA--C 1.494 -1.274 0 N-CA-C 107.672 -2.171 . . . . 0.0 107.672 179.404 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.496 ' HE2' ' HE1' ' A' ' 95' ' ' HIS . 68.7 mttm -132.03 138.79 48.34 Favored 'General case' 0 CA--C 1.497 -1.065 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 178.958 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -66.83 -41.69 87.05 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 179.142 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 62.7 mtpt -136.43 151.3 49.35 Favored 'General case' 0 CA--C 1.497 -1.059 0 N-CA-C 106.882 -1.525 . . . . 0.0 106.882 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -112.39 140.76 46.84 Favored 'General case' 0 CA--C 1.497 -1.07 0 N-CA-C 107.031 -1.47 . . . . 0.0 107.031 179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 72.3 m -85.24 127.4 34.29 Favored 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 -179.776 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 73.2 m -67.0 -39.61 87.14 Favored 'General case' 0 CA--C 1.503 -0.844 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 85.1 mt -116.37 127.56 73.94 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.001 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 -179.326 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 93.1 m-85 -91.03 140.3 29.96 Favored 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -178.39 -170.34 40.36 Favored Glycine 0 CA--C 1.491 -1.424 0 N-CA-C 106.759 -2.536 . . . . 0.0 106.759 -179.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 64.4 tt0 -83.7 116.97 22.92 Favored 'General case' 0 N--CA 1.438 -1.027 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 5.6 t -169.33 -169.02 0.88 Allowed 'General case' 0 N--CA 1.437 -1.082 0 N-CA-C 106.208 -1.775 . . . . 0.0 106.208 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 50.0 mt-10 -83.45 133.03 34.93 Favored 'General case' 0 N--CA 1.44 -0.968 0 N-CA-C 107.03 -1.47 . . . . 0.0 107.03 179.628 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 34.8 t -155.86 150.33 25.89 Favored 'General case' 0 CA--C 1.498 -1.042 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 -179.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 86.0 mtp180 -127.19 145.85 50.62 Favored 'General case' 0 CA--C 1.496 -1.109 0 N-CA-C 106.813 -1.551 . . . . 0.0 106.813 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 36.5 t -149.58 140.0 22.39 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 -179.677 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -124.87 134.21 52.79 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 106.96 -1.496 . . . . 0.0 106.96 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 86.0 m -128.55 133.38 48.37 Favored 'General case' 0 CA--C 1.495 -1.149 0 N-CA-C 106.573 -1.64 . . . . 0.0 106.573 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 93.2 p -147.2 160.73 42.12 Favored 'General case' 0 CA--C 1.496 -1.119 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 89.4 mt -96.65 144.09 27.0 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -118.09 138.12 52.47 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 107.445 -1.316 . . . . 0.0 107.445 -179.288 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -132.65 149.38 52.31 Favored 'General case' 0 CA--C 1.494 -1.174 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 179.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -164.53 173.47 40.47 Favored Glycine 0 N--CA 1.433 -1.508 0 N-CA-C 107.925 -2.07 . . . . 0.0 107.925 179.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -150.72 157.63 43.19 Favored 'General case' 0 CA--C 1.492 -1.264 0 N-CA-C 106.001 -1.851 . . . . 0.0 106.001 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -159.08 167.44 34.89 Favored Glycine 0 N--CA 1.435 -1.432 0 N-CA-C 108.834 -1.706 . . . . 0.0 108.834 -179.477 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 88.9 mt -121.28 149.27 43.15 Favored 'General case' 0 CA--C 1.497 -1.069 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -117.18 127.62 54.29 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 179.588 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -112.77 138.82 49.02 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 107.088 -1.449 . . . . 0.0 107.088 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 67.0 m-20 -127.24 77.68 75.29 Favored Pre-proline 0 N--CA 1.442 -0.829 0 N-CA-C 107.004 -1.48 . . . . 0.0 107.004 -179.381 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -69.34 -28.62 27.04 Favored 'Trans proline' 0 CA--C 1.5 -1.207 0 C-N-CA 121.9 1.733 . . . . 0.0 113.326 -179.47 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -137.55 151.36 70.84 Favored Pre-proline 0 N--CA 1.438 -1.049 0 N-CA-C 106.86 -1.533 . . . . 0.0 106.86 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 92.6 Cg_endo -84.03 65.88 7.09 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 C-N-CA 122.003 1.802 . . . . 0.0 112.325 179.691 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.99 -33.66 0.04 OUTLIER 'General case' 0 N--CA 1.44 -0.97 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 -179.589 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -141.86 159.82 41.44 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 -179.468 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 32.7 m -130.06 158.0 42.56 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.009 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 -179.159 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 51.4 mm -116.63 125.06 73.42 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 106.352 -1.721 . . . . 0.0 106.352 179.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -114.2 136.03 53.4 Favored 'General case' 0 CA--C 1.5 -0.958 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 -179.147 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -137.67 139.95 40.54 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 105.428 -2.064 . . . . 0.0 105.428 178.487 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 34.1 t -157.99 153.01 25.39 Favored 'General case' 0 CA--C 1.501 -0.927 0 C-N-CA 119.326 -0.95 . . . . 0.0 108.527 -179.12 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 79.7 t80 -121.23 129.73 53.34 Favored 'General case' 0 N--CA 1.441 -0.896 0 N-CA-C 105.856 -1.905 . . . . 0.0 105.856 178.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -114.24 133.34 55.7 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 107.996 -1.112 . . . . 0.0 107.996 -179.128 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 86.3 t80 -116.51 126.15 52.94 Favored 'General case' 0 N--CA 1.439 -0.975 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 69.2 m -132.12 151.0 52.02 Favored 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 106.468 -1.678 . . . . 0.0 106.468 179.393 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -134.39 124.86 26.4 Favored 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 81.8 mt -120.65 113.9 20.9 Favored 'General case' 0 CA--C 1.495 -1.146 0 N-CA-C 106.939 -1.504 . . . . 0.0 106.939 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 65.2 m-20 60.64 -118.87 0.81 Allowed 'General case' 0 C--N 1.352 0.702 0 N-CA-C 108.131 -1.062 . . . . 0.0 108.131 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -108.99 16.55 22.53 Favored 'General case' 0 N--CA 1.443 -0.794 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 76.7 t -109.26 124.47 65.97 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.878 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 -179.037 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -94.78 134.01 37.86 Favored 'General case' 0 N--CA 1.439 -1.002 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 80.4 t -124.86 124.67 68.33 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.028 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 -179.633 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -123.72 133.73 8.99 Favored Glycine 0 CA--C 1.491 -1.445 0 N-CA-C 106.318 -2.713 . . . . 0.0 106.318 179.238 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 82.8 p -131.25 151.19 51.73 Favored 'General case' 0 CA--C 1.495 -1.159 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 -179.606 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 28.0 m-90 -113.29 138.05 50.59 Favored 'General case' 0 CA--C 1.495 -1.154 0 N-CA-C 106.472 -1.677 . . . . 0.0 106.472 179.39 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 2.5 mpp? -119.23 122.59 42.3 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -129.12 137.58 51.29 Favored 'General case' 0 CA--C 1.494 -1.201 0 N-CA-C 106.049 -1.834 . . . . 0.0 106.049 179.46 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -170.65 -175.39 39.3 Favored Glycine 0 N--CA 1.435 -1.398 0 N-CA-C 108.667 -1.773 . . . . 0.0 108.667 -179.668 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -145.67 161.3 40.18 Favored 'General case' 0 N--CA 1.436 -1.16 0 N-CA-C 106.346 -1.724 . . . . 0.0 106.346 -179.355 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -140.17 166.74 25.66 Favored Glycine 0 CA--C 1.487 -1.719 0 N-CA-C 108.641 -1.784 . . . . 0.0 108.641 -179.188 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 51.8 t80 -117.0 136.52 52.87 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 -179.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 58.7 ttp180 -86.6 127.13 34.89 Favored 'General case' 0 N--CA 1.441 -0.886 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 -179.311 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 . . . . . 0 C--O 1.262 1.747 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 -179.686 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 52.7 tp10 . . . . . 0 N--CA 1.489 1.501 0 CA-C-O 120.883 0.373 . . . . 0.0 110.491 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 179.5 177.84 48.04 Favored Glycine 0 CA--C 1.492 -1.383 0 N-CA-C 106.908 -2.477 . . . . 0.0 106.908 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 80.3 mm-40 -133.73 146.56 50.9 Favored 'General case' 0 CA--C 1.497 -1.069 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 66.9 m -132.85 146.84 52.16 Favored 'General case' 0 CA--C 1.496 -1.113 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 54.2 m -130.21 148.95 52.1 Favored 'General case' 0 CA--C 1.495 -1.135 0 N-CA-C 106.957 -1.498 . . . . 0.0 106.957 179.554 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 83.6 mt -117.15 126.93 74.77 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.072 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 -179.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 59.2 m -124.23 142.97 50.8 Favored 'General case' 0 CA--C 1.496 -1.113 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 -179.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 46.1 pt -132.65 157.96 43.16 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.103 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 179.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -173.23 -175.82 41.29 Favored Glycine 0 CA--C 1.491 -1.447 0 N-CA-C 107.682 -2.167 . . . . 0.0 107.682 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -125.46 151.36 46.35 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 107.088 -1.449 . . . . 0.0 107.088 -179.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -115.9 141.07 48.6 Favored 'General case' 0 N--CA 1.439 -0.979 0 N-CA-C 107.467 -1.308 . . . . 0.0 107.467 -179.575 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 85.9 mm-40 -129.09 148.5 51.04 Favored 'General case' 0 CA--C 1.497 -1.068 0 N-CA-C 107.198 -1.408 . . . . 0.0 107.198 179.745 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 31.9 m -137.32 21.66 2.97 Favored 'General case' 0 CA--C 1.499 -0.989 0 N-CA-C 108.196 -1.038 . . . . 0.0 108.196 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 79.7 ttt180 -131.02 124.94 31.99 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 -179.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 27.4 m -136.62 153.02 29.9 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.026 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 178.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 58.0 mtmt -137.04 146.47 45.26 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 106.951 -1.5 . . . . 0.0 106.951 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -66.92 -39.41 87.36 Favored 'General case' 0 CA--C 1.503 -0.839 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 179.399 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 18.0 t0 -161.63 161.08 29.48 Favored 'General case' 0 N--CA 1.434 -1.235 0 N-CA-C 106.391 -1.707 . . . . 0.0 106.391 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -168.18 169.1 41.27 Favored Glycine 0 CA--C 1.491 -1.413 0 N-CA-C 106.979 -2.448 . . . . 0.0 106.979 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -104.24 -22.17 13.42 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 64.5 pttt -159.46 162.69 35.67 Favored 'General case' 0 N--CA 1.436 -1.133 0 N-CA-C 107.351 -1.352 . . . . 0.0 107.351 -179.837 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 88.3 mt -116.91 137.58 52.11 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 106.546 -1.65 . . . . 0.0 106.546 179.472 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 22.3 t0 -160.99 150.06 16.66 Favored 'General case' 0 N--CA 1.435 -1.189 0 N-CA-C 106.906 -1.516 . . . . 0.0 106.906 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 99.3 mttt 58.28 46.4 15.66 Favored 'General case' 0 C--N 1.357 0.897 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 91.7 m-20 -74.28 151.33 87.79 Favored Pre-proline 0 N--CA 1.443 -0.822 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 179.483 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -70.65 152.46 64.71 Favored 'Trans proline' 0 CA--C 1.497 -1.368 0 C-N-CA 121.778 1.652 . . . . 0.0 112.442 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.46 HH21 ' HD3' ' A' ' 51' ' ' ARG . 72.7 mtm-85 -110.39 131.64 54.88 Favored 'General case' 0 CA--C 1.495 -1.138 0 N-CA-C 107.209 -1.404 . . . . 0.0 107.209 -179.336 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -153.39 148.59 19.51 Favored Glycine 0 CA--C 1.489 -1.536 0 N-CA-C 107.307 -2.317 . . . . 0.0 107.307 179.725 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -130.01 147.31 51.74 Favored 'General case' 0 CA--C 1.495 -1.153 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 50.2 t30 -128.45 114.6 17.0 Favored 'General case' 0 N--CA 1.44 -0.96 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 60.1 tp -111.38 122.11 46.98 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 105.879 -1.897 . . . . 0.0 105.879 179.534 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 39.2 ttpt -135.23 137.89 43.05 Favored 'General case' 0 CA--C 1.503 -0.863 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 -177.548 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -121.17 145.14 48.14 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 179.382 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 53.2 ttp180 -115.67 129.32 56.44 Favored 'General case' 0 CA--C 1.496 -1.124 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 179.514 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -114.29 116.44 29.0 Favored 'General case' 0 CA--C 1.498 -1.055 0 N-CA-C 106.335 -1.728 . . . . 0.0 106.335 179.359 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -113.01 118.22 34.2 Favored 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 -179.222 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -105.06 -28.39 11.06 Favored 'General case' 0 CA--C 1.5 -0.968 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 179.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 32.4 m120 -130.57 146.68 52.14 Favored 'General case' 0 CA--C 1.496 -1.102 0 N-CA-C 106.231 -1.766 . . . . 0.0 106.231 179.575 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 65.2 t30 -83.97 69.66 10.34 Favored 'General case' 0 N--CA 1.443 -0.808 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 -179.64 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 19.9 t0 179.78 -33.74 0.01 OUTLIER 'General case' 0 N--CA 1.441 -0.915 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 -179.742 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 90.5 t90 -146.26 143.41 29.17 Favored 'General case' 0 CA--C 1.5 -0.967 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 -179.007 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -156.41 -177.41 29.55 Favored Glycine 0 C--N 1.351 1.381 0 N-CA-C 107.443 -2.263 . . . . 0.0 107.443 -179.62 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.7 m -131.55 158.06 43.25 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.027 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 -179.634 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 32.8 pt -130.68 159.27 42.83 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.115 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -137.3 141.7 12.6 Favored Glycine 0 CA--C 1.49 -1.508 0 N-CA-C 104.716 -3.353 . . . . 0.0 104.716 177.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 33.8 t -145.2 144.22 30.72 Favored 'General case' 0 CA--C 1.498 -1.038 0 C-N-CA 118.966 -1.094 . . . . 0.0 108.858 -178.514 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 89.3 t80 -129.17 129.9 45.68 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 105.162 -2.162 . . . . 0.0 105.162 179.181 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -135.15 145.87 48.21 Favored 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 -178.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 64.1 tt0 -134.4 129.76 35.82 Favored 'General case' 0 CA--C 1.495 -1.171 0 N-CA-C 105.773 -1.936 . . . . 0.0 105.773 179.264 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 87.5 m -129.38 130.44 46.02 Favored 'General case' 0 CA--C 1.496 -1.112 0 N-CA-C 107.472 -1.306 . . . . 0.0 107.472 -179.519 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.46 ' HD3' HH21 ' A' ' 27' ' ' ARG . 80.2 ttt180 -106.03 126.88 52.72 Favored 'General case' 0 N--CA 1.438 -1.026 0 N-CA-C 106.736 -1.579 . . . . 0.0 106.736 179.602 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 42.6 ttm180 -89.28 124.46 34.43 Favored 'General case' 0 N--CA 1.44 -0.952 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 -179.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -96.23 -161.23 32.74 Favored Glycine 0 C--N 1.352 1.468 0 N-CA-C 107.646 -2.182 . . . . 0.0 107.646 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -103.4 133.91 47.67 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -98.57 127.67 44.59 Favored 'General case' 0 CA--C 1.5 -0.967 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 -179.375 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -142.17 156.01 45.32 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 179.582 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 46.1 t -146.76 146.79 30.4 Favored 'General case' 0 CA--C 1.497 -1.059 0 N-CA-C 106.218 -1.771 . . . . 0.0 106.218 179.526 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.2 m -73.2 -23.87 20.28 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.812 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 -179.47 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 98.3 m-20 -65.52 -39.62 92.02 Favored 'General case' 0 C--N 1.356 0.856 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 179.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 149.41 -179.14 26.44 Favored Glycine 0 CA--C 1.493 -1.319 0 N-CA-C 106.828 -2.509 . . . . 0.0 106.828 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 38.5 t80 75.84 114.87 0.06 Allowed 'General case' 0 C--N 1.356 0.875 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 179.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 30.0 mtpp -124.68 137.25 54.37 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 106.602 -1.629 . . . . 0.0 106.602 179.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 59.6 tp -110.59 120.9 43.92 Favored 'General case' 0 N--CA 1.438 -1.037 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 45.5 pt -96.78 -3.67 10.12 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.837 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 -179.232 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 38.3 t70 -87.8 107.89 18.88 Favored 'General case' 0 N--CA 1.439 -0.982 0 N-CA-C 106.773 -1.566 . . . . 0.0 106.773 179.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -173.04 -171.62 37.9 Favored Glycine 0 CA--C 1.491 -1.438 0 N-CA-C 107.085 -2.406 . . . . 0.0 107.085 -179.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 26.0 t0 66.29 45.78 2.16 Favored 'General case' 0 C--N 1.354 0.796 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 -179.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 45.2 t80 -131.72 131.94 43.47 Favored 'General case' 0 N--CA 1.439 -1.012 0 N-CA-C 106.096 -1.816 . . . . 0.0 106.096 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -99.48 130.28 45.72 Favored 'General case' 0 N--CA 1.44 -0.971 0 N-CA-C 107.829 -1.175 . . . . 0.0 107.829 -179.129 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -111.35 137.38 49.18 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 106.768 -1.567 . . . . 0.0 106.768 179.107 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -121.26 137.24 54.78 Favored 'General case' 0 CA--C 1.496 -1.122 0 N-CA-C 106.247 -1.76 . . . . 0.0 106.247 179.697 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 70.9 m -134.22 138.92 45.44 Favored 'General case' 0 CA--C 1.494 -1.201 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 61.5 t -128.5 136.99 58.59 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.265 0 N-CA-C 104.697 -2.334 . . . . 0.0 104.697 178.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.436 ' HG1' ' C ' ' A' ' 91' ' ' LEU . 13.8 t -156.45 158.26 36.96 Favored 'General case' 0 N--CA 1.437 -1.075 0 C-N-CA 119.015 -1.074 . . . . 0.0 108.679 -178.663 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -157.09 159.84 38.29 Favored 'General case' 0 N--CA 1.435 -1.206 0 N-CA-C 106.24 -1.763 . . . . 0.0 106.24 179.68 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -176.47 173.99 46.68 Favored Glycine 0 C--N 1.349 1.259 0 N-CA-C 108.384 -1.886 . . . . 0.0 108.384 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -84.28 162.07 13.17 Favored 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.992 2.462 . . . . 0.0 113.829 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 97.8 t -122.61 126.85 74.61 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.029 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 178.679 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 99.5 m-85 -115.37 132.53 56.59 Favored 'General case' 0 CA--C 1.498 -1.037 0 N-CA-C 107.467 -1.309 . . . . 0.0 107.467 -179.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 44.3 ttm180 -111.6 132.89 54.24 Favored 'General case' 0 CA--C 1.498 -1.021 0 N-CA-C 106.835 -1.543 . . . . 0.0 106.835 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 97.0 mt -73.51 -64.24 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.896 0 N-CA-C 107.037 -1.468 . . . . 0.0 107.037 179.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 66.0 t30 -177.97 94.09 0.03 OUTLIER 'General case' 0 CA--C 1.502 -0.881 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 177.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 38.03 46.06 0.78 Allowed 'General case' 0 C--N 1.36 1.062 0 C-N-CA 123.094 0.558 . . . . 0.0 111.796 177.803 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 60.5 t80 -141.9 -43.34 0.35 Allowed 'General case' 0 CA--C 1.5 -0.959 0 C-N-CA 119.005 -1.078 . . . . 0.0 108.917 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 12.6 p -161.28 149.58 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.097 0 N-CA-C 106.977 -1.49 . . . . 0.0 106.977 -179.597 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 68.2 m -116.25 135.34 53.98 Favored 'General case' 0 N--CA 1.438 -1.044 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 179.341 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -97.56 128.46 44.31 Favored 'General case' 0 CA--C 1.496 -1.112 0 N-CA-C 106.508 -1.664 . . . . 0.0 106.508 -179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 2.9 m-85 -107.61 141.22 39.41 Favored 'General case' 0 N--CA 1.437 -1.102 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 -179.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -135.86 151.42 20.67 Favored Glycine 0 CA--C 1.487 -1.702 0 N-CA-C 105.462 -3.055 . . . . 0.0 105.462 178.774 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -158.01 143.63 17.01 Favored 'General case' 0 N--CA 1.435 -1.188 0 C-N-CA 118.999 -1.08 . . . . 0.0 108.91 -179.193 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.436 ' C ' ' HG1' ' A' ' 74' ' ' THR . 5.0 tt -136.82 138.92 41.33 Favored 'General case' 0 CA--C 1.498 -1.053 0 N-CA-C 105.498 -2.038 . . . . 0.0 105.498 179.348 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -162.66 -154.87 7.78 Favored Glycine 0 CA--C 1.491 -1.424 0 N-CA-C 108.487 -1.845 . . . . 0.0 108.487 -179.052 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -145.47 156.1 43.53 Favored 'General case' 0 N--CA 1.435 -1.182 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 -179.148 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -101.91 143.7 16.09 Favored Glycine 0 C--N 1.35 1.35 0 N-CA-C 107.091 -2.403 . . . . 0.0 107.091 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -131.52 145.34 51.7 Favored 'General case' 0 CA--C 1.498 -1.026 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 -179.439 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -154.24 168.95 32.62 Favored Glycine 0 CA--C 1.491 -1.422 0 N-CA-C 106.457 -2.657 . . . . 0.0 106.457 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 59.1 mtmt -77.11 129.57 36.2 Favored 'General case' 0 CA--C 1.5 -0.947 0 N-CA-C 107.593 -1.262 . . . . 0.0 107.593 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -160.82 160.34 31.02 Favored 'General case' 0 N--CA 1.434 -1.273 0 N-CA-C 106.717 -1.586 . . . . 0.0 106.717 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -87.68 135.14 33.49 Favored 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 179.725 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -129.65 147.19 51.42 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 5.6 t -159.38 179.91 8.53 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 106.523 -1.658 . . . . 0.0 106.523 179.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 46.3 t -72.27 140.34 48.56 Favored 'General case' 0 CA--C 1.504 -0.804 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 96.4 mt -64.0 -44.58 97.88 Favored 'Isoleucine or valine' 0 C--N 1.354 0.769 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -109.28 135.9 49.62 Favored 'General case' 0 CA--C 1.499 -1.001 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 -179.566 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 170.12 -160.0 32.71 Favored Glycine 0 CA--C 1.491 -1.427 0 N-CA-C 106.778 -2.529 . . . . 0.0 106.778 -179.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 26.0 mp0 -64.1 -39.3 93.75 Favored 'General case' 0 CA--C 1.504 -0.81 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 179.634 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 46.4 t -121.48 130.03 53.31 Favored 'General case' 0 CA--C 1.496 -1.122 0 N-CA-C 106.236 -1.764 . . . . 0.0 106.236 179.402 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 99.7 mt-10 -80.2 151.35 29.73 Favored 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 107.764 -1.199 . . . . 0.0 107.764 -179.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 42.4 t -146.19 143.76 29.48 Favored 'General case' 0 CA--C 1.497 -1.07 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -82.45 152.24 26.2 Favored 'General case' 0 N--CA 1.438 -1.029 0 N-CA-C 107.7 -1.222 . . . . 0.0 107.7 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 46.7 t -98.05 137.03 37.45 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 106.746 -1.576 . . . . 0.0 106.746 179.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 8.5 mptt -119.22 141.61 48.75 Favored 'General case' 0 CA--C 1.499 -1.003 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 -179.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 14.1 t -152.91 161.23 42.8 Favored 'General case' 0 CA--C 1.498 -1.053 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 179.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 36.9 t -149.14 136.31 19.96 Favored 'General case' 0 CA--C 1.497 -1.064 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 89.8 mt -114.53 143.53 44.82 Favored 'General case' 0 CA--C 1.496 -1.128 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -123.15 140.29 53.18 Favored 'General case' 0 N--CA 1.438 -1.039 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 -179.418 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 89.6 t80 -145.85 141.29 27.73 Favored 'General case' 0 CA--C 1.497 -1.06 0 N-CA-C 106.291 -1.744 . . . . 0.0 106.291 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -159.2 178.92 35.15 Favored Glycine 0 CA--C 1.491 -1.415 0 N-CA-C 108.653 -1.779 . . . . 0.0 108.653 -179.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -154.48 163.08 40.74 Favored 'General case' 0 N--CA 1.436 -1.14 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -160.81 171.37 36.9 Favored Glycine 0 CA--C 1.489 -1.562 0 N-CA-C 108.669 -1.772 . . . . 0.0 108.669 -179.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 88.6 mt -127.04 143.43 51.29 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 54.5 tt0 -121.73 129.5 52.76 Favored 'General case' 0 CA--C 1.496 -1.115 0 N-CA-C 106.699 -1.593 . . . . 0.0 106.699 179.074 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 34.4 t80 -125.59 131.09 52.78 Favored 'General case' 0 N--CA 1.437 -1.101 0 N-CA-C 106.196 -1.779 . . . . 0.0 106.196 -179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 11.8 p-10 -121.77 82.19 41.8 Favored Pre-proline 0 N--CA 1.443 -0.814 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 -178.51 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.24 -27.13 29.33 Favored 'Trans proline' 0 CA--C 1.498 -1.32 0 C-N-CA 121.667 1.578 . . . . 0.0 112.491 179.517 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -137.86 151.73 70.94 Favored Pre-proline 0 N--CA 1.436 -1.126 0 N-CA-C 106.287 -1.746 . . . . 0.0 106.287 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -74.62 -18.22 19.92 Favored 'Trans proline' 0 C--N 1.309 -1.533 0 C-N-CA 121.793 1.662 . . . . 0.0 113.031 179.312 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 27.7 m120 -64.82 -40.23 94.85 Favored 'General case' 0 C--N 1.353 0.72 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 -178.796 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 54.0 p90 -154.06 161.71 41.73 Favored 'General case' 0 CA--C 1.499 -1.015 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 -178.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 29.4 m -128.0 159.26 39.26 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.95 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 -179.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 50.9 mm -108.26 127.46 64.53 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.09 0 N-CA-C 106.57 -1.641 . . . . 0.0 106.57 -179.76 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -120.97 131.23 54.19 Favored 'General case' 0 N--CA 1.439 -1.015 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 -178.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -134.19 137.36 44.38 Favored 'General case' 0 CA--C 1.495 -1.165 0 N-CA-C 105.333 -2.099 . . . . 0.0 105.333 178.644 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 35.8 t -154.83 149.86 26.87 Favored 'General case' 0 CA--C 1.497 -1.086 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 -178.712 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 21.0 m-85 -123.18 138.71 54.58 Favored 'General case' 0 N--CA 1.436 -1.17 0 N-CA-C 105.292 -2.114 . . . . 0.0 105.292 179.117 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 88.2 tt0 -136.24 134.79 38.45 Favored 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 -178.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -123.39 140.97 52.47 Favored 'General case' 0 N--CA 1.436 -1.169 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 68.9 m -123.35 139.38 54.1 Favored 'General case' 0 CA--C 1.492 -1.252 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 64.7 tttm -113.48 126.14 54.99 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 107.341 -1.355 . . . . 0.0 107.341 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.14 159.47 20.85 Favored 'General case' 0 N--CA 1.437 -1.113 0 N-CA-C 105.595 -2.002 . . . . 0.0 105.595 178.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -62.2 -38.2 88.23 Favored 'General case' 0 N--CA 1.443 -0.802 0 O-C-N 122.131 -0.356 . . . . 0.0 110.361 -178.628 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -93.65 -38.72 11.18 Favored 'General case' 0 C--N 1.353 0.726 0 C-N-CA 119.862 -0.735 . . . . 0.0 111.642 -176.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 35.5 m -138.29 166.28 23.75 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.947 0 C-N-CA 119.44 -0.904 . . . . 0.0 109.604 -177.344 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -113.83 140.4 48.36 Favored 'General case' 0 CA--C 1.499 -0.986 0 N-CA-C 105.713 -1.958 . . . . 0.0 105.713 178.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 69.9 t -125.91 128.25 71.84 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.018 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 -178.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -114.43 134.87 11.99 Favored Glycine 0 CA--C 1.492 -1.397 0 N-CA-C 106.338 -2.705 . . . . 0.0 106.338 178.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 81.4 p -130.03 151.11 50.93 Favored 'General case' 0 CA--C 1.498 -1.04 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 -179.313 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 29.1 m-90 -124.83 138.54 54.26 Favored 'General case' 0 N--CA 1.437 -1.084 0 N-CA-C 105.692 -1.966 . . . . 0.0 105.692 179.236 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 3.5 mpp? -128.71 139.62 52.14 Favored 'General case' 0 CA--C 1.498 -1.033 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 -179.08 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 61.1 tp -142.11 134.12 27.39 Favored 'General case' 0 CA--C 1.497 -1.06 0 N-CA-C 105.698 -1.964 . . . . 0.0 105.698 179.304 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -168.93 -166.95 28.85 Favored Glycine 0 N--CA 1.436 -1.338 0 N-CA-C 108.966 -1.653 . . . . 0.0 108.966 -179.412 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -147.0 163.81 35.02 Favored 'General case' 0 N--CA 1.435 -1.185 0 N-CA-C 106.279 -1.749 . . . . 0.0 106.279 -179.332 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -144.24 173.43 24.95 Favored Glycine 0 CA--C 1.489 -1.539 0 N-CA-C 108.541 -1.824 . . . . 0.0 108.541 -179.114 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -124.66 143.39 50.76 Favored 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 -179.76 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 80.2 ttt180 -102.62 125.9 49.51 Favored 'General case' 0 CA--C 1.499 -0.984 0 N-CA-C 107.226 -1.398 . . . . 0.0 107.226 -179.386 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 43.6 t80 . . . . . 0 C--O 1.262 1.749 0 CA-C-O 117.764 -1.112 . . . . 0.0 108.3 179.835 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 . . . . . 0 N--CA 1.487 1.376 0 CA-C-O 121.347 0.594 . . . . 0.0 110.378 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -179.55 -179.4 48.76 Favored Glycine 0 CA--C 1.49 -1.487 0 N-CA-C 106.872 -2.491 . . . . 0.0 106.872 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -155.31 160.25 40.62 Favored 'General case' 0 N--CA 1.437 -1.107 0 N-CA-C 107.24 -1.392 . . . . 0.0 107.24 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 96.8 p -153.4 161.67 42.06 Favored 'General case' 0 CA--C 1.497 -1.087 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 63.0 m -131.62 154.74 48.59 Favored 'General case' 0 CA--C 1.496 -1.106 0 N-CA-C 107.208 -1.404 . . . . 0.0 107.208 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 20.6 tt -126.61 140.98 47.33 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.998 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.428 ' HB2' ' HB3' ' A' ' 32' ' ' LYS . 51.0 m -127.58 142.42 51.37 Favored 'General case' 0 CA--C 1.497 -1.095 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 85.6 mt -123.61 129.99 74.3 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.061 0 N-CA-C 106.644 -1.613 . . . . 0.0 106.644 -179.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -146.72 177.95 24.7 Favored Glycine 0 C--N 1.35 1.322 0 N-CA-C 107.905 -2.078 . . . . 0.0 107.905 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -126.31 147.29 49.75 Favored 'General case' 0 CA--C 1.495 -1.168 0 N-CA-C 106.844 -1.539 . . . . 0.0 106.844 -179.759 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -100.99 129.04 46.76 Favored 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 -179.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 83.5 mm-40 -129.62 149.79 51.23 Favored 'General case' 0 CA--C 1.496 -1.122 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 35.9 t -145.94 115.71 7.28 Favored 'General case' 0 CA--C 1.498 -1.056 0 N-CA-C 106.41 -1.7 . . . . 0.0 106.41 179.311 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 73.1 ttt180 -160.91 142.58 12.1 Favored 'General case' 0 N--CA 1.436 -1.172 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 179.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 14.4 p -136.61 143.32 35.7 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.0 0 N-CA-C 106.812 -1.551 . . . . 0.0 106.812 -179.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -90.91 120.48 31.96 Favored 'General case' 0 N--CA 1.439 -1.013 0 N-CA-C 107.252 -1.388 . . . . 0.0 107.252 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -159.72 -55.7 0.06 Allowed 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -133.06 105.55 7.12 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 179.726 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -87.5 67.84 3.21 Favored Glycine 0 C--N 1.352 1.433 0 N-CA-C 108.035 -2.026 . . . . 0.0 108.035 -179.541 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 35.2 t80 -158.05 -64.71 0.09 Allowed 'General case' 0 N--CA 1.438 -1.039 0 N-CA-C 106.432 -1.692 . . . . 0.0 106.432 179.688 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 62.4 mtpt -67.26 -38.7 85.54 Favored 'General case' 0 C--N 1.355 0.823 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.467 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 62.7 tp -102.39 127.09 49.55 Favored 'General case' 0 CA--C 1.499 -1.001 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -154.8 164.56 38.64 Favored 'General case' 0 N--CA 1.437 -1.109 0 N-CA-C 106.514 -1.661 . . . . 0.0 106.514 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 34.5 mmtp 68.91 -173.28 0.19 Allowed 'General case' 0 C--N 1.358 0.952 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 -179.724 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 5.9 m120 -134.74 150.33 73.17 Favored Pre-proline 0 N--CA 1.441 -0.9 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 -179.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -80.31 161.01 22.96 Favored 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.31 2.007 . . . . 0.0 112.406 179.026 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -99.99 125.84 46.08 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 179.592 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -148.9 148.15 19.29 Favored Glycine 0 CA--C 1.492 -1.399 0 N-CA-C 108.085 -2.006 . . . . 0.0 108.085 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 93.6 m-85 -131.24 147.48 52.6 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 24.4 t-20 -142.73 120.69 12.05 Favored 'General case' 0 N--CA 1.438 -1.05 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -179.823 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 89.8 mt -110.62 135.46 51.21 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 106.261 -1.755 . . . . 0.0 106.261 179.072 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.428 ' HB3' ' HB2' ' A' ' 7' ' ' SER . 28.4 ttpp -130.41 133.54 46.43 Favored 'General case' 0 CA--C 1.498 -1.037 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 -179.31 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -117.62 139.35 51.11 Favored 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 107.067 -1.456 . . . . 0.0 107.067 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 60.5 ttp180 -119.26 129.08 54.73 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 107.141 -1.429 . . . . 0.0 107.141 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -120.51 139.6 52.67 Favored 'General case' 0 N--CA 1.438 -1.035 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -107.78 126.51 52.72 Favored 'General case' 0 N--CA 1.438 -1.073 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 -179.521 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -129.42 160.86 31.81 Favored 'General case' 0 CA--C 1.495 -1.139 0 N-CA-C 106.26 -1.755 . . . . 0.0 106.26 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 52.6 t30 -80.11 99.57 7.8 Favored 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 106.877 -1.527 . . . . 0.0 106.877 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 9.5 t-20 -164.72 -176.28 4.19 Favored 'General case' 0 N--CA 1.434 -1.24 0 N-CA-C 106.207 -1.775 . . . . 0.0 106.207 -179.455 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -87.54 -2.0 58.32 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 -179.431 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 46.3 p90 -150.37 157.91 43.58 Favored 'General case' 0 CA--C 1.5 -0.975 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 179.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -97.55 176.05 30.88 Favored Glycine 0 C--N 1.353 1.485 0 N-CA-C 107.421 -2.272 . . . . 0.0 107.421 179.708 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 71.8 t -130.23 130.97 65.89 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.95 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 -179.79 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 36.8 pt -127.63 159.02 38.83 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.072 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 179.323 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -139.06 141.72 12.16 Favored Glycine 0 CA--C 1.49 -1.473 0 N-CA-C 105.943 -2.863 . . . . 0.0 105.943 178.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 61.4 m -132.55 145.65 51.3 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 -179.281 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 72.0 t80 -127.63 123.95 36.85 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 105.242 -2.133 . . . . 0.0 105.242 179.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -119.87 140.28 51.08 Favored 'General case' 0 CA--C 1.499 -1.002 0 CA-C-O 121.588 0.708 . . . . 0.0 109.209 -177.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 67.0 mt-30 -128.75 133.13 48.01 Favored 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 105.999 -1.852 . . . . 0.0 105.999 178.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 85.3 m -133.2 131.12 40.0 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 179.578 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 -140.28 133.22 29.28 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 107.008 -1.478 . . . . 0.0 107.008 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 44.3 ttm180 -117.53 124.02 47.69 Favored 'General case' 0 CA--C 1.497 -1.069 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 179.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -129.24 134.53 8.01 Favored Glycine 0 CA--C 1.492 -1.383 0 N-CA-C 107.142 -2.383 . . . . 0.0 107.142 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 87.3 t80 -147.57 123.55 10.7 Favored 'General case' 0 N--CA 1.436 -1.148 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -149.21 105.35 3.49 Favored 'General case' 0 N--CA 1.436 -1.145 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 179.426 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -142.87 149.0 37.95 Favored 'General case' 0 CA--C 1.495 -1.159 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 44.7 t -107.74 109.4 20.97 Favored 'General case' 0 CA--C 1.496 -1.112 0 N-CA-C 106.17 -1.789 . . . . 0.0 106.17 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 31.5 m -135.03 156.85 40.25 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.017 0 N-CA-C 107.639 -1.245 . . . . 0.0 107.639 -179.434 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -110.01 20.29 18.1 Favored 'General case' 0 CA--C 1.502 -0.879 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 179.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -172.23 -159.75 19.31 Favored Glycine 0 CA--C 1.493 -1.341 0 N-CA-C 107.429 -2.268 . . . . 0.0 107.429 -179.322 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 92.2 m-85 70.79 -135.58 0.05 OUTLIER 'General case' 0 C--N 1.355 0.809 0 N-CA-C 107.859 -1.163 . . . . 0.0 107.859 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 29.6 tptp -149.71 137.01 19.84 Favored 'General case' 0 N--CA 1.436 -1.13 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 -179.634 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 7.9 mp -88.04 145.22 26.09 Favored 'General case' 0 CA--C 1.5 -0.96 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 179.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 83.8 mt -104.8 124.63 59.55 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.986 0 N-CA-C 107.211 -1.403 . . . . 0.0 107.211 -179.359 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -70.74 144.85 50.79 Favored 'General case' 0 CA--C 1.504 -0.801 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 179.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -173.69 -140.54 3.24 Favored Glycine 0 CA--C 1.492 -1.368 0 N-CA-C 107.147 -2.381 . . . . 0.0 107.147 -179.425 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 65.47 50.59 1.66 Allowed 'General case' 0 C--N 1.355 0.831 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 52.9 p90 -145.52 160.22 41.94 Favored 'General case' 0 CA--C 1.499 -1.001 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 179.19 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -123.27 143.9 49.77 Favored 'General case' 0 CA--C 1.498 -1.048 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 -179.525 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -135.93 132.01 35.9 Favored 'General case' 0 N--CA 1.438 -1.028 0 N-CA-C 106.603 -1.628 . . . . 0.0 106.603 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -127.48 145.79 50.72 Favored 'General case' 0 CA--C 1.496 -1.128 0 N-CA-C 107.289 -1.375 . . . . 0.0 107.289 -179.576 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 39.3 t -150.59 144.14 25.08 Favored 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 57.7 t -128.03 135.94 61.54 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.168 0 N-CA-C 105.802 -1.925 . . . . 0.0 105.802 179.752 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 67.6 p -137.85 159.09 42.93 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -157.97 160.44 37.52 Favored 'General case' 0 CA--C 1.494 -1.185 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 179.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 178.82 176.91 47.05 Favored Glycine 0 N--CA 1.436 -1.363 0 N-CA-C 108.392 -1.883 . . . . 0.0 108.392 179.509 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -83.01 163.45 15.59 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.818 2.345 . . . . 0.0 113.548 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 67.1 t -113.69 124.62 70.51 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.092 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 178.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 89.8 t80 -107.55 117.52 34.31 Favored 'General case' 0 CA--C 1.5 -0.963 0 N-CA-C 107.443 -1.317 . . . . 0.0 107.443 -179.287 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 82.2 mtp180 -112.84 137.45 51.17 Favored 'General case' 0 CA--C 1.497 -1.058 0 N-CA-C 106.503 -1.665 . . . . 0.0 106.503 179.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 97.2 mt -79.79 -64.59 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.502 -0.89 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 179.452 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 66.9 t30 179.64 94.73 0.02 OUTLIER 'General case' 0 CA--C 1.502 -0.885 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 178.204 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 77.6 mm-40 40.85 46.03 2.26 Favored 'General case' 0 C--N 1.359 1.005 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.122 178.252 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 51.5 t80 -141.59 -43.35 0.36 Allowed 'General case' 0 CA--C 1.501 -0.916 0 C-N-CA 118.985 -1.086 . . . . 0.0 109.023 -179.373 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 14.9 p -159.98 147.47 6.44 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.053 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 -179.259 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 52.0 m -119.33 137.37 53.75 Favored 'General case' 0 CA--C 1.496 -1.101 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 179.214 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 90.2 mt -115.35 142.6 46.46 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 106.69 -1.596 . . . . 0.0 106.69 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 24.2 m-85 -118.29 142.46 47.48 Favored 'General case' 0 CA--C 1.496 -1.134 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -116.25 133.1 10.57 Favored Glycine 0 CA--C 1.493 -1.342 0 N-CA-C 105.314 -3.114 . . . . 0.0 105.314 177.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 90.3 mt -122.65 134.88 54.48 Favored 'General case' 0 CA--C 1.497 -1.075 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 -178.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -153.43 148.39 26.62 Favored 'General case' 0 N--CA 1.437 -1.119 0 N-CA-C 105.92 -1.882 . . . . 0.0 105.92 178.375 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 171.16 -148.69 11.41 Favored Glycine 0 CA--C 1.492 -1.363 0 N-CA-C 108.04 -2.024 . . . . 0.0 108.04 -179.569 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -144.66 162.8 35.77 Favored 'General case' 0 N--CA 1.438 -1.036 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 -179.005 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -141.43 162.64 26.89 Favored Glycine 0 CA--C 1.493 -1.322 0 N-CA-C 108.02 -2.032 . . . . 0.0 108.02 -179.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 32.0 p80 -151.81 159.94 43.73 Favored 'General case' 0 N--CA 1.436 -1.129 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -141.07 160.38 26.73 Favored Glycine 0 CA--C 1.491 -1.452 0 N-CA-C 107.366 -2.294 . . . . 0.0 107.366 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 63.2 mtpt -87.89 64.48 7.9 Favored 'General case' 0 N--CA 1.441 -0.893 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 -179.669 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -65.04 -40.4 94.74 Favored 'General case' 0 N--CA 1.443 -0.82 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 15.0 ptmm? -157.41 167.55 29.93 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 -179.741 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -106.65 143.44 34.74 Favored 'General case' 0 CA--C 1.498 -1.019 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 96.1 p -155.37 160.71 40.91 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 179.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 99.1 p -157.12 160.67 39.05 Favored 'General case' 0 CA--C 1.497 -1.094 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 44.6 pt -132.21 154.89 40.88 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.037 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 179.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 90.1 t80 -62.73 -47.99 81.17 Favored 'General case' 0 C--N 1.355 0.808 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -163.68 -48.37 0.02 OUTLIER Glycine 0 CA--C 1.493 -1.32 0 N-CA-C 107.402 -2.279 . . . . 0.0 107.402 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 25.8 pt20 -149.17 152.54 36.24 Favored 'General case' 0 N--CA 1.436 -1.129 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 179.439 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 35.3 t -159.05 148.33 18.69 Favored 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 106.565 -1.643 . . . . 0.0 106.565 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -94.48 120.14 34.26 Favored 'General case' 0 N--CA 1.439 -1.015 0 N-CA-C 106.93 -1.507 . . . . 0.0 106.93 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 4.9 t -164.45 -165.97 1.03 Allowed 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 -179.672 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -127.63 148.81 50.38 Favored 'General case' 0 CA--C 1.498 -1.051 0 N-CA-C 106.78 -1.563 . . . . 0.0 106.78 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 36.8 t -149.32 147.05 27.87 Favored 'General case' 0 N--CA 1.438 -1.053 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 -179.693 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 65.3 mttp -129.1 151.24 50.0 Favored 'General case' 0 CA--C 1.498 -1.04 0 N-CA-C 107.081 -1.452 . . . . 0.0 107.081 -179.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 68.0 p -124.18 157.9 33.65 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 36.1 t -94.1 130.72 40.17 Favored 'General case' 0 CA--C 1.499 -1.019 0 N-CA-C 107.356 -1.35 . . . . 0.0 107.356 -179.533 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 91.1 mt -95.89 143.71 26.85 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 179.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -113.78 137.64 51.37 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 -179.451 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -145.37 139.02 26.68 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 106.375 -1.713 . . . . 0.0 106.375 179.758 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -167.69 -176.32 38.25 Favored Glycine 0 N--CA 1.436 -1.354 0 N-CA-C 108.313 -1.915 . . . . 0.0 108.313 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -152.83 165.82 34.22 Favored 'General case' 0 N--CA 1.435 -1.203 0 N-CA-C 106.367 -1.716 . . . . 0.0 106.367 -179.753 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -155.79 175.03 33.73 Favored Glycine 0 CA--C 1.491 -1.458 0 N-CA-C 108.423 -1.871 . . . . 0.0 108.423 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 3.1 pp -141.7 159.42 42.26 Favored 'General case' 0 CA--C 1.497 -1.068 0 N-CA-C 106.941 -1.504 . . . . 0.0 106.941 -179.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 3.6 tm0? -147.41 134.55 20.46 Favored 'General case' 0 N--CA 1.437 -1.092 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 -179.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -124.45 146.88 48.67 Favored 'General case' 0 CA--C 1.499 -1.006 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 179.479 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -130.01 76.6 77.87 Favored Pre-proline 0 N--CA 1.442 -0.832 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -72.06 -32.59 10.72 Favored 'Trans proline' 0 CA--C 1.498 -1.3 0 C-N-CA 121.706 1.604 . . . . 0.0 112.524 179.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 79.4 m80 -139.75 151.34 65.7 Favored Pre-proline 0 N--CA 1.436 -1.147 0 N-CA-C 106.194 -1.78 . . . . 0.0 106.194 179.576 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -75.82 -9.21 19.57 Favored 'Trans proline' 0 C--N 1.311 -1.399 0 C-N-CA 122.004 1.802 . . . . 0.0 112.762 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 27.7 m120 -63.68 -39.66 94.87 Favored 'General case' 0 N--CA 1.443 -0.782 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.197 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 55.1 p90 -154.01 160.86 42.21 Favored 'General case' 0 CA--C 1.5 -0.978 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 74.2 t -121.48 131.4 73.15 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.981 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 179.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 19.5 tt -99.31 133.45 42.0 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.843 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 -179.456 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 50.2 m-20 -127.61 138.85 52.97 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 -179.404 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -140.1 129.91 24.57 Favored 'General case' 0 CA--C 1.495 -1.137 0 N-CA-C 105.851 -1.907 . . . . 0.0 105.851 178.586 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 53.5 m -146.53 163.44 35.73 Favored 'General case' 0 CA--C 1.495 -1.139 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 -179.365 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -143.41 148.9 36.88 Favored 'General case' 0 N--CA 1.438 -1.048 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 178.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 62.1 mt-10 -138.22 149.51 45.85 Favored 'General case' 0 CA--C 1.498 -1.045 0 N-CA-C 107.964 -1.125 . . . . 0.0 107.964 -179.675 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -127.58 143.79 51.14 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 178.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 67.2 m -127.43 141.17 51.75 Favored 'General case' 0 CA--C 1.495 -1.158 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 179.465 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 40.2 ttpt -104.43 120.85 42.16 Favored 'General case' 0 N--CA 1.438 -1.026 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 -179.502 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 87.4 mt -120.76 158.34 27.74 Favored 'General case' 0 CA--C 1.496 -1.1 0 N-CA-C 105.884 -1.895 . . . . 0.0 105.884 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 44.5 p-10 -86.47 4.15 40.96 Favored 'General case' 0 N--CA 1.442 -0.87 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 -179.379 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -103.68 -66.25 0.96 Allowed 'General case' 0 N--CA 1.441 -0.885 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 179.826 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 34.8 m -139.76 161.15 26.96 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.985 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 -179.703 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 23.4 tptm -82.75 129.61 35.0 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 106.597 -1.631 . . . . 0.0 106.597 179.275 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 94.1 t -119.66 127.14 75.86 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.949 0 N-CA-C 108.42 -0.955 . . . . 0.0 108.42 -178.6 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -127.27 140.22 11.72 Favored Glycine 0 CA--C 1.492 -1.403 0 N-CA-C 105.879 -2.889 . . . . 0.0 105.879 178.66 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 82.8 p -129.9 151.13 50.8 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -179.166 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 29.1 m-90 -118.71 139.66 51.19 Favored 'General case' 0 CA--C 1.497 -1.086 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 178.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 1.8 tmt? -119.94 124.13 45.23 Favored 'General case' 0 CA--C 1.497 -1.059 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -178.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 89.9 mt -124.38 140.13 53.25 Favored 'General case' 0 CA--C 1.497 -1.096 0 N-CA-C 105.571 -2.011 . . . . 0.0 105.571 178.429 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -175.47 -170.11 37.98 Favored Glycine 0 CA--C 1.491 -1.452 0 N-CA-C 108.489 -1.844 . . . . 0.0 108.489 -179.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -135.15 154.06 51.76 Favored 'General case' 0 N--CA 1.437 -1.106 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 -179.339 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -109.97 146.41 17.13 Favored Glycine 0 CA--C 1.491 -1.45 0 N-CA-C 108.114 -1.994 . . . . 0.0 108.114 -179.378 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 92.5 t80 -115.11 134.43 55.17 Favored 'General case' 0 N--CA 1.439 -1.011 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 179.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 17.6 ptm180 -143.38 160.65 40.14 Favored 'General case' 0 N--CA 1.435 -1.201 0 N-CA-C 106.788 -1.56 . . . . 0.0 106.788 -179.675 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 35.0 t80 . . . . . 0 C--O 1.262 1.714 0 CA-C-O 117.638 -1.172 . . . . 0.0 108.089 -179.99 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 120.826 0.346 . . . . 0.0 110.702 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -178.67 -179.97 48.61 Favored Glycine 0 CA--C 1.491 -1.44 0 N-CA-C 107.106 -2.398 . . . . 0.0 107.106 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -136.7 136.25 38.88 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 106.892 -1.521 . . . . 0.0 106.892 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 63.3 m -122.22 142.24 50.64 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 107.035 -1.468 . . . . 0.0 107.035 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.469 ' HG ' ' CZ ' ' A' ' 34' ' ' ARG . 68.0 m -127.25 151.01 49.28 Favored 'General case' 0 CA--C 1.497 -1.074 0 N-CA-C 107.119 -1.438 . . . . 0.0 107.119 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 85.0 mt -115.53 129.46 71.78 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 -179.368 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.479 ' HB2' ' HB3' ' A' ' 32' ' ' LYS . 69.0 m -124.09 144.72 49.71 Favored 'General case' 0 CA--C 1.499 -0.996 0 N-CA-C 107.716 -1.216 . . . . 0.0 107.716 -179.788 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 85.5 mt -122.34 131.05 73.99 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.053 0 N-CA-C 106.398 -1.704 . . . . 0.0 106.398 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -137.85 164.12 25.52 Favored Glycine 0 C--N 1.354 1.539 0 N-CA-C 108.237 -1.945 . . . . 0.0 108.237 -179.314 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -127.66 147.24 50.37 Favored 'General case' 0 CA--C 1.499 -1.014 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.94 138.85 41.26 Favored 'General case' 0 CA--C 1.5 -0.975 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 97.0 mm-40 -111.51 122.4 47.73 Favored 'General case' 0 N--CA 1.438 -1.064 0 N-CA-C 107.173 -1.418 . . . . 0.0 107.173 179.653 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 73.4 m -162.03 -177.98 6.13 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 105.708 -1.96 . . . . 0.0 105.708 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 17.6 ptm180 -140.45 144.91 36.35 Favored 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 107.405 -1.331 . . . . 0.0 107.405 179.317 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 27.1 m -140.06 158.93 26.32 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.989 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -145.52 129.38 17.31 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 179.1 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -136.14 147.86 47.93 Favored 'General case' 0 CA--C 1.498 -1.019 0 N-CA-C 107.051 -1.462 . . . . 0.0 107.051 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 63.4 t0 -90.56 100.09 13.0 Favored 'General case' 0 N--CA 1.44 -0.937 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 167.98 -169.28 41.28 Favored Glycine 0 CA--C 1.491 -1.431 0 N-CA-C 107.001 -2.44 . . . . 0.0 107.001 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -90.31 70.83 7.13 Favored 'General case' 0 CA--C 1.501 -0.924 0 N-CA-C 107.011 -1.478 . . . . 0.0 107.011 179.713 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -135.44 158.04 45.37 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 106.69 -1.596 . . . . 0.0 106.69 -179.628 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 92.9 mt -73.41 135.91 44.25 Favored 'General case' 0 N--CA 1.441 -0.907 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 -179.517 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -114.61 149.87 35.93 Favored 'General case' 0 CA--C 1.499 -1.007 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 97.7 mttt 62.77 34.15 14.82 Favored 'General case' 0 C--N 1.356 0.879 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 45.3 m-80 -138.56 113.16 8.57 Favored Pre-proline 0 N--CA 1.441 -0.907 0 N-CA-C 106.658 -1.608 . . . . 0.0 106.658 179.115 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -75.73 153.08 38.13 Favored 'Trans proline' 0 CA--C 1.497 -1.357 0 C-N-CA 121.901 1.734 . . . . 0.0 113.113 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -129.66 109.27 10.85 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 179.463 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -170.9 167.87 41.02 Favored Glycine 0 CA--C 1.492 -1.389 0 N-CA-C 107.371 -2.291 . . . . 0.0 107.371 179.709 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 72.5 t80 -146.78 131.68 18.1 Favored 'General case' 0 CA--C 1.499 -1.007 0 N-CA-C 106.037 -1.838 . . . . 0.0 106.037 -179.806 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 80.3 m-20 -126.89 144.13 51.08 Favored 'General case' 0 CA--C 1.501 -0.933 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 -178.649 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 83.2 mt -119.77 139.12 52.8 Favored 'General case' 0 CA--C 1.495 -1.155 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 178.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.479 ' HB3' ' HB2' ' A' ' 7' ' ' SER . 86.6 tttt -137.22 133.84 35.57 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -124.36 139.13 54.19 Favored 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 106.671 -1.603 . . . . 0.0 106.671 179.529 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . 0.469 ' CZ ' ' HG ' ' A' ' 5' ' ' SER . 7.9 tmm_? -120.18 129.57 54.18 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 -179.371 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -115.19 126.87 55.09 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 106.803 -1.554 . . . . 0.0 106.803 179.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -116.56 130.6 56.84 Favored 'General case' 0 CA--C 1.497 -1.065 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 -179.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -119.94 176.45 5.41 Favored 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 67.0 t30 -79.89 78.25 6.5 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 -166.31 172.01 11.51 Favored 'General case' 0 N--CA 1.434 -1.226 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -89.71 -3.24 58.3 Favored 'General case' 0 N--CA 1.443 -0.793 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 54.3 m0 -113.73 140.14 48.51 Favored 'General case' 0 CA--C 1.499 -0.993 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 -179.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -129.17 178.46 17.31 Favored Glycine 0 C--N 1.349 1.262 0 N-CA-C 107.016 -2.434 . . . . 0.0 107.016 179.696 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.8 p -142.66 142.72 26.42 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.9 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 32.2 pt -129.88 157.88 42.44 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.052 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -137.62 139.87 10.81 Favored Glycine 0 CA--C 1.491 -1.454 0 N-CA-C 105.828 -2.909 . . . . 0.0 105.828 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 56.2 m -138.45 149.36 45.38 Favored 'General case' 0 CA--C 1.496 -1.107 0 C-N-CA 119.674 -0.81 . . . . 0.0 108.9 -179.242 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -125.93 139.96 53.03 Favored 'General case' 0 CA--C 1.496 -1.122 0 N-CA-C 105.06 -2.2 . . . . 0.0 105.06 178.746 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -134.18 138.98 45.53 Favored 'General case' 0 CA--C 1.498 -1.043 0 C-N-CA 119.575 -0.85 . . . . 0.0 108.902 -178.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 64.7 tt0 -137.83 123.54 19.87 Favored 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 106.109 -1.812 . . . . 0.0 106.109 178.561 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 11.4 t -147.53 174.66 11.51 Favored 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 107.137 -1.431 . . . . 0.0 107.137 -179.67 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 83.5 mtp180 -126.74 145.66 50.52 Favored 'General case' 0 CA--C 1.495 -1.155 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 179.594 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 31.8 tpt180 -97.26 121.46 39.18 Favored 'General case' 0 CA--C 1.499 -1.0 0 N-CA-C 106.746 -1.576 . . . . 0.0 106.746 -179.726 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -105.71 -139.43 9.68 Favored Glycine 0 C--N 1.349 1.276 0 N-CA-C 107.934 -2.066 . . . . 0.0 107.934 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -125.65 149.32 48.53 Favored 'General case' 0 N--CA 1.438 -1.065 0 N-CA-C 106.845 -1.539 . . . . 0.0 106.845 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -129.4 148.4 51.31 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 -179.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -136.33 128.97 30.66 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 106.77 -1.567 . . . . 0.0 106.77 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 11.5 p -157.51 -48.72 0.07 Allowed 'General case' 0 CA--C 1.498 -1.052 0 N-CA-C 107.362 -1.347 . . . . 0.0 107.362 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 73.4 t -119.68 128.84 75.9 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.053 0 N-CA-C 106.63 -1.619 . . . . 0.0 106.63 179.683 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -83.75 82.03 8.5 Favored 'General case' 0 N--CA 1.441 -0.898 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 -179.752 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -92.59 1.8 72.59 Favored Glycine 0 C--N 1.353 1.494 0 N-CA-C 108.332 -1.907 . . . . 0.0 108.332 179.694 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 64.93 38.71 6.26 Favored 'General case' 0 C--N 1.356 0.856 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -127.98 147.06 50.48 Favored 'General case' 0 CA--C 1.497 -1.07 0 N-CA-C 106.677 -1.601 . . . . 0.0 106.677 179.6 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 90.3 mt -112.46 134.38 54.03 Favored 'General case' 0 CA--C 1.497 -1.085 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 96.8 mt -65.53 -42.41 93.03 Favored 'Isoleucine or valine' 0 C--N 1.354 0.769 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.66 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 32.9 t0 64.86 53.86 1.4 Allowed 'General case' 0 C--N 1.359 0.988 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -93.66 -117.01 2.67 Favored Glycine 0 C--N 1.352 1.456 0 N-CA-C 107.661 -2.176 . . . . 0.0 107.661 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 34.8 t0 66.75 52.05 1.0 Allowed 'General case' 0 C--N 1.355 0.807 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 53.6 p90 -148.42 159.89 43.58 Favored 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 107.307 -1.368 . . . . 0.0 107.307 179.364 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 65.0 mttp -91.59 137.8 32.07 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 -179.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 86.3 t80 -117.22 125.79 51.72 Favored 'General case' 0 N--CA 1.44 -0.952 0 N-CA-C 107.297 -1.372 . . . . 0.0 107.297 -178.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -116.47 140.64 49.15 Favored 'General case' 0 CA--C 1.494 -1.189 0 N-CA-C 106.148 -1.797 . . . . 0.0 106.148 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 34.8 t -150.12 145.98 26.64 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 -179.554 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 35.3 m -128.79 149.2 33.32 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.152 0 N-CA-C 105.678 -1.971 . . . . 0.0 105.678 179.025 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 12.9 t -156.75 154.58 30.2 Favored 'General case' 0 N--CA 1.437 -1.121 0 C-N-CA 119.205 -0.998 . . . . 0.0 108.37 -178.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -157.04 159.39 37.92 Favored 'General case' 0 N--CA 1.436 -1.171 0 N-CA-C 105.841 -1.911 . . . . 0.0 105.841 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -174.68 170.2 43.28 Favored Glycine 0 N--CA 1.437 -1.241 0 N-CA-C 108.365 -1.894 . . . . 0.0 108.365 179.714 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo -80.17 155.0 22.35 Favored 'Trans proline' 0 C--N 1.312 -1.371 0 C-N-CA 122.596 2.197 . . . . 0.0 113.255 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 65.9 t -123.98 128.71 74.29 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.062 0 N-CA-C 106.695 -1.594 . . . . 0.0 106.695 179.511 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -113.18 124.91 53.65 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 107.06 -1.459 . . . . 0.0 107.06 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 45.1 ttm180 -111.73 132.73 54.43 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 49.7 mm -74.58 -64.68 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.937 0 N-CA-C 107.033 -1.469 . . . . 0.0 107.033 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 66.4 t30 -179.24 94.54 0.03 OUTLIER 'General case' 0 CA--C 1.502 -0.892 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 178.127 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 58.7 mt-10 39.63 45.88 1.45 Allowed 'General case' 0 C--N 1.359 0.996 0 C-N-CA 122.972 0.509 . . . . 0.0 111.647 177.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 85.3 t80 -141.46 -43.52 0.36 Allowed 'General case' 0 CA--C 1.501 -0.905 0 C-N-CA 118.942 -1.103 . . . . 0.0 108.785 -179.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 9.9 p -162.69 150.34 3.77 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.055 0 N-CA-C 107.127 -1.434 . . . . 0.0 107.127 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 70.1 m -123.38 136.98 54.91 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 179.199 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 65.4 tp -117.38 130.76 56.7 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 106.429 -1.693 . . . . 0.0 106.429 -179.724 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -141.67 158.05 44.31 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 -179.55 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -124.46 154.35 17.92 Favored Glycine 0 CA--C 1.49 -1.472 0 N-CA-C 106.968 -2.453 . . . . 0.0 106.968 -179.457 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 93.6 mt -123.25 139.64 53.84 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 -179.12 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -148.84 146.57 28.03 Favored 'General case' 0 N--CA 1.437 -1.083 0 N-CA-C 105.962 -1.866 . . . . 0.0 105.962 178.494 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 175.01 -155.53 20.79 Favored Glycine 0 CA--C 1.492 -1.352 0 N-CA-C 108.217 -1.953 . . . . 0.0 108.217 -179.468 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -148.31 159.49 43.94 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -144.9 167.48 27.2 Favored Glycine 0 CA--C 1.493 -1.338 0 N-CA-C 107.901 -2.08 . . . . 0.0 107.901 -179.291 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 31.3 p80 -149.61 159.64 44.16 Favored 'General case' 0 N--CA 1.439 -1.005 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -124.79 138.06 10.87 Favored Glycine 0 C--N 1.351 1.368 0 N-CA-C 108.059 -2.016 . . . . 0.0 108.059 -179.456 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 75.2 mmtt -133.17 142.12 48.47 Favored 'General case' 0 CA--C 1.497 -1.06 0 N-CA-C 107.064 -1.458 . . . . 0.0 107.064 179.73 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -105.74 -57.23 2.07 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 179.573 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 38.7 mtmm -135.4 150.15 49.82 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 106.679 -1.6 . . . . 0.0 106.679 179.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -107.02 126.47 52.37 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 75.1 m -143.11 36.29 1.37 Allowed 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 -179.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 80.9 p -96.97 1.84 50.81 Favored 'General case' 0 CA--C 1.504 -0.818 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 46.1 pt -83.35 -15.09 11.63 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.805 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 -179.192 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 -69.97 -39.0 76.25 Favored 'General case' 0 CA--C 1.503 -0.853 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 104.09 110.32 3.47 Favored Glycine 0 C--N 1.351 1.388 0 N-CA-C 107.456 -2.258 . . . . 0.0 107.456 179.773 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 13.5 pm0 -153.82 154.83 34.69 Favored 'General case' 0 N--CA 1.436 -1.157 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 85.5 p -94.06 -16.52 23.75 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 -179.088 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -110.33 118.14 35.52 Favored 'General case' 0 CA--C 1.497 -1.075 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 -179.647 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 70.4 m -130.78 150.04 52.14 Favored 'General case' 0 CA--C 1.495 -1.156 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 30.8 mmm180 -118.95 139.51 51.54 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 106.667 -1.605 . . . . 0.0 106.667 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 35.5 t -154.19 146.28 23.68 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -128.51 145.56 51.08 Favored 'General case' 0 CA--C 1.497 -1.074 0 N-CA-C 106.765 -1.569 . . . . 0.0 106.765 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 71.9 p -128.93 156.09 44.27 Favored 'General case' 0 CA--C 1.497 -1.091 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 54.5 m -129.58 151.11 50.55 Favored 'General case' 0 CA--C 1.496 -1.133 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 89.5 mt -92.86 141.37 28.5 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -119.25 129.35 54.88 Favored 'General case' 0 N--CA 1.438 -1.059 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -178.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -135.49 150.04 49.68 Favored 'General case' 0 CA--C 1.494 -1.175 0 N-CA-C 105.985 -1.857 . . . . 0.0 105.985 178.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -173.95 -179.31 44.51 Favored Glycine 0 CA--C 1.491 -1.432 0 N-CA-C 108.796 -1.722 . . . . 0.0 108.796 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -157.27 163.36 38.82 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 105.748 -1.945 . . . . 0.0 105.748 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -161.05 167.37 36.0 Favored Glycine 0 N--CA 1.436 -1.365 0 N-CA-C 108.618 -1.793 . . . . 0.0 108.618 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 87.9 mt -123.09 147.41 46.78 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 -179.714 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 6.5 mt-30 -121.86 127.16 50.19 Favored 'General case' 0 CA--C 1.498 -1.052 0 N-CA-C 106.96 -1.496 . . . . 0.0 106.96 179.168 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 83.9 t80 -133.71 135.7 44.18 Favored 'General case' 0 N--CA 1.439 -1.013 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 61.8 m-20 -116.0 96.92 48.3 Favored Pre-proline 0 N--CA 1.442 -0.838 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 -179.111 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -71.45 -24.06 22.93 Favored 'Trans proline' 0 CA--C 1.496 -1.393 0 C-N-CA 121.746 1.63 . . . . 0.0 112.058 178.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -135.45 153.3 77.7 Favored Pre-proline 0 N--CA 1.434 -1.245 0 N-CA-C 105.73 -1.952 . . . . 0.0 105.73 179.687 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -67.0 -19.7 51.57 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 121.81 1.673 . . . . 0.0 113.566 -179.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -112.52 19.0 17.94 Favored 'General case' 0 N--CA 1.443 -0.783 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 -179.146 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 47.8 t80 -143.85 127.34 16.92 Favored 'General case' 0 CA--C 1.503 -0.864 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 -179.658 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 96.4 t -120.79 129.65 75.43 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.93 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -179.353 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 89.4 mt -100.14 124.01 53.35 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.04 0 N-CA-C 106.719 -1.585 . . . . 0.0 106.719 179.293 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 51.1 m-20 -114.63 123.6 49.72 Favored 'General case' 0 N--CA 1.439 -0.998 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 -179.549 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -129.07 126.42 39.36 Favored 'General case' 0 CA--C 1.496 -1.115 0 N-CA-C 105.754 -1.943 . . . . 0.0 105.754 178.425 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 63.7 m -139.81 150.66 44.98 Favored 'General case' 0 CA--C 1.493 -1.237 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 -179.028 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 90.0 t80 -124.24 126.6 46.36 Favored 'General case' 0 CA--C 1.496 -1.106 0 N-CA-C 105.555 -2.017 . . . . 0.0 105.555 178.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -118.51 130.26 55.82 Favored 'General case' 0 CA--C 1.497 -1.096 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 -179.056 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 82.8 t80 -118.49 126.11 51.32 Favored 'General case' 0 N--CA 1.436 -1.173 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 42.7 t -91.99 121.61 33.72 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 105.82 -1.919 . . . . 0.0 105.82 179.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 60.1 tptt -108.77 119.96 41.07 Favored 'General case' 0 N--CA 1.438 -1.027 0 CA-C-O 121.74 0.781 . . . . 0.0 109.021 -178.156 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 43.2 tp -158.08 144.47 17.49 Favored 'General case' 0 N--CA 1.431 -1.391 0 N-CA-C 104.526 -2.398 . . . . 0.0 104.526 177.754 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -62.44 -38.44 89.76 Favored 'General case' 0 N--CA 1.446 -0.656 0 O-C-N 121.958 -0.464 . . . . 0.0 110.262 -178.36 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -89.52 -28.4 19.65 Favored 'General case' 0 N--CA 1.444 -0.767 0 C-N-CA 120.255 -0.578 . . . . 0.0 111.129 -177.399 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 67.6 t -126.28 125.59 67.88 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.789 0 C-N-CA 119.547 -0.861 . . . . 0.0 109.637 -177.461 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 65.4 mttp -125.6 111.39 14.94 Favored 'General case' 0 CA--C 1.5 -0.966 0 N-CA-C 105.845 -1.909 . . . . 0.0 105.845 178.367 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 86.4 t -133.76 131.16 56.53 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.98 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -178.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -109.06 130.21 9.9 Favored Glycine 0 C--N 1.353 1.493 0 N-CA-C 105.809 -2.916 . . . . 0.0 105.809 178.086 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 89.2 m -130.2 134.89 47.6 Favored 'General case' 0 CA--C 1.498 -1.053 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 -178.794 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 25.4 t90 -107.63 137.36 45.8 Favored 'General case' 0 CA--C 1.5 -0.967 0 N-CA-C 105.665 -1.976 . . . . 0.0 105.665 179.21 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 2.7 mpp? -118.22 131.66 56.36 Favored 'General case' 0 CA--C 1.496 -1.112 0 N-CA-C 108.026 -1.102 . . . . 0.0 108.026 -179.106 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 62.1 tp -128.18 130.62 48.33 Favored 'General case' 0 N--CA 1.437 -1.084 0 N-CA-C 105.833 -1.914 . . . . 0.0 105.833 179.299 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -159.72 -179.06 34.26 Favored Glycine 0 CA--C 1.492 -1.373 0 N-CA-C 108.426 -1.869 . . . . 0.0 108.426 -179.554 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -135.04 153.32 52.1 Favored 'General case' 0 N--CA 1.437 -1.111 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 -179.486 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -116.07 156.04 15.88 Favored Glycine 0 CA--C 1.49 -1.521 0 N-CA-C 108.154 -1.979 . . . . 0.0 108.154 -179.309 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 55.3 p90 -145.35 160.73 41.09 Favored 'General case' 0 N--CA 1.435 -1.194 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 34.5 ptt180 -151.86 159.07 43.98 Favored 'General case' 0 N--CA 1.436 -1.136 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 -179.503 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 72.0 m-85 . . . . . 0 C--O 1.262 1.749 0 CA-C-O 117.906 -1.045 . . . . 0.0 108.637 -179.869 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 . . . . . 0 N--CA 1.489 1.499 0 CA-C-O 120.944 0.402 . . . . 0.0 110.76 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 176.08 -170.55 43.47 Favored Glycine 0 CA--C 1.491 -1.422 0 N-CA-C 107.002 -2.439 . . . . 0.0 107.002 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 49.3 mp0 -120.51 143.24 48.66 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 106.729 -1.582 . . . . 0.0 106.729 179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 63.8 m -129.53 143.44 50.83 Favored 'General case' 0 CA--C 1.495 -1.172 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.404 ' HB2' ' HB3' ' A' ' 34' ' ' ARG . 51.6 m -132.96 144.51 50.17 Favored 'General case' 0 CA--C 1.496 -1.119 0 N-CA-C 106.559 -1.645 . . . . 0.0 106.559 179.404 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 50.4 mm -119.34 126.39 75.29 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.152 0 N-CA-C 106.648 -1.612 . . . . 0.0 106.648 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 64.4 m -122.58 142.03 51.06 Favored 'General case' 0 CA--C 1.495 -1.158 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 46.6 pt -133.12 155.86 41.45 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.148 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 179.593 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -166.36 176.45 41.59 Favored Glycine 0 CA--C 1.491 -1.419 0 N-CA-C 107.949 -2.06 . . . . 0.0 107.949 -179.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -104.05 144.96 30.85 Favored 'General case' 0 CA--C 1.496 -1.115 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 -179.421 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -109.42 135.17 50.9 Favored 'General case' 0 N--CA 1.437 -1.08 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 94.5 mm-40 -129.39 158.62 38.65 Favored 'General case' 0 CA--C 1.498 -1.028 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 6.1 t -125.61 -165.89 1.48 Allowed 'General case' 0 CA--C 1.501 -0.94 0 N-CA-C 106.884 -1.524 . . . . 0.0 106.884 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 85.4 mtp180 -74.02 140.81 45.69 Favored 'General case' 0 N--CA 1.441 -0.902 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 -179.285 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 72.6 t -125.09 129.1 73.34 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.028 0 N-CA-C 106.23 -1.767 . . . . 0.0 106.23 179.668 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 17.5 tptp -84.73 124.31 31.38 Favored 'General case' 0 N--CA 1.441 -0.911 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 -179.412 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -145.01 121.62 11.11 Favored 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 107.022 -1.473 . . . . 0.0 107.022 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 48.5 m-20 -144.58 81.82 1.67 Allowed 'General case' 0 CA--C 1.503 -0.861 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 79.61 22.84 63.58 Favored Glycine 0 C--N 1.352 1.472 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 178.724 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -126.01 154.1 43.44 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 107.19 -1.411 . . . . 0.0 107.19 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 59.7 mtmt -70.91 149.15 47.01 Favored 'General case' 0 CA--C 1.502 -0.898 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 58.1 tp -76.23 121.97 23.69 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -179.399 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 12.9 t0 -161.01 165.21 30.22 Favored 'General case' 0 N--CA 1.435 -1.222 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 99.5 mttt 60.82 49.63 5.94 Favored 'General case' 0 C--N 1.358 0.948 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 179.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 95.4 m-20 -72.02 149.15 92.18 Favored Pre-proline 0 N--CA 1.442 -0.844 0 N-CA-C 107.094 -1.446 . . . . 0.0 107.094 179.367 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -70.57 149.64 62.06 Favored 'Trans proline' 0 CA--C 1.497 -1.357 0 C-N-CA 121.792 1.661 . . . . 0.0 112.756 -179.753 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 2.0 mpp_? -101.26 125.57 47.9 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -156.88 158.83 29.12 Favored Glycine 0 CA--C 1.49 -1.482 0 N-CA-C 106.941 -2.464 . . . . 0.0 106.941 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -146.94 146.34 30.09 Favored 'General case' 0 N--CA 1.437 -1.108 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 -179.652 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 27.9 t-20 -126.87 129.91 49.15 Favored 'General case' 0 N--CA 1.44 -0.956 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 -179.092 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 87.6 mt -114.16 138.47 50.4 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 179.062 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 37.8 ttpt -133.98 131.19 38.67 Favored 'General case' 0 CA--C 1.498 -1.038 0 N-CA-C 107.294 -1.372 . . . . 0.0 107.294 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -111.59 128.85 56.17 Favored 'General case' 0 N--CA 1.437 -1.093 0 N-CA-C 106.263 -1.754 . . . . 0.0 106.263 179.574 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . 0.404 ' HB3' ' HB2' ' A' ' 5' ' ' SER . 79.2 ttt-85 -119.14 127.55 53.44 Favored 'General case' 0 CA--C 1.494 -1.176 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 -179.498 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -124.73 131.81 53.43 Favored 'General case' 0 N--CA 1.435 -1.184 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -116.91 126.49 53.06 Favored 'General case' 0 N--CA 1.436 -1.139 0 N-CA-C 106.917 -1.512 . . . . 0.0 106.917 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 94.0 m-85 -122.95 176.25 6.12 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 106.279 -1.749 . . . . 0.0 106.279 -179.646 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 66.1 t30 -80.53 70.43 7.24 Favored 'General case' 0 N--CA 1.442 -0.86 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 -179.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 33.9 m120 -139.73 169.17 18.23 Favored 'General case' 0 N--CA 1.437 -1.107 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 179.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -85.71 -5.3 59.28 Favored 'General case' 0 N--CA 1.441 -0.892 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 -179.305 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 55.1 m95 -130.49 149.12 52.31 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 -179.51 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.04 159.84 17.11 Favored Glycine 0 C--N 1.354 1.533 0 N-CA-C 107.629 -2.189 . . . . 0.0 107.629 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 81.2 t -123.74 126.93 73.53 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.965 0 N-CA-C 107.051 -1.462 . . . . 0.0 107.051 -179.657 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 41.0 pt -129.71 162.69 36.83 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.974 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -142.61 152.73 24.06 Favored Glycine 0 CA--C 1.492 -1.347 0 N-CA-C 105.558 -3.017 . . . . 0.0 105.558 178.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 40.9 t -145.38 147.05 31.84 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 -179.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 93.2 t80 -127.87 129.54 47.08 Favored 'General case' 0 N--CA 1.439 -1.008 0 N-CA-C 106.09 -1.818 . . . . 0.0 106.09 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -124.59 137.49 54.38 Favored 'General case' 0 CA--C 1.499 -0.985 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 -179.617 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 63.0 tt0 -136.84 128.23 28.32 Favored 'General case' 0 CA--C 1.499 -1.015 0 N-CA-C 107.47 -1.307 . . . . 0.0 107.47 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 91.5 m -127.75 127.97 44.54 Favored 'General case' 0 CA--C 1.496 -1.099 0 N-CA-C 106.313 -1.736 . . . . 0.0 106.313 179.018 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 4.7 tmt_? -149.09 129.11 13.49 Favored 'General case' 0 CA--C 1.498 -1.035 0 N-CA-C 107.32 -1.363 . . . . 0.0 107.32 -179.559 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 4.0 tmt_? -106.13 -67.67 0.92 Allowed 'General case' 0 CA--C 1.502 -0.881 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 155.51 -167.96 33.12 Favored Glycine 0 CA--C 1.493 -1.33 0 N-CA-C 106.832 -2.507 . . . . 0.0 106.832 -179.779 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 88.6 t80 -140.14 115.42 9.87 Favored 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 179.744 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -140.49 140.98 35.42 Favored 'General case' 0 CA--C 1.501 -0.921 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 78.7 mm-40 -109.79 4.77 22.09 Favored 'General case' 0 CA--C 1.503 -0.864 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 179.691 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 70.6 m -120.51 131.73 54.85 Favored 'General case' 0 CA--C 1.496 -1.106 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 -179.708 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 67.2 t -128.69 125.92 64.25 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.014 0 N-CA-C 106.514 -1.662 . . . . 0.0 106.514 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 68.4 m-20 -88.51 -31.68 18.59 Favored 'General case' 0 CA--C 1.502 -0.886 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 179.88 176.0 47.01 Favored Glycine 0 CA--C 1.491 -1.434 0 N-CA-C 106.615 -2.594 . . . . 0.0 106.615 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 60.64 52.13 4.64 Favored 'General case' 0 C--N 1.356 0.851 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 39.8 ttpt -70.43 129.54 39.53 Favored 'General case' 0 N--CA 1.441 -0.909 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 -179.661 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 90.6 mt -116.56 157.78 24.73 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 45.7 pt -111.94 161.23 10.79 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.047 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 61.2 39.43 15.84 Favored 'General case' 0 C--N 1.358 0.938 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 -179.183 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -117.77 -175.99 17.09 Favored Glycine 0 C--N 1.352 1.431 0 N-CA-C 107.223 -2.351 . . . . 0.0 107.223 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 59.48 41.57 19.04 Favored 'General case' 0 C--N 1.357 0.906 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 -179.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 85.0 t80 -139.23 138.57 36.95 Favored 'General case' 0 N--CA 1.436 -1.142 0 N-CA-C 106.435 -1.691 . . . . 0.0 106.435 -179.677 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 18.6 ptpt -128.6 153.45 47.23 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 -179.648 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 49.6 p90 -157.97 160.29 37.38 Favored 'General case' 0 N--CA 1.437 -1.103 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 -179.489 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -127.93 140.18 52.15 Favored 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 105.991 -1.855 . . . . 0.0 105.991 179.83 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 58.6 m -139.28 140.37 37.61 Favored 'General case' 0 CA--C 1.497 -1.091 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 58.7 t -129.09 136.14 60.32 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.125 0 N-CA-C 105.545 -2.021 . . . . 0.0 105.545 179.01 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 80.4 p -139.85 160.37 40.05 Favored 'General case' 0 CA--C 1.499 -1.008 0 N-CA-C 108.747 -0.835 . . . . 0.0 108.747 -179.479 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -156.47 155.29 31.78 Favored 'General case' 0 CA--C 1.497 -1.075 0 N-CA-C 105.772 -1.936 . . . . 0.0 105.772 178.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -178.57 173.16 45.56 Favored Glycine 0 C--N 1.349 1.253 0 N-CA-C 108.711 -1.756 . . . . 0.0 108.711 179.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_endo -82.81 160.46 16.23 Favored 'Trans proline' 0 C--N 1.311 -1.437 0 C-N-CA 122.996 2.464 . . . . 0.0 113.369 179.735 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 66.7 t -115.0 125.86 72.43 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.958 0 N-CA-C 106.876 -1.528 . . . . 0.0 106.876 179.554 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 70.7 t80 -102.31 121.74 42.87 Favored 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 -179.753 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 93.2 mtm-85 -111.83 137.21 50.09 Favored 'General case' 0 CA--C 1.497 -1.085 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 83.7 mt -83.17 -64.03 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.833 0 N-CA-C 106.49 -1.67 . . . . 0.0 106.49 179.418 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.2 p30 179.93 93.61 0.02 OUTLIER 'General case' 0 C--N 1.355 0.82 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 177.51 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 69.4 tt0 36.67 48.46 0.64 Allowed 'General case' 0 C--N 1.362 1.137 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.213 178.397 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 63.9 t80 -141.97 -43.52 0.34 Allowed 'General case' 0 CA--C 1.499 -0.992 0 C-N-CA 119.27 -0.972 . . . . 0.0 108.57 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 11.0 p -161.65 151.08 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.144 0 N-CA-C 106.933 -1.506 . . . . 0.0 106.933 -179.675 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 67.6 m -124.92 140.94 52.46 Favored 'General case' 0 CA--C 1.498 -1.056 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 179.611 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 6.6 tt -129.72 134.92 47.91 Favored 'General case' 0 CA--C 1.494 -1.2 0 N-CA-C 105.801 -1.926 . . . . 0.0 105.801 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 26.9 p90 -134.56 157.45 46.52 Favored 'General case' 0 CA--C 1.494 -1.181 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 -179.403 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -115.07 150.08 18.77 Favored Glycine 0 CA--C 1.491 -1.417 0 N-CA-C 107.167 -2.373 . . . . 0.0 107.167 -179.423 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 88.1 mt -114.12 133.99 55.19 Favored 'General case' 0 CA--C 1.497 -1.058 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 63.1 tp -137.19 132.41 33.86 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 179.489 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -178.47 -152.98 10.81 Favored Glycine 0 CA--C 1.491 -1.423 0 N-CA-C 108.239 -1.944 . . . . 0.0 108.239 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -145.43 156.91 44.04 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 -179.297 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -142.85 142.37 11.44 Favored Glycine 0 CA--C 1.491 -1.457 0 N-CA-C 107.526 -2.23 . . . . 0.0 107.526 -179.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 98.6 m-70 -142.76 151.74 41.57 Favored 'General case' 0 CA--C 1.497 -1.079 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 -179.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -149.65 145.13 12.97 Favored Glycine 0 CA--C 1.492 -1.4 0 N-CA-C 106.972 -2.451 . . . . 0.0 106.972 179.449 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 21.9 ptmt -163.99 164.07 23.23 Favored 'General case' 0 N--CA 1.436 -1.155 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -104.89 128.26 53.05 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 106.906 -1.516 . . . . 0.0 106.906 179.598 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 60.8 tptt -126.56 123.46 37.76 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -120.29 -51.59 2.19 Favored 'General case' 0 CA--C 1.499 -1.003 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 179.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 3.6 p -169.9 -68.58 0.02 OUTLIER 'General case' 0 CA--C 1.5 -0.973 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 36.9 t -151.58 145.83 25.41 Favored 'General case' 0 CA--C 1.497 -1.096 0 N-CA-C 106.578 -1.638 . . . . 0.0 106.578 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 46.3 pt -129.81 160.25 41.02 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.068 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -125.13 137.84 54.17 Favored 'General case' 0 CA--C 1.497 -1.077 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 -179.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 172.8 -179.24 44.41 Favored Glycine 0 CA--C 1.491 -1.448 0 N-CA-C 106.763 -2.535 . . . . 0.0 106.763 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 78.9 mt-30 -131.81 135.54 46.82 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 179.704 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 37.0 t -158.95 145.81 17.19 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 106.49 -1.67 . . . . 0.0 106.49 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -120.33 117.07 26.83 Favored 'General case' 0 CA--C 1.497 -1.059 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 179.677 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 70.6 m -141.75 148.06 38.38 Favored 'General case' 0 CA--C 1.494 -1.177 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 179.617 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -105.64 -66.93 0.95 Allowed 'General case' 0 CA--C 1.5 -0.961 0 N-CA-C 107.111 -1.44 . . . . 0.0 107.111 179.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 70.6 m -143.24 140.75 30.82 Favored 'General case' 0 CA--C 1.496 -1.131 0 N-CA-C 106.764 -1.569 . . . . 0.0 106.764 179.316 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 39.7 ttmt -157.11 136.68 12.23 Favored 'General case' 0 CA--C 1.496 -1.106 0 N-CA-C 107.116 -1.439 . . . . 0.0 107.116 179.691 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 15.2 t -152.6 153.67 33.83 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 106.456 -1.683 . . . . 0.0 106.456 179.608 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 58.2 m -117.94 129.22 55.48 Favored 'General case' 0 CA--C 1.496 -1.133 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 91.6 mt -97.74 147.58 24.22 Favored 'General case' 0 CA--C 1.497 -1.065 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 -179.775 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -116.36 138.54 51.25 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 107.551 -1.277 . . . . 0.0 107.551 -179.312 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -130.4 148.93 52.27 Favored 'General case' 0 CA--C 1.497 -1.081 0 N-CA-C 106.695 -1.595 . . . . 0.0 106.695 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -170.86 178.98 43.07 Favored Glycine 0 N--CA 1.436 -1.331 0 N-CA-C 108.106 -1.998 . . . . 0.0 108.106 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -156.55 163.57 39.21 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 106.169 -1.789 . . . . 0.0 106.169 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -153.0 160.61 29.17 Favored Glycine 0 CA--C 1.491 -1.412 0 N-CA-C 108.847 -1.701 . . . . 0.0 108.847 -179.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 88.3 mt -117.44 144.4 45.05 Favored 'General case' 0 CA--C 1.497 -1.076 0 N-CA-C 106.364 -1.717 . . . . 0.0 106.364 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 46.6 tt0 -130.28 131.38 45.43 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -125.28 146.51 49.52 Favored 'General case' 0 CA--C 1.497 -1.096 0 N-CA-C 106.541 -1.651 . . . . 0.0 106.541 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 29.4 t30 -128.43 79.5 74.05 Favored Pre-proline 0 N--CA 1.439 -1.007 0 N-CA-C 107.424 -1.324 . . . . 0.0 107.424 -179.18 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.79 -28.43 16.83 Favored 'Trans proline' 0 CA--C 1.497 -1.33 0 C-N-CA 121.869 1.713 . . . . 0.0 112.612 179.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -137.58 150.48 68.42 Favored Pre-proline 0 N--CA 1.437 -1.115 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -70.14 -18.55 35.14 Favored 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 121.761 1.64 . . . . 0.0 113.501 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 34.8 m120 -108.68 15.35 23.76 Favored 'General case' 0 N--CA 1.442 -0.868 0 N-CA-C 109.157 -0.682 . . . . 0.0 109.157 -179.068 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -152.16 117.94 5.43 Favored 'General case' 0 CA--C 1.502 -0.878 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 67.5 t -112.43 129.55 67.77 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.97 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 -179.552 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 84.9 mt -113.86 127.8 71.08 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.029 0 N-CA-C 107.032 -1.469 . . . . 0.0 107.032 -179.534 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -141.5 160.43 40.17 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -147.79 146.42 29.15 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 105.382 -2.081 . . . . 0.0 105.382 179.122 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 55.4 m -150.27 164.02 36.8 Favored 'General case' 0 CA--C 1.494 -1.182 0 C-N-CA 119.207 -0.997 . . . . 0.0 109.107 -178.741 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 51.7 p90 -139.59 148.84 43.08 Favored 'General case' 0 N--CA 1.435 -1.21 0 N-CA-C 106.23 -1.767 . . . . 0.0 106.23 178.453 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -139.22 135.65 34.16 Favored 'General case' 0 N--CA 1.438 -1.051 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 -179.465 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -126.51 138.46 53.49 Favored 'General case' 0 CA--C 1.496 -1.114 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 178.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 66.8 m -130.02 143.93 51.06 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 179.72 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 30.2 mtpp -101.96 118.11 36.22 Favored 'General case' 0 CA--C 1.498 -1.044 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 -179.561 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 5.0 mp -126.18 140.28 52.68 Favored 'General case' 0 N--CA 1.438 -1.031 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 179.237 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -65.48 -39.59 92.13 Favored 'General case' 0 N--CA 1.444 -0.733 0 C-N-CA 120.74 -0.384 . . . . 0.0 110.015 -179.024 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -63.55 -50.01 71.19 Favored 'General case' 0 C--N 1.355 0.804 0 C-N-CA 120.461 -0.496 . . . . 0.0 110.734 -177.668 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 15.6 m -151.54 160.44 3.67 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.018 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 -178.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 40.0 ttpt -84.36 128.96 34.89 Favored 'General case' 0 CA--C 1.501 -0.935 0 N-CA-C 105.786 -1.931 . . . . 0.0 105.786 178.244 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 71.1 t -111.94 122.11 65.65 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.0 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 -178.115 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -125.53 131.21 7.54 Favored Glycine 0 C--N 1.351 1.37 0 N-CA-C 105.701 -2.959 . . . . 0.0 105.701 178.498 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 87.0 m -127.48 130.53 49.39 Favored 'General case' 0 CA--C 1.496 -1.125 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 -178.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 28.3 m-90 -120.85 140.44 51.76 Favored 'General case' 0 CA--C 1.495 -1.15 0 N-CA-C 105.31 -2.107 . . . . 0.0 105.31 178.225 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -144.86 151.24 38.43 Favored 'General case' 0 N--CA 1.438 -1.05 0 C-N-CA 119.183 -1.007 . . . . 0.0 108.86 -179.127 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 2.3 tt -146.86 143.76 28.8 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 105.874 -1.899 . . . . 0.0 105.874 179.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -168.33 -164.32 23.82 Favored Glycine 0 CA--C 1.491 -1.408 0 N-CA-C 108.77 -1.732 . . . . 0.0 108.77 -179.242 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -146.2 163.83 34.19 Favored 'General case' 0 N--CA 1.435 -1.218 0 N-CA-C 106.571 -1.641 . . . . 0.0 106.571 -179.35 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -144.6 171.97 25.72 Favored Glycine 0 CA--C 1.49 -1.502 0 N-CA-C 108.544 -1.822 . . . . 0.0 108.544 -179.235 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 92.3 m-85 -130.88 149.51 52.48 Favored 'General case' 0 N--CA 1.437 -1.084 0 N-CA-C 107.03 -1.47 . . . . 0.0 107.03 -179.608 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 58.9 ttp180 -89.25 129.08 35.87 Favored 'General case' 0 CA--C 1.501 -0.916 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 58.0 m-85 . . . . . 0 C--O 1.262 1.73 0 CA-C-O 117.992 -1.004 . . . . 0.0 108.317 -179.555 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 49.8 tt0 . . . . . 0 N--CA 1.487 1.399 0 CA-C-O 121.452 0.644 . . . . 0.0 110.385 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -179.5 179.43 48.86 Favored Glycine 0 CA--C 1.492 -1.399 0 N-CA-C 106.943 -2.463 . . . . 0.0 106.943 179.834 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -115.32 126.88 55.0 Favored 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 107.274 -1.38 . . . . 0.0 107.274 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 71.1 m -129.27 152.12 49.19 Favored 'General case' 0 CA--C 1.494 -1.199 0 N-CA-C 106.646 -1.613 . . . . 0.0 106.646 179.592 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 61.7 m -125.37 142.38 51.53 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 85.7 mt -119.46 130.69 73.7 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.107 0 N-CA-C 106.285 -1.746 . . . . 0.0 106.285 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 47.7 t -130.69 137.34 49.5 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 -179.608 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 47.1 pt -128.65 157.65 41.22 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.093 0 N-CA-C 106.784 -1.562 . . . . 0.0 106.784 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -173.01 -161.73 23.9 Favored Glycine 0 CA--C 1.491 -1.435 0 N-CA-C 107.618 -2.193 . . . . 0.0 107.618 -179.655 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 41.2 p90 -138.38 158.39 44.38 Favored 'General case' 0 N--CA 1.438 -1.062 0 N-CA-C 106.784 -1.561 . . . . 0.0 106.784 -179.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -112.4 138.37 49.23 Favored 'General case' 0 N--CA 1.44 -0.938 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 -179.128 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 21.0 pt20 -131.29 163.38 27.93 Favored 'General case' 0 CA--C 1.502 -0.886 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 179.494 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 6.7 t -134.45 -157.05 0.78 Allowed 'General case' 0 CA--C 1.503 -0.845 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 -179.706 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -82.66 107.93 15.65 Favored 'General case' 0 CA--C 1.501 -0.929 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 -179.302 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 75.5 t -127.6 128.01 69.2 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.068 0 N-CA-C 106.386 -1.709 . . . . 0.0 106.386 179.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -152.18 160.92 43.29 Favored 'General case' 0 N--CA 1.437 -1.117 0 N-CA-C 107.47 -1.307 . . . . 0.0 107.47 -179.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -137.81 165.54 26.2 Favored 'General case' 0 N--CA 1.438 -1.027 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 44.7 p-10 -91.86 11.93 23.23 Favored 'General case' 0 N--CA 1.444 -0.74 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 -179.573 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -154.42 171.39 32.91 Favored Glycine 0 CA--C 1.492 -1.374 0 N-CA-C 106.666 -2.574 . . . . 0.0 106.666 179.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -103.91 102.62 12.41 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 -179.592 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 54.2 tptt -160.43 140.81 11.58 Favored 'General case' 0 N--CA 1.436 -1.164 0 N-CA-C 106.107 -1.812 . . . . 0.0 106.107 179.521 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 91.8 mt -88.63 66.17 8.04 Favored 'General case' 0 CA--C 1.502 -0.882 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -179.683 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -65.63 -39.77 91.81 Favored 'General case' 0 C--N 1.355 0.847 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 179.409 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 26.6 pttm -158.58 165.7 33.86 Favored 'General case' 0 N--CA 1.435 -1.188 0 N-CA-C 106.92 -1.511 . . . . 0.0 106.92 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 69.0 m-80 -129.52 153.86 80.73 Favored Pre-proline 0 N--CA 1.438 -1.047 0 N-CA-C 106.291 -1.744 . . . . 0.0 106.291 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -59.29 141.72 98.16 Favored 'Trans proline' 0 CA--C 1.501 -1.174 0 C-N-CA 122.158 1.906 . . . . 0.0 112.832 179.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -119.12 127.04 52.98 Favored 'General case' 0 CA--C 1.497 -1.087 0 N-CA-C 107.37 -1.345 . . . . 0.0 107.37 -179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -171.48 160.84 33.04 Favored Glycine 0 N--CA 1.435 -1.424 0 N-CA-C 107.103 -2.399 . . . . 0.0 107.103 179.521 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 -135.65 148.81 49.11 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 23.3 t-20 -143.51 121.03 11.73 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 179.47 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 67.2 tp -123.65 126.26 46.28 Favored 'General case' 0 CA--C 1.499 -0.998 0 N-CA-C 106.997 -1.482 . . . . 0.0 106.997 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 17.1 mtpp -125.95 148.33 49.27 Favored 'General case' 0 CA--C 1.501 -0.925 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 40.3 t80 -137.44 130.47 30.54 Favored 'General case' 0 N--CA 1.441 -0.905 0 N-CA-C 106.285 -1.746 . . . . 0.0 106.285 179.343 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 7.7 tmm_? -102.28 127.86 49.07 Favored 'General case' 0 CA--C 1.5 -0.952 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 -179.427 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -108.4 137.63 46.03 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 106.679 -1.601 . . . . 0.0 106.679 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -88.98 75.48 8.0 Favored 'General case' 0 N--CA 1.442 -0.868 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 91.7 t80 -63.51 -48.1 78.99 Favored 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 179.077 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 -154.76 162.49 41.1 Favored 'General case' 0 N--CA 1.436 -1.164 0 N-CA-C 105.719 -1.956 . . . . 0.0 105.719 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 9.5 p-10 -79.0 -30.09 44.08 Favored 'General case' 0 N--CA 1.44 -0.933 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 -179.633 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -71.08 -41.94 70.01 Favored 'General case' 0 C--N 1.356 0.887 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 -179.327 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 23.0 m-90 -140.14 139.22 35.72 Favored 'General case' 0 CA--C 1.495 -1.144 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -110.52 169.25 13.34 Favored Glycine 0 C--N 1.349 1.258 0 N-CA-C 107.466 -2.254 . . . . 0.0 107.466 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 99.6 t -130.76 131.56 64.53 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.028 0 N-CA-C 106.777 -1.564 . . . . 0.0 106.777 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 38.5 pt -124.9 158.86 32.2 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.152 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 179.734 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -140.03 142.23 12.36 Favored Glycine 0 CA--C 1.489 -1.548 0 N-CA-C 105.267 -3.133 . . . . 0.0 105.267 178.453 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 89.6 p -146.29 151.1 37.0 Favored 'General case' 0 CA--C 1.497 -1.077 0 C-N-CA 119.112 -1.035 . . . . 0.0 109.187 -179.3 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -121.4 141.45 50.96 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 105.745 -1.946 . . . . 0.0 105.745 179.271 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -135.91 141.35 44.53 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 -179.53 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 72.4 mt-30 -131.73 138.37 48.61 Favored 'General case' 0 CA--C 1.495 -1.15 0 N-CA-C 106.402 -1.703 . . . . 0.0 106.402 179.327 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 84.7 m -132.67 129.91 39.43 Favored 'General case' 0 CA--C 1.497 -1.076 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 179.634 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 79.8 ttt180 -126.15 129.94 50.04 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.192 -1.411 . . . . 0.0 107.192 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 85.4 mtp180 -129.34 140.5 51.36 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 106.706 -1.59 . . . . 0.0 106.706 179.409 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -179.94 172.29 43.85 Favored Glycine 0 CA--C 1.491 -1.467 0 N-CA-C 107.326 -2.31 . . . . 0.0 107.326 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 90.5 t80 -137.42 129.94 29.81 Favored 'General case' 0 N--CA 1.438 -1.067 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 -179.8 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -94.09 123.3 37.38 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 -179.67 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -95.23 94.05 7.66 Favored 'General case' 0 N--CA 1.439 -1.002 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 69.5 m -93.55 -5.8 48.13 Favored 'General case' 0 CA--C 1.501 -0.933 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 179.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.2 m -132.77 159.68 43.03 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.097 0 N-CA-C 106.943 -1.502 . . . . 0.0 106.943 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 67.6 t0 -89.84 102.26 14.96 Favored 'General case' 0 N--CA 1.439 -0.976 0 N-CA-C 106.774 -1.565 . . . . 0.0 106.774 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -133.79 41.06 1.51 Allowed Glycine 0 CA--C 1.491 -1.434 0 N-CA-C 106.992 -2.443 . . . . 0.0 106.992 179.626 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 5.3 t80 76.51 -171.61 0.09 Allowed 'General case' 0 C--N 1.357 0.923 0 N-CA-C 107.289 -1.375 . . . . 0.0 107.289 -179.672 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 18.0 tppt? -91.51 118.55 30.68 Favored 'General case' 0 CA--C 1.499 -0.998 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 88.9 mt -119.63 139.25 52.49 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 45.8 pt -130.53 153.61 39.32 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.055 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 53.3 t0 -164.92 88.62 0.47 Allowed 'General case' 0 N--CA 1.436 -1.151 0 N-CA-C 106.158 -1.793 . . . . 0.0 106.158 179.718 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 85.66 -91.97 1.74 Allowed Glycine 0 C--N 1.349 1.3 0 N-CA-C 107.531 -2.228 . . . . 0.0 107.531 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 59.24 43.0 17.56 Favored 'General case' 0 C--N 1.359 0.98 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -149.66 141.67 23.88 Favored 'General case' 0 N--CA 1.434 -1.251 0 N-CA-C 106.25 -1.759 . . . . 0.0 106.25 -179.311 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -102.16 139.37 37.87 Favored 'General case' 0 CA--C 1.496 -1.121 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 -179.722 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -126.88 139.97 52.69 Favored 'General case' 0 CA--C 1.497 -1.06 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -128.82 143.18 50.84 Favored 'General case' 0 CA--C 1.495 -1.148 0 N-CA-C 105.877 -1.897 . . . . 0.0 105.877 179.627 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 40.0 t -149.93 145.15 26.33 Favored 'General case' 0 CA--C 1.496 -1.098 0 N-CA-C 107.9 -1.148 . . . . 0.0 107.9 -179.346 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.4 p -136.64 137.47 47.5 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.116 0 N-CA-C 105.694 -1.965 . . . . 0.0 105.694 178.663 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 74.4 p -142.09 160.88 39.35 Favored 'General case' 0 CA--C 1.497 -1.076 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 -179.235 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -155.09 157.93 38.27 Favored 'General case' 0 N--CA 1.433 -1.318 0 N-CA-C 105.539 -2.023 . . . . 0.0 105.539 178.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -179.96 177.0 47.82 Favored Glycine 0 N--CA 1.437 -1.268 0 N-CA-C 108.909 -1.676 . . . . 0.0 108.909 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 68.5 Cg_endo -81.86 162.05 18.57 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 123.101 2.534 . . . . 0.0 114.012 -179.488 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 60.1 t -115.52 127.12 73.21 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.045 0 N-CA-C 106.079 -1.823 . . . . 0.0 106.079 179.264 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 83.9 t80 -128.75 121.99 29.63 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 -179.317 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 90.9 mtm180 -112.06 141.93 45.12 Favored 'General case' 0 CA--C 1.497 -1.058 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 49.3 mm -74.35 -64.23 0.87 Allowed 'Isoleucine or valine' 0 CA--C 1.503 -0.839 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 179.764 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 66.5 t30 179.86 94.92 0.02 OUTLIER 'General case' 0 CA--C 1.501 -0.93 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 178.258 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 23.0 tt0 37.57 48.47 0.91 Allowed 'General case' 0 C--N 1.36 1.051 0 C-N-CA 122.973 0.509 . . . . 0.0 110.976 178.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 73.7 t80 -141.8 -43.3 0.35 Allowed 'General case' 0 CA--C 1.5 -0.973 0 C-N-CA 119.427 -0.909 . . . . 0.0 108.574 -179.631 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 11.1 p -159.17 149.55 7.19 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.138 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 -179.591 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 42.4 t -117.89 129.28 55.54 Favored 'General case' 0 N--CA 1.438 -1.044 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 87.8 mt -109.63 140.14 43.81 Favored 'General case' 0 CA--C 1.497 -1.068 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 -179.412 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -128.01 142.4 51.24 Favored 'General case' 0 CA--C 1.493 -1.23 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 -179.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -111.86 134.48 12.1 Favored Glycine 0 CA--C 1.489 -1.559 0 N-CA-C 105.683 -2.967 . . . . 0.0 105.683 178.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 89.8 mt -120.6 134.67 55.26 Favored 'General case' 0 CA--C 1.497 -1.085 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 -179.071 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -150.78 149.44 29.75 Favored 'General case' 0 N--CA 1.436 -1.17 0 N-CA-C 105.875 -1.898 . . . . 0.0 105.875 178.69 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 171.89 -146.36 9.31 Favored Glycine 0 CA--C 1.49 -1.511 0 N-CA-C 107.782 -2.127 . . . . 0.0 107.782 -179.48 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -141.54 157.21 45.41 Favored 'General case' 0 N--CA 1.435 -1.206 0 N-CA-C 107.57 -1.271 . . . . 0.0 107.57 -178.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -130.72 154.04 20.53 Favored Glycine 0 CA--C 1.493 -1.294 0 N-CA-C 107.35 -2.3 . . . . 0.0 107.35 -179.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 79.4 m80 -136.62 152.64 50.66 Favored 'General case' 0 N--CA 1.437 -1.111 0 N-CA-C 107.164 -1.421 . . . . 0.0 107.164 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -121.8 146.68 17.12 Favored Glycine 0 CA--C 1.491 -1.423 0 N-CA-C 106.899 -2.481 . . . . 0.0 106.899 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 28.9 tptp -138.19 131.96 31.13 Favored 'General case' 0 N--CA 1.438 -1.031 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 -179.367 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -85.4 155.93 21.07 Favored 'General case' 0 N--CA 1.439 -0.979 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 179.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 62.8 mtpt -72.9 150.66 42.41 Favored 'General case' 0 CA--C 1.503 -0.857 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -86.44 119.79 27.08 Favored 'General case' 0 CA--C 1.499 -1.007 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 39.1 t -169.71 -80.11 0.02 OUTLIER 'General case' 0 N--CA 1.438 -1.055 0 N-CA-C 106.772 -1.566 . . . . 0.0 106.772 179.589 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 37.1 t -155.71 145.05 20.9 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 20.5 tt -146.93 138.07 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.057 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 88.4 t80 -143.36 122.15 12.66 Favored 'General case' 0 N--CA 1.436 -1.129 0 N-CA-C 106.367 -1.716 . . . . 0.0 106.367 179.581 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 155.96 -168.76 33.5 Favored Glycine 0 CA--C 1.491 -1.407 0 N-CA-C 107.119 -2.393 . . . . 0.0 107.119 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 99.0 mt-30 -131.35 147.77 52.6 Favored 'General case' 0 CA--C 1.497 -1.064 0 N-CA-C 106.695 -1.594 . . . . 0.0 106.695 179.753 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 38.5 t -150.29 143.2 24.77 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -144.9 132.84 21.3 Favored 'General case' 0 N--CA 1.436 -1.142 0 N-CA-C 106.679 -1.6 . . . . 0.0 106.679 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 34.8 t -149.79 148.41 29.17 Favored 'General case' 0 CA--C 1.496 -1.122 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 96.3 mtm-85 -89.06 -5.44 57.86 Favored 'General case' 0 N--CA 1.442 -0.871 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 -179.334 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 42.7 t -151.01 140.32 21.35 Favored 'General case' 0 CA--C 1.498 -1.026 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -100.87 1.79 40.33 Favored 'General case' 0 CA--C 1.502 -0.891 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 179.141 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 92.3 m -118.16 130.97 56.42 Favored 'General case' 0 CA--C 1.497 -1.072 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 -179.344 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 67.8 m -107.2 147.27 30.35 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -83.67 150.16 26.04 Favored 'General case' 0 N--CA 1.442 -0.838 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 -179.596 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -130.07 139.29 50.98 Favored 'General case' 0 N--CA 1.439 -0.993 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 179.696 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 90.7 t80 -145.12 141.95 29.22 Favored 'General case' 0 CA--C 1.499 -1.018 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -166.66 -171.46 32.81 Favored Glycine 0 N--CA 1.437 -1.293 0 N-CA-C 108.363 -1.895 . . . . 0.0 108.363 -179.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -149.56 161.49 42.05 Favored 'General case' 0 N--CA 1.436 -1.126 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -133.1 148.41 19.31 Favored Glycine 0 C--N 1.35 1.345 0 N-CA-C 108.221 -1.952 . . . . 0.0 108.221 -179.633 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -124.22 143.9 50.26 Favored 'General case' 0 CA--C 1.498 -1.021 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 179.663 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 40.4 tt0 -143.04 139.05 30.38 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 -179.322 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -126.11 141.49 51.92 Favored 'General case' 0 N--CA 1.436 -1.131 0 N-CA-C 106.139 -1.801 . . . . 0.0 106.139 178.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -128.81 74.76 80.59 Favored Pre-proline 0 CA--C 1.503 -0.855 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 -179.087 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.22 -30.35 20.28 Favored 'Trans proline' 0 CA--C 1.499 -1.246 0 C-N-CA 121.496 1.464 . . . . 0.0 112.344 179.265 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 79.3 m80 -139.78 151.52 66.04 Favored Pre-proline 0 N--CA 1.437 -1.083 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 179.483 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 94.4 Cg_endo -78.82 -12.07 15.01 Favored 'Trans proline' 0 C--N 1.312 -1.366 0 C-N-CA 121.943 1.762 . . . . 0.0 112.84 179.203 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 24.2 m120 -64.5 -38.68 91.88 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.118 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 50.6 p90 -149.41 158.56 44.28 Favored 'General case' 0 CA--C 1.5 -0.953 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 -178.752 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 62.1 t -125.75 131.9 71.41 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.897 0 N-CA-C 107.424 -1.324 . . . . 0.0 107.424 -179.063 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 86.1 mt -109.43 129.05 64.91 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.986 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -140.52 160.54 39.78 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 -179.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -146.99 147.12 30.38 Favored 'General case' 0 N--CA 1.436 -1.126 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 69.1 m -142.88 159.85 41.45 Favored 'General case' 0 CA--C 1.492 -1.262 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 -179.391 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 51.2 p90 -146.37 149.46 33.81 Favored 'General case' 0 N--CA 1.435 -1.176 0 N-CA-C 106.9 -1.519 . . . . 0.0 106.9 179.033 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -138.05 145.8 42.22 Favored 'General case' 0 CA--C 1.498 -1.052 0 N-CA-C 107.274 -1.38 . . . . 0.0 107.274 179.616 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 78.5 m-85 -129.72 144.37 51.26 Favored 'General case' 0 CA--C 1.496 -1.111 0 N-CA-C 107.494 -1.299 . . . . 0.0 107.494 179.09 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 34.7 t -140.79 137.92 33.71 Favored 'General case' 0 N--CA 1.437 -1.087 0 N-CA-C 105.388 -2.079 . . . . 0.0 105.388 178.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 59.9 mtpt -115.89 131.15 57.02 Favored 'General case' 0 CA--C 1.496 -1.134 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 -178.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 5.0 mp -125.05 154.87 40.65 Favored 'General case' 0 N--CA 1.435 -1.206 0 N-CA-C 105.312 -2.107 . . . . 0.0 105.312 178.21 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -63.18 -38.1 89.83 Favored 'General case' 0 N--CA 1.445 -0.722 0 C-N-CA 120.602 -0.439 . . . . 0.0 110.036 -178.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 69.0 m-20 -76.71 -47.81 20.77 Favored 'General case' 0 C--N 1.352 0.702 0 C-N-CA 119.998 -0.681 . . . . 0.0 111.136 -177.623 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 31.0 m -143.56 166.49 13.91 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.91 0 C-N-CA 119.818 -0.753 . . . . 0.0 109.282 -177.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 35.5 mmtp -106.73 140.45 39.57 Favored 'General case' 0 CA--C 1.5 -0.944 0 N-CA-C 105.585 -2.006 . . . . 0.0 105.585 178.479 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 99.1 t -124.2 127.74 73.51 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.956 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -178.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -123.78 132.99 8.64 Favored Glycine 0 C--N 1.352 1.427 0 N-CA-C 105.972 -2.851 . . . . 0.0 105.972 178.529 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 86.3 m -127.05 130.75 50.56 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 -179.029 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 91.6 m95 -114.65 138.93 50.08 Favored 'General case' 0 CA--C 1.497 -1.076 0 N-CA-C 106.136 -1.801 . . . . 0.0 106.136 179.12 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 2.1 mpt? -127.68 139.83 52.46 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -179.292 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 63.1 tp -133.6 132.78 41.22 Favored 'General case' 0 CA--C 1.497 -1.059 0 N-CA-C 105.707 -1.96 . . . . 0.0 105.707 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -163.15 -172.23 30.38 Favored Glycine 0 C--N 1.35 1.354 0 N-CA-C 108.807 -1.717 . . . . 0.0 108.807 -179.241 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -135.54 154.25 51.44 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 -179.581 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -115.74 149.88 18.75 Favored Glycine 0 CA--C 1.492 -1.372 0 N-CA-C 108.411 -1.876 . . . . 0.0 108.411 -179.013 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 85.9 t80 -129.78 128.77 43.06 Favored 'General case' 0 N--CA 1.437 -1.08 0 N-CA-C 106.16 -1.792 . . . . 0.0 106.16 179.476 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 82.7 mtp180 -80.47 137.58 36.48 Favored 'General case' 0 CA--C 1.501 -0.938 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 -179.413 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 . . . . . 0 C--O 1.262 1.733 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.586 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 . . . . . 0 N--CA 1.489 1.487 0 CA-C-O 120.887 0.375 . . . . 0.0 110.648 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -179.74 178.71 48.72 Favored Glycine 0 CA--C 1.493 -1.32 0 N-CA-C 106.879 -2.488 . . . . 0.0 106.879 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -133.04 142.98 49.08 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 65.6 m -139.52 143.63 37.52 Favored 'General case' 0 CA--C 1.495 -1.146 0 N-CA-C 106.572 -1.64 . . . . 0.0 106.572 179.037 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 64.2 m -129.95 147.95 51.76 Favored 'General case' 0 CA--C 1.497 -1.058 0 N-CA-C 107.37 -1.344 . . . . 0.0 107.37 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 85.4 mt -118.41 130.33 73.41 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.015 0 N-CA-C 106.498 -1.667 . . . . 0.0 106.498 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 48.4 t -135.32 140.71 45.31 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 -179.533 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 46.6 pt -130.77 155.58 41.98 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.124 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 179.487 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -164.63 179.67 39.22 Favored Glycine 0 CA--C 1.49 -1.489 0 N-CA-C 107.924 -2.07 . . . . 0.0 107.924 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -126.31 147.0 49.8 Favored 'General case' 0 CA--C 1.494 -1.174 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 -179.609 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -99.26 129.86 45.51 Favored 'General case' 0 N--CA 1.438 -1.075 0 N-CA-C 106.844 -1.539 . . . . 0.0 106.844 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 75.5 mt-30 -129.36 147.94 51.24 Favored 'General case' 0 CA--C 1.498 -1.021 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 -179.435 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 35.3 t -154.45 141.98 19.76 Favored 'General case' 0 CA--C 1.497 -1.058 0 N-CA-C 106.577 -1.638 . . . . 0.0 106.577 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 30.6 tpt180 -154.51 137.88 15.82 Favored 'General case' 0 N--CA 1.436 -1.138 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 70.3 t -108.67 119.55 58.45 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.061 0 N-CA-C 106.005 -1.85 . . . . 0.0 106.005 179.319 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -82.56 136.84 34.74 Favored 'General case' 0 CA--C 1.498 -1.027 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 -179.088 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -133.6 -67.36 0.61 Allowed 'General case' 0 CA--C 1.498 -1.037 0 N-CA-C 106.786 -1.561 . . . . 0.0 106.786 179.33 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 -94.19 -29.52 15.07 Favored 'General case' 0 N--CA 1.441 -0.885 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 179.482 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 174.92 -171.22 44.41 Favored Glycine 0 CA--C 1.492 -1.358 0 N-CA-C 106.912 -2.475 . . . . 0.0 106.912 -179.836 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 87.2 t80 -105.07 119.92 40.22 Favored 'General case' 0 CA--C 1.501 -0.941 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 32.2 mmmt -131.85 149.38 52.47 Favored 'General case' 0 CA--C 1.498 -1.028 0 N-CA-C 107.341 -1.355 . . . . 0.0 107.341 -179.614 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 87.2 mt -103.19 76.63 1.46 Allowed 'General case' 0 CA--C 1.5 -0.975 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 45.7 t0 -154.96 111.54 3.25 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 -179.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 31.1 ttpt 70.71 73.45 0.2 Allowed 'General case' 0 C--N 1.357 0.903 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 179.347 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -127.23 149.62 70.12 Favored Pre-proline 0 CA--C 1.5 -0.956 0 N-CA-C 106.487 -1.671 . . . . 0.0 106.487 179.761 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_endo -73.04 153.91 52.39 Favored 'Trans proline' 0 CA--C 1.499 -1.258 0 C-N-CA 121.825 1.683 . . . . 0.0 112.522 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 22.7 tpt180 -136.33 135.36 38.82 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 106.25 -1.759 . . . . 0.0 106.25 -179.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -135.35 156.29 22.58 Favored Glycine 0 CA--C 1.493 -1.334 0 N-CA-C 107.621 -2.192 . . . . 0.0 107.621 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -111.18 141.53 44.57 Favored 'General case' 0 CA--C 1.496 -1.122 0 N-CA-C 106.574 -1.639 . . . . 0.0 106.574 -179.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -136.6 126.47 25.8 Favored 'General case' 0 N--CA 1.439 -1.016 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 -179.521 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 88.6 mt -114.51 139.0 49.92 Favored 'General case' 0 CA--C 1.496 -1.102 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 178.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 40.5 ttpt -136.7 132.86 35.47 Favored 'General case' 0 CA--C 1.5 -0.967 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 -179.292 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -123.5 140.38 53.07 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 106.697 -1.594 . . . . 0.0 106.697 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 2.6 tmt_? -121.97 132.42 54.52 Favored 'General case' 0 CA--C 1.498 -1.051 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 -179.233 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -125.91 138.37 53.78 Favored 'General case' 0 N--CA 1.437 -1.094 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 179.597 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -90.97 102.4 15.17 Favored 'General case' 0 N--CA 1.439 -1.001 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 -179.441 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 89.8 t80 -63.7 -47.44 81.15 Favored 'General case' 0 CA--C 1.505 -0.756 0 N-CA-C 108.204 -1.036 . . . . 0.0 108.204 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.9 t-20 -156.06 175.15 14.34 Favored 'General case' 0 N--CA 1.436 -1.141 0 N-CA-C 106.574 -1.639 . . . . 0.0 106.574 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -83.23 68.69 9.72 Favored 'General case' 0 N--CA 1.443 -0.822 0 N-CA-C 107.845 -1.168 . . . . 0.0 107.845 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -171.32 -62.33 0.02 OUTLIER 'General case' 0 N--CA 1.439 -1.025 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 179.745 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 41.8 m0 -126.28 147.58 49.68 Favored 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 -179.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -123.27 172.05 15.99 Favored Glycine 0 CA--C 1.492 -1.372 0 N-CA-C 107.076 -2.41 . . . . 0.0 107.076 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.8 m -130.88 152.5 37.66 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.148 0 N-CA-C 107.049 -1.463 . . . . 0.0 107.049 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 33.1 pt -133.12 160.24 42.65 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.151 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -136.68 139.86 10.98 Favored Glycine 0 CA--C 1.489 -1.553 0 N-CA-C 104.658 -3.377 . . . . 0.0 104.658 177.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 44.9 t -145.38 144.61 30.77 Favored 'General case' 0 CA--C 1.498 -1.045 0 C-N-CA 119.257 -0.977 . . . . 0.0 108.431 -178.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -127.1 142.36 51.54 Favored 'General case' 0 N--CA 1.437 -1.104 0 N-CA-C 106.057 -1.831 . . . . 0.0 106.057 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -137.77 143.17 40.98 Favored 'General case' 0 CA--C 1.497 -1.069 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 76.3 mt-30 -132.24 137.11 47.42 Favored 'General case' 0 CA--C 1.498 -1.038 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 179.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 71.8 p -135.3 159.04 42.81 Favored 'General case' 0 CA--C 1.501 -0.938 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 179.667 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 78.9 ttt180 -142.31 135.63 28.9 Favored 'General case' 0 N--CA 1.439 -0.998 0 N-CA-C 106.665 -1.605 . . . . 0.0 106.665 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 82.3 mtp180 -119.39 129.3 54.74 Favored 'General case' 0 CA--C 1.499 -0.995 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -174.83 164.76 35.67 Favored Glycine 0 CA--C 1.492 -1.364 0 N-CA-C 106.618 -2.593 . . . . 0.0 106.618 179.477 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 94.8 m-85 -110.49 -5.38 15.15 Favored 'General case' 0 CA--C 1.5 -0.958 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 81.2 mm-40 -136.48 146.23 46.04 Favored 'General case' 0 CA--C 1.497 -1.076 0 N-CA-C 107.354 -1.351 . . . . 0.0 107.354 -179.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -101.91 7.44 41.5 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 107.816 -1.179 . . . . 0.0 107.816 179.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 34.6 t -147.5 150.91 35.45 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 -179.461 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 34.9 m -126.85 158.56 37.47 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.002 0 N-CA-C 107.292 -1.373 . . . . 0.0 107.292 -179.463 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 13.9 t0 -159.87 166.18 30.75 Favored 'General case' 0 N--CA 1.435 -1.177 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 -179.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -78.35 164.72 51.22 Favored Glycine 0 C--N 1.35 1.356 0 N-CA-C 108.059 -2.016 . . . . 0.0 108.059 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 63.86 32.28 13.44 Favored 'General case' 0 C--N 1.356 0.883 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 29.6 tptp -148.66 133.08 17.59 Favored 'General case' 0 N--CA 1.437 -1.122 0 N-CA-C 106.917 -1.512 . . . . 0.0 106.917 179.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 7.6 mp -103.8 118.97 37.94 Favored 'General case' 0 CA--C 1.498 -1.042 0 N-CA-C 106.656 -1.609 . . . . 0.0 106.656 179.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 82.7 mt -124.73 125.58 70.14 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.01 0 N-CA-C 107.137 -1.431 . . . . 0.0 107.137 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -100.4 116.85 33.34 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 179.169 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 149.53 -142.91 10.2 Favored Glycine 0 CA--C 1.492 -1.391 0 N-CA-C 106.965 -2.454 . . . . 0.0 106.965 -179.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 26.2 t0 71.11 47.49 0.4 Allowed 'General case' 0 C--N 1.355 0.828 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.509 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -113.12 136.75 52.38 Favored 'General case' 0 CA--C 1.498 -1.033 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 38.3 mtmm -119.53 141.3 49.34 Favored 'General case' 0 CA--C 1.495 -1.137 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -129.45 144.01 51.07 Favored 'General case' 0 CA--C 1.496 -1.114 0 N-CA-C 107.332 -1.358 . . . . 0.0 107.332 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 90.3 m-85 -125.5 135.54 52.4 Favored 'General case' 0 N--CA 1.437 -1.102 0 N-CA-C 106.162 -1.792 . . . . 0.0 106.162 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 69.6 m -133.06 142.63 48.87 Favored 'General case' 0 CA--C 1.493 -1.249 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 60.0 t -128.78 136.05 60.78 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.155 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 179.033 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 70.3 p -139.19 159.54 41.92 Favored 'General case' 0 CA--C 1.5 -0.973 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 -179.701 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -157.78 159.86 37.22 Favored 'General case' 0 N--CA 1.436 -1.149 0 N-CA-C 105.768 -1.938 . . . . 0.0 105.768 179.211 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -179.63 175.65 47.05 Favored Glycine 0 N--CA 1.437 -1.274 0 N-CA-C 108.613 -1.795 . . . . 0.0 108.613 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -85.19 162.01 11.45 Favored 'Trans proline' 0 C--N 1.311 -1.433 0 C-N-CA 122.99 2.46 . . . . 0.0 113.771 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 69.7 t -124.2 126.83 72.82 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.023 0 N-CA-C 106.371 -1.715 . . . . 0.0 106.371 178.733 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -118.65 125.05 48.88 Favored 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 10.8 ptm180 -112.71 142.4 45.37 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 107.32 -1.363 . . . . 0.0 107.32 179.76 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 50.9 mm -77.71 -64.58 0.87 Allowed 'Isoleucine or valine' 0 CA--C 1.501 -0.94 0 N-CA-C 106.347 -1.723 . . . . 0.0 106.347 179.126 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 65.2 t30 178.66 94.72 0.02 OUTLIER 'General case' 0 N--CA 1.44 -0.952 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 177.679 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 60.8 mt-10 41.57 44.92 2.73 Favored 'General case' 0 C--N 1.358 0.959 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.278 178.121 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 48.6 t80 -141.47 -43.76 0.36 Allowed 'General case' 0 CA--C 1.5 -0.96 0 C-N-CA 119.056 -1.058 . . . . 0.0 108.772 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 9.7 p -163.47 150.18 3.24 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.095 0 N-CA-C 106.957 -1.498 . . . . 0.0 106.957 -179.675 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 64.0 m -126.28 140.65 52.36 Favored 'General case' 0 CA--C 1.496 -1.104 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 179.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 66.0 tp -103.86 125.73 50.48 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 4.6 m-85 -108.7 141.2 41.01 Favored 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 -179.286 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -128.53 138.18 10.17 Favored Glycine 0 CA--C 1.491 -1.468 0 N-CA-C 106.343 -2.703 . . . . 0.0 106.343 178.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.2 mp -128.71 138.53 52.18 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 -179.681 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -150.91 149.9 30.21 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 106.08 -1.822 . . . . 0.0 106.08 178.56 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 174.78 -150.46 11.3 Favored Glycine 0 CA--C 1.492 -1.374 0 N-CA-C 108.128 -1.989 . . . . 0.0 108.128 -179.627 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -144.16 162.18 36.97 Favored 'General case' 0 N--CA 1.437 -1.112 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -178.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -119.34 160.03 14.45 Favored Glycine 0 C--N 1.35 1.331 0 N-CA-C 107.555 -2.218 . . . . 0.0 107.555 -179.708 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 86.3 t60 -147.32 142.23 26.91 Favored 'General case' 0 N--CA 1.438 -1.05 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -133.47 161.93 24.29 Favored Glycine 0 CA--C 1.49 -1.475 0 N-CA-C 107.173 -2.371 . . . . 0.0 107.173 -179.681 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 29.0 ttpp -80.69 124.43 29.01 Favored 'General case' 0 N--CA 1.439 -0.977 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 -179.609 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -155.78 157.8 37.09 Favored 'General case' 0 N--CA 1.435 -1.175 0 N-CA-C 106.516 -1.661 . . . . 0.0 106.516 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -94.49 124.25 38.4 Favored 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 -179.805 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -125.77 138.09 53.83 Favored 'General case' 0 CA--C 1.496 -1.1 0 N-CA-C 106.64 -1.615 . . . . 0.0 106.64 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 96.3 p -158.51 161.19 37.34 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 35.0 t -156.12 145.72 20.97 Favored 'General case' 0 N--CA 1.437 -1.087 0 N-CA-C 106.401 -1.703 . . . . 0.0 106.401 179.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 96.6 mt -66.35 -44.42 90.89 Favored 'Isoleucine or valine' 0 C--N 1.354 0.792 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 -179.764 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 -126.18 147.09 49.72 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -63.73 -39.96 98.03 Favored Glycine 0 C--N 1.352 1.433 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 19.7 mp0 -86.87 74.88 9.68 Favored 'General case' 0 N--CA 1.44 -0.93 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 -179.332 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 68.0 m -132.08 149.95 52.28 Favored 'General case' 0 CA--C 1.496 -1.114 0 N-CA-C 107.091 -1.448 . . . . 0.0 107.091 179.506 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -136.03 128.23 29.94 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 179.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 16.9 m -157.8 -67.48 0.09 Allowed 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 179.741 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 85.1 mtp180 -134.72 148.07 50.21 Favored 'General case' 0 CA--C 1.496 -1.114 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 70.0 m -134.95 149.13 50.19 Favored 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 179.434 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 41.2 ttmt -130.34 124.31 31.97 Favored 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 88.2 m -130.67 130.94 44.53 Favored 'General case' 0 CA--C 1.496 -1.119 0 N-CA-C 106.889 -1.522 . . . . 0.0 106.889 179.695 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 69.8 m -110.36 119.66 39.94 Favored 'General case' 0 CA--C 1.497 -1.081 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 179.629 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 64.4 tp -110.48 128.92 55.84 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 -178.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -111.88 132.87 54.44 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 107.34 -1.355 . . . . 0.0 107.34 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 91.3 t80 -147.6 140.89 25.23 Favored 'General case' 0 CA--C 1.498 -1.036 0 N-CA-C 106.549 -1.649 . . . . 0.0 106.549 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -157.16 169.93 34.31 Favored Glycine 0 N--CA 1.436 -1.329 0 N-CA-C 108.288 -1.925 . . . . 0.0 108.288 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -154.0 157.08 38.56 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 106.122 -1.807 . . . . 0.0 106.122 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -164.35 173.56 40.33 Favored Glycine 0 CA--C 1.49 -1.51 0 N-CA-C 108.469 -1.853 . . . . 0.0 108.469 -179.68 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 6.6 mp -126.98 146.57 50.29 Favored 'General case' 0 N--CA 1.436 -1.131 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 -179.734 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 34.6 tt0 -117.61 133.26 56.14 Favored 'General case' 0 CA--C 1.496 -1.123 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 179.678 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -121.44 138.57 54.22 Favored 'General case' 0 N--CA 1.437 -1.084 0 N-CA-C 106.77 -1.567 . . . . 0.0 106.77 179.558 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 8.8 m120 -128.6 77.68 77.03 Favored Pre-proline 0 CA--C 1.502 -0.87 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 -179.456 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -69.72 -25.95 28.29 Favored 'Trans proline' 0 CA--C 1.5 -1.203 0 C-N-CA 121.685 1.59 . . . . 0.0 112.688 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 78.7 m80 -136.52 151.86 73.68 Favored Pre-proline 0 N--CA 1.439 -1.012 0 N-CA-C 106.49 -1.67 . . . . 0.0 106.49 179.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -83.96 62.09 6.84 Favored 'Trans proline' 0 C--N 1.313 -1.329 0 C-N-CA 121.941 1.761 . . . . 0.0 112.44 179.704 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -166.66 -54.9 0.03 OUTLIER 'General case' 0 CA--C 1.499 -0.995 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 -179.827 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -100.67 135.58 41.89 Favored 'General case' 0 CA--C 1.497 -1.069 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 -179.481 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 57.8 t -118.05 129.52 74.29 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.023 0 N-CA-C 106.964 -1.495 . . . . 0.0 106.964 -179.671 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 85.3 mt -97.07 122.33 48.49 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.975 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 -179.777 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 56.0 m-20 -123.2 131.11 53.56 Favored 'General case' 0 N--CA 1.439 -0.982 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 -178.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -136.64 126.67 26.04 Favored 'General case' 0 CA--C 1.496 -1.119 0 N-CA-C 105.338 -2.097 . . . . 0.0 105.338 178.144 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 53.3 m -142.61 153.43 43.48 Favored 'General case' 0 CA--C 1.493 -1.226 0 C-N-CA 119.487 -0.885 . . . . 0.0 108.726 -178.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -114.61 136.66 52.79 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 105.514 -2.032 . . . . 0.0 105.514 178.624 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 49.7 mt-10 -121.83 136.02 54.92 Favored 'General case' 0 CA--C 1.495 -1.136 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 -179.303 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -129.53 126.58 38.91 Favored 'General case' 0 N--CA 1.433 -1.282 0 N-CA-C 107.052 -1.462 . . . . 0.0 107.052 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 67.2 m -116.94 126.43 52.93 Favored 'General case' 0 CA--C 1.492 -1.265 0 N-CA-C 106.236 -1.764 . . . . 0.0 106.236 179.374 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 65.2 tttm -106.92 118.71 37.42 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 -179.225 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 4.0 mp -120.8 151.23 39.85 Favored 'General case' 0 N--CA 1.436 -1.167 0 N-CA-C 105.266 -2.124 . . . . 0.0 105.266 178.434 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -64.19 -39.48 94.07 Favored 'General case' 0 N--CA 1.441 -0.882 0 C-N-CA 120.36 -0.536 . . . . 0.0 109.873 -179.027 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -71.85 -44.13 64.35 Favored 'General case' 0 C--N 1.354 0.763 0 C-N-CA 120.136 -0.626 . . . . 0.0 111.321 -177.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 31.6 m -147.51 164.93 6.33 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.934 0 C-N-CA 119.738 -0.785 . . . . 0.0 109.367 -177.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -108.74 133.16 53.19 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 105.576 -2.009 . . . . 0.0 105.576 178.43 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 75.5 t -127.84 128.61 69.41 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.976 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 -178.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -125.25 133.58 8.49 Favored Glycine 0 C--N 1.351 1.412 0 N-CA-C 106.097 -2.801 . . . . 0.0 106.097 178.627 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 80.9 p -134.21 152.23 51.72 Favored 'General case' 0 CA--C 1.501 -0.936 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 -179.263 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 25.8 t90 -109.06 136.91 47.8 Favored 'General case' 0 N--CA 1.439 -0.99 0 N-CA-C 105.862 -1.903 . . . . 0.0 105.862 179.003 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 16.5 tmm? -113.3 122.86 48.7 Favored 'General case' 0 CA--C 1.498 -1.056 0 N-CA-C 107.631 -1.248 . . . . 0.0 107.631 -179.324 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 64.1 tp -122.77 129.14 51.38 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 105.772 -1.936 . . . . 0.0 105.772 179.22 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -166.73 -170.83 32.13 Favored Glycine 0 CA--C 1.491 -1.458 0 N-CA-C 108.514 -1.834 . . . . 0.0 108.514 -179.385 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -145.05 156.54 43.99 Favored 'General case' 0 N--CA 1.433 -1.282 0 N-CA-C 106.773 -1.565 . . . . 0.0 106.773 -179.373 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -124.09 167.88 16.32 Favored Glycine 0 CA--C 1.49 -1.505 0 N-CA-C 108.218 -1.953 . . . . 0.0 108.218 -179.314 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 91.5 t80 -131.63 138.57 48.83 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 -179.734 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 17.4 ptm180 -145.07 160.74 40.92 Favored 'General case' 0 N--CA 1.437 -1.089 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 34.6 t80 . . . . . 0 C--O 1.262 1.742 0 CA-C-O 117.673 -1.156 . . . . 0.0 108.146 179.934 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 . . . . . 0 N--CA 1.489 1.515 0 CA-C-O 120.915 0.388 . . . . 0.0 110.583 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -179.73 176.81 47.81 Favored Glycine 0 CA--C 1.492 -1.375 0 N-CA-C 106.803 -2.519 . . . . 0.0 106.803 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -136.25 147.49 47.58 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 107.414 -1.328 . . . . 0.0 107.414 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 97.1 p -154.94 161.25 41.47 Favored 'General case' 0 N--CA 1.436 -1.139 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 179.63 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 54.8 m -135.97 146.1 46.88 Favored 'General case' 0 CA--C 1.496 -1.113 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 85.3 mt -119.64 129.31 75.5 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.083 0 N-CA-C 105.322 -2.103 . . . . 0.0 105.322 179.026 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 48.2 t -135.33 142.08 45.73 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 -178.609 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 46.9 pt -130.79 157.4 43.1 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.14 0 N-CA-C 106.001 -1.851 . . . . 0.0 106.001 179.047 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -163.66 178.53 39.13 Favored Glycine 0 CA--C 1.49 -1.486 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -179.669 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -117.51 149.44 40.61 Favored 'General case' 0 CA--C 1.495 -1.148 0 N-CA-C 106.854 -1.536 . . . . 0.0 106.854 -179.394 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -96.31 133.25 40.9 Favored 'General case' 0 N--CA 1.437 -1.088 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 -179.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 98.6 mm-40 -110.16 139.72 45.01 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 179.421 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 35.8 t -151.59 150.18 30.02 Favored 'General case' 0 CA--C 1.498 -1.036 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 -179.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 77.1 ttt180 -85.64 118.58 25.24 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 83.6 t -105.98 -56.37 4.99 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.016 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.4 tttm -156.75 141.71 17.11 Favored 'General case' 0 N--CA 1.437 -1.123 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 99.3 mt-10 -127.1 147.24 50.17 Favored 'General case' 0 CA--C 1.497 -1.074 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 179.478 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -159.96 170.83 20.52 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -88.8 64.26 3.43 Favored Glycine 0 C--N 1.351 1.391 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -178.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 44.1 m-85 -132.59 148.77 52.37 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 178.69 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 40.2 ttpt -62.51 -44.44 96.37 Favored 'General case' 0 CA--C 1.505 -0.777 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 89.2 mt -114.91 137.71 51.66 Favored 'General case' 0 CA--C 1.497 -1.076 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -149.6 67.93 1.01 Allowed 'General case' 0 N--CA 1.437 -1.104 0 N-CA-C 106.59 -1.633 . . . . 0.0 106.59 179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 68.0 mttm 65.04 -168.15 0.21 Allowed 'General case' 0 C--N 1.357 0.914 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 69.1 m-80 -138.49 151.45 69.14 Favored Pre-proline 0 N--CA 1.44 -0.932 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -74.89 160.09 40.9 Favored 'Trans proline' 0 C--N 1.314 -1.251 0 C-N-CA 122.116 1.877 . . . . 0.0 112.282 179.051 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 36.3 ptt-85 -149.42 157.04 42.96 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 -179.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 141.65 136.49 3.27 Favored Glycine 0 C--N 1.349 1.301 0 N-CA-C 106.6 -2.6 . . . . 0.0 106.6 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 -127.24 138.61 53.13 Favored 'General case' 0 CA--C 1.496 -1.111 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 -179.238 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 84.4 m-20 -131.54 135.81 47.34 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 179.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 88.5 mt -117.25 141.12 48.69 Favored 'General case' 0 CA--C 1.498 -1.055 0 N-CA-C 106.328 -1.73 . . . . 0.0 106.328 179.303 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 41.1 ttmt -141.17 135.7 31.09 Favored 'General case' 0 CA--C 1.502 -0.9 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 -179.552 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -127.31 143.65 51.19 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.208 -1.405 . . . . 0.0 107.208 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 75.7 ttt180 -124.9 130.37 52.23 Favored 'General case' 0 CA--C 1.499 -0.995 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 -179.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 64.7 t80 -121.35 126.49 49.58 Favored 'General case' 0 N--CA 1.44 -0.964 0 N-CA-C 106.156 -1.794 . . . . 0.0 106.156 179.249 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -99.13 112.05 24.28 Favored 'General case' 0 CA--C 1.5 -0.956 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 -179.032 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 78.7 m-85 -80.8 -35.58 32.84 Favored 'General case' 0 CA--C 1.503 -0.856 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 178.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 12.1 t-20 -164.1 172.57 13.58 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 106.565 -1.643 . . . . 0.0 106.565 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 54.3 m-80 -86.2 73.21 10.26 Favored 'General case' 0 CA--C 1.502 -0.884 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 -179.751 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -162.2 -66.65 0.05 Allowed 'General case' 0 N--CA 1.437 -1.1 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 179.645 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 42.1 m0 -126.59 146.49 50.14 Favored 'General case' 0 CA--C 1.499 -1.005 0 N-CA-C 106.806 -1.553 . . . . 0.0 106.806 -179.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -128.78 163.69 22.12 Favored Glycine 0 CA--C 1.494 -1.277 0 N-CA-C 107.259 -2.336 . . . . 0.0 107.259 179.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 70.8 t -129.09 132.8 66.85 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.009 0 N-CA-C 106.977 -1.49 . . . . 0.0 106.977 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 35.5 pt -123.21 159.65 27.11 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.129 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -137.99 147.31 19.15 Favored Glycine 0 CA--C 1.491 -1.451 0 N-CA-C 105.563 -3.015 . . . . 0.0 105.563 178.631 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 39.7 t -145.38 146.7 31.66 Favored 'General case' 0 N--CA 1.438 -1.065 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 -179.231 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 87.6 t80 -126.79 131.61 51.23 Favored 'General case' 0 N--CA 1.439 -1.002 0 N-CA-C 106.01 -1.848 . . . . 0.0 106.01 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -127.67 143.23 51.17 Favored 'General case' 0 CA--C 1.501 -0.932 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 -179.102 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 63.4 tt0 -136.57 133.57 36.52 Favored 'General case' 0 CA--C 1.5 -0.943 0 N-CA-C 106.772 -1.566 . . . . 0.0 106.772 179.768 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 15.2 t -146.12 156.16 43.24 Favored 'General case' 0 N--CA 1.443 -0.809 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 -179.753 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 61.7 ttp180 -114.05 129.31 56.62 Favored 'General case' 0 CA--C 1.498 -1.036 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 32.2 tpt180 -102.52 123.87 47.05 Favored 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -173.91 169.88 42.96 Favored Glycine 0 CA--C 1.491 -1.442 0 N-CA-C 107.163 -2.375 . . . . 0.0 107.163 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 84.6 t80 -140.29 125.84 19.1 Favored 'General case' 0 N--CA 1.436 -1.131 0 N-CA-C 106.021 -1.844 . . . . 0.0 106.021 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 48.8 mp0 -95.95 132.72 40.96 Favored 'General case' 0 N--CA 1.439 -1.005 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 -179.43 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -144.86 136.47 25.47 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 106.416 -1.698 . . . . 0.0 106.416 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 47.3 t -87.83 117.65 26.81 Favored 'General case' 0 CA--C 1.499 -0.991 0 N-CA-C 107.105 -1.443 . . . . 0.0 107.105 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 32.1 m -135.2 159.08 41.12 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.086 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 36.1 t70 -65.55 -44.57 86.39 Favored 'General case' 0 C--N 1.354 0.787 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 179.692 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 150.69 -178.92 27.83 Favored Glycine 0 CA--C 1.493 -1.329 0 N-CA-C 107.254 -2.338 . . . . 0.0 107.254 179.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 63.45 36.16 11.54 Favored 'General case' 0 C--N 1.354 0.786 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.521 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 32.7 mmmt -128.7 146.19 50.95 Favored 'General case' 0 CA--C 1.496 -1.127 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 179.582 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 89.6 mt -117.18 138.73 51.48 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 106.708 -1.59 . . . . 0.0 106.708 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 46.0 pt -131.6 156.85 42.98 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.055 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 -179.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 37.8 t70 -100.86 108.8 20.67 Favored 'General case' 0 N--CA 1.438 -1.059 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 179.768 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -179.98 -167.35 36.96 Favored Glycine 0 CA--C 1.493 -1.311 0 N-CA-C 107.456 -2.258 . . . . 0.0 107.456 -179.603 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 30.2 t0 73.38 49.25 0.14 Allowed 'General case' 0 C--N 1.356 0.874 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -121.4 141.65 50.77 Favored 'General case' 0 CA--C 1.497 -1.058 0 N-CA-C 107.065 -1.457 . . . . 0.0 107.065 179.492 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -101.8 130.1 48.15 Favored 'General case' 0 CA--C 1.498 -1.051 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -119.02 136.63 54.03 Favored 'General case' 0 CA--C 1.495 -1.156 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 179.687 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 90.3 m-85 -127.21 137.6 52.94 Favored 'General case' 0 CA--C 1.494 -1.181 0 N-CA-C 106.022 -1.844 . . . . 0.0 106.022 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 69.6 m -132.11 142.77 49.62 Favored 'General case' 0 CA--C 1.493 -1.245 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 61.4 t -128.33 137.74 56.57 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.154 0 N-CA-C 105.298 -2.112 . . . . 0.0 105.298 179.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.404 ' HG1' ' C ' ' A' ' 91' ' ' LEU . 10.5 t -150.15 153.77 36.9 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 -178.902 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -154.26 160.4 41.78 Favored 'General case' 0 N--CA 1.435 -1.204 0 N-CA-C 105.825 -1.917 . . . . 0.0 105.825 179.686 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -176.05 176.58 47.66 Favored Glycine 0 CA--C 1.494 -1.237 0 N-CA-C 108.764 -1.734 . . . . 0.0 108.764 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -79.8 160.54 24.56 Favored 'Trans proline' 0 C--N 1.312 -1.347 0 C-N-CA 122.907 2.405 . . . . 0.0 113.537 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 67.8 t -119.34 129.33 75.41 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.084 0 N-CA-C 106.936 -1.505 . . . . 0.0 106.936 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -112.97 137.28 51.61 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 44.5 ttm180 -111.67 130.26 55.83 Favored 'General case' 0 CA--C 1.5 -0.943 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 -179.579 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 49.0 mm -78.87 -65.92 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.359 1.003 0 N-CA-C 106.854 -1.536 . . . . 0.0 106.854 179.281 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 34.0 m120 -162.7 91.06 0.73 Allowed 'General case' 0 C--N 1.357 0.927 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 177.782 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 14.3 tt0 37.39 22.77 0.0 OUTLIER 'General case' 0 C--N 1.359 0.999 0 N-CA-C 114.313 1.227 . . . . 0.0 114.313 177.572 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -144.02 -41.31 0.27 Allowed 'General case' 0 CA--C 1.499 -0.996 0 CA-C-N 120.397 1.453 . . . . 0.0 110.477 -178.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 86.6 t -119.64 131.23 72.76 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.166 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 -177.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 69.0 m -119.71 145.52 46.45 Favored 'General case' 0 CA--C 1.499 -1.005 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 179.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.0 mp -116.34 146.02 42.76 Favored 'General case' 0 CA--C 1.496 -1.131 0 N-CA-C 106.7 -1.592 . . . . 0.0 106.7 179.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 33.0 m-85 -126.29 143.42 51.16 Favored 'General case' 0 CA--C 1.496 -1.1 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 -179.432 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -116.81 138.0 13.99 Favored Glycine 0 CA--C 1.493 -1.326 0 N-CA-C 105.216 -3.154 . . . . 0.0 105.216 177.792 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 87.5 mt -117.62 134.42 54.9 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 -178.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.404 ' C ' ' HG1' ' A' ' 74' ' ' THR . 4.4 tt -146.7 130.23 16.84 Favored 'General case' 0 N--CA 1.437 -1.078 0 N-CA-C 105.322 -2.103 . . . . 0.0 105.322 178.504 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -176.86 -160.51 24.02 Favored Glycine 0 CA--C 1.492 -1.387 0 N-CA-C 108.578 -1.809 . . . . 0.0 108.578 -179.373 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -149.91 161.99 41.21 Favored 'General case' 0 N--CA 1.434 -1.234 0 N-CA-C 107.346 -1.353 . . . . 0.0 107.346 -179.202 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -141.79 164.73 26.69 Favored Glycine 0 CA--C 1.493 -1.294 0 N-CA-C 107.304 -2.318 . . . . 0.0 107.304 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 72.6 t60 -151.89 150.14 29.75 Favored 'General case' 0 N--CA 1.438 -1.029 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 -179.721 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -99.79 143.51 16.48 Favored Glycine 0 C--N 1.352 1.468 0 N-CA-C 107.994 -2.042 . . . . 0.0 107.994 -179.532 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -119.82 148.44 43.45 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -147.82 154.12 40.06 Favored 'General case' 0 N--CA 1.436 -1.143 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 40.9 ttmt -92.99 119.72 32.55 Favored 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 -179.722 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 92.1 t80 -145.13 129.16 17.51 Favored 'General case' 0 N--CA 1.437 -1.088 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 179.608 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 37.6 t -146.63 125.47 12.69 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 106.956 -1.498 . . . . 0.0 106.956 179.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 1.7 m -175.6 -81.34 0.01 OUTLIER 'General case' 0 CA--C 1.498 -1.055 0 N-CA-C 106.497 -1.668 . . . . 0.0 106.497 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 85.4 mt -123.16 126.35 73.37 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.042 0 N-CA-C 106.299 -1.741 . . . . 0.0 106.299 179.595 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -113.91 124.09 51.34 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 -179.802 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 175.91 175.41 43.27 Favored Glycine 0 CA--C 1.491 -1.418 0 N-CA-C 106.855 -2.498 . . . . 0.0 106.855 179.629 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 3.7 mm-40 -151.61 156.31 40.18 Favored 'General case' 0 CA--C 1.495 -1.147 0 N-CA-C 107.159 -1.422 . . . . 0.0 107.159 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 10.4 t -128.29 2.32 5.73 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -154.77 163.79 39.74 Favored 'General case' 0 N--CA 1.437 -1.08 0 N-CA-C 107.108 -1.441 . . . . 0.0 107.108 -179.72 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 67.6 m -104.32 128.6 52.15 Favored 'General case' 0 CA--C 1.495 -1.147 0 N-CA-C 106.822 -1.547 . . . . 0.0 106.822 179.667 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 42.0 ptt180 -158.22 163.84 37.08 Favored 'General case' 0 N--CA 1.437 -1.105 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 -179.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 98.4 p -154.26 159.6 41.37 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 106.9 -1.519 . . . . 0.0 106.9 179.787 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 39.6 ttmt -148.07 127.12 12.83 Favored 'General case' 0 N--CA 1.438 -1.064 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 88.9 m -138.37 135.14 35.04 Favored 'General case' 0 CA--C 1.498 -1.037 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 46.7 t -95.14 124.59 39.27 Favored 'General case' 0 CA--C 1.498 -1.035 0 N-CA-C 106.672 -1.603 . . . . 0.0 106.672 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 90.9 mt -86.8 143.44 27.49 Favored 'General case' 0 CA--C 1.499 -0.994 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 -179.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -124.61 134.64 52.86 Favored 'General case' 0 N--CA 1.439 -1.025 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 -179.47 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -135.74 153.24 51.63 Favored 'General case' 0 CA--C 1.496 -1.134 0 N-CA-C 106.367 -1.716 . . . . 0.0 106.367 179.579 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -174.43 179.86 45.49 Favored Glycine 0 CA--C 1.491 -1.454 0 N-CA-C 108.65 -1.78 . . . . 0.0 108.65 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -155.99 160.65 40.24 Favored 'General case' 0 N--CA 1.435 -1.218 0 N-CA-C 106.174 -1.787 . . . . 0.0 106.174 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -162.39 -178.86 36.6 Favored Glycine 0 CA--C 1.49 -1.526 0 N-CA-C 108.209 -1.956 . . . . 0.0 108.209 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -151.16 164.58 36.2 Favored 'General case' 0 N--CA 1.436 -1.154 0 N-CA-C 107.297 -1.372 . . . . 0.0 107.297 -179.66 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 40.0 tt0 -142.84 139.5 30.91 Favored 'General case' 0 CA--C 1.496 -1.113 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 -179.303 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -106.18 139.47 40.65 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 178.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 75.4 m-20 -125.47 74.43 68.86 Favored Pre-proline 0 N--CA 1.443 -0.777 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 -179.401 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -71.64 -28.56 17.13 Favored 'Trans proline' 0 CA--C 1.501 -1.161 0 C-N-CA 121.794 1.663 . . . . 0.0 112.983 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 79.0 m80 -136.54 151.92 73.77 Favored Pre-proline 0 N--CA 1.439 -1.02 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -85.92 62.12 5.19 Favored 'Trans proline' 0 C--N 1.312 -1.345 0 C-N-CA 122.138 1.892 . . . . 0.0 112.654 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.87 -65.25 0.04 OUTLIER 'General case' 0 N--CA 1.44 -0.97 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -108.78 137.65 46.37 Favored 'General case' 0 CA--C 1.496 -1.124 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 32.7 m -130.52 156.92 42.85 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.0 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 86.0 mt -121.46 130.69 74.39 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.114 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 -179.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 14.7 p-10 -136.12 160.22 39.31 Favored 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 108.361 -0.978 . . . . 0.0 108.361 -179.126 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -151.51 151.66 31.91 Favored 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 105.92 -1.881 . . . . 0.0 105.92 179.263 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 94.2 p -155.77 164.12 38.97 Favored 'General case' 0 CA--C 1.495 -1.154 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -122.12 139.8 53.31 Favored 'General case' 0 CA--C 1.495 -1.135 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 -179.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -126.37 128.45 47.08 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 106.922 -1.51 . . . . 0.0 106.922 179.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 90.6 t80 -124.32 128.65 49.43 Favored 'General case' 0 N--CA 1.439 -1.008 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 70.3 m -114.16 136.96 52.37 Favored 'General case' 0 CA--C 1.495 -1.164 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 65.4 tttm -116.16 125.03 51.75 Favored 'General case' 0 CA--C 1.499 -1.008 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 -179.041 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 35.2 tp -150.15 140.9 22.69 Favored 'General case' 0 N--CA 1.436 -1.162 0 N-CA-C 105.459 -2.052 . . . . 0.0 105.459 179.046 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -62.72 -38.27 89.8 Favored 'General case' 0 CA--C 1.507 -0.682 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 -179.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -62.87 -41.84 99.54 Favored 'General case' 0 C--N 1.353 0.728 0 O-C-N 122.114 -0.366 . . . . 0.0 110.09 -178.578 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 14.6 p -162.64 142.1 2.48 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.879 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 -179.273 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 56.5 mtmt -110.0 137.44 47.76 Favored 'General case' 0 CA--C 1.497 -1.07 0 N-CA-C 105.899 -1.889 . . . . 0.0 105.899 179.196 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 13.3 p -150.57 145.8 16.73 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 -178.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -128.93 140.55 11.8 Favored Glycine 0 C--N 1.349 1.297 0 N-CA-C 105.953 -2.859 . . . . 0.0 105.953 178.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 68.4 p -128.35 152.18 48.46 Favored 'General case' 0 CA--C 1.498 -1.044 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 -179.209 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 52.5 m0 -108.88 139.22 44.03 Favored 'General case' 0 CA--C 1.497 -1.061 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 179.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 26.8 ttt -114.65 124.58 52.19 Favored 'General case' 0 CA--C 1.498 -1.053 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 -179.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 62.9 tp -130.68 129.99 43.3 Favored 'General case' 0 N--CA 1.438 -1.041 0 N-CA-C 105.744 -1.947 . . . . 0.0 105.744 179.005 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -168.89 -167.67 29.85 Favored Glycine 0 CA--C 1.492 -1.391 0 N-CA-C 108.648 -1.781 . . . . 0.0 108.648 -179.321 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -144.43 164.57 30.44 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 106.26 -1.756 . . . . 0.0 106.26 -179.443 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -139.41 168.33 24.94 Favored Glycine 0 CA--C 1.489 -1.559 0 N-CA-C 108.642 -1.783 . . . . 0.0 108.642 -179.167 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 56.5 t80 -123.32 128.48 49.99 Favored 'General case' 0 N--CA 1.437 -1.104 0 N-CA-C 106.063 -1.828 . . . . 0.0 106.063 179.808 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 6.6 tmm_? -107.51 129.83 54.92 Favored 'General case' 0 CA--C 1.499 -1.005 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 -178.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 19.1 t80 . . . . . 0 C--O 1.262 1.718 0 CA-C-O 117.806 -1.092 . . . . 0.0 108.448 179.309 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 120.998 0.428 . . . . 0.0 110.789 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.93 178.05 48.43 Favored Glycine 0 CA--C 1.492 -1.37 0 N-CA-C 106.805 -2.518 . . . . 0.0 106.805 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 99.7 mt-10 -130.22 145.65 51.76 Favored 'General case' 0 N--CA 1.438 -1.055 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 62.9 m -129.78 157.81 41.17 Favored 'General case' 0 CA--C 1.496 -1.131 0 N-CA-C 106.763 -1.569 . . . . 0.0 106.763 -179.848 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 35.6 t -136.37 141.46 43.71 Favored 'General case' 0 CA--C 1.497 -1.061 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 -179.764 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 85.5 mt -121.26 130.68 74.42 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.998 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.433 ' HA ' ' HA2' ' A' ' 153' ' ' GLY . 44.1 t -128.63 137.58 51.74 Favored 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 107.205 -1.405 . . . . 0.0 107.205 -179.73 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.583 HG22 ' HG ' ' A' ' 31' ' ' LEU . 47.4 pt -127.13 157.82 38.45 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.059 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -166.28 -179.55 39.73 Favored Glycine 0 CA--C 1.492 -1.371 0 N-CA-C 108.184 -1.966 . . . . 0.0 108.184 -179.71 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -127.85 149.05 50.46 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 -179.517 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -74.16 143.09 45.42 Favored 'General case' 0 N--CA 1.44 -0.967 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -122.28 152.11 40.41 Favored 'General case' 0 CA--C 1.499 -1.003 0 N-CA-C 106.877 -1.527 . . . . 0.0 106.877 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 37.8 t -144.63 150.39 37.33 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 106.567 -1.642 . . . . 0.0 106.567 -179.591 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -72.07 129.36 38.32 Favored 'General case' 0 N--CA 1.44 -0.945 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 -179.478 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 31.5 m -133.53 159.75 42.58 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.004 0 N-CA-C 106.604 -1.628 . . . . 0.0 106.604 179.412 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -111.93 138.01 49.13 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 107.273 -1.38 . . . . 0.0 107.273 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 79.4 mm-40 -124.78 125.14 43.56 Favored 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -109.58 20.65 17.92 Favored 'General case' 0 CA--C 1.503 -0.841 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.35 -6.44 71.63 Favored Glycine 0 C--N 1.352 1.463 0 N-CA-C 107.494 -2.242 . . . . 0.0 107.494 -179.14 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -128.31 152.03 48.62 Favored 'General case' 0 N--CA 1.436 -1.136 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 179.675 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 61.9 mtpt -81.6 63.09 5.73 Favored 'General case' 0 CA--C 1.504 -0.808 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -179.121 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 87.6 mt -70.26 -38.18 75.05 Favored 'General case' 0 N--CA 1.442 -0.845 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 179.23 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -98.58 137.96 36.47 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 107.602 -1.258 . . . . 0.0 107.602 -179.597 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -85.11 151.75 23.9 Favored 'General case' 0 N--CA 1.441 -0.902 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 179.246 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 97.2 m-20 -71.95 147.0 90.99 Favored Pre-proline 0 N--CA 1.443 -0.814 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 -179.276 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -78.37 160.94 28.95 Favored 'Trans proline' 0 CA--C 1.499 -1.233 0 C-N-CA 122.437 2.092 . . . . 0.0 112.632 179.403 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 95.2 mtm-85 -125.56 129.51 49.84 Favored 'General case' 0 CA--C 1.5 -0.971 0 N-CA-C 107.451 -1.314 . . . . 0.0 107.451 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -178.68 167.16 37.4 Favored Glycine 0 C--N 1.35 1.317 0 N-CA-C 106.995 -2.442 . . . . 0.0 106.995 179.597 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 54.9 p90 -157.23 164.57 37.58 Favored 'General case' 0 CA--C 1.5 -0.951 0 N-CA-C 107.418 -1.327 . . . . 0.0 107.418 -179.809 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 12.7 p30 -151.42 156.62 41.04 Favored 'General case' 0 N--CA 1.438 -1.07 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 179.613 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.583 ' HG ' HG22 ' A' ' 8' ' ' ILE . 0.8 OUTLIER -145.39 137.64 25.73 Favored 'General case' 0 N--CA 1.437 -1.087 0 N-CA-C 106.444 -1.687 . . . . 0.0 106.444 179.974 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.423 ' HZ1' HD21 ' A' ' 90' ' ' LEU . 68.2 mttm -128.82 144.36 51.15 Favored 'General case' 0 N--CA 1.44 -0.955 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 -179.65 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' TYR . . . . . 0.527 ' CZ ' HD22 ' A' ' 31' ' ' LEU . 96.4 m-85 -127.39 138.71 53.07 Favored 'General case' 0 CA--C 1.499 -1.003 0 N-CA-C 106.806 -1.553 . . . . 0.0 106.806 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ARG . . . . . 0.536 ' HA ' HG22 ' A' ' 44' ' ' ILE . 48.3 ttp180 -112.36 128.16 56.21 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 107.069 -1.456 . . . . 0.0 107.069 179.661 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 10.7 t80 -117.95 129.43 55.61 Favored 'General case' 0 N--CA 1.439 -1.002 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 179.618 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -96.08 126.63 41.45 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 -178.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 74.8 m-85 -120.99 161.1 22.2 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 106.124 -1.806 . . . . 0.0 106.124 178.491 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 66.0 t30 -80.29 95.32 6.3 Favored 'General case' 0 N--CA 1.439 -1.006 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -165.32 -178.84 5.22 Favored 'General case' 0 N--CA 1.434 -1.267 0 N-CA-C 106.047 -1.835 . . . . 0.0 106.047 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -83.64 -16.76 43.9 Favored 'General case' 0 N--CA 1.441 -0.882 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 -179.311 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 53.3 m95 -133.95 151.24 51.41 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 -179.366 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -100.19 -175.59 30.3 Favored Glycine 0 C--N 1.354 1.551 0 N-CA-C 107.842 -2.103 . . . . 0.0 107.842 -179.737 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 10.1 p -143.11 146.14 21.93 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.895 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.619 HD13 ' CD2' ' A' ' 88' ' ' TYR . 43.4 pt -130.16 161.63 39.52 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.053 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 -179.592 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -125.15 137.44 10.39 Favored Glycine 0 CA--C 1.492 -1.375 0 N-CA-C 105.202 -3.159 . . . . 0.0 105.202 178.119 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 53.3 m -130.89 145.75 52.11 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 -178.635 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 88.6 t80 -131.77 132.19 43.59 Favored 'General case' 0 CA--C 1.498 -1.023 0 N-CA-C 105.695 -1.965 . . . . 0.0 105.695 178.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -138.44 143.98 39.93 Favored 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 -179.339 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 59.7 tt0 -142.01 136.3 30.13 Favored 'General case' 0 N--CA 1.437 -1.107 0 N-CA-C 106.278 -1.749 . . . . 0.0 106.278 179.428 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 15.2 t -145.42 152.22 39.48 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 79.2 ttt-85 -103.51 130.97 50.99 Favored 'General case' 0 N--CA 1.438 -1.036 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 4.7 tmt_? -112.77 130.38 56.09 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 -178.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -169.5 174.03 43.82 Favored Glycine 0 CA--C 1.491 -1.45 0 N-CA-C 106.486 -2.645 . . . . 0.0 106.486 179.756 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -88.03 96.14 10.4 Favored 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 106.352 -1.722 . . . . 0.0 106.352 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 72.9 mm-40 -95.79 2.59 53.91 Favored 'General case' 0 CA--C 1.504 -0.817 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 -178.757 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -91.16 149.81 21.64 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 -179.704 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 45.4 m -98.49 132.37 43.98 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 179.131 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 78.6 t -64.67 -47.41 88.96 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.754 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -179.662 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 62.4 m-20 -129.78 -51.45 1.14 Allowed 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 107.042 -1.466 . . . . 0.0 107.042 179.448 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 170.88 122.79 0.66 Allowed Glycine 0 CA--C 1.492 -1.398 0 N-CA-C 106.746 -2.542 . . . . 0.0 106.746 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 94.8 m-85 62.48 31.19 17.18 Favored 'General case' 0 C--N 1.356 0.85 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 17.3 tppt? -144.36 126.15 15.23 Favored 'General case' 0 CA--C 1.495 -1.151 0 N-CA-C 106.411 -1.7 . . . . 0.0 106.411 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -157.38 173.94 16.17 Favored 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 -179.101 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 83.7 mt -97.1 122.56 48.77 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.023 0 N-CA-C 106.558 -1.645 . . . . 0.0 106.558 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -82.19 132.45 35.24 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 -179.242 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -168.17 159.05 32.13 Favored Glycine 0 CA--C 1.491 -1.413 0 N-CA-C 106.253 -2.739 . . . . 0.0 106.253 179.373 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 63.7 m-20 -132.83 129.28 38.28 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 9.2 t80 -158.15 133.98 9.11 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 106.273 -1.751 . . . . 0.0 106.273 178.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 57.3 mtmt -127.95 142.96 51.1 Favored 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 107.602 -1.258 . . . . 0.0 107.602 -179.276 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -117.09 133.02 56.52 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 179.359 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -114.09 127.53 55.97 Favored 'General case' 0 CA--C 1.495 -1.146 0 N-CA-C 105.227 -2.138 . . . . 0.0 105.227 178.606 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 70.1 m -132.86 140.51 47.96 Favored 'General case' 0 CA--C 1.493 -1.231 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 -179.338 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 61.6 t -128.61 135.18 63.04 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.242 0 N-CA-C 105.097 -2.186 . . . . 0.0 105.097 178.584 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 68.0 p -140.26 160.66 39.46 Favored 'General case' 0 CA--C 1.495 -1.153 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 -179.425 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -153.7 155.69 36.44 Favored 'General case' 0 N--CA 1.433 -1.275 0 N-CA-C 106.108 -1.812 . . . . 0.0 106.108 179.272 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -178.83 171.64 43.81 Favored Glycine 0 N--CA 1.435 -1.388 0 N-CA-C 107.949 -2.06 . . . . 0.0 107.949 179.554 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_endo -81.8 165.18 17.88 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 122.734 2.289 . . . . 0.0 113.361 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 8.3 p -121.43 132.65 70.16 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.989 0 N-CA-C 106.181 -1.785 . . . . 0.0 106.181 178.771 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -115.41 124.81 52.13 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 -178.846 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 56.3 ttp180 -112.15 132.44 54.88 Favored 'General case' 0 CA--C 1.498 -1.04 0 N-CA-C 106.131 -1.803 . . . . 0.0 106.131 179.253 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 97.1 mt -71.97 -63.95 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.912 0 N-CA-C 106.981 -1.488 . . . . 0.0 106.981 179.741 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 65.8 t30 -175.25 93.89 0.07 Allowed 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 177.693 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 39.69 44.13 1.23 Allowed 'General case' 0 C--N 1.357 0.905 0 C-N-CA 123.103 0.561 . . . . 0.0 112.21 177.857 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -141.62 -46.26 0.37 Allowed 'General case' 0 CA--C 1.501 -0.93 0 C-N-CA 118.824 -1.15 . . . . 0.0 109.022 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 22.1 m -149.02 158.08 6.6 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.149 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 64.2 m -133.95 142.93 47.89 Favored 'General case' 0 CA--C 1.496 -1.109 0 N-CA-C 106.622 -1.622 . . . . 0.0 106.622 178.568 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 89.9 mt -117.05 139.72 50.36 Favored 'General case' 0 CA--C 1.497 -1.079 0 N-CA-C 107.16 -1.422 . . . . 0.0 107.16 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.619 ' CD2' HD13 ' A' ' 44' ' ' ILE . 64.3 m-85 -116.57 142.83 46.38 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 -179.775 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -114.66 138.35 14.75 Favored Glycine 0 C--N 1.35 1.341 0 N-CA-C 105.727 -2.949 . . . . 0.0 105.727 178.302 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.423 HD21 ' HZ1' ' A' ' 32' ' ' LYS . 8.7 mp -117.77 133.2 56.18 Favored 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 -179.136 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.3 tt -150.33 133.51 16.25 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 106.194 -1.78 . . . . 0.0 106.194 178.837 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 179.01 -151.24 10.09 Favored Glycine 0 CA--C 1.493 -1.332 0 N-CA-C 108.016 -2.034 . . . . 0.0 108.016 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -143.67 160.15 41.21 Favored 'General case' 0 N--CA 1.437 -1.124 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 -179.071 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -131.69 155.77 21.56 Favored Glycine 0 CA--C 1.493 -1.3 0 N-CA-C 107.751 -2.14 . . . . 0.0 107.751 -179.713 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 60.3 t-80 -151.57 141.67 22.2 Favored 'General case' 0 N--CA 1.437 -1.102 0 N-CA-C 106.952 -1.499 . . . . 0.0 106.952 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -147.44 140.5 8.56 Favored Glycine 0 CA--C 1.492 -1.39 0 N-CA-C 107.032 -2.427 . . . . 0.0 107.032 179.458 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -157.33 134.92 10.62 Favored 'General case' 0 N--CA 1.436 -1.126 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -143.68 52.54 1.32 Allowed 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 107.359 -1.348 . . . . 0.0 107.359 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -125.47 139.88 53.25 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 107.097 -1.445 . . . . 0.0 107.097 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -132.57 147.46 52.35 Favored 'General case' 0 CA--C 1.498 -1.056 0 N-CA-C 106.835 -1.543 . . . . 0.0 106.835 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 32.6 t -147.37 -72.19 0.22 Allowed 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 37.2 t -155.1 149.57 26.24 Favored 'General case' 0 N--CA 1.437 -1.103 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 45.5 pt -96.83 -3.19 10.19 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.869 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 88.5 t80 -138.57 124.2 19.65 Favored 'General case' 0 N--CA 1.439 -1.016 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 159.88 -175.52 36.7 Favored Glycine 0 CA--C 1.491 -1.414 0 N-CA-C 107.107 -2.397 . . . . 0.0 107.107 179.706 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 64.7 tt0 -135.42 120.31 18.55 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 106.666 -1.605 . . . . 0.0 106.666 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 36.7 t -160.31 151.24 18.92 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 63.0 mt-10 -74.22 141.15 45.44 Favored 'General case' 0 N--CA 1.44 -0.942 0 N-CA-C 107.022 -1.473 . . . . 0.0 107.022 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 68.0 m -129.77 151.14 50.68 Favored 'General case' 0 CA--C 1.494 -1.179 0 N-CA-C 107.577 -1.268 . . . . 0.0 107.577 -179.415 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -128.68 150.83 50.09 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 38.4 t -148.26 147.9 29.87 Favored 'General case' 0 CA--C 1.497 -1.096 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 -179.397 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 65.3 mttp -125.39 148.69 48.68 Favored 'General case' 0 CA--C 1.497 -1.061 0 N-CA-C 106.803 -1.555 . . . . 0.0 106.803 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 93.0 m -110.2 128.46 55.5 Favored 'General case' 0 CA--C 1.495 -1.148 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 -179.762 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 51.1 m -88.56 144.06 26.56 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 -179.575 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 63.6 tp -94.95 123.5 38.46 Favored 'General case' 0 CA--C 1.498 -1.044 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 179.671 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -114.9 130.57 56.93 Favored 'General case' 0 N--CA 1.438 -1.051 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -178.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 55.5 p90 -149.87 161.28 42.58 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 106.48 -1.674 . . . . 0.0 106.48 179.17 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 179.36 -169.43 40.56 Favored Glycine 0 CA--C 1.491 -1.423 0 N-CA-C 108.056 -2.018 . . . . 0.0 108.056 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -153.13 159.37 42.73 Favored 'General case' 0 CA--C 1.495 -1.158 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 -179.53 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -144.07 154.2 25.51 Favored Glycine 0 CA--C 1.491 -1.442 0 N-CA-C 108.496 -1.842 . . . . 0.0 108.496 -179.763 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 3.9 mp -121.63 140.59 52.07 Favored 'General case' 0 N--CA 1.437 -1.119 0 N-CA-C 106.543 -1.651 . . . . 0.0 106.543 179.666 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 38.5 tt0 -116.65 131.88 56.83 Favored 'General case' 0 CA--C 1.495 -1.167 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 -179.693 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -122.57 140.66 52.55 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 106.188 -1.782 . . . . 0.0 106.188 179.044 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 7.5 m120 -127.69 79.14 73.99 Favored Pre-proline 0 CA--C 1.502 -0.893 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 -179.054 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.08 -25.36 27.18 Favored 'Trans proline' 0 CA--C 1.499 -1.23 0 C-N-CA 121.665 1.577 . . . . 0.0 112.156 179.15 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 78.7 m80 -135.8 152.19 75.47 Favored Pre-proline 0 N--CA 1.437 -1.115 0 N-CA-C 105.849 -1.908 . . . . 0.0 105.849 179.301 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.11 -20.97 37.18 Favored 'Trans proline' 0 C--N 1.31 -1.477 0 C-N-CA 121.719 1.613 . . . . 0.0 113.637 -179.645 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -109.45 14.54 23.54 Favored 'General case' 0 N--CA 1.444 -0.766 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 -179.028 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 50.3 t80 -142.44 121.44 12.85 Favored 'General case' 0 CA--C 1.5 -0.967 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 59.7 t -119.39 129.49 75.22 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.972 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 -179.27 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 85.4 mt -101.61 126.2 55.54 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.026 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -119.59 112.78 19.76 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 -179.263 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -118.44 132.69 56.24 Favored 'General case' 0 CA--C 1.498 -1.054 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 178.754 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 97.7 p -156.2 170.81 21.36 Favored 'General case' 0 CA--C 1.497 -1.085 0 C-N-CA 119.384 -0.926 . . . . 0.0 108.683 -178.696 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 54.4 p90 -142.28 155.81 45.24 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 179.406 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -137.0 133.53 35.64 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 87.5 t80 -118.33 129.31 55.37 Favored 'General case' 0 N--CA 1.438 -1.043 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 47.9 t -103.98 121.8 43.91 Favored 'General case' 0 CA--C 1.497 -1.068 0 N-CA-C 106.14 -1.8 . . . . 0.0 106.14 179.501 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 60.3 tptt -93.38 119.79 32.91 Favored 'General case' 0 N--CA 1.439 -1.021 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 -178.814 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -152.97 126.87 8.95 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 105.282 -2.118 . . . . 0.0 105.282 178.623 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -64.76 -39.54 93.78 Favored 'General case' 0 N--CA 1.445 -0.694 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.129 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -63.17 -47.87 80.79 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 120.53 -0.468 . . . . 0.0 110.581 -178.268 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 58.6 t -142.21 128.2 18.23 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.004 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 -179.098 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -91.21 127.71 36.75 Favored 'General case' 0 CA--C 1.501 -0.937 0 N-CA-C 106.036 -1.839 . . . . 0.0 106.036 178.7 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 81.5 t -126.75 127.1 69.74 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.013 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -178.733 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -117.28 134.16 11.03 Favored Glycine 0 C--N 1.351 1.416 0 N-CA-C 105.671 -2.972 . . . . 0.0 105.671 178.341 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 88.8 m -129.87 135.3 48.22 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 -178.862 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 92.9 m95 -107.66 140.56 40.5 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 105.314 -2.106 . . . . 0.0 105.314 178.796 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 78.7 mtm -125.32 132.74 52.8 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 -178.543 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -133.53 138.4 46.05 Favored 'General case' 0 CA--C 1.495 -1.157 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 179.563 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -170.58 -168.75 32.81 Favored Glycine 0 N--CA 1.434 -1.436 0 N-CA-C 108.374 -1.89 . . . . 0.0 108.374 -179.55 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -139.19 160.86 38.81 Favored 'General case' 0 N--CA 1.435 -1.197 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 -179.293 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 153' ' ' GLY . . . . . 0.433 ' HA2' ' HA ' ' A' ' 7' ' ' SER . . . -133.78 165.26 24.27 Favored Glycine 0 CA--C 1.491 -1.447 0 N-CA-C 108.183 -1.967 . . . . 0.0 108.183 -179.311 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 88.2 t80 -132.21 135.18 46.13 Favored 'General case' 0 N--CA 1.435 -1.179 0 N-CA-C 106.49 -1.671 . . . . 0.0 106.49 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 6.8 tmm_? -136.94 139.68 41.7 Favored 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 -179.522 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 31.7 t80 . . . . . 0 C--O 1.263 1.815 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 179.826 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 80.3 mm-40 . . . . . 0 N--CA 1.488 1.461 0 CA-C-O 120.886 0.374 . . . . 0.0 110.549 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 179.41 -179.81 48.82 Favored Glycine 0 N--CA 1.436 -1.351 0 N-CA-C 107.224 -2.351 . . . . 0.0 107.224 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 24.1 pt-20 -154.59 156.04 35.84 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 55.8 m -116.05 -60.49 1.86 Allowed 'General case' 0 CA--C 1.498 -1.033 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 38.7 t -154.51 145.96 23.08 Favored 'General case' 0 CA--C 1.498 -1.037 0 N-CA-C 107.413 -1.329 . . . . 0.0 107.413 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 47.4 pt -129.01 149.5 33.75 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.097 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 179.278 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.418 ' HB2' ' HB2' ' A' ' 32' ' ' LYS . 63.6 m -138.75 149.32 44.91 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 -179.498 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 46.5 pt -131.94 157.09 43.06 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.057 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 179.216 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -176.83 -168.3 36.59 Favored Glycine 0 CA--C 1.492 -1.394 0 N-CA-C 108.19 -1.964 . . . . 0.0 108.19 -179.703 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -127.54 149.21 50.25 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 -179.492 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -111.68 134.06 53.51 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 107.375 -1.342 . . . . 0.0 107.375 -179.672 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 84.2 mt-30 -123.23 136.31 54.67 Favored 'General case' 0 CA--C 1.495 -1.149 0 N-CA-C 106.681 -1.599 . . . . 0.0 106.681 179.508 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 66.6 m -120.73 145.77 47.16 Favored 'General case' 0 CA--C 1.493 -1.226 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -142.05 153.19 44.03 Favored 'General case' 0 N--CA 1.437 -1.103 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 -179.761 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.2 p -143.81 142.7 24.56 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.166 0 N-CA-C 106.42 -1.696 . . . . 0.0 106.42 179.808 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 75.5 mmtt -109.19 124.89 51.57 Favored 'General case' 0 CA--C 1.497 -1.091 0 N-CA-C 106.984 -1.488 . . . . 0.0 106.984 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -153.27 140.56 19.56 Favored 'General case' 0 N--CA 1.435 -1.201 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 -179.882 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -65.01 136.99 57.43 Favored 'General case' 0 N--CA 1.442 -0.868 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 -179.765 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 104.35 -16.29 49.17 Favored Glycine 0 C--N 1.352 1.452 0 N-CA-C 108.365 -1.894 . . . . 0.0 108.365 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 88.8 m-85 -115.19 128.83 56.43 Favored 'General case' 0 CA--C 1.497 -1.065 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 179.446 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 60.8 tptt -110.49 -58.04 2.14 Favored 'General case' 0 CA--C 1.501 -0.915 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 -179.494 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.537 ' HG ' ' H ' ' A' ' 24' ' ' LYS . 58.3 tp -120.77 121.77 38.9 Favored 'General case' 0 N--CA 1.44 -0.954 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 -179.04 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 97.5 m-20 -98.3 6.33 47.46 Favored 'General case' 0 C--N 1.356 0.891 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 -179.474 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.537 ' H ' ' HG ' ' A' ' 22' ' ' LEU . 48.3 mmtm 69.98 -147.67 0.1 Allowed 'General case' 0 C--N 1.355 0.818 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 47.3 t30 -130.69 116.69 17.24 Favored Pre-proline 0 N--CA 1.439 -0.982 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 -179.751 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -74.05 156.43 47.34 Favored 'Trans proline' 0 CA--C 1.499 -1.253 0 C-N-CA 121.758 1.639 . . . . 0.0 112.495 179.583 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -94.78 122.04 37.0 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -152.1 156.2 26.56 Favored Glycine 0 C--N 1.351 1.399 0 N-CA-C 107.942 -2.063 . . . . 0.0 107.942 -179.852 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -131.82 151.72 51.48 Favored 'General case' 0 CA--C 1.498 -1.021 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 -179.668 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.524 HD22 ' HB2' ' A' ' 48' ' ' ALA . 10.8 t-20 -137.25 125.25 22.79 Favored 'General case' 0 N--CA 1.441 -0.909 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 -179.688 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 89.7 mt -119.64 135.47 54.8 Favored 'General case' 0 CA--C 1.499 -1.006 0 N-CA-C 106.153 -1.795 . . . . 0.0 106.153 178.714 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.418 ' HB2' ' HB2' ' A' ' 7' ' ' SER . 37.8 mtmm -133.36 144.68 49.76 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 107.859 -1.163 . . . . 0.0 107.859 -179.483 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 92.3 m-85 -132.19 136.78 47.29 Favored 'General case' 0 CA--C 1.498 -1.042 0 N-CA-C 106.764 -1.569 . . . . 0.0 106.764 179.577 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 79.2 ttt180 -119.22 132.33 55.92 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 98.4 m-85 -117.57 130.2 56.25 Favored 'General case' 0 N--CA 1.438 -1.061 0 N-CA-C 106.346 -1.724 . . . . 0.0 106.346 179.148 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -109.2 127.07 53.93 Favored 'General case' 0 CA--C 1.498 -1.036 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 -179.381 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 -127.99 147.68 50.5 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 179.646 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -86.65 72.92 10.14 Favored 'General case' 0 N--CA 1.441 -0.893 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 -179.375 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 31.9 m120 -124.13 -54.96 1.69 Allowed 'General case' 0 CA--C 1.499 -1.017 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 178.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -178.45 -55.22 0.01 OUTLIER 'General case' 0 N--CA 1.439 -0.987 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 35.7 m0 -125.25 149.47 47.98 Favored 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 -178.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -87.32 -179.48 48.29 Favored Glycine 0 C--N 1.351 1.41 0 N-CA-C 107.716 -2.154 . . . . 0.0 107.716 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.9 p -138.68 143.05 33.09 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.891 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.3 tt -131.96 141.19 46.17 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.951 0 N-CA-C 107.37 -1.344 . . . . 0.0 107.37 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -118.91 145.91 18.29 Favored Glycine 0 CA--C 1.492 -1.359 0 N-CA-C 106.459 -2.656 . . . . 0.0 106.459 179.56 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 45.3 t -138.66 136.67 36.11 Favored 'General case' 0 CA--C 1.499 -0.995 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 -179.205 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 91.2 t80 -131.02 130.42 43.3 Favored 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 105.765 -1.939 . . . . 0.0 105.765 179.248 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.524 ' HB2' HD22 ' A' ' 30' ' ' ASN . . . -146.86 152.89 39.46 Favored 'General case' 0 N--CA 1.436 -1.126 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 -179.314 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 20.6 pt20 -150.96 152.25 33.3 Favored 'General case' 0 N--CA 1.433 -1.287 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 179.398 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 10.1 t -146.38 152.11 38.55 Favored 'General case' 0 CA--C 1.499 -1.003 0 N-CA-C 107.215 -1.402 . . . . 0.0 107.215 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 5.6 tmm_? -132.84 129.62 38.7 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 107.004 -1.48 . . . . 0.0 107.004 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 72.3 ttp85 -133.71 127.02 31.98 Favored 'General case' 0 CA--C 1.495 -1.156 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 179.6 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -173.57 160.39 30.64 Favored Glycine 0 CA--C 1.489 -1.583 0 N-CA-C 108.1 -2.0 . . . . 0.0 108.1 179.795 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 95.7 m-85 -135.96 152.38 50.9 Favored 'General case' 0 N--CA 1.437 -1.106 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 179.723 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -63.93 -39.87 95.16 Favored 'General case' 0 CA--C 1.505 -0.787 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 -179.83 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -138.81 132.7 31.02 Favored 'General case' 0 N--CA 1.439 -0.999 0 N-CA-C 106.753 -1.573 . . . . 0.0 106.753 179.906 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 69.3 m -128.03 142.01 51.35 Favored 'General case' 0 CA--C 1.496 -1.113 0 N-CA-C 107.224 -1.398 . . . . 0.0 107.224 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 76.6 t -65.55 -45.57 92.16 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.826 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 179.294 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 61.2 t0 -152.36 100.98 2.64 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 106.302 -1.74 . . . . 0.0 106.302 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -150.6 43.95 0.7 Allowed Glycine 0 CA--C 1.491 -1.413 0 N-CA-C 107.427 -2.269 . . . . 0.0 107.427 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 6.5 t80 79.58 -54.43 0.41 Allowed 'General case' 0 C--N 1.358 0.966 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -117.31 137.33 52.5 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 179.786 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 87.8 mt -67.11 -40.09 86.79 Favored 'General case' 0 CA--C 1.505 -0.786 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 -179.628 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 45.5 pt -133.67 157.8 42.38 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.086 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 -179.517 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 59.04 41.42 20.8 Favored 'General case' 0 C--N 1.358 0.962 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 179.548 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -92.36 85.55 1.19 Allowed Glycine 0 C--N 1.35 1.36 0 N-CA-C 107.555 -2.218 . . . . 0.0 107.555 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -112.25 135.38 53.01 Favored 'General case' 0 CA--C 1.499 -0.996 0 N-CA-C 107.397 -1.335 . . . . 0.0 107.397 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -127.33 125.4 40.73 Favored 'General case' 0 N--CA 1.439 -0.986 0 N-CA-C 106.708 -1.59 . . . . 0.0 106.708 179.739 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 65.0 mttp -109.11 140.63 42.42 Favored 'General case' 0 CA--C 1.496 -1.1 0 N-CA-C 106.733 -1.58 . . . . 0.0 106.733 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 49.9 t80 -136.29 127.36 27.88 Favored 'General case' 0 N--CA 1.438 -1.058 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -120.29 140.76 50.76 Favored 'General case' 0 CA--C 1.495 -1.137 0 N-CA-C 106.813 -1.551 . . . . 0.0 106.813 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 67.9 m -132.33 136.15 46.68 Favored 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 108.015 -1.105 . . . . 0.0 108.015 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 61.1 t -129.12 136.39 59.71 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.211 0 N-CA-C 105.013 -2.217 . . . . 0.0 105.013 178.572 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 11.2 t -159.08 154.84 26.28 Favored 'General case' 0 N--CA 1.436 -1.137 0 C-N-CA 119.152 -1.019 . . . . 0.0 108.609 -179.086 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -156.52 159.43 38.58 Favored 'General case' 0 N--CA 1.435 -1.182 0 N-CA-C 106.119 -1.808 . . . . 0.0 106.119 179.447 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -174.33 175.46 46.7 Favored Glycine 0 C--N 1.348 1.233 0 N-CA-C 108.208 -1.957 . . . . 0.0 108.208 179.759 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -77.68 155.49 31.27 Favored 'Trans proline' 0 C--N 1.312 -1.394 0 C-N-CA 122.547 2.165 . . . . 0.0 113.239 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 65.8 t -115.26 128.31 72.5 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.995 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 94.8 m-85 -113.79 130.4 56.46 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 -179.191 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 54.2 ttp180 -112.64 134.58 54.09 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 179.163 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 51.2 mm -73.16 -64.26 0.85 Allowed 'Isoleucine or valine' 0 CA--C 1.503 -0.841 0 N-CA-C 106.972 -1.492 . . . . 0.0 106.972 179.779 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 65.7 t30 -176.75 93.59 0.04 OUTLIER 'General case' 0 N--CA 1.441 -0.911 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 177.655 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 70.8 tt0 36.48 46.72 0.45 Allowed 'General case' 0 C--N 1.359 0.984 0 C-N-CA 123.378 0.671 . . . . 0.0 111.365 178.337 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 18.2 t80 -142.57 -45.96 0.32 Allowed 'General case' 0 CA--C 1.501 -0.922 0 C-N-CA 118.823 -1.151 . . . . 0.0 108.641 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 16.6 m -148.85 157.89 6.97 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.159 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 179.618 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 66.3 m -132.09 145.96 51.74 Favored 'General case' 0 CA--C 1.497 -1.079 0 N-CA-C 106.52 -1.659 . . . . 0.0 106.52 178.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 1.1 pp -142.47 159.63 41.86 Favored 'General case' 0 CA--C 1.493 -1.226 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 23.7 p90 -152.64 158.76 42.88 Favored 'General case' 0 N--CA 1.435 -1.175 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 -179.566 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -109.05 151.22 17.15 Favored Glycine 0 CA--C 1.491 -1.447 0 N-CA-C 107.059 -2.416 . . . . 0.0 107.059 -179.518 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 92.0 mt -115.88 133.52 55.94 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 -179.473 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 64.5 tp -137.42 128.08 26.93 Favored 'General case' 0 N--CA 1.437 -1.092 0 N-CA-C 105.312 -2.107 . . . . 0.0 105.312 178.599 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -178.71 -158.26 20.9 Favored Glycine 0 CA--C 1.491 -1.431 0 N-CA-C 108.518 -1.833 . . . . 0.0 108.518 -179.319 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -146.66 158.37 43.89 Favored 'General case' 0 N--CA 1.434 -1.246 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 -179.206 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -117.49 150.67 18.33 Favored Glycine 0 CA--C 1.493 -1.342 0 N-CA-C 107.166 -2.374 . . . . 0.0 107.166 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 96.8 m-70 -126.56 137.36 53.33 Favored 'General case' 0 CA--C 1.497 -1.086 0 N-CA-C 107.164 -1.421 . . . . 0.0 107.164 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -113.15 141.28 16.84 Favored Glycine 0 C--N 1.35 1.358 0 N-CA-C 107.313 -2.315 . . . . 0.0 107.313 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 17.9 tppt? -137.6 128.91 27.9 Favored 'General case' 0 CA--C 1.5 -0.973 0 N-CA-C 107.443 -1.317 . . . . 0.0 107.443 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -155.04 33.02 0.39 Allowed 'General case' 0 N--CA 1.44 -0.97 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 179.58 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 40.0 ttpt -147.86 137.47 22.5 Favored 'General case' 0 N--CA 1.436 -1.131 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 -179.535 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -97.74 134.27 41.14 Favored 'General case' 0 CA--C 1.497 -1.072 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 31.2 t -152.82 153.92 34.09 Favored 'General case' 0 N--CA 1.438 -1.054 0 N-CA-C 106.666 -1.605 . . . . 0.0 106.666 -179.52 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 44.3 t -66.86 142.31 57.37 Favored 'General case' 0 CA--C 1.504 -0.823 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 93.8 mt -62.09 -44.58 99.19 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.828 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -102.63 115.46 30.63 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 106.53 -1.655 . . . . 0.0 106.53 179.54 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 166.58 -167.8 39.75 Favored Glycine 0 CA--C 1.492 -1.383 0 N-CA-C 106.782 -2.527 . . . . 0.0 106.782 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 54.3 tt0 -104.36 119.39 38.85 Favored 'General case' 0 N--CA 1.439 -0.992 0 N-CA-C 107.004 -1.48 . . . . 0.0 107.004 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 70.9 m -132.48 148.84 52.4 Favored 'General case' 0 CA--C 1.495 -1.149 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 179.643 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -131.93 144.28 50.72 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 107.154 -1.425 . . . . 0.0 107.154 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 66.4 m -133.21 139.83 47.21 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 179.599 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 60.8 ttp180 -84.18 -52.19 6.46 Favored 'General case' 0 CA--C 1.503 -0.863 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.2 m -168.29 80.27 0.16 Allowed 'General case' 0 CA--C 1.497 -1.068 0 N-CA-C 107.305 -1.368 . . . . 0.0 107.305 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -98.73 1.4 46.04 Favored 'General case' 0 CA--C 1.502 -0.88 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 89.2 m -115.09 129.08 56.6 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 106.83 -1.545 . . . . 0.0 106.83 -179.592 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 63.8 m -128.66 148.28 50.8 Favored 'General case' 0 CA--C 1.496 -1.098 0 N-CA-C 107.359 -1.349 . . . . 0.0 107.359 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 92.1 mt -79.72 149.62 31.11 Favored 'General case' 0 CA--C 1.499 -0.998 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -136.01 144.89 45.55 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 -179.548 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -134.04 152.05 51.68 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 106.396 -1.705 . . . . 0.0 106.396 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -174.39 -175.69 42.16 Favored Glycine 0 CA--C 1.491 -1.431 0 N-CA-C 108.612 -1.795 . . . . 0.0 108.612 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -154.78 159.98 40.99 Favored 'General case' 0 N--CA 1.435 -1.199 0 N-CA-C 106.129 -1.804 . . . . 0.0 106.129 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -142.65 152.68 24.04 Favored Glycine 0 CA--C 1.491 -1.427 0 N-CA-C 108.477 -1.849 . . . . 0.0 108.477 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 89.0 mt -120.36 142.62 48.99 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 106.384 -1.71 . . . . 0.0 106.384 179.76 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 51.8 tt0 -125.02 126.92 46.17 Favored 'General case' 0 N--CA 1.437 -1.112 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -114.77 120.27 39.49 Favored 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 106.467 -1.679 . . . . 0.0 106.467 179.651 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 12.7 p-10 -133.36 75.17 70.63 Favored Pre-proline 0 N--CA 1.439 -0.996 0 N-CA-C 108.401 -0.962 . . . . 0.0 108.401 -179.34 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -67.54 -22.49 44.6 Favored 'Trans proline' 0 CA--C 1.499 -1.274 0 C-N-CA 121.761 1.641 . . . . 0.0 111.914 179.202 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 4.3 p80 -152.51 152.8 29.61 Favored Pre-proline 0 N--CA 1.433 -1.282 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 179.037 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -72.05 -15.03 29.2 Favored 'Trans proline' 0 C--N 1.31 -1.456 0 C-N-CA 122.004 1.802 . . . . 0.0 114.074 -179.049 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 27.1 m120 -62.93 -41.83 99.61 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 -178.784 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -139.5 140.8 37.31 Favored 'General case' 0 CA--C 1.498 -1.04 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 -179.658 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 75.7 t -124.77 129.73 73.52 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.006 0 N-CA-C 106.16 -1.793 . . . . 0.0 106.16 179.21 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 84.6 mt -101.16 125.62 55.09 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.995 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 -179.064 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 45.3 m-20 -119.26 134.13 55.38 Favored 'General case' 0 N--CA 1.44 -0.931 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -139.7 128.68 23.57 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 106.089 -1.819 . . . . 0.0 106.089 178.721 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 63.6 m -136.46 150.1 48.55 Favored 'General case' 0 CA--C 1.494 -1.196 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -179.214 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -126.73 134.78 50.57 Favored 'General case' 0 N--CA 1.438 -1.055 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 179.348 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -137.06 133.27 35.24 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 -179.751 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -130.96 150.07 52.29 Favored 'General case' 0 CA--C 1.498 -1.053 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 -179.593 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 47.1 t -134.65 135.15 41.88 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 179.751 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -112.89 124.9 53.66 Favored 'General case' 0 CA--C 1.498 -1.037 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 -178.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 52.8 tp -138.81 142.74 38.7 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 104.946 -2.242 . . . . 0.0 104.946 178.861 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -61.46 -38.62 87.9 Favored 'General case' 0 CA--C 1.508 -0.658 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 -178.487 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -62.98 -41.87 99.68 Favored 'General case' 0 C--N 1.352 0.711 0 C-N-CA 120.604 -0.438 . . . . 0.0 110.113 -178.842 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 13.8 p -166.49 144.5 1.36 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.79 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 -179.461 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 57.5 mtmt -107.53 135.92 48.17 Favored 'General case' 0 CA--C 1.498 -1.038 0 N-CA-C 106.18 -1.785 . . . . 0.0 106.18 179.145 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 35.2 m -133.83 157.98 42.28 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.06 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 -179.019 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -128.17 140.07 11.52 Favored Glycine 0 C--N 1.352 1.423 0 N-CA-C 106.702 -2.559 . . . . 0.0 106.702 179.284 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 92.1 m -126.65 129.66 48.92 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 -179.614 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 54.1 m0 -113.64 138.84 49.63 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 106.216 -1.772 . . . . 0.0 106.216 179.519 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 64.5 mtt -126.37 126.48 43.94 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 -179.321 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 89.9 mt -126.88 142.66 51.49 Favored 'General case' 0 CA--C 1.494 -1.177 0 N-CA-C 105.998 -1.853 . . . . 0.0 105.998 179.293 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -172.72 -171.89 37.91 Favored Glycine 0 CA--C 1.492 -1.389 0 N-CA-C 108.737 -1.745 . . . . 0.0 108.737 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -143.67 160.18 41.16 Favored 'General case' 0 N--CA 1.434 -1.242 0 N-CA-C 106.508 -1.664 . . . . 0.0 106.508 -179.376 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -142.46 -178.16 18.18 Favored Glycine 0 CA--C 1.49 -1.481 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -179.116 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 93.5 t80 -143.2 143.4 31.76 Favored 'General case' 0 N--CA 1.436 -1.14 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 -179.579 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 17.7 ptm180 -145.67 159.85 42.56 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 36.1 t80 . . . . . 0 C--O 1.264 1.832 0 N-CA-C 108.134 -1.062 . . . . 0.0 108.134 -179.995 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 . . . . . 0 N--CA 1.489 1.501 0 CA-C-O 120.865 0.364 . . . . 0.0 110.564 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 179.67 -176.42 47.57 Favored Glycine 0 CA--C 1.492 -1.377 0 N-CA-C 107.162 -2.375 . . . . 0.0 107.162 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -129.38 146.35 51.26 Favored 'General case' 0 CA--C 1.497 -1.072 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 13.2 m -120.96 -88.28 0.63 Allowed 'General case' 0 CA--C 1.5 -0.946 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 -179.827 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 64.0 m -139.7 150.99 45.52 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 107.902 -1.148 . . . . 0.0 107.902 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 20.1 tt -133.43 138.96 50.08 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.996 0 N-CA-C 106.208 -1.775 . . . . 0.0 106.208 179.542 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.439 ' HB2' ' HB2' ' A' ' 32' ' ' LYS . 49.7 m -131.57 148.55 52.63 Favored 'General case' 0 CA--C 1.497 -1.079 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 -179.156 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 45.6 pt -131.6 158.24 43.27 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.106 0 N-CA-C 106.311 -1.737 . . . . 0.0 106.311 179.205 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -167.19 -176.05 37.74 Favored Glycine 0 CA--C 1.493 -1.329 0 N-CA-C 108.506 -1.837 . . . . 0.0 108.506 -179.547 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -125.38 150.77 46.93 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 106.849 -1.538 . . . . 0.0 106.849 -179.43 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -100.62 135.44 42.06 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 -179.469 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 7.5 tp-100 -117.69 129.17 55.56 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 179.383 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 43.8 m -122.04 -3.11 9.1 Favored 'General case' 0 CA--C 1.502 -0.892 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 -179.27 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 79.6 ttt180 -134.46 127.59 31.77 Favored 'General case' 0 CA--C 1.497 -1.072 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 -179.02 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 64.9 t -122.44 118.13 54.28 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.013 0 N-CA-C 106.174 -1.787 . . . . 0.0 106.174 178.841 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 65.8 tttm -161.49 141.42 10.5 Favored 'General case' 0 CA--C 1.497 -1.069 0 N-CA-C 106.803 -1.555 . . . . 0.0 106.803 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 89.1 tt0 -91.07 109.17 20.41 Favored 'General case' 0 N--CA 1.438 -1.035 0 N-CA-C 107.006 -1.479 . . . . 0.0 107.006 179.693 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -158.44 97.05 1.45 Allowed 'General case' 0 N--CA 1.436 -1.153 0 N-CA-C 106.667 -1.605 . . . . 0.0 106.667 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -102.1 1.17 51.07 Favored Glycine 0 C--N 1.35 1.361 0 N-CA-C 108.514 -1.834 . . . . 0.0 108.514 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -71.09 -40.06 71.77 Favored 'General case' 0 CA--C 1.503 -0.843 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 -179.493 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 39.9 ttmt -157.56 137.66 12.58 Favored 'General case' 0 N--CA 1.437 -1.083 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 88.9 mt -108.99 123.42 49.09 Favored 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 179.549 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 19.9 t0 -167.62 155.88 9.23 Favored 'General case' 0 N--CA 1.435 -1.192 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 57.0 mtmt 58.85 43.93 17.5 Favored 'General case' 0 C--N 1.357 0.932 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 179.503 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 36.2 m120 -106.42 147.53 35.1 Favored Pre-proline 0 N--CA 1.441 -0.916 0 N-CA-C 107.059 -1.459 . . . . 0.0 107.059 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -75.65 155.59 39.98 Favored 'Trans proline' 0 CA--C 1.497 -1.328 0 C-N-CA 122.224 1.95 . . . . 0.0 112.88 179.811 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 16.0 mtm180 -136.57 129.76 31.35 Favored 'General case' 0 N--CA 1.438 -1.039 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -159.21 160.03 30.91 Favored Glycine 0 CA--C 1.492 -1.367 0 N-CA-C 107.595 -2.202 . . . . 0.0 107.595 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -130.16 145.71 51.74 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 107.045 -1.465 . . . . 0.0 107.045 -179.499 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 85.0 m-20 -125.06 136.8 54.03 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 7.0 mp -124.69 129.85 51.29 Favored 'General case' 0 CA--C 1.497 -1.081 0 N-CA-C 105.682 -1.97 . . . . 0.0 105.682 178.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.439 ' HB2' ' HB2' ' A' ' 7' ' ' SER . 97.4 mttt -128.37 142.53 51.09 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 -179.044 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -127.13 137.28 52.95 Favored 'General case' 0 CA--C 1.495 -1.135 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 179.632 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 78.5 ttt180 -117.86 129.24 55.53 Favored 'General case' 0 CA--C 1.495 -1.147 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 -179.496 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -110.88 127.38 55.42 Favored 'General case' 0 N--CA 1.438 -1.048 0 N-CA-C 106.153 -1.795 . . . . 0.0 106.153 179.007 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 50.1 mt-10 -105.8 139.56 40.19 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 108.007 -1.108 . . . . 0.0 108.007 -179.167 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -132.18 164.82 25.49 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 66.9 t30 -79.62 77.79 6.21 Favored 'General case' 0 N--CA 1.443 -0.806 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 9.3 t-20 -165.94 175.98 8.18 Favored 'General case' 0 N--CA 1.433 -1.277 0 N-CA-C 106.056 -1.831 . . . . 0.0 106.056 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -91.11 -0.17 57.66 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 93.7 m95 -115.52 139.47 50.04 Favored 'General case' 0 CA--C 1.498 -1.036 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -124.85 174.43 17.19 Favored Glycine 0 C--N 1.35 1.307 0 N-CA-C 107.265 -2.334 . . . . 0.0 107.265 179.704 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 92.6 t -127.5 131.94 69.75 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.997 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 19.8 tt -127.24 138.05 55.97 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.878 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -120.76 140.03 13.93 Favored Glycine 0 CA--C 1.489 -1.532 0 N-CA-C 106.12 -2.792 . . . . 0.0 106.12 179.297 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 54.8 m -133.04 139.51 47.23 Favored 'General case' 0 CA--C 1.497 -1.071 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 -179.021 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -123.5 133.21 54.05 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 105.814 -1.921 . . . . 0.0 105.814 178.831 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -128.96 130.14 46.32 Favored 'General case' 0 CA--C 1.496 -1.099 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 -179.428 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 71.5 mt-30 -129.78 127.52 40.52 Favored 'General case' 0 CA--C 1.497 -1.085 0 N-CA-C 106.447 -1.686 . . . . 0.0 106.447 179.353 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 88.0 m -121.77 121.7 37.84 Favored 'General case' 0 CA--C 1.498 -1.051 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 71.7 ttp85 -70.12 -43.19 71.48 Favored 'General case' 0 CA--C 1.502 -0.889 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 -179.521 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 76.0 ttt180 -151.07 135.25 16.78 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -120.62 149.67 17.5 Favored Glycine 0 C--N 1.352 1.418 0 N-CA-C 107.04 -2.424 . . . . 0.0 107.04 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 89.9 t80 -137.94 130.17 29.01 Favored 'General case' 0 N--CA 1.438 -1.032 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 -179.653 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -98.47 139.25 34.49 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 106.851 -1.537 . . . . 0.0 106.851 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 36.3 mp0 -73.1 102.83 3.66 Favored 'General case' 0 CA--C 1.501 -0.91 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 -179.793 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 34.8 t -159.89 152.54 21.29 Favored 'General case' 0 N--CA 1.435 -1.18 0 N-CA-C 105.909 -1.886 . . . . 0.0 105.909 179.845 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 58.8 t -85.66 95.29 4.43 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.968 0 N-CA-C 106.827 -1.546 . . . . 0.0 106.827 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -158.74 110.76 2.2 Favored 'General case' 0 N--CA 1.434 -1.243 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -168.5 173.17 43.18 Favored Glycine 0 CA--C 1.492 -1.376 0 N-CA-C 107.429 -2.268 . . . . 0.0 107.429 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 18.8 t80 77.83 -70.31 0.12 Allowed 'General case' 0 C--N 1.356 0.864 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 179.492 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -66.14 -39.81 90.11 Favored 'General case' 0 CA--C 1.504 -0.813 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -124.87 144.52 50.27 Favored 'General case' 0 CA--C 1.497 -1.077 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 -179.711 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 46.6 mm -66.32 -45.1 90.48 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.759 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 179.599 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 33.7 t0 58.83 50.01 9.17 Favored 'General case' 0 C--N 1.359 1.02 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.556 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 176.58 -167.67 39.28 Favored Glycine 0 CA--C 1.491 -1.412 0 N-CA-C 107.131 -2.387 . . . . 0.0 107.131 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 33.3 t0 62.19 48.26 5.04 Favored 'General case' 0 C--N 1.355 0.83 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 33.9 t80 -135.86 125.82 25.92 Favored 'General case' 0 N--CA 1.438 -1.052 0 N-CA-C 106.034 -1.839 . . . . 0.0 106.034 179.718 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 8.0 mptt -89.69 141.9 28.18 Favored 'General case' 0 CA--C 1.501 -0.942 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 -179.096 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -126.34 134.66 51.03 Favored 'General case' 0 CA--C 1.499 -1.007 0 N-CA-C 106.957 -1.497 . . . . 0.0 106.957 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -130.64 136.49 48.89 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 179.228 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 70.9 m -145.02 142.76 30.04 Favored 'General case' 0 CA--C 1.493 -1.234 0 N-CA-C 108.106 -1.072 . . . . 0.0 108.106 179.809 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 71.2 t -128.7 135.55 62.05 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.246 0 N-CA-C 105.271 -2.122 . . . . 0.0 105.271 178.611 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 67.5 p -140.19 159.95 41.04 Favored 'General case' 0 CA--C 1.499 -1.007 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 -179.408 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -156.94 156.63 33.37 Favored 'General case' 0 N--CA 1.436 -1.17 0 N-CA-C 106.19 -1.781 . . . . 0.0 106.19 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -177.12 177.16 48.28 Favored Glycine 0 N--CA 1.436 -1.328 0 N-CA-C 108.355 -1.898 . . . . 0.0 108.355 179.618 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 69.5 Cg_endo -82.45 157.76 16.84 Favored 'Trans proline' 0 C--N 1.309 -1.501 0 C-N-CA 122.754 2.303 . . . . 0.0 113.836 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 66.4 t -119.74 130.09 74.57 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.017 0 N-CA-C 105.641 -1.985 . . . . 0.0 105.641 178.733 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 86.9 t80 -124.96 131.5 53.41 Favored 'General case' 0 N--CA 1.441 -0.917 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 -179.077 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 41.6 ptt180 -112.17 142.89 44.08 Favored 'General case' 0 CA--C 1.5 -0.969 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 179.689 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 49.1 mm -75.07 -63.28 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.502 -0.885 0 N-CA-C 106.787 -1.56 . . . . 0.0 106.787 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -174.8 92.82 0.07 Allowed 'General case' 0 N--CA 1.442 -0.865 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 177.508 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 38.93 41.45 0.54 Allowed 'General case' 0 C--N 1.357 0.898 0 CA-C-N 115.596 -0.729 . . . . 0.0 112.136 177.749 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 19.8 t80 -142.19 -45.62 0.34 Allowed 'General case' 0 CA--C 1.501 -0.93 0 C-N-CA 118.749 -1.18 . . . . 0.0 108.655 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 27.8 m -144.74 155.48 14.41 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.184 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 66.0 m -136.26 147.1 47.38 Favored 'General case' 0 CA--C 1.496 -1.132 0 N-CA-C 106.908 -1.516 . . . . 0.0 106.908 178.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 1.1 pp -134.54 158.79 43.05 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -151.46 158.93 44.31 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 -179.47 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -123.16 147.58 16.7 Favored Glycine 0 CA--C 1.489 -1.574 0 N-CA-C 106.356 -2.698 . . . . 0.0 106.356 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 94.8 mt -123.85 140.05 53.37 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 -179.36 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -148.72 149.01 30.68 Favored 'General case' 0 N--CA 1.436 -1.157 0 N-CA-C 106.078 -1.823 . . . . 0.0 106.078 178.602 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 175.6 -147.28 8.7 Favored Glycine 0 CA--C 1.491 -1.423 0 N-CA-C 107.704 -2.158 . . . . 0.0 107.704 -179.46 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -140.78 155.77 46.32 Favored 'General case' 0 N--CA 1.438 -1.052 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 -178.78 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -119.72 142.83 16.6 Favored Glycine 0 C--N 1.351 1.404 0 N-CA-C 107.118 -2.393 . . . . 0.0 107.118 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' HIS . . . . . 0.458 ' HE1' ' HE2' ' A' ' 97' ' ' LYS . 58.8 t-80 -151.67 136.45 17.15 Favored 'General case' 0 N--CA 1.438 -1.026 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 -179.504 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -154.82 152.83 24.34 Favored Glycine 0 CA--C 1.494 -1.274 0 N-CA-C 107.672 -2.171 . . . . 0.0 107.672 179.404 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.458 ' HE2' ' HE1' ' A' ' 95' ' ' HIS . 68.7 mttm -132.03 138.79 48.34 Favored 'General case' 0 CA--C 1.497 -1.065 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 178.958 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -66.83 -41.69 87.05 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 179.142 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 62.7 mtpt -136.43 151.3 49.35 Favored 'General case' 0 CA--C 1.497 -1.059 0 N-CA-C 106.882 -1.525 . . . . 0.0 106.882 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -112.39 140.76 46.84 Favored 'General case' 0 CA--C 1.497 -1.07 0 N-CA-C 107.031 -1.47 . . . . 0.0 107.031 179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 72.3 m -85.24 127.4 34.29 Favored 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 -179.776 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 73.2 m -67.0 -39.61 87.14 Favored 'General case' 0 CA--C 1.503 -0.844 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 85.1 mt -116.37 127.56 73.94 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.001 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 -179.326 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 93.1 m-85 -91.03 140.3 29.96 Favored 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -178.39 -170.34 40.36 Favored Glycine 0 CA--C 1.491 -1.424 0 N-CA-C 106.759 -2.536 . . . . 0.0 106.759 -179.634 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 64.4 tt0 -83.7 116.97 22.92 Favored 'General case' 0 N--CA 1.438 -1.027 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 5.6 t -169.33 -169.02 0.88 Allowed 'General case' 0 N--CA 1.437 -1.082 0 N-CA-C 106.208 -1.775 . . . . 0.0 106.208 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 50.0 mt-10 -83.45 133.03 34.93 Favored 'General case' 0 N--CA 1.44 -0.968 0 N-CA-C 107.03 -1.47 . . . . 0.0 107.03 179.628 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 34.8 t -155.86 150.33 25.89 Favored 'General case' 0 CA--C 1.498 -1.042 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 -179.58 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 86.0 mtp180 -127.19 145.85 50.62 Favored 'General case' 0 CA--C 1.496 -1.109 0 N-CA-C 106.813 -1.551 . . . . 0.0 106.813 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 36.5 t -149.58 140.0 22.39 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 -179.677 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -124.87 134.21 52.79 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 106.96 -1.496 . . . . 0.0 106.96 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 86.0 m -128.55 133.38 48.37 Favored 'General case' 0 CA--C 1.495 -1.149 0 N-CA-C 106.573 -1.64 . . . . 0.0 106.573 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 93.2 p -147.2 160.73 42.12 Favored 'General case' 0 CA--C 1.496 -1.119 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 89.4 mt -96.65 144.09 27.0 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -118.09 138.12 52.47 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 107.445 -1.316 . . . . 0.0 107.445 -179.288 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -132.65 149.38 52.31 Favored 'General case' 0 CA--C 1.494 -1.174 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 179.778 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -164.53 173.47 40.47 Favored Glycine 0 N--CA 1.433 -1.508 0 N-CA-C 107.925 -2.07 . . . . 0.0 107.925 179.745 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -150.72 157.63 43.19 Favored 'General case' 0 CA--C 1.492 -1.264 0 N-CA-C 106.001 -1.851 . . . . 0.0 106.001 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -159.08 167.44 34.89 Favored Glycine 0 N--CA 1.435 -1.432 0 N-CA-C 108.834 -1.706 . . . . 0.0 108.834 -179.477 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 88.9 mt -121.28 149.27 43.15 Favored 'General case' 0 CA--C 1.497 -1.069 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -117.18 127.62 54.29 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 179.588 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -112.77 138.82 49.02 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 107.088 -1.449 . . . . 0.0 107.088 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 67.0 m-20 -127.24 77.68 75.29 Favored Pre-proline 0 N--CA 1.442 -0.829 0 N-CA-C 107.004 -1.48 . . . . 0.0 107.004 -179.381 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -69.34 -28.62 27.04 Favored 'Trans proline' 0 CA--C 1.5 -1.207 0 C-N-CA 121.9 1.733 . . . . 0.0 113.326 -179.47 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -137.55 151.36 70.84 Favored Pre-proline 0 N--CA 1.438 -1.049 0 N-CA-C 106.86 -1.533 . . . . 0.0 106.86 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 92.6 Cg_endo -84.03 65.88 7.09 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 C-N-CA 122.003 1.802 . . . . 0.0 112.325 179.691 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.99 -33.66 0.04 OUTLIER 'General case' 0 N--CA 1.44 -0.97 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 -179.589 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -141.86 159.82 41.44 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 -179.468 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 32.7 m -130.06 158.0 42.56 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.009 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 -179.159 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 51.4 mm -116.63 125.06 73.42 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 106.352 -1.721 . . . . 0.0 106.352 179.553 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -114.2 136.03 53.4 Favored 'General case' 0 CA--C 1.5 -0.958 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 -179.147 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -137.67 139.95 40.54 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 105.428 -2.064 . . . . 0.0 105.428 178.487 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 34.1 t -157.99 153.01 25.39 Favored 'General case' 0 CA--C 1.501 -0.927 0 C-N-CA 119.326 -0.95 . . . . 0.0 108.527 -179.12 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 79.7 t80 -121.23 129.73 53.34 Favored 'General case' 0 N--CA 1.441 -0.896 0 N-CA-C 105.856 -1.905 . . . . 0.0 105.856 178.68 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -114.24 133.34 55.7 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 107.996 -1.112 . . . . 0.0 107.996 -179.128 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 86.3 t80 -116.51 126.15 52.94 Favored 'General case' 0 N--CA 1.439 -0.975 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 69.2 m -132.12 151.0 52.02 Favored 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 106.468 -1.678 . . . . 0.0 106.468 179.393 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -134.39 124.86 26.4 Favored 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 81.8 mt -120.65 113.9 20.9 Favored 'General case' 0 CA--C 1.495 -1.146 0 N-CA-C 106.939 -1.504 . . . . 0.0 106.939 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 65.2 m-20 60.64 -118.87 0.81 Allowed 'General case' 0 C--N 1.352 0.702 0 N-CA-C 108.131 -1.062 . . . . 0.0 108.131 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -108.99 16.55 22.53 Favored 'General case' 0 N--CA 1.443 -0.794 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 76.7 t -109.26 124.47 65.97 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.878 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 -179.037 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -94.78 134.01 37.86 Favored 'General case' 0 N--CA 1.439 -1.002 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 80.4 t -124.86 124.67 68.33 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.028 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 -179.633 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -123.72 133.73 8.99 Favored Glycine 0 CA--C 1.491 -1.445 0 N-CA-C 106.318 -2.713 . . . . 0.0 106.318 179.238 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 82.8 p -131.25 151.19 51.73 Favored 'General case' 0 CA--C 1.495 -1.159 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 -179.606 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 28.0 m-90 -113.29 138.05 50.59 Favored 'General case' 0 CA--C 1.495 -1.154 0 N-CA-C 106.472 -1.677 . . . . 0.0 106.472 179.39 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 2.5 mpp? -119.23 122.59 42.3 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -129.12 137.58 51.29 Favored 'General case' 0 CA--C 1.494 -1.201 0 N-CA-C 106.049 -1.834 . . . . 0.0 106.049 179.46 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -170.65 -175.39 39.3 Favored Glycine 0 N--CA 1.435 -1.398 0 N-CA-C 108.667 -1.773 . . . . 0.0 108.667 -179.668 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -145.67 161.3 40.18 Favored 'General case' 0 N--CA 1.436 -1.16 0 N-CA-C 106.346 -1.724 . . . . 0.0 106.346 -179.355 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -140.17 166.74 25.66 Favored Glycine 0 CA--C 1.487 -1.719 0 N-CA-C 108.641 -1.784 . . . . 0.0 108.641 -179.188 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 51.8 t80 -117.0 136.52 52.87 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 -179.573 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 58.7 ttp180 -86.6 127.13 34.89 Favored 'General case' 0 N--CA 1.441 -0.886 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 -179.311 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 . . . . . 0 C--O 1.262 1.747 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 -179.686 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 52.7 tp10 . . . . . 0 N--CA 1.489 1.501 0 CA-C-O 120.883 0.373 . . . . 0.0 110.491 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 179.5 177.84 48.04 Favored Glycine 0 CA--C 1.492 -1.383 0 N-CA-C 106.908 -2.477 . . . . 0.0 106.908 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 80.3 mm-40 -133.73 146.56 50.9 Favored 'General case' 0 CA--C 1.497 -1.069 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 66.9 m -132.85 146.84 52.16 Favored 'General case' 0 CA--C 1.496 -1.113 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 54.2 m -130.21 148.95 52.1 Favored 'General case' 0 CA--C 1.495 -1.135 0 N-CA-C 106.957 -1.498 . . . . 0.0 106.957 179.554 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 83.6 mt -117.15 126.93 74.77 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.072 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 -179.828 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 59.2 m -124.23 142.97 50.8 Favored 'General case' 0 CA--C 1.496 -1.113 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 -179.641 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 46.1 pt -132.65 157.96 43.16 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.103 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 179.797 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -173.23 -175.82 41.29 Favored Glycine 0 CA--C 1.491 -1.447 0 N-CA-C 107.682 -2.167 . . . . 0.0 107.682 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -125.46 151.36 46.35 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 107.088 -1.449 . . . . 0.0 107.088 -179.532 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -115.9 141.07 48.6 Favored 'General case' 0 N--CA 1.439 -0.979 0 N-CA-C 107.467 -1.308 . . . . 0.0 107.467 -179.575 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 85.9 mm-40 -129.09 148.5 51.04 Favored 'General case' 0 CA--C 1.497 -1.068 0 N-CA-C 107.198 -1.408 . . . . 0.0 107.198 179.745 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 31.9 m -137.32 21.66 2.97 Favored 'General case' 0 CA--C 1.499 -0.989 0 N-CA-C 108.196 -1.038 . . . . 0.0 108.196 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 79.7 ttt180 -131.02 124.94 31.99 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 -179.579 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 27.4 m -136.62 153.02 29.9 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.026 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 178.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 58.0 mtmt -137.04 146.47 45.26 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 106.951 -1.5 . . . . 0.0 106.951 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -66.92 -39.41 87.36 Favored 'General case' 0 CA--C 1.503 -0.839 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 179.399 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 18.0 t0 -161.63 161.08 29.48 Favored 'General case' 0 N--CA 1.434 -1.235 0 N-CA-C 106.391 -1.707 . . . . 0.0 106.391 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -168.18 169.1 41.27 Favored Glycine 0 CA--C 1.491 -1.413 0 N-CA-C 106.979 -2.448 . . . . 0.0 106.979 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -104.24 -22.17 13.42 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 64.5 pttt -159.46 162.69 35.67 Favored 'General case' 0 N--CA 1.436 -1.133 0 N-CA-C 107.351 -1.352 . . . . 0.0 107.351 -179.837 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 88.3 mt -116.91 137.58 52.11 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 106.546 -1.65 . . . . 0.0 106.546 179.472 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 22.3 t0 -160.99 150.06 16.66 Favored 'General case' 0 N--CA 1.435 -1.189 0 N-CA-C 106.906 -1.516 . . . . 0.0 106.906 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 99.3 mttt 58.28 46.4 15.66 Favored 'General case' 0 C--N 1.357 0.897 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 91.7 m-20 -74.28 151.33 87.79 Favored Pre-proline 0 N--CA 1.443 -0.822 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 179.483 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -70.65 152.46 64.71 Favored 'Trans proline' 0 CA--C 1.497 -1.368 0 C-N-CA 121.778 1.652 . . . . 0.0 112.442 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.436 HH21 ' HD3' ' A' ' 51' ' ' ARG . 72.7 mtm-85 -110.39 131.64 54.88 Favored 'General case' 0 CA--C 1.495 -1.138 0 N-CA-C 107.209 -1.404 . . . . 0.0 107.209 -179.336 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -153.39 148.59 19.51 Favored Glycine 0 CA--C 1.489 -1.536 0 N-CA-C 107.307 -2.317 . . . . 0.0 107.307 179.725 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -130.01 147.31 51.74 Favored 'General case' 0 CA--C 1.495 -1.153 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 50.2 t30 -128.45 114.6 17.0 Favored 'General case' 0 N--CA 1.44 -0.96 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 60.1 tp -111.38 122.11 46.98 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 105.879 -1.897 . . . . 0.0 105.879 179.534 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 39.2 ttpt -135.23 137.89 43.05 Favored 'General case' 0 CA--C 1.503 -0.863 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 -177.548 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -121.17 145.14 48.14 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 179.382 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ARG . . . . . 0.443 ' HA ' HG22 ' A' ' 44' ' ' ILE . 53.2 ttp180 -115.67 129.32 56.44 Favored 'General case' 0 CA--C 1.496 -1.124 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 179.514 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -114.29 116.44 29.0 Favored 'General case' 0 CA--C 1.498 -1.055 0 N-CA-C 106.335 -1.728 . . . . 0.0 106.335 179.359 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -113.01 118.22 34.2 Favored 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 -179.222 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -105.06 -28.39 11.06 Favored 'General case' 0 CA--C 1.5 -0.968 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 179.632 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 32.4 m120 -130.57 146.68 52.14 Favored 'General case' 0 CA--C 1.496 -1.102 0 N-CA-C 106.231 -1.766 . . . . 0.0 106.231 179.575 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 65.2 t30 -83.97 69.66 10.34 Favored 'General case' 0 N--CA 1.443 -0.808 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 -179.64 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 19.9 t0 179.78 -33.74 0.01 OUTLIER 'General case' 0 N--CA 1.441 -0.915 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 -179.742 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 90.5 t90 -146.26 143.41 29.17 Favored 'General case' 0 CA--C 1.5 -0.967 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 -179.007 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -156.41 -177.41 29.55 Favored Glycine 0 C--N 1.351 1.381 0 N-CA-C 107.443 -2.263 . . . . 0.0 107.443 -179.62 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.7 m -131.55 158.06 43.25 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.027 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 -179.634 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.619 HD13 ' CD2' ' A' ' 88' ' ' TYR . 32.8 pt -130.68 159.27 42.83 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.115 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 -179.847 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -137.3 141.7 12.6 Favored Glycine 0 CA--C 1.49 -1.508 0 N-CA-C 104.716 -3.353 . . . . 0.0 104.716 177.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 33.8 t -145.2 144.22 30.72 Favored 'General case' 0 CA--C 1.498 -1.038 0 C-N-CA 118.966 -1.094 . . . . 0.0 108.858 -178.514 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 89.3 t80 -129.17 129.9 45.68 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 105.162 -2.162 . . . . 0.0 105.162 179.181 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -135.15 145.87 48.21 Favored 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 -178.773 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 64.1 tt0 -134.4 129.76 35.82 Favored 'General case' 0 CA--C 1.495 -1.171 0 N-CA-C 105.773 -1.936 . . . . 0.0 105.773 179.264 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 87.5 m -129.38 130.44 46.02 Favored 'General case' 0 CA--C 1.496 -1.112 0 N-CA-C 107.472 -1.306 . . . . 0.0 107.472 -179.519 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.436 ' HD3' HH21 ' A' ' 27' ' ' ARG . 80.2 ttt180 -106.03 126.88 52.72 Favored 'General case' 0 N--CA 1.438 -1.026 0 N-CA-C 106.736 -1.579 . . . . 0.0 106.736 179.602 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 42.6 ttm180 -89.28 124.46 34.43 Favored 'General case' 0 N--CA 1.44 -0.952 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 -179.482 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -96.23 -161.23 32.74 Favored Glycine 0 C--N 1.352 1.468 0 N-CA-C 107.646 -2.182 . . . . 0.0 107.646 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -103.4 133.91 47.67 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -98.57 127.67 44.59 Favored 'General case' 0 CA--C 1.5 -0.967 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 -179.375 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -142.17 156.01 45.32 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 179.582 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 46.1 t -146.76 146.79 30.4 Favored 'General case' 0 CA--C 1.497 -1.059 0 N-CA-C 106.218 -1.771 . . . . 0.0 106.218 179.526 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.2 m -73.2 -23.87 20.28 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.812 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 -179.47 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 98.3 m-20 -65.52 -39.62 92.02 Favored 'General case' 0 C--N 1.356 0.856 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 179.798 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 149.41 -179.14 26.44 Favored Glycine 0 CA--C 1.493 -1.319 0 N-CA-C 106.828 -2.509 . . . . 0.0 106.828 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 38.5 t80 75.84 114.87 0.06 Allowed 'General case' 0 C--N 1.356 0.875 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 179.69 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 30.0 mtpp -124.68 137.25 54.37 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 106.602 -1.629 . . . . 0.0 106.602 179.57 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 59.6 tp -110.59 120.9 43.92 Favored 'General case' 0 N--CA 1.438 -1.037 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 45.5 pt -96.78 -3.67 10.12 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.837 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 -179.232 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 38.3 t70 -87.8 107.89 18.88 Favored 'General case' 0 N--CA 1.439 -0.982 0 N-CA-C 106.773 -1.566 . . . . 0.0 106.773 179.706 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -173.04 -171.62 37.9 Favored Glycine 0 CA--C 1.491 -1.438 0 N-CA-C 107.085 -2.406 . . . . 0.0 107.085 -179.633 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 26.0 t0 66.29 45.78 2.16 Favored 'General case' 0 C--N 1.354 0.796 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 -179.636 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 45.2 t80 -131.72 131.94 43.47 Favored 'General case' 0 N--CA 1.439 -1.012 0 N-CA-C 106.096 -1.816 . . . . 0.0 106.096 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -99.48 130.28 45.72 Favored 'General case' 0 N--CA 1.44 -0.971 0 N-CA-C 107.829 -1.175 . . . . 0.0 107.829 -179.129 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -111.35 137.38 49.18 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 106.768 -1.567 . . . . 0.0 106.768 179.107 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -121.26 137.24 54.78 Favored 'General case' 0 CA--C 1.496 -1.122 0 N-CA-C 106.247 -1.76 . . . . 0.0 106.247 179.697 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 70.9 m -134.22 138.92 45.44 Favored 'General case' 0 CA--C 1.494 -1.201 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 61.5 t -128.5 136.99 58.59 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.265 0 N-CA-C 104.697 -2.334 . . . . 0.0 104.697 178.836 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.565 HG21 HD13 ' A' ' 90' ' ' LEU . 13.8 t -156.45 158.26 36.96 Favored 'General case' 0 N--CA 1.437 -1.075 0 C-N-CA 119.015 -1.074 . . . . 0.0 108.679 -178.663 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -157.09 159.84 38.29 Favored 'General case' 0 N--CA 1.435 -1.206 0 N-CA-C 106.24 -1.763 . . . . 0.0 106.24 179.68 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -176.47 173.99 46.68 Favored Glycine 0 C--N 1.349 1.259 0 N-CA-C 108.384 -1.886 . . . . 0.0 108.384 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -84.28 162.07 13.17 Favored 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.992 2.462 . . . . 0.0 113.829 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.476 ' CG2' HG23 ' A' ' 44' ' ' ILE . 97.8 t -122.61 126.85 74.61 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.029 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 178.679 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 99.5 m-85 -115.37 132.53 56.59 Favored 'General case' 0 CA--C 1.498 -1.037 0 N-CA-C 107.467 -1.309 . . . . 0.0 107.467 -179.529 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 44.3 ttm180 -111.6 132.89 54.24 Favored 'General case' 0 CA--C 1.498 -1.021 0 N-CA-C 106.835 -1.543 . . . . 0.0 106.835 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 97.0 mt -73.51 -64.24 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.896 0 N-CA-C 107.037 -1.468 . . . . 0.0 107.037 179.821 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 66.0 t30 -177.97 94.09 0.03 OUTLIER 'General case' 0 CA--C 1.502 -0.881 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 177.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 38.03 46.06 0.78 Allowed 'General case' 0 C--N 1.36 1.062 0 C-N-CA 123.094 0.558 . . . . 0.0 111.796 177.803 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 60.5 t80 -141.9 -43.34 0.35 Allowed 'General case' 0 CA--C 1.5 -0.959 0 C-N-CA 119.005 -1.078 . . . . 0.0 108.917 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 12.6 p -161.28 149.58 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.097 0 N-CA-C 106.977 -1.49 . . . . 0.0 106.977 -179.597 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 68.2 m -116.25 135.34 53.98 Favored 'General case' 0 N--CA 1.438 -1.044 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 179.341 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -97.56 128.46 44.31 Favored 'General case' 0 CA--C 1.496 -1.112 0 N-CA-C 106.508 -1.664 . . . . 0.0 106.508 -179.898 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.619 ' CD2' HD13 ' A' ' 44' ' ' ILE . 2.9 m-85 -107.61 141.22 39.41 Favored 'General case' 0 N--CA 1.437 -1.102 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 -179.538 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -135.86 151.42 20.67 Favored Glycine 0 CA--C 1.487 -1.702 0 N-CA-C 105.462 -3.055 . . . . 0.0 105.462 178.774 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.565 HD13 HG21 ' A' ' 74' ' ' THR . 0.5 OUTLIER -158.01 143.63 17.01 Favored 'General case' 0 N--CA 1.435 -1.188 0 C-N-CA 118.999 -1.08 . . . . 0.0 108.91 -179.193 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 5.0 tt -136.82 138.92 41.33 Favored 'General case' 0 CA--C 1.498 -1.053 0 N-CA-C 105.498 -2.038 . . . . 0.0 105.498 179.348 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -162.66 -154.87 7.78 Favored Glycine 0 CA--C 1.491 -1.424 0 N-CA-C 108.487 -1.845 . . . . 0.0 108.487 -179.052 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -145.47 156.1 43.53 Favored 'General case' 0 N--CA 1.435 -1.182 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 -179.148 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -101.91 143.7 16.09 Favored Glycine 0 C--N 1.35 1.35 0 N-CA-C 107.091 -2.403 . . . . 0.0 107.091 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -131.52 145.34 51.7 Favored 'General case' 0 CA--C 1.498 -1.026 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 -179.439 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -154.24 168.95 32.62 Favored Glycine 0 CA--C 1.491 -1.422 0 N-CA-C 106.457 -2.657 . . . . 0.0 106.457 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 59.1 mtmt -77.11 129.57 36.2 Favored 'General case' 0 CA--C 1.5 -0.947 0 N-CA-C 107.593 -1.262 . . . . 0.0 107.593 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -160.82 160.34 31.02 Favored 'General case' 0 N--CA 1.434 -1.273 0 N-CA-C 106.717 -1.586 . . . . 0.0 106.717 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -87.68 135.14 33.49 Favored 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 179.725 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -129.65 147.19 51.42 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 5.6 t -159.38 179.91 8.53 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 106.523 -1.658 . . . . 0.0 106.523 179.759 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 46.3 t -72.27 140.34 48.56 Favored 'General case' 0 CA--C 1.504 -0.804 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 96.4 mt -64.0 -44.58 97.88 Favored 'Isoleucine or valine' 0 C--N 1.354 0.769 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -109.28 135.9 49.62 Favored 'General case' 0 CA--C 1.499 -1.001 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 -179.566 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 170.12 -160.0 32.71 Favored Glycine 0 CA--C 1.491 -1.427 0 N-CA-C 106.778 -2.529 . . . . 0.0 106.778 -179.66 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 26.0 mp0 -64.1 -39.3 93.75 Favored 'General case' 0 CA--C 1.504 -0.81 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 179.634 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 46.4 t -121.48 130.03 53.31 Favored 'General case' 0 CA--C 1.496 -1.122 0 N-CA-C 106.236 -1.764 . . . . 0.0 106.236 179.402 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 99.7 mt-10 -80.2 151.35 29.73 Favored 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 107.764 -1.199 . . . . 0.0 107.764 -179.698 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 42.4 t -146.19 143.76 29.48 Favored 'General case' 0 CA--C 1.497 -1.07 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -82.45 152.24 26.2 Favored 'General case' 0 N--CA 1.438 -1.029 0 N-CA-C 107.7 -1.222 . . . . 0.0 107.7 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 46.7 t -98.05 137.03 37.45 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 106.746 -1.576 . . . . 0.0 106.746 179.867 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 8.5 mptt -119.22 141.61 48.75 Favored 'General case' 0 CA--C 1.499 -1.003 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 -179.391 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 14.1 t -152.91 161.23 42.8 Favored 'General case' 0 CA--C 1.498 -1.053 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 179.608 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 36.9 t -149.14 136.31 19.96 Favored 'General case' 0 CA--C 1.497 -1.064 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 89.8 mt -114.53 143.53 44.82 Favored 'General case' 0 CA--C 1.496 -1.128 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -123.15 140.29 53.18 Favored 'General case' 0 N--CA 1.438 -1.039 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 -179.418 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 89.6 t80 -145.85 141.29 27.73 Favored 'General case' 0 CA--C 1.497 -1.06 0 N-CA-C 106.291 -1.744 . . . . 0.0 106.291 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -159.2 178.92 35.15 Favored Glycine 0 CA--C 1.491 -1.415 0 N-CA-C 108.653 -1.779 . . . . 0.0 108.653 -179.599 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -154.48 163.08 40.74 Favored 'General case' 0 N--CA 1.436 -1.14 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -160.81 171.37 36.9 Favored Glycine 0 CA--C 1.489 -1.562 0 N-CA-C 108.669 -1.772 . . . . 0.0 108.669 -179.777 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 88.6 mt -127.04 143.43 51.29 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 54.5 tt0 -121.73 129.5 52.76 Favored 'General case' 0 CA--C 1.496 -1.115 0 N-CA-C 106.699 -1.593 . . . . 0.0 106.699 179.074 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 34.4 t80 -125.59 131.09 52.78 Favored 'General case' 0 N--CA 1.437 -1.101 0 N-CA-C 106.196 -1.779 . . . . 0.0 106.196 -179.914 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 11.8 p-10 -121.77 82.19 41.8 Favored Pre-proline 0 N--CA 1.443 -0.814 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 -178.51 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.24 -27.13 29.33 Favored 'Trans proline' 0 CA--C 1.498 -1.32 0 C-N-CA 121.667 1.578 . . . . 0.0 112.491 179.517 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -137.86 151.73 70.94 Favored Pre-proline 0 N--CA 1.436 -1.126 0 N-CA-C 106.287 -1.746 . . . . 0.0 106.287 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -74.62 -18.22 19.92 Favored 'Trans proline' 0 C--N 1.309 -1.533 0 C-N-CA 121.793 1.662 . . . . 0.0 113.031 179.312 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 27.7 m120 -64.82 -40.23 94.85 Favored 'General case' 0 C--N 1.353 0.72 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 -178.796 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 54.0 p90 -154.06 161.71 41.73 Favored 'General case' 0 CA--C 1.499 -1.015 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 -178.949 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 29.4 m -128.0 159.26 39.26 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.95 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 -179.56 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 50.9 mm -108.26 127.46 64.53 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.09 0 N-CA-C 106.57 -1.641 . . . . 0.0 106.57 -179.76 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -120.97 131.23 54.19 Favored 'General case' 0 N--CA 1.439 -1.015 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 -178.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -134.19 137.36 44.38 Favored 'General case' 0 CA--C 1.495 -1.165 0 N-CA-C 105.333 -2.099 . . . . 0.0 105.333 178.644 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 35.8 t -154.83 149.86 26.87 Favored 'General case' 0 CA--C 1.497 -1.086 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 -178.712 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 21.0 m-85 -123.18 138.71 54.58 Favored 'General case' 0 N--CA 1.436 -1.17 0 N-CA-C 105.292 -2.114 . . . . 0.0 105.292 179.117 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 88.2 tt0 -136.24 134.79 38.45 Favored 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 -178.797 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -123.39 140.97 52.47 Favored 'General case' 0 N--CA 1.436 -1.169 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 68.9 m -123.35 139.38 54.1 Favored 'General case' 0 CA--C 1.492 -1.252 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 64.7 tttm -113.48 126.14 54.99 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 107.341 -1.355 . . . . 0.0 107.341 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.14 159.47 20.85 Favored 'General case' 0 N--CA 1.437 -1.113 0 N-CA-C 105.595 -2.002 . . . . 0.0 105.595 178.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -62.2 -38.2 88.23 Favored 'General case' 0 N--CA 1.443 -0.802 0 O-C-N 122.131 -0.356 . . . . 0.0 110.361 -178.628 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -93.65 -38.72 11.18 Favored 'General case' 0 C--N 1.353 0.726 0 C-N-CA 119.862 -0.735 . . . . 0.0 111.642 -176.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 35.5 m -138.29 166.28 23.75 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.947 0 C-N-CA 119.44 -0.904 . . . . 0.0 109.604 -177.344 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -113.83 140.4 48.36 Favored 'General case' 0 CA--C 1.499 -0.986 0 N-CA-C 105.713 -1.958 . . . . 0.0 105.713 178.765 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 69.9 t -125.91 128.25 71.84 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.018 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 -178.767 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -114.43 134.87 11.99 Favored Glycine 0 CA--C 1.492 -1.397 0 N-CA-C 106.338 -2.705 . . . . 0.0 106.338 178.887 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 81.4 p -130.03 151.11 50.93 Favored 'General case' 0 CA--C 1.498 -1.04 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 -179.313 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 29.1 m-90 -124.83 138.54 54.26 Favored 'General case' 0 N--CA 1.437 -1.084 0 N-CA-C 105.692 -1.966 . . . . 0.0 105.692 179.236 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 3.5 mpp? -128.71 139.62 52.14 Favored 'General case' 0 CA--C 1.498 -1.033 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 -179.08 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 61.1 tp -142.11 134.12 27.39 Favored 'General case' 0 CA--C 1.497 -1.06 0 N-CA-C 105.698 -1.964 . . . . 0.0 105.698 179.304 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -168.93 -166.95 28.85 Favored Glycine 0 N--CA 1.436 -1.338 0 N-CA-C 108.966 -1.653 . . . . 0.0 108.966 -179.412 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -147.0 163.81 35.02 Favored 'General case' 0 N--CA 1.435 -1.185 0 N-CA-C 106.279 -1.749 . . . . 0.0 106.279 -179.332 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -144.24 173.43 24.95 Favored Glycine 0 CA--C 1.489 -1.539 0 N-CA-C 108.541 -1.824 . . . . 0.0 108.541 -179.114 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -124.66 143.39 50.76 Favored 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 -179.76 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 80.2 ttt180 -102.62 125.9 49.51 Favored 'General case' 0 CA--C 1.499 -0.984 0 N-CA-C 107.226 -1.398 . . . . 0.0 107.226 -179.386 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 43.6 t80 . . . . . 0 C--O 1.262 1.749 0 CA-C-O 117.764 -1.112 . . . . 0.0 108.3 179.835 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 . . . . . 0 N--CA 1.487 1.376 0 CA-C-O 121.347 0.594 . . . . 0.0 110.378 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -179.55 -179.4 48.76 Favored Glycine 0 CA--C 1.49 -1.487 0 N-CA-C 106.872 -2.491 . . . . 0.0 106.872 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -155.31 160.25 40.62 Favored 'General case' 0 N--CA 1.437 -1.107 0 N-CA-C 107.24 -1.392 . . . . 0.0 107.24 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 96.8 p -153.4 161.67 42.06 Favored 'General case' 0 CA--C 1.497 -1.087 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 63.0 m -131.62 154.74 48.59 Favored 'General case' 0 CA--C 1.496 -1.106 0 N-CA-C 107.208 -1.404 . . . . 0.0 107.208 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 20.6 tt -126.61 140.98 47.33 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.998 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.434 ' HA ' ' HA2' ' A' ' 153' ' ' GLY . 51.0 m -127.58 142.42 51.37 Favored 'General case' 0 CA--C 1.497 -1.095 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 85.6 mt -123.61 129.99 74.3 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.061 0 N-CA-C 106.644 -1.613 . . . . 0.0 106.644 -179.647 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -146.72 177.95 24.7 Favored Glycine 0 C--N 1.35 1.322 0 N-CA-C 107.905 -2.078 . . . . 0.0 107.905 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -126.31 147.29 49.75 Favored 'General case' 0 CA--C 1.495 -1.168 0 N-CA-C 106.844 -1.539 . . . . 0.0 106.844 -179.759 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -100.99 129.04 46.76 Favored 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 -179.782 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 83.5 mm-40 -129.62 149.79 51.23 Favored 'General case' 0 CA--C 1.496 -1.122 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 35.9 t -145.94 115.71 7.28 Favored 'General case' 0 CA--C 1.498 -1.056 0 N-CA-C 106.41 -1.7 . . . . 0.0 106.41 179.311 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 73.1 ttt180 -160.91 142.58 12.1 Favored 'General case' 0 N--CA 1.436 -1.172 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 179.731 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 14.4 p -136.61 143.32 35.7 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.0 0 N-CA-C 106.812 -1.551 . . . . 0.0 106.812 -179.844 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -90.91 120.48 31.96 Favored 'General case' 0 N--CA 1.439 -1.013 0 N-CA-C 107.252 -1.388 . . . . 0.0 107.252 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -159.72 -55.7 0.06 Allowed 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -133.06 105.55 7.12 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 179.726 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -87.5 67.84 3.21 Favored Glycine 0 C--N 1.352 1.433 0 N-CA-C 108.035 -2.026 . . . . 0.0 108.035 -179.541 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 35.2 t80 -158.05 -64.71 0.09 Allowed 'General case' 0 N--CA 1.438 -1.039 0 N-CA-C 106.432 -1.692 . . . . 0.0 106.432 179.688 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 62.4 mtpt -67.26 -38.7 85.54 Favored 'General case' 0 C--N 1.355 0.823 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.467 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 62.7 tp -102.39 127.09 49.55 Favored 'General case' 0 CA--C 1.499 -1.001 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -154.8 164.56 38.64 Favored 'General case' 0 N--CA 1.437 -1.109 0 N-CA-C 106.514 -1.661 . . . . 0.0 106.514 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 34.5 mmtp 68.91 -173.28 0.19 Allowed 'General case' 0 C--N 1.358 0.952 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 -179.724 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 5.9 m120 -134.74 150.33 73.17 Favored Pre-proline 0 N--CA 1.441 -0.9 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 -179.717 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -80.31 161.01 22.96 Favored 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.31 2.007 . . . . 0.0 112.406 179.026 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -99.99 125.84 46.08 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 179.592 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -148.9 148.15 19.29 Favored Glycine 0 CA--C 1.492 -1.399 0 N-CA-C 108.085 -2.006 . . . . 0.0 108.085 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 93.6 m-85 -131.24 147.48 52.6 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.4 t30 -142.73 120.69 12.05 Favored 'General case' 0 N--CA 1.438 -1.05 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -179.823 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 89.8 mt -110.62 135.46 51.21 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 106.261 -1.755 . . . . 0.0 106.261 179.072 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 28.4 ttpp -130.41 133.54 46.43 Favored 'General case' 0 CA--C 1.498 -1.037 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 -179.31 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -117.62 139.35 51.11 Favored 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 107.067 -1.456 . . . . 0.0 107.067 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ARG . . . . . 0.55 ' HA ' HG22 ' A' ' 44' ' ' ILE . 60.5 ttp180 -119.26 129.08 54.73 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 107.141 -1.429 . . . . 0.0 107.141 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -120.51 139.6 52.67 Favored 'General case' 0 N--CA 1.438 -1.035 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -107.78 126.51 52.72 Favored 'General case' 0 N--CA 1.438 -1.073 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 -179.521 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -129.42 160.86 31.81 Favored 'General case' 0 CA--C 1.495 -1.139 0 N-CA-C 106.26 -1.755 . . . . 0.0 106.26 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 52.6 t30 -80.11 99.57 7.8 Favored 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 106.877 -1.527 . . . . 0.0 106.877 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 9.5 t-20 -164.72 -176.28 4.19 Favored 'General case' 0 N--CA 1.434 -1.24 0 N-CA-C 106.207 -1.775 . . . . 0.0 106.207 -179.455 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -87.54 -2.0 58.32 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 -179.431 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 46.3 p90 -150.37 157.91 43.58 Favored 'General case' 0 CA--C 1.5 -0.975 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 179.837 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -97.55 176.05 30.88 Favored Glycine 0 C--N 1.353 1.485 0 N-CA-C 107.421 -2.272 . . . . 0.0 107.421 179.708 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 71.8 t -130.23 130.97 65.89 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.95 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 -179.79 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.55 HG22 ' HA ' ' A' ' 34' ' ' ARG . 36.8 pt -127.63 159.02 38.83 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.072 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 179.323 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -139.06 141.72 12.16 Favored Glycine 0 CA--C 1.49 -1.473 0 N-CA-C 105.943 -2.863 . . . . 0.0 105.943 178.755 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 61.4 m -132.55 145.65 51.3 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 -179.281 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.42 ' CD1' HG22 ' A' ' 73' ' ' VAL . 72.0 t80 -127.63 123.95 36.85 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 105.242 -2.133 . . . . 0.0 105.242 179.448 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -119.87 140.28 51.08 Favored 'General case' 0 CA--C 1.499 -1.002 0 CA-C-O 121.588 0.708 . . . . 0.0 109.209 -177.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 67.0 mt-30 -128.75 133.13 48.01 Favored 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 105.999 -1.852 . . . . 0.0 105.999 178.86 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 85.3 m -133.2 131.12 40.0 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 179.578 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 -140.28 133.22 29.28 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 107.008 -1.478 . . . . 0.0 107.008 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 44.3 ttm180 -117.53 124.02 47.69 Favored 'General case' 0 CA--C 1.497 -1.069 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 179.719 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -129.24 134.53 8.01 Favored Glycine 0 CA--C 1.492 -1.383 0 N-CA-C 107.142 -2.383 . . . . 0.0 107.142 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 87.3 t80 -147.57 123.55 10.7 Favored 'General case' 0 N--CA 1.436 -1.148 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -149.21 105.35 3.49 Favored 'General case' 0 N--CA 1.436 -1.145 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 179.426 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -142.87 149.0 37.95 Favored 'General case' 0 CA--C 1.495 -1.159 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 44.7 t -107.74 109.4 20.97 Favored 'General case' 0 CA--C 1.496 -1.112 0 N-CA-C 106.17 -1.789 . . . . 0.0 106.17 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 31.5 m -135.03 156.85 40.25 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.017 0 N-CA-C 107.639 -1.245 . . . . 0.0 107.639 -179.434 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -110.01 20.29 18.1 Favored 'General case' 0 CA--C 1.502 -0.879 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 179.859 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -172.23 -159.75 19.31 Favored Glycine 0 CA--C 1.493 -1.341 0 N-CA-C 107.429 -2.268 . . . . 0.0 107.429 -179.322 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 92.2 m-85 70.79 -135.58 0.05 OUTLIER 'General case' 0 C--N 1.355 0.809 0 N-CA-C 107.859 -1.163 . . . . 0.0 107.859 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 29.6 tptp -149.71 137.01 19.84 Favored 'General case' 0 N--CA 1.436 -1.13 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 -179.634 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 7.9 mp -88.04 145.22 26.09 Favored 'General case' 0 CA--C 1.5 -0.96 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 179.674 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 83.8 mt -104.8 124.63 59.55 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.986 0 N-CA-C 107.211 -1.403 . . . . 0.0 107.211 -179.359 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -70.74 144.85 50.79 Favored 'General case' 0 CA--C 1.504 -0.801 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 179.742 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -173.69 -140.54 3.24 Favored Glycine 0 CA--C 1.492 -1.368 0 N-CA-C 107.147 -2.381 . . . . 0.0 107.147 -179.425 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 65.47 50.59 1.66 Allowed 'General case' 0 C--N 1.355 0.831 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 52.9 p90 -145.52 160.22 41.94 Favored 'General case' 0 CA--C 1.499 -1.001 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 179.19 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -123.27 143.9 49.77 Favored 'General case' 0 CA--C 1.498 -1.048 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 -179.525 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -135.93 132.01 35.9 Favored 'General case' 0 N--CA 1.438 -1.028 0 N-CA-C 106.603 -1.628 . . . . 0.0 106.603 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -127.48 145.79 50.72 Favored 'General case' 0 CA--C 1.496 -1.128 0 N-CA-C 107.289 -1.375 . . . . 0.0 107.289 -179.576 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 39.3 t -150.59 144.14 25.08 Favored 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.42 HG22 ' CD1' ' A' ' 47' ' ' PHE . 57.7 t -128.03 135.94 61.54 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.168 0 N-CA-C 105.802 -1.925 . . . . 0.0 105.802 179.752 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 67.6 p -137.85 159.09 42.93 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -157.97 160.44 37.52 Favored 'General case' 0 CA--C 1.494 -1.185 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 179.544 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 178.82 176.91 47.05 Favored Glycine 0 N--CA 1.436 -1.363 0 N-CA-C 108.392 -1.883 . . . . 0.0 108.392 179.509 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -83.01 163.45 15.59 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.818 2.345 . . . . 0.0 113.548 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.472 ' CG2' HG23 ' A' ' 44' ' ' ILE . 67.1 t -113.69 124.62 70.51 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.092 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 178.775 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 89.8 t80 -107.55 117.52 34.31 Favored 'General case' 0 CA--C 1.5 -0.963 0 N-CA-C 107.443 -1.317 . . . . 0.0 107.443 -179.287 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 82.2 mtp180 -112.84 137.45 51.17 Favored 'General case' 0 CA--C 1.497 -1.058 0 N-CA-C 106.503 -1.665 . . . . 0.0 106.503 179.579 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 97.2 mt -79.79 -64.59 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.502 -0.89 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 179.452 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 66.9 t30 179.64 94.73 0.02 OUTLIER 'General case' 0 CA--C 1.502 -0.885 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 178.204 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 77.6 mm-40 40.85 46.03 2.26 Favored 'General case' 0 C--N 1.359 1.005 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.122 178.252 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 51.5 t80 -141.59 -43.35 0.36 Allowed 'General case' 0 CA--C 1.501 -0.916 0 C-N-CA 118.985 -1.086 . . . . 0.0 109.023 -179.373 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 14.9 p -159.98 147.47 6.44 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.053 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 -179.259 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 52.0 m -119.33 137.37 53.75 Favored 'General case' 0 CA--C 1.496 -1.101 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 179.214 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 90.2 mt -115.35 142.6 46.46 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 106.69 -1.596 . . . . 0.0 106.69 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 24.2 m-85 -118.29 142.46 47.48 Favored 'General case' 0 CA--C 1.496 -1.134 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -116.25 133.1 10.57 Favored Glycine 0 CA--C 1.493 -1.342 0 N-CA-C 105.314 -3.114 . . . . 0.0 105.314 177.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 90.3 mt -122.65 134.88 54.48 Favored 'General case' 0 CA--C 1.497 -1.075 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 -178.873 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -153.43 148.39 26.62 Favored 'General case' 0 N--CA 1.437 -1.119 0 N-CA-C 105.92 -1.882 . . . . 0.0 105.92 178.375 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 171.16 -148.69 11.41 Favored Glycine 0 CA--C 1.492 -1.363 0 N-CA-C 108.04 -2.024 . . . . 0.0 108.04 -179.569 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -144.66 162.8 35.77 Favored 'General case' 0 N--CA 1.438 -1.036 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 -179.005 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -141.43 162.64 26.89 Favored Glycine 0 CA--C 1.493 -1.322 0 N-CA-C 108.02 -2.032 . . . . 0.0 108.02 -179.737 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 32.0 p80 -151.81 159.94 43.73 Favored 'General case' 0 N--CA 1.436 -1.129 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -141.07 160.38 26.73 Favored Glycine 0 CA--C 1.491 -1.452 0 N-CA-C 107.366 -2.294 . . . . 0.0 107.366 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 63.2 mtpt -87.89 64.48 7.9 Favored 'General case' 0 N--CA 1.441 -0.893 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 -179.669 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -65.04 -40.4 94.74 Favored 'General case' 0 N--CA 1.443 -0.82 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 15.0 ptmm? -157.41 167.55 29.93 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 -179.741 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -106.65 143.44 34.74 Favored 'General case' 0 CA--C 1.498 -1.019 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 96.1 p -155.37 160.71 40.91 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 179.772 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 99.1 p -157.12 160.67 39.05 Favored 'General case' 0 CA--C 1.497 -1.094 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 44.6 pt -132.21 154.89 40.88 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.037 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 179.832 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 90.1 t80 -62.73 -47.99 81.17 Favored 'General case' 0 C--N 1.355 0.808 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -163.68 -48.37 0.02 OUTLIER Glycine 0 CA--C 1.493 -1.32 0 N-CA-C 107.402 -2.279 . . . . 0.0 107.402 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 25.8 pt20 -149.17 152.54 36.24 Favored 'General case' 0 N--CA 1.436 -1.129 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 179.439 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 35.3 t -159.05 148.33 18.69 Favored 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 106.565 -1.643 . . . . 0.0 106.565 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -94.48 120.14 34.26 Favored 'General case' 0 N--CA 1.439 -1.015 0 N-CA-C 106.93 -1.507 . . . . 0.0 106.93 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 4.9 t -164.45 -165.97 1.03 Allowed 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 -179.672 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -127.63 148.81 50.38 Favored 'General case' 0 CA--C 1.498 -1.051 0 N-CA-C 106.78 -1.563 . . . . 0.0 106.78 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 36.8 t -149.32 147.05 27.87 Favored 'General case' 0 N--CA 1.438 -1.053 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 -179.693 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 65.3 mttp -129.1 151.24 50.0 Favored 'General case' 0 CA--C 1.498 -1.04 0 N-CA-C 107.081 -1.452 . . . . 0.0 107.081 -179.629 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 68.0 p -124.18 157.9 33.65 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 36.1 t -94.1 130.72 40.17 Favored 'General case' 0 CA--C 1.499 -1.019 0 N-CA-C 107.356 -1.35 . . . . 0.0 107.356 -179.533 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 91.1 mt -95.89 143.71 26.85 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 179.716 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -113.78 137.64 51.37 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 -179.451 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -145.37 139.02 26.68 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 106.375 -1.713 . . . . 0.0 106.375 179.758 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -167.69 -176.32 38.25 Favored Glycine 0 N--CA 1.436 -1.354 0 N-CA-C 108.313 -1.915 . . . . 0.0 108.313 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -152.83 165.82 34.22 Favored 'General case' 0 N--CA 1.435 -1.203 0 N-CA-C 106.367 -1.716 . . . . 0.0 106.367 -179.753 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -155.79 175.03 33.73 Favored Glycine 0 CA--C 1.491 -1.458 0 N-CA-C 108.423 -1.871 . . . . 0.0 108.423 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.558 HD13 ' CE1' ' A' ' 123' ' ' PHE . 3.1 pp -141.7 159.42 42.26 Favored 'General case' 0 CA--C 1.497 -1.068 0 N-CA-C 106.941 -1.504 . . . . 0.0 106.941 -179.698 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 3.6 tm0? -147.41 134.55 20.46 Favored 'General case' 0 N--CA 1.437 -1.092 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 -179.685 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.558 ' CE1' HD13 ' A' ' 121' ' ' LEU . 97.4 m-85 -124.45 146.88 48.67 Favored 'General case' 0 CA--C 1.499 -1.006 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 179.479 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -130.01 76.6 77.87 Favored Pre-proline 0 N--CA 1.442 -0.832 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -72.06 -32.59 10.72 Favored 'Trans proline' 0 CA--C 1.498 -1.3 0 C-N-CA 121.706 1.604 . . . . 0.0 112.524 179.483 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 79.4 m80 -139.75 151.34 65.7 Favored Pre-proline 0 N--CA 1.436 -1.147 0 N-CA-C 106.194 -1.78 . . . . 0.0 106.194 179.576 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -75.82 -9.21 19.57 Favored 'Trans proline' 0 C--N 1.311 -1.399 0 C-N-CA 122.004 1.802 . . . . 0.0 112.762 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 27.7 m120 -63.68 -39.66 94.87 Favored 'General case' 0 N--CA 1.443 -0.782 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.197 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 55.1 p90 -154.01 160.86 42.21 Favored 'General case' 0 CA--C 1.5 -0.978 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 74.2 t -121.48 131.4 73.15 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.981 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 179.762 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 19.5 tt -99.31 133.45 42.0 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.843 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 -179.456 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 50.2 m-20 -127.61 138.85 52.97 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 -179.404 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -140.1 129.91 24.57 Favored 'General case' 0 CA--C 1.495 -1.137 0 N-CA-C 105.851 -1.907 . . . . 0.0 105.851 178.586 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 53.5 m -146.53 163.44 35.73 Favored 'General case' 0 CA--C 1.495 -1.139 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 -179.365 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -143.41 148.9 36.88 Favored 'General case' 0 N--CA 1.438 -1.048 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 178.799 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 62.1 mt-10 -138.22 149.51 45.85 Favored 'General case' 0 CA--C 1.498 -1.045 0 N-CA-C 107.964 -1.125 . . . . 0.0 107.964 -179.675 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -127.58 143.79 51.14 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 178.678 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 67.2 m -127.43 141.17 51.75 Favored 'General case' 0 CA--C 1.495 -1.158 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 179.465 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 40.2 ttpt -104.43 120.85 42.16 Favored 'General case' 0 N--CA 1.438 -1.026 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 -179.502 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 87.4 mt -120.76 158.34 27.74 Favored 'General case' 0 CA--C 1.496 -1.1 0 N-CA-C 105.884 -1.895 . . . . 0.0 105.884 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 44.5 p-10 -86.47 4.15 40.96 Favored 'General case' 0 N--CA 1.442 -0.87 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 -179.379 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -103.68 -66.25 0.96 Allowed 'General case' 0 N--CA 1.441 -0.885 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 179.826 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 34.8 m -139.76 161.15 26.96 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.985 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 -179.703 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 23.4 tptm -82.75 129.61 35.0 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 106.597 -1.631 . . . . 0.0 106.597 179.275 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 94.1 t -119.66 127.14 75.86 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.949 0 N-CA-C 108.42 -0.955 . . . . 0.0 108.42 -178.6 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -127.27 140.22 11.72 Favored Glycine 0 CA--C 1.492 -1.403 0 N-CA-C 105.879 -2.889 . . . . 0.0 105.879 178.66 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 82.8 p -129.9 151.13 50.8 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -179.166 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 29.1 m-90 -118.71 139.66 51.19 Favored 'General case' 0 CA--C 1.497 -1.086 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 178.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 1.8 tmt? -119.94 124.13 45.23 Favored 'General case' 0 CA--C 1.497 -1.059 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -178.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 89.9 mt -124.38 140.13 53.25 Favored 'General case' 0 CA--C 1.497 -1.096 0 N-CA-C 105.571 -2.011 . . . . 0.0 105.571 178.429 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -175.47 -170.11 37.98 Favored Glycine 0 CA--C 1.491 -1.452 0 N-CA-C 108.489 -1.844 . . . . 0.0 108.489 -179.558 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -135.15 154.06 51.76 Favored 'General case' 0 N--CA 1.437 -1.106 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 -179.339 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 153' ' ' GLY . . . . . 0.434 ' HA2' ' HA ' ' A' ' 7' ' ' SER . . . -109.97 146.41 17.13 Favored Glycine 0 CA--C 1.491 -1.45 0 N-CA-C 108.114 -1.994 . . . . 0.0 108.114 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 92.5 t80 -115.11 134.43 55.17 Favored 'General case' 0 N--CA 1.439 -1.011 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 179.771 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 17.6 ptm180 -143.38 160.65 40.14 Favored 'General case' 0 N--CA 1.435 -1.201 0 N-CA-C 106.788 -1.56 . . . . 0.0 106.788 -179.675 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 35.0 t80 . . . . . 0 C--O 1.262 1.714 0 CA-C-O 117.638 -1.172 . . . . 0.0 108.089 -179.99 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 120.826 0.346 . . . . 0.0 110.702 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -178.67 -179.97 48.61 Favored Glycine 0 CA--C 1.491 -1.44 0 N-CA-C 107.106 -2.398 . . . . 0.0 107.106 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -136.7 136.25 38.88 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 106.892 -1.521 . . . . 0.0 106.892 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 63.3 m -122.22 142.24 50.64 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 107.035 -1.468 . . . . 0.0 107.035 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 68.0 m -127.25 151.01 49.28 Favored 'General case' 0 CA--C 1.497 -1.074 0 N-CA-C 107.119 -1.438 . . . . 0.0 107.119 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 85.0 mt -115.53 129.46 71.78 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 -179.368 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.474 ' HB2' ' HB3' ' A' ' 32' ' ' LYS . 69.0 m -124.09 144.72 49.71 Favored 'General case' 0 CA--C 1.499 -0.996 0 N-CA-C 107.716 -1.216 . . . . 0.0 107.716 -179.788 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 85.5 mt -122.34 131.05 73.99 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.053 0 N-CA-C 106.398 -1.704 . . . . 0.0 106.398 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -137.85 164.12 25.52 Favored Glycine 0 C--N 1.354 1.539 0 N-CA-C 108.237 -1.945 . . . . 0.0 108.237 -179.314 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -127.66 147.24 50.37 Favored 'General case' 0 CA--C 1.499 -1.014 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.94 138.85 41.26 Favored 'General case' 0 CA--C 1.5 -0.975 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 97.0 mm-40 -111.51 122.4 47.73 Favored 'General case' 0 N--CA 1.438 -1.064 0 N-CA-C 107.173 -1.418 . . . . 0.0 107.173 179.653 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 73.4 m -162.03 -177.98 6.13 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 105.708 -1.96 . . . . 0.0 105.708 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 17.6 ptm180 -140.45 144.91 36.35 Favored 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 107.405 -1.331 . . . . 0.0 107.405 179.317 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 27.1 m -140.06 158.93 26.32 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.989 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -145.52 129.38 17.31 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 179.1 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -136.14 147.86 47.93 Favored 'General case' 0 CA--C 1.498 -1.019 0 N-CA-C 107.051 -1.462 . . . . 0.0 107.051 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 63.4 t0 -90.56 100.09 13.0 Favored 'General case' 0 N--CA 1.44 -0.937 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 167.98 -169.28 41.28 Favored Glycine 0 CA--C 1.491 -1.431 0 N-CA-C 107.001 -2.44 . . . . 0.0 107.001 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -90.31 70.83 7.13 Favored 'General case' 0 CA--C 1.501 -0.924 0 N-CA-C 107.011 -1.478 . . . . 0.0 107.011 179.713 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -135.44 158.04 45.37 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 106.69 -1.596 . . . . 0.0 106.69 -179.628 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 92.9 mt -73.41 135.91 44.25 Favored 'General case' 0 N--CA 1.441 -0.907 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 -179.517 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -114.61 149.87 35.93 Favored 'General case' 0 CA--C 1.499 -1.007 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 97.7 mttt 62.77 34.15 14.82 Favored 'General case' 0 C--N 1.356 0.879 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 45.3 m-80 -138.56 113.16 8.57 Favored Pre-proline 0 N--CA 1.441 -0.907 0 N-CA-C 106.658 -1.608 . . . . 0.0 106.658 179.115 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -75.73 153.08 38.13 Favored 'Trans proline' 0 CA--C 1.497 -1.357 0 C-N-CA 121.901 1.734 . . . . 0.0 113.113 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -129.66 109.27 10.85 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 179.463 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -170.9 167.87 41.02 Favored Glycine 0 CA--C 1.492 -1.389 0 N-CA-C 107.371 -2.291 . . . . 0.0 107.371 179.709 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 72.5 t80 -146.78 131.68 18.1 Favored 'General case' 0 CA--C 1.499 -1.007 0 N-CA-C 106.037 -1.838 . . . . 0.0 106.037 -179.806 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 80.3 m-20 -126.89 144.13 51.08 Favored 'General case' 0 CA--C 1.501 -0.933 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 -178.649 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 83.2 mt -119.77 139.12 52.8 Favored 'General case' 0 CA--C 1.495 -1.155 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 178.882 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.474 ' HB3' ' HB2' ' A' ' 7' ' ' SER . 86.6 tttt -137.22 133.84 35.57 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -124.36 139.13 54.19 Favored 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 106.671 -1.603 . . . . 0.0 106.671 179.529 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ARG . . . . . 0.581 ' HA ' HG22 ' A' ' 44' ' ' ILE . 7.9 tmm_? -120.18 129.57 54.18 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 -179.371 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -115.19 126.87 55.09 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 106.803 -1.554 . . . . 0.0 106.803 179.624 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -116.56 130.6 56.84 Favored 'General case' 0 CA--C 1.497 -1.065 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 -179.889 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -119.94 176.45 5.41 Favored 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 67.0 t30 -79.89 78.25 6.5 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 -166.31 172.01 11.51 Favored 'General case' 0 N--CA 1.434 -1.226 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -89.71 -3.24 58.3 Favored 'General case' 0 N--CA 1.443 -0.793 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 54.3 m0 -113.73 140.14 48.51 Favored 'General case' 0 CA--C 1.499 -0.993 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 -179.791 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -129.17 178.46 17.31 Favored Glycine 0 C--N 1.349 1.262 0 N-CA-C 107.016 -2.434 . . . . 0.0 107.016 179.696 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.8 p -142.66 142.72 26.42 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.9 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.581 HG22 ' HA ' ' A' ' 34' ' ' ARG . 32.2 pt -129.88 157.88 42.44 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.052 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -137.62 139.87 10.81 Favored Glycine 0 CA--C 1.491 -1.454 0 N-CA-C 105.828 -2.909 . . . . 0.0 105.828 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 56.2 m -138.45 149.36 45.38 Favored 'General case' 0 CA--C 1.496 -1.107 0 C-N-CA 119.674 -0.81 . . . . 0.0 108.9 -179.242 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -125.93 139.96 53.03 Favored 'General case' 0 CA--C 1.496 -1.122 0 N-CA-C 105.06 -2.2 . . . . 0.0 105.06 178.746 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -134.18 138.98 45.53 Favored 'General case' 0 CA--C 1.498 -1.043 0 C-N-CA 119.575 -0.85 . . . . 0.0 108.902 -178.624 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 64.7 tt0 -137.83 123.54 19.87 Favored 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 106.109 -1.812 . . . . 0.0 106.109 178.561 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 11.4 t -147.53 174.66 11.51 Favored 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 107.137 -1.431 . . . . 0.0 107.137 -179.67 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 83.5 mtp180 -126.74 145.66 50.52 Favored 'General case' 0 CA--C 1.495 -1.155 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 179.594 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 31.8 tpt180 -97.26 121.46 39.18 Favored 'General case' 0 CA--C 1.499 -1.0 0 N-CA-C 106.746 -1.576 . . . . 0.0 106.746 -179.726 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -105.71 -139.43 9.68 Favored Glycine 0 C--N 1.349 1.276 0 N-CA-C 107.934 -2.066 . . . . 0.0 107.934 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -125.65 149.32 48.53 Favored 'General case' 0 N--CA 1.438 -1.065 0 N-CA-C 106.845 -1.539 . . . . 0.0 106.845 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.415 ' H ' HD12 ' A' ' 64' ' ' ILE . 97.8 mt-10 -129.4 148.4 51.31 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -136.33 128.97 30.66 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 106.77 -1.567 . . . . 0.0 106.77 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 11.5 p -157.51 -48.72 0.07 Allowed 'General case' 0 CA--C 1.498 -1.052 0 N-CA-C 107.362 -1.347 . . . . 0.0 107.362 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 73.4 t -119.68 128.84 75.9 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.053 0 N-CA-C 106.63 -1.619 . . . . 0.0 106.63 179.683 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -83.75 82.03 8.5 Favored 'General case' 0 N--CA 1.441 -0.898 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 -179.752 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -92.59 1.8 72.59 Favored Glycine 0 C--N 1.353 1.494 0 N-CA-C 108.332 -1.907 . . . . 0.0 108.332 179.694 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 64.93 38.71 6.26 Favored 'General case' 0 C--N 1.356 0.856 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -127.98 147.06 50.48 Favored 'General case' 0 CA--C 1.497 -1.07 0 N-CA-C 106.677 -1.601 . . . . 0.0 106.677 179.6 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 90.3 mt -112.46 134.38 54.03 Favored 'General case' 0 CA--C 1.497 -1.085 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.415 HD12 ' H ' ' A' ' 55' ' ' GLU . 96.8 mt -65.53 -42.41 93.03 Favored 'Isoleucine or valine' 0 C--N 1.354 0.769 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.66 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 32.9 t0 64.86 53.86 1.4 Allowed 'General case' 0 C--N 1.359 0.988 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -93.66 -117.01 2.67 Favored Glycine 0 C--N 1.352 1.456 0 N-CA-C 107.661 -2.176 . . . . 0.0 107.661 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 34.8 t0 66.75 52.05 1.0 Allowed 'General case' 0 C--N 1.355 0.807 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 53.6 p90 -148.42 159.89 43.58 Favored 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 107.307 -1.368 . . . . 0.0 107.307 179.364 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 65.0 mttp -91.59 137.8 32.07 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 -179.534 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 86.3 t80 -117.22 125.79 51.72 Favored 'General case' 0 N--CA 1.44 -0.952 0 N-CA-C 107.297 -1.372 . . . . 0.0 107.297 -178.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -116.47 140.64 49.15 Favored 'General case' 0 CA--C 1.494 -1.189 0 N-CA-C 106.148 -1.797 . . . . 0.0 106.148 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 34.8 t -150.12 145.98 26.64 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 -179.554 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 35.3 m -128.79 149.2 33.32 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.152 0 N-CA-C 105.678 -1.971 . . . . 0.0 105.678 179.025 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 12.9 t -156.75 154.58 30.2 Favored 'General case' 0 N--CA 1.437 -1.121 0 C-N-CA 119.205 -0.998 . . . . 0.0 108.37 -178.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -157.04 159.39 37.92 Favored 'General case' 0 N--CA 1.436 -1.171 0 N-CA-C 105.841 -1.911 . . . . 0.0 105.841 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -174.68 170.2 43.28 Favored Glycine 0 N--CA 1.437 -1.241 0 N-CA-C 108.365 -1.894 . . . . 0.0 108.365 179.714 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo -80.17 155.0 22.35 Favored 'Trans proline' 0 C--N 1.312 -1.371 0 C-N-CA 122.596 2.197 . . . . 0.0 113.255 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.491 HG21 HG23 ' A' ' 44' ' ' ILE . 65.9 t -123.98 128.71 74.29 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.062 0 N-CA-C 106.695 -1.594 . . . . 0.0 106.695 179.511 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -113.18 124.91 53.65 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 107.06 -1.459 . . . . 0.0 107.06 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 45.1 ttm180 -111.73 132.73 54.43 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 49.7 mm -74.58 -64.68 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.937 0 N-CA-C 107.033 -1.469 . . . . 0.0 107.033 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 66.4 t30 -179.24 94.54 0.03 OUTLIER 'General case' 0 CA--C 1.502 -0.892 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 178.127 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 58.7 mt-10 39.63 45.88 1.45 Allowed 'General case' 0 C--N 1.359 0.996 0 C-N-CA 122.972 0.509 . . . . 0.0 111.647 177.892 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 85.3 t80 -141.46 -43.52 0.36 Allowed 'General case' 0 CA--C 1.501 -0.905 0 C-N-CA 118.942 -1.103 . . . . 0.0 108.785 -179.737 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 9.9 p -162.69 150.34 3.77 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.055 0 N-CA-C 107.127 -1.434 . . . . 0.0 107.127 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 70.1 m -123.38 136.98 54.91 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 179.199 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 65.4 tp -117.38 130.76 56.7 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 106.429 -1.693 . . . . 0.0 106.429 -179.724 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.426 ' HB3' HG22 ' A' ' 78' ' ' VAL . 48.2 p90 -141.67 158.05 44.31 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 -179.55 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -124.46 154.35 17.92 Favored Glycine 0 CA--C 1.49 -1.472 0 N-CA-C 106.968 -2.453 . . . . 0.0 106.968 -179.457 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 93.6 mt -123.25 139.64 53.84 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 -179.12 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -148.84 146.57 28.03 Favored 'General case' 0 N--CA 1.437 -1.083 0 N-CA-C 105.962 -1.866 . . . . 0.0 105.962 178.494 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 175.01 -155.53 20.79 Favored Glycine 0 CA--C 1.492 -1.352 0 N-CA-C 108.217 -1.953 . . . . 0.0 108.217 -179.468 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -148.31 159.49 43.94 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -144.9 167.48 27.2 Favored Glycine 0 CA--C 1.493 -1.338 0 N-CA-C 107.901 -2.08 . . . . 0.0 107.901 -179.291 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 31.3 p80 -149.61 159.64 44.16 Favored 'General case' 0 N--CA 1.439 -1.005 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -124.79 138.06 10.87 Favored Glycine 0 C--N 1.351 1.368 0 N-CA-C 108.059 -2.016 . . . . 0.0 108.059 -179.456 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 75.2 mmtt -133.17 142.12 48.47 Favored 'General case' 0 CA--C 1.497 -1.06 0 N-CA-C 107.064 -1.458 . . . . 0.0 107.064 179.73 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -105.74 -57.23 2.07 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 179.573 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 38.7 mtmm -135.4 150.15 49.82 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 106.679 -1.6 . . . . 0.0 106.679 179.822 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -107.02 126.47 52.37 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 75.1 m -143.11 36.29 1.37 Allowed 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 -179.896 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 80.9 p -96.97 1.84 50.81 Favored 'General case' 0 CA--C 1.504 -0.818 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 46.1 pt -83.35 -15.09 11.63 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.805 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 -179.192 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 -69.97 -39.0 76.25 Favored 'General case' 0 CA--C 1.503 -0.853 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 104.09 110.32 3.47 Favored Glycine 0 C--N 1.351 1.388 0 N-CA-C 107.456 -2.258 . . . . 0.0 107.456 179.773 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 13.5 pm0 -153.82 154.83 34.69 Favored 'General case' 0 N--CA 1.436 -1.157 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 85.5 p -94.06 -16.52 23.75 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 -179.088 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -110.33 118.14 35.52 Favored 'General case' 0 CA--C 1.497 -1.075 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 -179.647 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 70.4 m -130.78 150.04 52.14 Favored 'General case' 0 CA--C 1.495 -1.156 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 30.8 mmm180 -118.95 139.51 51.54 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 106.667 -1.605 . . . . 0.0 106.667 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 35.5 t -154.19 146.28 23.68 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -128.51 145.56 51.08 Favored 'General case' 0 CA--C 1.497 -1.074 0 N-CA-C 106.765 -1.569 . . . . 0.0 106.765 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 71.9 p -128.93 156.09 44.27 Favored 'General case' 0 CA--C 1.497 -1.091 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 54.5 m -129.58 151.11 50.55 Favored 'General case' 0 CA--C 1.496 -1.133 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 89.5 mt -92.86 141.37 28.5 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -119.25 129.35 54.88 Favored 'General case' 0 N--CA 1.438 -1.059 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -178.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -135.49 150.04 49.68 Favored 'General case' 0 CA--C 1.494 -1.175 0 N-CA-C 105.985 -1.857 . . . . 0.0 105.985 178.716 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -173.95 -179.31 44.51 Favored Glycine 0 CA--C 1.491 -1.432 0 N-CA-C 108.796 -1.722 . . . . 0.0 108.796 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -157.27 163.36 38.82 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 105.748 -1.945 . . . . 0.0 105.748 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -161.05 167.37 36.0 Favored Glycine 0 N--CA 1.436 -1.365 0 N-CA-C 108.618 -1.793 . . . . 0.0 108.618 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 87.9 mt -123.09 147.41 46.78 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 -179.714 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 6.5 mt-30 -121.86 127.16 50.19 Favored 'General case' 0 CA--C 1.498 -1.052 0 N-CA-C 106.96 -1.496 . . . . 0.0 106.96 179.168 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 83.9 t80 -133.71 135.7 44.18 Favored 'General case' 0 N--CA 1.439 -1.013 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' ASN . . . . . 0.412 ' OD1' HG13 ' A' ' 130' ' ' VAL . 61.8 m-20 -116.0 96.92 48.3 Favored Pre-proline 0 N--CA 1.442 -0.838 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 -179.111 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -71.45 -24.06 22.93 Favored 'Trans proline' 0 CA--C 1.496 -1.393 0 C-N-CA 121.746 1.63 . . . . 0.0 112.058 178.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -135.45 153.3 77.7 Favored Pre-proline 0 N--CA 1.434 -1.245 0 N-CA-C 105.73 -1.952 . . . . 0.0 105.73 179.687 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -67.0 -19.7 51.57 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 121.81 1.673 . . . . 0.0 113.566 -179.57 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -112.52 19.0 17.94 Favored 'General case' 0 N--CA 1.443 -0.783 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 -179.146 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 47.8 t80 -143.85 127.34 16.92 Favored 'General case' 0 CA--C 1.503 -0.864 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 -179.658 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' VAL . . . . . 0.412 HG13 ' OD1' ' A' ' 124' ' ' ASN . 96.4 t -120.79 129.65 75.43 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.93 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -179.353 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 89.4 mt -100.14 124.01 53.35 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.04 0 N-CA-C 106.719 -1.585 . . . . 0.0 106.719 179.293 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 51.1 m-20 -114.63 123.6 49.72 Favored 'General case' 0 N--CA 1.439 -0.998 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 -179.549 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -129.07 126.42 39.36 Favored 'General case' 0 CA--C 1.496 -1.115 0 N-CA-C 105.754 -1.943 . . . . 0.0 105.754 178.425 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 63.7 m -139.81 150.66 44.98 Favored 'General case' 0 CA--C 1.493 -1.237 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 -179.028 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 90.0 t80 -124.24 126.6 46.36 Favored 'General case' 0 CA--C 1.496 -1.106 0 N-CA-C 105.555 -2.017 . . . . 0.0 105.555 178.158 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -118.51 130.26 55.82 Favored 'General case' 0 CA--C 1.497 -1.096 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 -179.056 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 82.8 t80 -118.49 126.11 51.32 Favored 'General case' 0 N--CA 1.436 -1.173 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 42.7 t -91.99 121.61 33.72 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 105.82 -1.919 . . . . 0.0 105.82 179.446 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 60.1 tptt -108.77 119.96 41.07 Favored 'General case' 0 N--CA 1.438 -1.027 0 CA-C-O 121.74 0.781 . . . . 0.0 109.021 -178.156 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 43.2 tp -158.08 144.47 17.49 Favored 'General case' 0 N--CA 1.431 -1.391 0 N-CA-C 104.526 -2.398 . . . . 0.0 104.526 177.754 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -62.44 -38.44 89.76 Favored 'General case' 0 N--CA 1.446 -0.656 0 O-C-N 121.958 -0.464 . . . . 0.0 110.262 -178.36 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -89.52 -28.4 19.65 Favored 'General case' 0 N--CA 1.444 -0.767 0 C-N-CA 120.255 -0.578 . . . . 0.0 111.129 -177.399 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 67.6 t -126.28 125.59 67.88 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.789 0 C-N-CA 119.547 -0.861 . . . . 0.0 109.637 -177.461 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 65.4 mttp -125.6 111.39 14.94 Favored 'General case' 0 CA--C 1.5 -0.966 0 N-CA-C 105.845 -1.909 . . . . 0.0 105.845 178.367 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 86.4 t -133.76 131.16 56.53 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.98 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -178.712 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -109.06 130.21 9.9 Favored Glycine 0 C--N 1.353 1.493 0 N-CA-C 105.809 -2.916 . . . . 0.0 105.809 178.086 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 89.2 m -130.2 134.89 47.6 Favored 'General case' 0 CA--C 1.498 -1.053 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 -178.794 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 25.4 t90 -107.63 137.36 45.8 Favored 'General case' 0 CA--C 1.5 -0.967 0 N-CA-C 105.665 -1.976 . . . . 0.0 105.665 179.21 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 2.7 mpp? -118.22 131.66 56.36 Favored 'General case' 0 CA--C 1.496 -1.112 0 N-CA-C 108.026 -1.102 . . . . 0.0 108.026 -179.106 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 62.1 tp -128.18 130.62 48.33 Favored 'General case' 0 N--CA 1.437 -1.084 0 N-CA-C 105.833 -1.914 . . . . 0.0 105.833 179.299 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -159.72 -179.06 34.26 Favored Glycine 0 CA--C 1.492 -1.373 0 N-CA-C 108.426 -1.869 . . . . 0.0 108.426 -179.554 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -135.04 153.32 52.1 Favored 'General case' 0 N--CA 1.437 -1.111 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 -179.486 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -116.07 156.04 15.88 Favored Glycine 0 CA--C 1.49 -1.521 0 N-CA-C 108.154 -1.979 . . . . 0.0 108.154 -179.309 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 55.3 p90 -145.35 160.73 41.09 Favored 'General case' 0 N--CA 1.435 -1.194 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 34.5 ptt180 -151.86 159.07 43.98 Favored 'General case' 0 N--CA 1.436 -1.136 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 -179.503 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 72.0 m-85 . . . . . 0 C--O 1.262 1.749 0 CA-C-O 117.906 -1.045 . . . . 0.0 108.637 -179.869 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 . . . . . 0 N--CA 1.489 1.499 0 CA-C-O 120.944 0.402 . . . . 0.0 110.76 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 176.08 -170.55 43.47 Favored Glycine 0 CA--C 1.491 -1.422 0 N-CA-C 107.002 -2.439 . . . . 0.0 107.002 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 49.3 mp0 -120.51 143.24 48.66 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 106.729 -1.582 . . . . 0.0 106.729 179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 63.8 m -129.53 143.44 50.83 Favored 'General case' 0 CA--C 1.495 -1.172 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 51.6 m -132.96 144.51 50.17 Favored 'General case' 0 CA--C 1.496 -1.119 0 N-CA-C 106.559 -1.645 . . . . 0.0 106.559 179.404 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 50.4 mm -119.34 126.39 75.29 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.152 0 N-CA-C 106.648 -1.612 . . . . 0.0 106.648 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 64.4 m -122.58 142.03 51.06 Favored 'General case' 0 CA--C 1.495 -1.158 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 46.6 pt -133.12 155.86 41.45 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.148 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 179.593 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -166.36 176.45 41.59 Favored Glycine 0 CA--C 1.491 -1.419 0 N-CA-C 107.949 -2.06 . . . . 0.0 107.949 -179.839 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -104.05 144.96 30.85 Favored 'General case' 0 CA--C 1.496 -1.115 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 -179.421 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -109.42 135.17 50.9 Favored 'General case' 0 N--CA 1.437 -1.08 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 94.5 mm-40 -129.39 158.62 38.65 Favored 'General case' 0 CA--C 1.498 -1.028 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 6.1 t -125.61 -165.89 1.48 Allowed 'General case' 0 CA--C 1.501 -0.94 0 N-CA-C 106.884 -1.524 . . . . 0.0 106.884 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 85.4 mtp180 -74.02 140.81 45.69 Favored 'General case' 0 N--CA 1.441 -0.902 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 -179.285 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 72.6 t -125.09 129.1 73.34 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.028 0 N-CA-C 106.23 -1.767 . . . . 0.0 106.23 179.668 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 17.5 tptp -84.73 124.31 31.38 Favored 'General case' 0 N--CA 1.441 -0.911 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 -179.412 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -145.01 121.62 11.11 Favored 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 107.022 -1.473 . . . . 0.0 107.022 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 48.5 m-20 -144.58 81.82 1.67 Allowed 'General case' 0 CA--C 1.503 -0.861 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 79.61 22.84 63.58 Favored Glycine 0 C--N 1.352 1.472 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 178.724 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -126.01 154.1 43.44 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 107.19 -1.411 . . . . 0.0 107.19 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 59.7 mtmt -70.91 149.15 47.01 Favored 'General case' 0 CA--C 1.502 -0.898 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 58.1 tp -76.23 121.97 23.69 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -179.399 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 12.9 t0 -161.01 165.21 30.22 Favored 'General case' 0 N--CA 1.435 -1.222 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 99.5 mttt 60.82 49.63 5.94 Favored 'General case' 0 C--N 1.358 0.948 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 179.831 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 95.4 m-20 -72.02 149.15 92.18 Favored Pre-proline 0 N--CA 1.442 -0.844 0 N-CA-C 107.094 -1.446 . . . . 0.0 107.094 179.367 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -70.57 149.64 62.06 Favored 'Trans proline' 0 CA--C 1.497 -1.357 0 C-N-CA 121.792 1.661 . . . . 0.0 112.756 -179.753 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 2.0 mpp_? -101.26 125.57 47.9 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -156.88 158.83 29.12 Favored Glycine 0 CA--C 1.49 -1.482 0 N-CA-C 106.941 -2.464 . . . . 0.0 106.941 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -146.94 146.34 30.09 Favored 'General case' 0 N--CA 1.437 -1.108 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 -179.652 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 27.9 t-20 -126.87 129.91 49.15 Favored 'General case' 0 N--CA 1.44 -0.956 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 -179.092 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 87.6 mt -114.16 138.47 50.4 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 179.062 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 37.8 ttpt -133.98 131.19 38.67 Favored 'General case' 0 CA--C 1.498 -1.038 0 N-CA-C 107.294 -1.372 . . . . 0.0 107.294 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -111.59 128.85 56.17 Favored 'General case' 0 N--CA 1.437 -1.093 0 N-CA-C 106.263 -1.754 . . . . 0.0 106.263 179.574 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ARG . . . . . 0.572 ' HA ' HG22 ' A' ' 44' ' ' ILE . 79.2 ttt-85 -119.14 127.55 53.44 Favored 'General case' 0 CA--C 1.494 -1.176 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 -179.498 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -124.73 131.81 53.43 Favored 'General case' 0 N--CA 1.435 -1.184 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -116.91 126.49 53.06 Favored 'General case' 0 N--CA 1.436 -1.139 0 N-CA-C 106.917 -1.512 . . . . 0.0 106.917 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 94.0 m-85 -122.95 176.25 6.12 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 106.279 -1.749 . . . . 0.0 106.279 -179.646 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 66.1 t30 -80.53 70.43 7.24 Favored 'General case' 0 N--CA 1.442 -0.86 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 -179.841 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 33.9 m120 -139.73 169.17 18.23 Favored 'General case' 0 N--CA 1.437 -1.107 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 179.683 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -85.71 -5.3 59.28 Favored 'General case' 0 N--CA 1.441 -0.892 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 -179.305 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 55.1 m95 -130.49 149.12 52.31 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 -179.51 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.04 159.84 17.11 Favored Glycine 0 C--N 1.354 1.533 0 N-CA-C 107.629 -2.189 . . . . 0.0 107.629 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 81.2 t -123.74 126.93 73.53 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.965 0 N-CA-C 107.051 -1.462 . . . . 0.0 107.051 -179.657 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.572 HG22 ' HA ' ' A' ' 34' ' ' ARG . 41.0 pt -129.71 162.69 36.83 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.974 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -142.61 152.73 24.06 Favored Glycine 0 CA--C 1.492 -1.347 0 N-CA-C 105.558 -3.017 . . . . 0.0 105.558 178.846 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 40.9 t -145.38 147.05 31.84 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 -179.019 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 93.2 t80 -127.87 129.54 47.08 Favored 'General case' 0 N--CA 1.439 -1.008 0 N-CA-C 106.09 -1.818 . . . . 0.0 106.09 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -124.59 137.49 54.38 Favored 'General case' 0 CA--C 1.499 -0.985 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 -179.617 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 63.0 tt0 -136.84 128.23 28.32 Favored 'General case' 0 CA--C 1.499 -1.015 0 N-CA-C 107.47 -1.307 . . . . 0.0 107.47 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 91.5 m -127.75 127.97 44.54 Favored 'General case' 0 CA--C 1.496 -1.099 0 N-CA-C 106.313 -1.736 . . . . 0.0 106.313 179.018 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 4.7 tmt_? -149.09 129.11 13.49 Favored 'General case' 0 CA--C 1.498 -1.035 0 N-CA-C 107.32 -1.363 . . . . 0.0 107.32 -179.559 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 4.0 tmt_? -106.13 -67.67 0.92 Allowed 'General case' 0 CA--C 1.502 -0.881 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 155.51 -167.96 33.12 Favored Glycine 0 CA--C 1.493 -1.33 0 N-CA-C 106.832 -2.507 . . . . 0.0 106.832 -179.779 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 88.6 t80 -140.14 115.42 9.87 Favored 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 179.744 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -140.49 140.98 35.42 Favored 'General case' 0 CA--C 1.501 -0.921 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 78.7 mm-40 -109.79 4.77 22.09 Favored 'General case' 0 CA--C 1.503 -0.864 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 179.691 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 70.6 m -120.51 131.73 54.85 Favored 'General case' 0 CA--C 1.496 -1.106 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 -179.708 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 67.2 t -128.69 125.92 64.25 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.014 0 N-CA-C 106.514 -1.662 . . . . 0.0 106.514 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 68.4 m-20 -88.51 -31.68 18.59 Favored 'General case' 0 CA--C 1.502 -0.886 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 179.88 176.0 47.01 Favored Glycine 0 CA--C 1.491 -1.434 0 N-CA-C 106.615 -2.594 . . . . 0.0 106.615 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 60.64 52.13 4.64 Favored 'General case' 0 C--N 1.356 0.851 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 39.8 ttpt -70.43 129.54 39.53 Favored 'General case' 0 N--CA 1.441 -0.909 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 -179.661 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 90.6 mt -116.56 157.78 24.73 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 45.7 pt -111.94 161.23 10.79 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.047 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 61.2 39.43 15.84 Favored 'General case' 0 C--N 1.358 0.938 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 -179.183 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -117.77 -175.99 17.09 Favored Glycine 0 C--N 1.352 1.431 0 N-CA-C 107.223 -2.351 . . . . 0.0 107.223 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 59.48 41.57 19.04 Favored 'General case' 0 C--N 1.357 0.906 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 -179.709 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 85.0 t80 -139.23 138.57 36.95 Favored 'General case' 0 N--CA 1.436 -1.142 0 N-CA-C 106.435 -1.691 . . . . 0.0 106.435 -179.677 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 18.6 ptpt -128.6 153.45 47.23 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 -179.648 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 49.6 p90 -157.97 160.29 37.38 Favored 'General case' 0 N--CA 1.437 -1.103 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 -179.489 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -127.93 140.18 52.15 Favored 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 105.991 -1.855 . . . . 0.0 105.991 179.83 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 58.6 m -139.28 140.37 37.61 Favored 'General case' 0 CA--C 1.497 -1.091 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 58.7 t -129.09 136.14 60.32 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.125 0 N-CA-C 105.545 -2.021 . . . . 0.0 105.545 179.01 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 80.4 p -139.85 160.37 40.05 Favored 'General case' 0 CA--C 1.499 -1.008 0 N-CA-C 108.747 -0.835 . . . . 0.0 108.747 -179.479 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -156.47 155.29 31.78 Favored 'General case' 0 CA--C 1.497 -1.075 0 N-CA-C 105.772 -1.936 . . . . 0.0 105.772 178.653 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -178.57 173.16 45.56 Favored Glycine 0 C--N 1.349 1.253 0 N-CA-C 108.711 -1.756 . . . . 0.0 108.711 179.764 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_endo -82.81 160.46 16.23 Favored 'Trans proline' 0 C--N 1.311 -1.437 0 C-N-CA 122.996 2.464 . . . . 0.0 113.369 179.735 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 66.7 t -115.0 125.86 72.43 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.958 0 N-CA-C 106.876 -1.528 . . . . 0.0 106.876 179.554 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 70.7 t80 -102.31 121.74 42.87 Favored 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 -179.753 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 93.2 mtm-85 -111.83 137.21 50.09 Favored 'General case' 0 CA--C 1.497 -1.085 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 83.7 mt -83.17 -64.03 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.833 0 N-CA-C 106.49 -1.67 . . . . 0.0 106.49 179.418 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 179.93 93.61 0.02 OUTLIER 'General case' 0 C--N 1.355 0.82 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 177.51 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 69.4 tt0 36.67 48.46 0.64 Allowed 'General case' 0 C--N 1.362 1.137 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.213 178.397 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 63.9 t80 -141.97 -43.52 0.34 Allowed 'General case' 0 CA--C 1.499 -0.992 0 C-N-CA 119.27 -0.972 . . . . 0.0 108.57 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 11.0 p -161.65 151.08 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.144 0 N-CA-C 106.933 -1.506 . . . . 0.0 106.933 -179.675 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 67.6 m -124.92 140.94 52.46 Favored 'General case' 0 CA--C 1.498 -1.056 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 179.611 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 6.6 tt -129.72 134.92 47.91 Favored 'General case' 0 CA--C 1.494 -1.2 0 N-CA-C 105.801 -1.926 . . . . 0.0 105.801 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 26.9 p90 -134.56 157.45 46.52 Favored 'General case' 0 CA--C 1.494 -1.181 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 -179.403 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -115.07 150.08 18.77 Favored Glycine 0 CA--C 1.491 -1.417 0 N-CA-C 107.167 -2.373 . . . . 0.0 107.167 -179.423 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 88.1 mt -114.12 133.99 55.19 Favored 'General case' 0 CA--C 1.497 -1.058 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 63.1 tp -137.19 132.41 33.86 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 179.489 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -178.47 -152.98 10.81 Favored Glycine 0 CA--C 1.491 -1.423 0 N-CA-C 108.239 -1.944 . . . . 0.0 108.239 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -145.43 156.91 44.04 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 -179.297 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -142.85 142.37 11.44 Favored Glycine 0 CA--C 1.491 -1.457 0 N-CA-C 107.526 -2.23 . . . . 0.0 107.526 -179.837 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 53.2 m80 -142.76 151.74 41.57 Favored 'General case' 0 CA--C 1.497 -1.079 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 -179.806 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -149.65 145.13 12.97 Favored Glycine 0 CA--C 1.492 -1.4 0 N-CA-C 106.972 -2.451 . . . . 0.0 106.972 179.449 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 21.9 ptmt -163.99 164.07 23.23 Favored 'General case' 0 N--CA 1.436 -1.155 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -104.89 128.26 53.05 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 106.906 -1.516 . . . . 0.0 106.906 179.598 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 60.8 tptt -126.56 123.46 37.76 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -120.29 -51.59 2.19 Favored 'General case' 0 CA--C 1.499 -1.003 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 179.727 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 3.6 p -169.9 -68.58 0.02 OUTLIER 'General case' 0 CA--C 1.5 -0.973 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 36.9 t -151.58 145.83 25.41 Favored 'General case' 0 CA--C 1.497 -1.096 0 N-CA-C 106.578 -1.638 . . . . 0.0 106.578 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 46.3 pt -129.81 160.25 41.02 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.068 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -125.13 137.84 54.17 Favored 'General case' 0 CA--C 1.497 -1.077 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 -179.801 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 172.8 -179.24 44.41 Favored Glycine 0 CA--C 1.491 -1.448 0 N-CA-C 106.763 -2.535 . . . . 0.0 106.763 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 78.9 mt-30 -131.81 135.54 46.82 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 179.704 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 37.0 t -158.95 145.81 17.19 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 106.49 -1.67 . . . . 0.0 106.49 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -120.33 117.07 26.83 Favored 'General case' 0 CA--C 1.497 -1.059 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 179.677 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 70.6 m -141.75 148.06 38.38 Favored 'General case' 0 CA--C 1.494 -1.177 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 179.617 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -105.64 -66.93 0.95 Allowed 'General case' 0 CA--C 1.5 -0.961 0 N-CA-C 107.111 -1.44 . . . . 0.0 107.111 179.553 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 70.6 m -143.24 140.75 30.82 Favored 'General case' 0 CA--C 1.496 -1.131 0 N-CA-C 106.764 -1.569 . . . . 0.0 106.764 179.316 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 39.7 ttmt -157.11 136.68 12.23 Favored 'General case' 0 CA--C 1.496 -1.106 0 N-CA-C 107.116 -1.439 . . . . 0.0 107.116 179.691 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 15.2 t -152.6 153.67 33.83 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 106.456 -1.683 . . . . 0.0 106.456 179.608 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 58.2 m -117.94 129.22 55.48 Favored 'General case' 0 CA--C 1.496 -1.133 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 91.6 mt -97.74 147.58 24.22 Favored 'General case' 0 CA--C 1.497 -1.065 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 -179.775 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -116.36 138.54 51.25 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 107.551 -1.277 . . . . 0.0 107.551 -179.312 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -130.4 148.93 52.27 Favored 'General case' 0 CA--C 1.497 -1.081 0 N-CA-C 106.695 -1.595 . . . . 0.0 106.695 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -170.86 178.98 43.07 Favored Glycine 0 N--CA 1.436 -1.331 0 N-CA-C 108.106 -1.998 . . . . 0.0 108.106 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -156.55 163.57 39.21 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 106.169 -1.789 . . . . 0.0 106.169 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -153.0 160.61 29.17 Favored Glycine 0 CA--C 1.491 -1.412 0 N-CA-C 108.847 -1.701 . . . . 0.0 108.847 -179.71 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 88.3 mt -117.44 144.4 45.05 Favored 'General case' 0 CA--C 1.497 -1.076 0 N-CA-C 106.364 -1.717 . . . . 0.0 106.364 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 46.6 tt0 -130.28 131.38 45.43 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -125.28 146.51 49.52 Favored 'General case' 0 CA--C 1.497 -1.096 0 N-CA-C 106.541 -1.651 . . . . 0.0 106.541 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 29.4 t30 -128.43 79.5 74.05 Favored Pre-proline 0 N--CA 1.439 -1.007 0 N-CA-C 107.424 -1.324 . . . . 0.0 107.424 -179.18 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.79 -28.43 16.83 Favored 'Trans proline' 0 CA--C 1.497 -1.33 0 C-N-CA 121.869 1.713 . . . . 0.0 112.612 179.457 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -137.58 150.48 68.42 Favored Pre-proline 0 N--CA 1.437 -1.115 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -70.14 -18.55 35.14 Favored 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 121.761 1.64 . . . . 0.0 113.501 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 34.8 m120 -108.68 15.35 23.76 Favored 'General case' 0 N--CA 1.442 -0.868 0 N-CA-C 109.157 -0.682 . . . . 0.0 109.157 -179.068 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -152.16 117.94 5.43 Favored 'General case' 0 CA--C 1.502 -0.878 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 67.5 t -112.43 129.55 67.77 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.97 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 -179.552 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 84.9 mt -113.86 127.8 71.08 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.029 0 N-CA-C 107.032 -1.469 . . . . 0.0 107.032 -179.534 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -141.5 160.43 40.17 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -147.79 146.42 29.15 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 105.382 -2.081 . . . . 0.0 105.382 179.122 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 55.4 m -150.27 164.02 36.8 Favored 'General case' 0 CA--C 1.494 -1.182 0 C-N-CA 119.207 -0.997 . . . . 0.0 109.107 -178.741 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 51.7 p90 -139.59 148.84 43.08 Favored 'General case' 0 N--CA 1.435 -1.21 0 N-CA-C 106.23 -1.767 . . . . 0.0 106.23 178.453 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -139.22 135.65 34.16 Favored 'General case' 0 N--CA 1.438 -1.051 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 -179.465 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -126.51 138.46 53.49 Favored 'General case' 0 CA--C 1.496 -1.114 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 178.898 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 66.8 m -130.02 143.93 51.06 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 179.72 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 30.2 mtpp -101.96 118.11 36.22 Favored 'General case' 0 CA--C 1.498 -1.044 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 -179.561 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 5.0 mp -126.18 140.28 52.68 Favored 'General case' 0 N--CA 1.438 -1.031 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 179.237 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -65.48 -39.59 92.13 Favored 'General case' 0 N--CA 1.444 -0.733 0 C-N-CA 120.74 -0.384 . . . . 0.0 110.015 -179.024 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -63.55 -50.01 71.19 Favored 'General case' 0 C--N 1.355 0.804 0 C-N-CA 120.461 -0.496 . . . . 0.0 110.734 -177.668 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 15.6 m -151.54 160.44 3.67 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.018 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 -178.806 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 40.0 ttpt -84.36 128.96 34.89 Favored 'General case' 0 CA--C 1.501 -0.935 0 N-CA-C 105.786 -1.931 . . . . 0.0 105.786 178.244 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 71.1 t -111.94 122.11 65.65 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.0 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 -178.115 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -125.53 131.21 7.54 Favored Glycine 0 C--N 1.351 1.37 0 N-CA-C 105.701 -2.959 . . . . 0.0 105.701 178.498 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 87.0 m -127.48 130.53 49.39 Favored 'General case' 0 CA--C 1.496 -1.125 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 -178.769 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 28.3 m-90 -120.85 140.44 51.76 Favored 'General case' 0 CA--C 1.495 -1.15 0 N-CA-C 105.31 -2.107 . . . . 0.0 105.31 178.225 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -144.86 151.24 38.43 Favored 'General case' 0 N--CA 1.438 -1.05 0 C-N-CA 119.183 -1.007 . . . . 0.0 108.86 -179.127 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 2.3 tt -146.86 143.76 28.8 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 105.874 -1.899 . . . . 0.0 105.874 179.81 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -168.33 -164.32 23.82 Favored Glycine 0 CA--C 1.491 -1.408 0 N-CA-C 108.77 -1.732 . . . . 0.0 108.77 -179.242 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -146.2 163.83 34.19 Favored 'General case' 0 N--CA 1.435 -1.218 0 N-CA-C 106.571 -1.641 . . . . 0.0 106.571 -179.35 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -144.6 171.97 25.72 Favored Glycine 0 CA--C 1.49 -1.502 0 N-CA-C 108.544 -1.822 . . . . 0.0 108.544 -179.235 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 92.3 m-85 -130.88 149.51 52.48 Favored 'General case' 0 N--CA 1.437 -1.084 0 N-CA-C 107.03 -1.47 . . . . 0.0 107.03 -179.608 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 58.9 ttp180 -89.25 129.08 35.87 Favored 'General case' 0 CA--C 1.501 -0.916 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 58.0 m-85 . . . . . 0 C--O 1.262 1.73 0 CA-C-O 117.992 -1.004 . . . . 0.0 108.317 -179.555 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 49.8 tt0 . . . . . 0 N--CA 1.487 1.399 0 CA-C-O 121.452 0.644 . . . . 0.0 110.385 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -179.5 179.43 48.86 Favored Glycine 0 CA--C 1.492 -1.399 0 N-CA-C 106.943 -2.463 . . . . 0.0 106.943 179.834 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -115.32 126.88 55.0 Favored 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 107.274 -1.38 . . . . 0.0 107.274 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 71.1 m -129.27 152.12 49.19 Favored 'General case' 0 CA--C 1.494 -1.199 0 N-CA-C 106.646 -1.613 . . . . 0.0 106.646 179.592 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 61.7 m -125.37 142.38 51.53 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 85.7 mt -119.46 130.69 73.7 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.107 0 N-CA-C 106.285 -1.746 . . . . 0.0 106.285 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 47.7 t -130.69 137.34 49.5 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 -179.608 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 47.1 pt -128.65 157.65 41.22 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.093 0 N-CA-C 106.784 -1.562 . . . . 0.0 106.784 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -173.01 -161.73 23.9 Favored Glycine 0 CA--C 1.491 -1.435 0 N-CA-C 107.618 -2.193 . . . . 0.0 107.618 -179.655 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 41.2 p90 -138.38 158.39 44.38 Favored 'General case' 0 N--CA 1.438 -1.062 0 N-CA-C 106.784 -1.561 . . . . 0.0 106.784 -179.401 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -112.4 138.37 49.23 Favored 'General case' 0 N--CA 1.44 -0.938 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 -179.128 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 21.0 pt20 -131.29 163.38 27.93 Favored 'General case' 0 CA--C 1.502 -0.886 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 179.494 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 6.7 t -134.45 -157.05 0.78 Allowed 'General case' 0 CA--C 1.503 -0.845 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 -179.706 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -82.66 107.93 15.65 Favored 'General case' 0 CA--C 1.501 -0.929 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 -179.302 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 75.5 t -127.6 128.01 69.2 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.068 0 N-CA-C 106.386 -1.709 . . . . 0.0 106.386 179.333 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -152.18 160.92 43.29 Favored 'General case' 0 N--CA 1.437 -1.117 0 N-CA-C 107.47 -1.307 . . . . 0.0 107.47 -179.707 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -137.81 165.54 26.2 Favored 'General case' 0 N--CA 1.438 -1.027 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 44.7 p-10 -91.86 11.93 23.23 Favored 'General case' 0 N--CA 1.444 -0.74 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 -179.573 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -154.42 171.39 32.91 Favored Glycine 0 CA--C 1.492 -1.374 0 N-CA-C 106.666 -2.574 . . . . 0.0 106.666 179.87 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -103.91 102.62 12.41 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 -179.592 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 54.2 tptt -160.43 140.81 11.58 Favored 'General case' 0 N--CA 1.436 -1.164 0 N-CA-C 106.107 -1.812 . . . . 0.0 106.107 179.521 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 91.8 mt -88.63 66.17 8.04 Favored 'General case' 0 CA--C 1.502 -0.882 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -179.683 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -65.63 -39.77 91.81 Favored 'General case' 0 C--N 1.355 0.847 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 179.409 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 26.6 pttm -158.58 165.7 33.86 Favored 'General case' 0 N--CA 1.435 -1.188 0 N-CA-C 106.92 -1.511 . . . . 0.0 106.92 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 69.0 m-80 -129.52 153.86 80.73 Favored Pre-proline 0 N--CA 1.438 -1.047 0 N-CA-C 106.291 -1.744 . . . . 0.0 106.291 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -59.29 141.72 98.16 Favored 'Trans proline' 0 CA--C 1.501 -1.174 0 C-N-CA 122.158 1.906 . . . . 0.0 112.832 179.831 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -119.12 127.04 52.98 Favored 'General case' 0 CA--C 1.497 -1.087 0 N-CA-C 107.37 -1.345 . . . . 0.0 107.37 -179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -171.48 160.84 33.04 Favored Glycine 0 N--CA 1.435 -1.424 0 N-CA-C 107.103 -2.399 . . . . 0.0 107.103 179.521 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 -135.65 148.81 49.11 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 23.3 t-20 -143.51 121.03 11.73 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 179.47 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 67.2 tp -123.65 126.26 46.28 Favored 'General case' 0 CA--C 1.499 -0.998 0 N-CA-C 106.997 -1.482 . . . . 0.0 106.997 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 17.1 mtpp -125.95 148.33 49.27 Favored 'General case' 0 CA--C 1.501 -0.925 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 40.3 t80 -137.44 130.47 30.54 Favored 'General case' 0 N--CA 1.441 -0.905 0 N-CA-C 106.285 -1.746 . . . . 0.0 106.285 179.343 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ARG . . . . . 0.649 ' HA ' HG22 ' A' ' 44' ' ' ILE . 7.7 tmm_? -102.28 127.86 49.07 Favored 'General case' 0 CA--C 1.5 -0.952 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 -179.427 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -108.4 137.63 46.03 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 106.679 -1.601 . . . . 0.0 106.679 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -88.98 75.48 8.0 Favored 'General case' 0 N--CA 1.442 -0.868 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 91.7 t80 -63.51 -48.1 78.99 Favored 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 179.077 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 -154.76 162.49 41.1 Favored 'General case' 0 N--CA 1.436 -1.164 0 N-CA-C 105.719 -1.956 . . . . 0.0 105.719 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 9.5 p-10 -79.0 -30.09 44.08 Favored 'General case' 0 N--CA 1.44 -0.933 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 -179.633 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -71.08 -41.94 70.01 Favored 'General case' 0 C--N 1.356 0.887 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 -179.327 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 23.0 m-90 -140.14 139.22 35.72 Favored 'General case' 0 CA--C 1.495 -1.144 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -110.52 169.25 13.34 Favored Glycine 0 C--N 1.349 1.258 0 N-CA-C 107.466 -2.254 . . . . 0.0 107.466 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 99.6 t -130.76 131.56 64.53 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.028 0 N-CA-C 106.777 -1.564 . . . . 0.0 106.777 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.649 HG22 ' HA ' ' A' ' 34' ' ' ARG . 38.5 pt -124.9 158.86 32.2 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.152 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -140.03 142.23 12.36 Favored Glycine 0 CA--C 1.489 -1.548 0 N-CA-C 105.267 -3.133 . . . . 0.0 105.267 178.453 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 89.6 p -146.29 151.1 37.0 Favored 'General case' 0 CA--C 1.497 -1.077 0 C-N-CA 119.112 -1.035 . . . . 0.0 109.187 -179.3 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -121.4 141.45 50.96 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 105.745 -1.946 . . . . 0.0 105.745 179.271 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -135.91 141.35 44.53 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 -179.53 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 72.4 mt-30 -131.73 138.37 48.61 Favored 'General case' 0 CA--C 1.495 -1.15 0 N-CA-C 106.402 -1.703 . . . . 0.0 106.402 179.327 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 84.7 m -132.67 129.91 39.43 Favored 'General case' 0 CA--C 1.497 -1.076 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 179.634 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 79.8 ttt180 -126.15 129.94 50.04 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.192 -1.411 . . . . 0.0 107.192 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 85.4 mtp180 -129.34 140.5 51.36 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 106.706 -1.59 . . . . 0.0 106.706 179.409 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -179.94 172.29 43.85 Favored Glycine 0 CA--C 1.491 -1.467 0 N-CA-C 107.326 -2.31 . . . . 0.0 107.326 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 90.5 t80 -137.42 129.94 29.81 Favored 'General case' 0 N--CA 1.438 -1.067 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 -179.8 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -94.09 123.3 37.38 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 -179.67 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -95.23 94.05 7.66 Favored 'General case' 0 N--CA 1.439 -1.002 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 69.5 m -93.55 -5.8 48.13 Favored 'General case' 0 CA--C 1.501 -0.933 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 179.805 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.2 m -132.77 159.68 43.03 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.097 0 N-CA-C 106.943 -1.502 . . . . 0.0 106.943 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 67.6 t0 -89.84 102.26 14.96 Favored 'General case' 0 N--CA 1.439 -0.976 0 N-CA-C 106.774 -1.565 . . . . 0.0 106.774 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -133.79 41.06 1.51 Allowed Glycine 0 CA--C 1.491 -1.434 0 N-CA-C 106.992 -2.443 . . . . 0.0 106.992 179.626 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 5.3 t80 76.51 -171.61 0.09 Allowed 'General case' 0 C--N 1.357 0.923 0 N-CA-C 107.289 -1.375 . . . . 0.0 107.289 -179.672 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 18.0 tppt? -91.51 118.55 30.68 Favored 'General case' 0 CA--C 1.499 -0.998 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 88.9 mt -119.63 139.25 52.49 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 45.8 pt -130.53 153.61 39.32 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.055 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 53.3 t0 -164.92 88.62 0.47 Allowed 'General case' 0 N--CA 1.436 -1.151 0 N-CA-C 106.158 -1.793 . . . . 0.0 106.158 179.718 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 85.66 -91.97 1.74 Allowed Glycine 0 C--N 1.349 1.3 0 N-CA-C 107.531 -2.228 . . . . 0.0 107.531 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 59.24 43.0 17.56 Favored 'General case' 0 C--N 1.359 0.98 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -149.66 141.67 23.88 Favored 'General case' 0 N--CA 1.434 -1.251 0 N-CA-C 106.25 -1.759 . . . . 0.0 106.25 -179.311 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -102.16 139.37 37.87 Favored 'General case' 0 CA--C 1.496 -1.121 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 -179.722 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -126.88 139.97 52.69 Favored 'General case' 0 CA--C 1.497 -1.06 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -128.82 143.18 50.84 Favored 'General case' 0 CA--C 1.495 -1.148 0 N-CA-C 105.877 -1.897 . . . . 0.0 105.877 179.627 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 40.0 t -149.93 145.15 26.33 Favored 'General case' 0 CA--C 1.496 -1.098 0 N-CA-C 107.9 -1.148 . . . . 0.0 107.9 -179.346 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.4 p -136.64 137.47 47.5 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.116 0 N-CA-C 105.694 -1.965 . . . . 0.0 105.694 178.663 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 74.4 p -142.09 160.88 39.35 Favored 'General case' 0 CA--C 1.497 -1.076 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 -179.235 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -155.09 157.93 38.27 Favored 'General case' 0 N--CA 1.433 -1.318 0 N-CA-C 105.539 -2.023 . . . . 0.0 105.539 178.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -179.96 177.0 47.82 Favored Glycine 0 N--CA 1.437 -1.268 0 N-CA-C 108.909 -1.676 . . . . 0.0 108.909 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 68.5 Cg_endo -81.86 162.05 18.57 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 123.101 2.534 . . . . 0.0 114.012 -179.488 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.432 HG22 ' CD2' ' A' ' 88' ' ' TYR . 60.1 t -115.52 127.12 73.21 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.045 0 N-CA-C 106.079 -1.823 . . . . 0.0 106.079 179.264 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 83.9 t80 -128.75 121.99 29.63 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 -179.317 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 90.9 mtm180 -112.06 141.93 45.12 Favored 'General case' 0 CA--C 1.497 -1.058 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 49.3 mm -74.35 -64.23 0.87 Allowed 'Isoleucine or valine' 0 CA--C 1.503 -0.839 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 179.764 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 66.5 t30 179.86 94.92 0.02 OUTLIER 'General case' 0 CA--C 1.501 -0.93 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 178.258 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 23.0 tt0 37.57 48.47 0.91 Allowed 'General case' 0 C--N 1.36 1.051 0 C-N-CA 122.973 0.509 . . . . 0.0 110.976 178.857 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 73.7 t80 -141.8 -43.3 0.35 Allowed 'General case' 0 CA--C 1.5 -0.973 0 C-N-CA 119.427 -0.909 . . . . 0.0 108.574 -179.631 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 11.1 p -159.17 149.55 7.19 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.138 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 -179.591 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 42.4 t -117.89 129.28 55.54 Favored 'General case' 0 N--CA 1.438 -1.044 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 87.8 mt -109.63 140.14 43.81 Favored 'General case' 0 CA--C 1.497 -1.068 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 -179.412 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.432 ' CD2' HG22 ' A' ' 78' ' ' VAL . 86.6 m-85 -128.01 142.4 51.24 Favored 'General case' 0 CA--C 1.493 -1.23 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 -179.712 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -111.86 134.48 12.1 Favored Glycine 0 CA--C 1.489 -1.559 0 N-CA-C 105.683 -2.967 . . . . 0.0 105.683 178.606 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 89.8 mt -120.6 134.67 55.26 Favored 'General case' 0 CA--C 1.497 -1.085 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 -179.071 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -150.78 149.44 29.75 Favored 'General case' 0 N--CA 1.436 -1.17 0 N-CA-C 105.875 -1.898 . . . . 0.0 105.875 178.69 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 171.89 -146.36 9.31 Favored Glycine 0 CA--C 1.49 -1.511 0 N-CA-C 107.782 -2.127 . . . . 0.0 107.782 -179.48 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -141.54 157.21 45.41 Favored 'General case' 0 N--CA 1.435 -1.206 0 N-CA-C 107.57 -1.271 . . . . 0.0 107.57 -178.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -130.72 154.04 20.53 Favored Glycine 0 CA--C 1.493 -1.294 0 N-CA-C 107.35 -2.3 . . . . 0.0 107.35 -179.71 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 79.4 m80 -136.62 152.64 50.66 Favored 'General case' 0 N--CA 1.437 -1.111 0 N-CA-C 107.164 -1.421 . . . . 0.0 107.164 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -121.8 146.68 17.12 Favored Glycine 0 CA--C 1.491 -1.423 0 N-CA-C 106.899 -2.481 . . . . 0.0 106.899 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 28.9 tptp -138.19 131.96 31.13 Favored 'General case' 0 N--CA 1.438 -1.031 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 -179.367 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -85.4 155.93 21.07 Favored 'General case' 0 N--CA 1.439 -0.979 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 179.564 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 62.8 mtpt -72.9 150.66 42.41 Favored 'General case' 0 CA--C 1.503 -0.857 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -86.44 119.79 27.08 Favored 'General case' 0 CA--C 1.499 -1.007 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 39.1 t -169.71 -80.11 0.02 OUTLIER 'General case' 0 N--CA 1.438 -1.055 0 N-CA-C 106.772 -1.566 . . . . 0.0 106.772 179.589 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 37.1 t -155.71 145.05 20.9 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 20.5 tt -146.93 138.07 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.057 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 88.4 t80 -143.36 122.15 12.66 Favored 'General case' 0 N--CA 1.436 -1.129 0 N-CA-C 106.367 -1.716 . . . . 0.0 106.367 179.581 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 155.96 -168.76 33.5 Favored Glycine 0 CA--C 1.491 -1.407 0 N-CA-C 107.119 -2.393 . . . . 0.0 107.119 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 99.0 mt-30 -131.35 147.77 52.6 Favored 'General case' 0 CA--C 1.497 -1.064 0 N-CA-C 106.695 -1.594 . . . . 0.0 106.695 179.753 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 38.5 t -150.29 143.2 24.77 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -144.9 132.84 21.3 Favored 'General case' 0 N--CA 1.436 -1.142 0 N-CA-C 106.679 -1.6 . . . . 0.0 106.679 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 34.8 t -149.79 148.41 29.17 Favored 'General case' 0 CA--C 1.496 -1.122 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 96.3 mtm-85 -89.06 -5.44 57.86 Favored 'General case' 0 N--CA 1.442 -0.871 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 -179.334 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 42.7 t -151.01 140.32 21.35 Favored 'General case' 0 CA--C 1.498 -1.026 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -100.87 1.79 40.33 Favored 'General case' 0 CA--C 1.502 -0.891 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 179.141 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 92.3 m -118.16 130.97 56.42 Favored 'General case' 0 CA--C 1.497 -1.072 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 -179.344 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 67.8 m -107.2 147.27 30.35 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -83.67 150.16 26.04 Favored 'General case' 0 N--CA 1.442 -0.838 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 -179.596 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -130.07 139.29 50.98 Favored 'General case' 0 N--CA 1.439 -0.993 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 179.696 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 90.7 t80 -145.12 141.95 29.22 Favored 'General case' 0 CA--C 1.499 -1.018 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -166.66 -171.46 32.81 Favored Glycine 0 N--CA 1.437 -1.293 0 N-CA-C 108.363 -1.895 . . . . 0.0 108.363 -179.632 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -149.56 161.49 42.05 Favored 'General case' 0 N--CA 1.436 -1.126 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -133.1 148.41 19.31 Favored Glycine 0 C--N 1.35 1.345 0 N-CA-C 108.221 -1.952 . . . . 0.0 108.221 -179.633 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -124.22 143.9 50.26 Favored 'General case' 0 CA--C 1.498 -1.021 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 179.663 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 40.4 tt0 -143.04 139.05 30.38 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 -179.322 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -126.11 141.49 51.92 Favored 'General case' 0 N--CA 1.436 -1.131 0 N-CA-C 106.139 -1.801 . . . . 0.0 106.139 178.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -128.81 74.76 80.59 Favored Pre-proline 0 CA--C 1.503 -0.855 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 -179.087 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.22 -30.35 20.28 Favored 'Trans proline' 0 CA--C 1.499 -1.246 0 C-N-CA 121.496 1.464 . . . . 0.0 112.344 179.265 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 79.3 m80 -139.78 151.52 66.04 Favored Pre-proline 0 N--CA 1.437 -1.083 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 179.483 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 94.4 Cg_endo -78.82 -12.07 15.01 Favored 'Trans proline' 0 C--N 1.312 -1.366 0 C-N-CA 121.943 1.762 . . . . 0.0 112.84 179.203 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 24.2 m120 -64.5 -38.68 91.88 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.118 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 50.6 p90 -149.41 158.56 44.28 Favored 'General case' 0 CA--C 1.5 -0.953 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 -178.752 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 62.1 t -125.75 131.9 71.41 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.897 0 N-CA-C 107.424 -1.324 . . . . 0.0 107.424 -179.063 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 86.1 mt -109.43 129.05 64.91 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.986 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -140.52 160.54 39.78 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 -179.636 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -146.99 147.12 30.38 Favored 'General case' 0 N--CA 1.436 -1.126 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 69.1 m -142.88 159.85 41.45 Favored 'General case' 0 CA--C 1.492 -1.262 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 -179.391 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 51.2 p90 -146.37 149.46 33.81 Favored 'General case' 0 N--CA 1.435 -1.176 0 N-CA-C 106.9 -1.519 . . . . 0.0 106.9 179.033 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -138.05 145.8 42.22 Favored 'General case' 0 CA--C 1.498 -1.052 0 N-CA-C 107.274 -1.38 . . . . 0.0 107.274 179.616 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 78.5 m-85 -129.72 144.37 51.26 Favored 'General case' 0 CA--C 1.496 -1.111 0 N-CA-C 107.494 -1.299 . . . . 0.0 107.494 179.09 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 34.7 t -140.79 137.92 33.71 Favored 'General case' 0 N--CA 1.437 -1.087 0 N-CA-C 105.388 -2.079 . . . . 0.0 105.388 178.795 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 59.9 mtpt -115.89 131.15 57.02 Favored 'General case' 0 CA--C 1.496 -1.134 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 -178.574 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 5.0 mp -125.05 154.87 40.65 Favored 'General case' 0 N--CA 1.435 -1.206 0 N-CA-C 105.312 -2.107 . . . . 0.0 105.312 178.21 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -63.18 -38.1 89.83 Favored 'General case' 0 N--CA 1.445 -0.722 0 C-N-CA 120.602 -0.439 . . . . 0.0 110.036 -178.815 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 69.0 m-20 -76.71 -47.81 20.77 Favored 'General case' 0 C--N 1.352 0.702 0 C-N-CA 119.998 -0.681 . . . . 0.0 111.136 -177.623 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 31.0 m -143.56 166.49 13.91 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.91 0 C-N-CA 119.818 -0.753 . . . . 0.0 109.282 -177.867 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 35.5 mmtp -106.73 140.45 39.57 Favored 'General case' 0 CA--C 1.5 -0.944 0 N-CA-C 105.585 -2.006 . . . . 0.0 105.585 178.479 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 99.1 t -124.2 127.74 73.51 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.956 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -178.606 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -123.78 132.99 8.64 Favored Glycine 0 C--N 1.352 1.427 0 N-CA-C 105.972 -2.851 . . . . 0.0 105.972 178.529 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 86.3 m -127.05 130.75 50.56 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 -179.029 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 91.6 m95 -114.65 138.93 50.08 Favored 'General case' 0 CA--C 1.497 -1.076 0 N-CA-C 106.136 -1.801 . . . . 0.0 106.136 179.12 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 2.1 mpt? -127.68 139.83 52.46 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -179.292 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 63.1 tp -133.6 132.78 41.22 Favored 'General case' 0 CA--C 1.497 -1.059 0 N-CA-C 105.707 -1.96 . . . . 0.0 105.707 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -163.15 -172.23 30.38 Favored Glycine 0 C--N 1.35 1.354 0 N-CA-C 108.807 -1.717 . . . . 0.0 108.807 -179.241 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -135.54 154.25 51.44 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 -179.581 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -115.74 149.88 18.75 Favored Glycine 0 CA--C 1.492 -1.372 0 N-CA-C 108.411 -1.876 . . . . 0.0 108.411 -179.013 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 85.9 t80 -129.78 128.77 43.06 Favored 'General case' 0 N--CA 1.437 -1.08 0 N-CA-C 106.16 -1.792 . . . . 0.0 106.16 179.476 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 82.7 mtp180 -80.47 137.58 36.48 Favored 'General case' 0 CA--C 1.501 -0.938 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 -179.413 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 . . . . . 0 C--O 1.262 1.733 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.586 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 . . . . . 0 N--CA 1.489 1.487 0 CA-C-O 120.887 0.375 . . . . 0.0 110.648 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -179.74 178.71 48.72 Favored Glycine 0 CA--C 1.493 -1.32 0 N-CA-C 106.879 -2.488 . . . . 0.0 106.879 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -133.04 142.98 49.08 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 65.6 m -139.52 143.63 37.52 Favored 'General case' 0 CA--C 1.495 -1.146 0 N-CA-C 106.572 -1.64 . . . . 0.0 106.572 179.037 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 64.2 m -129.95 147.95 51.76 Favored 'General case' 0 CA--C 1.497 -1.058 0 N-CA-C 107.37 -1.344 . . . . 0.0 107.37 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 85.4 mt -118.41 130.33 73.41 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.015 0 N-CA-C 106.498 -1.667 . . . . 0.0 106.498 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.43 ' HA ' ' HA2' ' A' ' 153' ' ' GLY . 48.4 t -135.32 140.71 45.31 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 -179.533 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 46.6 pt -130.77 155.58 41.98 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.124 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 179.487 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -164.63 179.67 39.22 Favored Glycine 0 CA--C 1.49 -1.489 0 N-CA-C 107.924 -2.07 . . . . 0.0 107.924 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -126.31 147.0 49.8 Favored 'General case' 0 CA--C 1.494 -1.174 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 -179.609 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -99.26 129.86 45.51 Favored 'General case' 0 N--CA 1.438 -1.075 0 N-CA-C 106.844 -1.539 . . . . 0.0 106.844 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 75.5 mt-30 -129.36 147.94 51.24 Favored 'General case' 0 CA--C 1.498 -1.021 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 -179.435 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.43 ' HB2' HG22 ' A' ' 147' ' ' THR . 35.3 t -154.45 141.98 19.76 Favored 'General case' 0 CA--C 1.497 -1.058 0 N-CA-C 106.577 -1.638 . . . . 0.0 106.577 179.552 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 30.6 tpt180 -154.51 137.88 15.82 Favored 'General case' 0 N--CA 1.436 -1.138 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 70.3 t -108.67 119.55 58.45 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.061 0 N-CA-C 106.005 -1.85 . . . . 0.0 106.005 179.319 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -82.56 136.84 34.74 Favored 'General case' 0 CA--C 1.498 -1.027 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 -179.088 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -133.6 -67.36 0.61 Allowed 'General case' 0 CA--C 1.498 -1.037 0 N-CA-C 106.786 -1.561 . . . . 0.0 106.786 179.33 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 -94.19 -29.52 15.07 Favored 'General case' 0 N--CA 1.441 -0.885 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 179.482 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 174.92 -171.22 44.41 Favored Glycine 0 CA--C 1.492 -1.358 0 N-CA-C 106.912 -2.475 . . . . 0.0 106.912 -179.836 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 87.2 t80 -105.07 119.92 40.22 Favored 'General case' 0 CA--C 1.501 -0.941 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 32.2 mmmt -131.85 149.38 52.47 Favored 'General case' 0 CA--C 1.498 -1.028 0 N-CA-C 107.341 -1.355 . . . . 0.0 107.341 -179.614 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 87.2 mt -103.19 76.63 1.46 Allowed 'General case' 0 CA--C 1.5 -0.975 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 45.7 t0 -154.96 111.54 3.25 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 -179.818 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 31.1 ttpt 70.71 73.45 0.2 Allowed 'General case' 0 C--N 1.357 0.903 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 179.347 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -127.23 149.62 70.12 Favored Pre-proline 0 CA--C 1.5 -0.956 0 N-CA-C 106.487 -1.671 . . . . 0.0 106.487 179.761 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_endo -73.04 153.91 52.39 Favored 'Trans proline' 0 CA--C 1.499 -1.258 0 C-N-CA 121.825 1.683 . . . . 0.0 112.522 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 22.7 tpt180 -136.33 135.36 38.82 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 106.25 -1.759 . . . . 0.0 106.25 -179.75 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -135.35 156.29 22.58 Favored Glycine 0 CA--C 1.493 -1.334 0 N-CA-C 107.621 -2.192 . . . . 0.0 107.621 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -111.18 141.53 44.57 Favored 'General case' 0 CA--C 1.496 -1.122 0 N-CA-C 106.574 -1.639 . . . . 0.0 106.574 -179.818 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 16.3 t30 -136.6 126.47 25.8 Favored 'General case' 0 N--CA 1.439 -1.016 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 -179.521 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 88.6 mt -114.51 139.0 49.92 Favored 'General case' 0 CA--C 1.496 -1.102 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 178.885 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 40.5 ttpt -136.7 132.86 35.47 Favored 'General case' 0 CA--C 1.5 -0.967 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 -179.292 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -123.5 140.38 53.07 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 106.697 -1.594 . . . . 0.0 106.697 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ARG . . . . . 0.462 ' HA ' HG22 ' A' ' 44' ' ' ILE . 2.6 tmt_? -121.97 132.42 54.52 Favored 'General case' 0 CA--C 1.498 -1.051 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 -179.233 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -125.91 138.37 53.78 Favored 'General case' 0 N--CA 1.437 -1.094 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 179.597 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -90.97 102.4 15.17 Favored 'General case' 0 N--CA 1.439 -1.001 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 -179.441 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 89.8 t80 -63.7 -47.44 81.15 Favored 'General case' 0 CA--C 1.505 -0.756 0 N-CA-C 108.204 -1.036 . . . . 0.0 108.204 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.9 t-20 -156.06 175.15 14.34 Favored 'General case' 0 N--CA 1.436 -1.141 0 N-CA-C 106.574 -1.639 . . . . 0.0 106.574 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -83.23 68.69 9.72 Favored 'General case' 0 N--CA 1.443 -0.822 0 N-CA-C 107.845 -1.168 . . . . 0.0 107.845 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -171.32 -62.33 0.02 OUTLIER 'General case' 0 N--CA 1.439 -1.025 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 179.745 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 41.8 m0 -126.28 147.58 49.68 Favored 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 -179.727 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -123.27 172.05 15.99 Favored Glycine 0 CA--C 1.492 -1.372 0 N-CA-C 107.076 -2.41 . . . . 0.0 107.076 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.8 m -130.88 152.5 37.66 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.148 0 N-CA-C 107.049 -1.463 . . . . 0.0 107.049 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.559 HG21 ' CE2' ' A' ' 88' ' ' TYR . 33.1 pt -133.12 160.24 42.65 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.151 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 -179.791 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -136.68 139.86 10.98 Favored Glycine 0 CA--C 1.489 -1.553 0 N-CA-C 104.658 -3.377 . . . . 0.0 104.658 177.826 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 44.9 t -145.38 144.61 30.77 Favored 'General case' 0 CA--C 1.498 -1.045 0 C-N-CA 119.257 -0.977 . . . . 0.0 108.431 -178.726 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -127.1 142.36 51.54 Favored 'General case' 0 N--CA 1.437 -1.104 0 N-CA-C 106.057 -1.831 . . . . 0.0 106.057 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -137.77 143.17 40.98 Favored 'General case' 0 CA--C 1.497 -1.069 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 76.3 mt-30 -132.24 137.11 47.42 Favored 'General case' 0 CA--C 1.498 -1.038 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 179.821 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 71.8 p -135.3 159.04 42.81 Favored 'General case' 0 CA--C 1.501 -0.938 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 179.667 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 78.9 ttt180 -142.31 135.63 28.9 Favored 'General case' 0 N--CA 1.439 -0.998 0 N-CA-C 106.665 -1.605 . . . . 0.0 106.665 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 82.3 mtp180 -119.39 129.3 54.74 Favored 'General case' 0 CA--C 1.499 -0.995 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -174.83 164.76 35.67 Favored Glycine 0 CA--C 1.492 -1.364 0 N-CA-C 106.618 -2.593 . . . . 0.0 106.618 179.477 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 94.8 m-85 -110.49 -5.38 15.15 Favored 'General case' 0 CA--C 1.5 -0.958 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 81.2 mm-40 -136.48 146.23 46.04 Favored 'General case' 0 CA--C 1.497 -1.076 0 N-CA-C 107.354 -1.351 . . . . 0.0 107.354 -179.72 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -101.91 7.44 41.5 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 107.816 -1.179 . . . . 0.0 107.816 179.778 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 34.6 t -147.5 150.91 35.45 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 -179.461 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 34.9 m -126.85 158.56 37.47 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.002 0 N-CA-C 107.292 -1.373 . . . . 0.0 107.292 -179.463 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 13.9 t0 -159.87 166.18 30.75 Favored 'General case' 0 N--CA 1.435 -1.177 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 -179.778 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -78.35 164.72 51.22 Favored Glycine 0 C--N 1.35 1.356 0 N-CA-C 108.059 -2.016 . . . . 0.0 108.059 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 63.86 32.28 13.44 Favored 'General case' 0 C--N 1.356 0.883 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 29.6 tptp -148.66 133.08 17.59 Favored 'General case' 0 N--CA 1.437 -1.122 0 N-CA-C 106.917 -1.512 . . . . 0.0 106.917 179.769 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 7.6 mp -103.8 118.97 37.94 Favored 'General case' 0 CA--C 1.498 -1.042 0 N-CA-C 106.656 -1.609 . . . . 0.0 106.656 179.599 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 82.7 mt -124.73 125.58 70.14 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.01 0 N-CA-C 107.137 -1.431 . . . . 0.0 107.137 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -100.4 116.85 33.34 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 179.169 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 149.53 -142.91 10.2 Favored Glycine 0 CA--C 1.492 -1.391 0 N-CA-C 106.965 -2.454 . . . . 0.0 106.965 -179.539 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 26.2 t0 71.11 47.49 0.4 Allowed 'General case' 0 C--N 1.355 0.828 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.509 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -113.12 136.75 52.38 Favored 'General case' 0 CA--C 1.498 -1.033 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 38.3 mtmm -119.53 141.3 49.34 Favored 'General case' 0 CA--C 1.495 -1.137 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -129.45 144.01 51.07 Favored 'General case' 0 CA--C 1.496 -1.114 0 N-CA-C 107.332 -1.358 . . . . 0.0 107.332 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 90.3 m-85 -125.5 135.54 52.4 Favored 'General case' 0 N--CA 1.437 -1.102 0 N-CA-C 106.162 -1.792 . . . . 0.0 106.162 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 69.6 m -133.06 142.63 48.87 Favored 'General case' 0 CA--C 1.493 -1.249 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 60.0 t -128.78 136.05 60.78 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.155 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 179.033 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 70.3 p -139.19 159.54 41.92 Favored 'General case' 0 CA--C 1.5 -0.973 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 -179.701 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -157.78 159.86 37.22 Favored 'General case' 0 N--CA 1.436 -1.149 0 N-CA-C 105.768 -1.938 . . . . 0.0 105.768 179.211 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -179.63 175.65 47.05 Favored Glycine 0 N--CA 1.437 -1.274 0 N-CA-C 108.613 -1.795 . . . . 0.0 108.613 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -85.19 162.01 11.45 Favored 'Trans proline' 0 C--N 1.311 -1.433 0 C-N-CA 122.99 2.46 . . . . 0.0 113.771 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.469 ' CG2' HG23 ' A' ' 44' ' ' ILE . 69.7 t -124.2 126.83 72.82 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.023 0 N-CA-C 106.371 -1.715 . . . . 0.0 106.371 178.733 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -118.65 125.05 48.88 Favored 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 10.8 ptm180 -112.71 142.4 45.37 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 107.32 -1.363 . . . . 0.0 107.32 179.76 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 50.9 mm -77.71 -64.58 0.87 Allowed 'Isoleucine or valine' 0 CA--C 1.501 -0.94 0 N-CA-C 106.347 -1.723 . . . . 0.0 106.347 179.126 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 65.2 t30 178.66 94.72 0.02 OUTLIER 'General case' 0 N--CA 1.44 -0.952 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 177.679 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 60.8 mt-10 41.57 44.92 2.73 Favored 'General case' 0 C--N 1.358 0.959 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.278 178.121 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 48.6 t80 -141.47 -43.76 0.36 Allowed 'General case' 0 CA--C 1.5 -0.96 0 C-N-CA 119.056 -1.058 . . . . 0.0 108.772 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 9.7 p -163.47 150.18 3.24 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.095 0 N-CA-C 106.957 -1.498 . . . . 0.0 106.957 -179.675 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 64.0 m -126.28 140.65 52.36 Favored 'General case' 0 CA--C 1.496 -1.104 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 179.476 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 66.0 tp -103.86 125.73 50.48 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.559 ' CE2' HG21 ' A' ' 44' ' ' ILE . 4.6 m-85 -108.7 141.2 41.01 Favored 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 -179.286 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -128.53 138.18 10.17 Favored Glycine 0 CA--C 1.491 -1.468 0 N-CA-C 106.343 -2.703 . . . . 0.0 106.343 178.875 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.2 mp -128.71 138.53 52.18 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 -179.681 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -150.91 149.9 30.21 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 106.08 -1.822 . . . . 0.0 106.08 178.56 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 174.78 -150.46 11.3 Favored Glycine 0 CA--C 1.492 -1.374 0 N-CA-C 108.128 -1.989 . . . . 0.0 108.128 -179.627 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -144.16 162.18 36.97 Favored 'General case' 0 N--CA 1.437 -1.112 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -178.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -119.34 160.03 14.45 Favored Glycine 0 C--N 1.35 1.331 0 N-CA-C 107.555 -2.218 . . . . 0.0 107.555 -179.708 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 86.3 t60 -147.32 142.23 26.91 Favored 'General case' 0 N--CA 1.438 -1.05 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -133.47 161.93 24.29 Favored Glycine 0 CA--C 1.49 -1.475 0 N-CA-C 107.173 -2.371 . . . . 0.0 107.173 -179.681 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 29.0 ttpp -80.69 124.43 29.01 Favored 'General case' 0 N--CA 1.439 -0.977 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 -179.609 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.438 ' HB3' ' CE1' ' A' ' 100' ' ' PHE . . . -155.78 157.8 37.09 Favored 'General case' 0 N--CA 1.435 -1.175 0 N-CA-C 106.516 -1.661 . . . . 0.0 106.516 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -94.49 124.25 38.4 Favored 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 -179.805 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' PHE . . . . . 0.438 ' CE1' ' HB3' ' A' ' 98' ' ' ALA . 98.5 m-85 -125.77 138.09 53.83 Favored 'General case' 0 CA--C 1.496 -1.1 0 N-CA-C 106.64 -1.615 . . . . 0.0 106.64 179.557 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 96.3 p -158.51 161.19 37.34 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 35.0 t -156.12 145.72 20.97 Favored 'General case' 0 N--CA 1.437 -1.087 0 N-CA-C 106.401 -1.703 . . . . 0.0 106.401 179.683 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 96.6 mt -66.35 -44.42 90.89 Favored 'Isoleucine or valine' 0 C--N 1.354 0.792 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 -179.764 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 -126.18 147.09 49.72 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -63.73 -39.96 98.03 Favored Glycine 0 C--N 1.352 1.433 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 19.7 mp0 -86.87 74.88 9.68 Favored 'General case' 0 N--CA 1.44 -0.93 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 -179.332 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 68.0 m -132.08 149.95 52.28 Favored 'General case' 0 CA--C 1.496 -1.114 0 N-CA-C 107.091 -1.448 . . . . 0.0 107.091 179.506 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -136.03 128.23 29.94 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 179.674 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 16.9 m -157.8 -67.48 0.09 Allowed 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 179.741 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 85.1 mtp180 -134.72 148.07 50.21 Favored 'General case' 0 CA--C 1.496 -1.114 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 70.0 m -134.95 149.13 50.19 Favored 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 179.434 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 41.2 ttmt -130.34 124.31 31.97 Favored 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 88.2 m -130.67 130.94 44.53 Favored 'General case' 0 CA--C 1.496 -1.119 0 N-CA-C 106.889 -1.522 . . . . 0.0 106.889 179.695 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 69.8 m -110.36 119.66 39.94 Favored 'General case' 0 CA--C 1.497 -1.081 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 179.629 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 64.4 tp -110.48 128.92 55.84 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 -178.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -111.88 132.87 54.44 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 107.34 -1.355 . . . . 0.0 107.34 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 91.3 t80 -147.6 140.89 25.23 Favored 'General case' 0 CA--C 1.498 -1.036 0 N-CA-C 106.549 -1.649 . . . . 0.0 106.549 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -157.16 169.93 34.31 Favored Glycine 0 N--CA 1.436 -1.329 0 N-CA-C 108.288 -1.925 . . . . 0.0 108.288 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -154.0 157.08 38.56 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 106.122 -1.807 . . . . 0.0 106.122 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -164.35 173.56 40.33 Favored Glycine 0 CA--C 1.49 -1.51 0 N-CA-C 108.469 -1.853 . . . . 0.0 108.469 -179.68 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 6.6 mp -126.98 146.57 50.29 Favored 'General case' 0 N--CA 1.436 -1.131 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 -179.734 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 34.6 tt0 -117.61 133.26 56.14 Favored 'General case' 0 CA--C 1.496 -1.123 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 179.678 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -121.44 138.57 54.22 Favored 'General case' 0 N--CA 1.437 -1.084 0 N-CA-C 106.77 -1.567 . . . . 0.0 106.77 179.558 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 8.8 m120 -128.6 77.68 77.03 Favored Pre-proline 0 CA--C 1.502 -0.87 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 -179.456 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -69.72 -25.95 28.29 Favored 'Trans proline' 0 CA--C 1.5 -1.203 0 C-N-CA 121.685 1.59 . . . . 0.0 112.688 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 78.7 m80 -136.52 151.86 73.68 Favored Pre-proline 0 N--CA 1.439 -1.012 0 N-CA-C 106.49 -1.67 . . . . 0.0 106.49 179.602 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -83.96 62.09 6.84 Favored 'Trans proline' 0 C--N 1.313 -1.329 0 C-N-CA 121.941 1.761 . . . . 0.0 112.44 179.704 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -166.66 -54.9 0.03 OUTLIER 'General case' 0 CA--C 1.499 -0.995 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 -179.827 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -100.67 135.58 41.89 Favored 'General case' 0 CA--C 1.497 -1.069 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 -179.481 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 57.8 t -118.05 129.52 74.29 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.023 0 N-CA-C 106.964 -1.495 . . . . 0.0 106.964 -179.671 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 85.3 mt -97.07 122.33 48.49 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.975 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 -179.777 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 56.0 m-20 -123.2 131.11 53.56 Favored 'General case' 0 N--CA 1.439 -0.982 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 -178.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -136.64 126.67 26.04 Favored 'General case' 0 CA--C 1.496 -1.119 0 N-CA-C 105.338 -2.097 . . . . 0.0 105.338 178.144 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 53.3 m -142.61 153.43 43.48 Favored 'General case' 0 CA--C 1.493 -1.226 0 C-N-CA 119.487 -0.885 . . . . 0.0 108.726 -178.875 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -114.61 136.66 52.79 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 105.514 -2.032 . . . . 0.0 105.514 178.624 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 49.7 mt-10 -121.83 136.02 54.92 Favored 'General case' 0 CA--C 1.495 -1.136 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 -179.303 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -129.53 126.58 38.91 Favored 'General case' 0 N--CA 1.433 -1.282 0 N-CA-C 107.052 -1.462 . . . . 0.0 107.052 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 67.2 m -116.94 126.43 52.93 Favored 'General case' 0 CA--C 1.492 -1.265 0 N-CA-C 106.236 -1.764 . . . . 0.0 106.236 179.374 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 65.2 tttm -106.92 118.71 37.42 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 -179.225 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 4.0 mp -120.8 151.23 39.85 Favored 'General case' 0 N--CA 1.436 -1.167 0 N-CA-C 105.266 -2.124 . . . . 0.0 105.266 178.434 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -64.19 -39.48 94.07 Favored 'General case' 0 N--CA 1.441 -0.882 0 C-N-CA 120.36 -0.536 . . . . 0.0 109.873 -179.027 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -71.85 -44.13 64.35 Favored 'General case' 0 C--N 1.354 0.763 0 C-N-CA 120.136 -0.626 . . . . 0.0 111.321 -177.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 31.6 m -147.51 164.93 6.33 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.934 0 C-N-CA 119.738 -0.785 . . . . 0.0 109.367 -177.837 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -108.74 133.16 53.19 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 105.576 -2.009 . . . . 0.0 105.576 178.43 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 75.5 t -127.84 128.61 69.41 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.976 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 -178.715 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -125.25 133.58 8.49 Favored Glycine 0 C--N 1.351 1.412 0 N-CA-C 106.097 -2.801 . . . . 0.0 106.097 178.627 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 147' ' ' THR . . . . . 0.43 HG22 ' HB2' ' A' ' 13' ' ' SER . 80.9 p -134.21 152.23 51.72 Favored 'General case' 0 CA--C 1.501 -0.936 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 -179.263 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 25.8 t90 -109.06 136.91 47.8 Favored 'General case' 0 N--CA 1.439 -0.99 0 N-CA-C 105.862 -1.903 . . . . 0.0 105.862 179.003 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 16.5 tmm? -113.3 122.86 48.7 Favored 'General case' 0 CA--C 1.498 -1.056 0 N-CA-C 107.631 -1.248 . . . . 0.0 107.631 -179.324 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 64.1 tp -122.77 129.14 51.38 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 105.772 -1.936 . . . . 0.0 105.772 179.22 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -166.73 -170.83 32.13 Favored Glycine 0 CA--C 1.491 -1.458 0 N-CA-C 108.514 -1.834 . . . . 0.0 108.514 -179.385 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -145.05 156.54 43.99 Favored 'General case' 0 N--CA 1.433 -1.282 0 N-CA-C 106.773 -1.565 . . . . 0.0 106.773 -179.373 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 153' ' ' GLY . . . . . 0.43 ' HA2' ' HA ' ' A' ' 7' ' ' SER . . . -124.09 167.88 16.32 Favored Glycine 0 CA--C 1.49 -1.505 0 N-CA-C 108.218 -1.953 . . . . 0.0 108.218 -179.314 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 91.5 t80 -131.63 138.57 48.83 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 -179.734 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 17.4 ptm180 -145.07 160.74 40.92 Favored 'General case' 0 N--CA 1.437 -1.089 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 34.6 t80 . . . . . 0 C--O 1.262 1.742 0 CA-C-O 117.673 -1.156 . . . . 0.0 108.146 179.934 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 . . . . . 0 N--CA 1.489 1.515 0 CA-C-O 120.915 0.388 . . . . 0.0 110.583 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -179.73 176.81 47.81 Favored Glycine 0 CA--C 1.492 -1.375 0 N-CA-C 106.803 -2.519 . . . . 0.0 106.803 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -136.25 147.49 47.58 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 107.414 -1.328 . . . . 0.0 107.414 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 97.1 p -154.94 161.25 41.47 Favored 'General case' 0 N--CA 1.436 -1.139 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 179.63 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 54.8 m -135.97 146.1 46.88 Favored 'General case' 0 CA--C 1.496 -1.113 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 85.3 mt -119.64 129.31 75.5 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.083 0 N-CA-C 105.322 -2.103 . . . . 0.0 105.322 179.026 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 48.2 t -135.33 142.08 45.73 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 -178.609 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 46.9 pt -130.79 157.4 43.1 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.14 0 N-CA-C 106.001 -1.851 . . . . 0.0 106.001 179.047 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -163.66 178.53 39.13 Favored Glycine 0 CA--C 1.49 -1.486 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -179.669 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -117.51 149.44 40.61 Favored 'General case' 0 CA--C 1.495 -1.148 0 N-CA-C 106.854 -1.536 . . . . 0.0 106.854 -179.394 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -96.31 133.25 40.9 Favored 'General case' 0 N--CA 1.437 -1.088 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 -179.623 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 98.6 mm-40 -110.16 139.72 45.01 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 179.421 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 35.8 t -151.59 150.18 30.02 Favored 'General case' 0 CA--C 1.498 -1.036 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 -179.339 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 77.1 ttt180 -85.64 118.58 25.24 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 83.6 t -105.98 -56.37 4.99 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.016 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.4 tttm -156.75 141.71 17.11 Favored 'General case' 0 N--CA 1.437 -1.123 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 99.3 mt-10 -127.1 147.24 50.17 Favored 'General case' 0 CA--C 1.497 -1.074 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 179.478 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -159.96 170.83 20.52 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -88.8 64.26 3.43 Favored Glycine 0 C--N 1.351 1.391 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -178.895 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 44.1 m-85 -132.59 148.77 52.37 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 178.69 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 40.2 ttpt -62.51 -44.44 96.37 Favored 'General case' 0 CA--C 1.505 -0.777 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 89.2 mt -114.91 137.71 51.66 Favored 'General case' 0 CA--C 1.497 -1.076 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -149.6 67.93 1.01 Allowed 'General case' 0 N--CA 1.437 -1.104 0 N-CA-C 106.59 -1.633 . . . . 0.0 106.59 179.809 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 68.0 mttm 65.04 -168.15 0.21 Allowed 'General case' 0 C--N 1.357 0.914 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 69.1 m-80 -138.49 151.45 69.14 Favored Pre-proline 0 N--CA 1.44 -0.932 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -74.89 160.09 40.9 Favored 'Trans proline' 0 C--N 1.314 -1.251 0 C-N-CA 122.116 1.877 . . . . 0.0 112.282 179.051 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 36.3 ptt-85 -149.42 157.04 42.96 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 -179.678 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 141.65 136.49 3.27 Favored Glycine 0 C--N 1.349 1.301 0 N-CA-C 106.6 -2.6 . . . . 0.0 106.6 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 -127.24 138.61 53.13 Favored 'General case' 0 CA--C 1.496 -1.111 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 -179.238 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 20.4 m120 -131.54 135.81 47.34 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 179.695 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 88.5 mt -117.25 141.12 48.69 Favored 'General case' 0 CA--C 1.498 -1.055 0 N-CA-C 106.328 -1.73 . . . . 0.0 106.328 179.303 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 41.1 ttmt -141.17 135.7 31.09 Favored 'General case' 0 CA--C 1.502 -0.9 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 -179.552 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -127.31 143.65 51.19 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.208 -1.405 . . . . 0.0 107.208 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ARG . . . . . 0.486 ' HA ' HG22 ' A' ' 44' ' ' ILE . 75.7 ttt180 -124.9 130.37 52.23 Favored 'General case' 0 CA--C 1.499 -0.995 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 -179.598 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 64.7 t80 -121.35 126.49 49.58 Favored 'General case' 0 N--CA 1.44 -0.964 0 N-CA-C 106.156 -1.794 . . . . 0.0 106.156 179.249 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -99.13 112.05 24.28 Favored 'General case' 0 CA--C 1.5 -0.956 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 -179.032 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 78.7 m-85 -80.8 -35.58 32.84 Favored 'General case' 0 CA--C 1.503 -0.856 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 178.872 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 12.1 t-20 -164.1 172.57 13.58 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 106.565 -1.643 . . . . 0.0 106.565 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 54.3 m-80 -86.2 73.21 10.26 Favored 'General case' 0 CA--C 1.502 -0.884 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 -179.751 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -162.2 -66.65 0.05 Allowed 'General case' 0 N--CA 1.437 -1.1 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 179.645 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 42.1 m0 -126.59 146.49 50.14 Favored 'General case' 0 CA--C 1.499 -1.005 0 N-CA-C 106.806 -1.553 . . . . 0.0 106.806 -179.82 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -128.78 163.69 22.12 Favored Glycine 0 CA--C 1.494 -1.277 0 N-CA-C 107.259 -2.336 . . . . 0.0 107.259 179.785 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 70.8 t -129.09 132.8 66.85 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.009 0 N-CA-C 106.977 -1.49 . . . . 0.0 106.977 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.558 HG23 ' CG2' ' A' ' 78' ' ' VAL . 35.5 pt -123.21 159.65 27.11 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.129 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 179.793 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -137.99 147.31 19.15 Favored Glycine 0 CA--C 1.491 -1.451 0 N-CA-C 105.563 -3.015 . . . . 0.0 105.563 178.631 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 39.7 t -145.38 146.7 31.66 Favored 'General case' 0 N--CA 1.438 -1.065 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 -179.231 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 87.6 t80 -126.79 131.61 51.23 Favored 'General case' 0 N--CA 1.439 -1.002 0 N-CA-C 106.01 -1.848 . . . . 0.0 106.01 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -127.67 143.23 51.17 Favored 'General case' 0 CA--C 1.501 -0.932 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 -179.102 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 63.4 tt0 -136.57 133.57 36.52 Favored 'General case' 0 CA--C 1.5 -0.943 0 N-CA-C 106.772 -1.566 . . . . 0.0 106.772 179.768 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 15.2 t -146.12 156.16 43.24 Favored 'General case' 0 N--CA 1.443 -0.809 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 -179.753 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 61.7 ttp180 -114.05 129.31 56.62 Favored 'General case' 0 CA--C 1.498 -1.036 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 32.2 tpt180 -102.52 123.87 47.05 Favored 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -173.91 169.88 42.96 Favored Glycine 0 CA--C 1.491 -1.442 0 N-CA-C 107.163 -2.375 . . . . 0.0 107.163 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 84.6 t80 -140.29 125.84 19.1 Favored 'General case' 0 N--CA 1.436 -1.131 0 N-CA-C 106.021 -1.844 . . . . 0.0 106.021 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 48.8 mp0 -95.95 132.72 40.96 Favored 'General case' 0 N--CA 1.439 -1.005 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 -179.43 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -144.86 136.47 25.47 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 106.416 -1.698 . . . . 0.0 106.416 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 47.3 t -87.83 117.65 26.81 Favored 'General case' 0 CA--C 1.499 -0.991 0 N-CA-C 107.105 -1.443 . . . . 0.0 107.105 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 32.1 m -135.2 159.08 41.12 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.086 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 36.1 t70 -65.55 -44.57 86.39 Favored 'General case' 0 C--N 1.354 0.787 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 179.692 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 150.69 -178.92 27.83 Favored Glycine 0 CA--C 1.493 -1.329 0 N-CA-C 107.254 -2.338 . . . . 0.0 107.254 179.688 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 63.45 36.16 11.54 Favored 'General case' 0 C--N 1.354 0.786 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.521 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 32.7 mmmt -128.7 146.19 50.95 Favored 'General case' 0 CA--C 1.496 -1.127 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 179.582 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 89.6 mt -117.18 138.73 51.48 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 106.708 -1.59 . . . . 0.0 106.708 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 46.0 pt -131.6 156.85 42.98 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.055 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 -179.762 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 37.8 t70 -100.86 108.8 20.67 Favored 'General case' 0 N--CA 1.438 -1.059 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 179.768 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -179.98 -167.35 36.96 Favored Glycine 0 CA--C 1.493 -1.311 0 N-CA-C 107.456 -2.258 . . . . 0.0 107.456 -179.603 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 30.2 t0 73.38 49.25 0.14 Allowed 'General case' 0 C--N 1.356 0.874 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -121.4 141.65 50.77 Favored 'General case' 0 CA--C 1.497 -1.058 0 N-CA-C 107.065 -1.457 . . . . 0.0 107.065 179.492 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -101.8 130.1 48.15 Favored 'General case' 0 CA--C 1.498 -1.051 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -119.02 136.63 54.03 Favored 'General case' 0 CA--C 1.495 -1.156 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 179.687 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 90.3 m-85 -127.21 137.6 52.94 Favored 'General case' 0 CA--C 1.494 -1.181 0 N-CA-C 106.022 -1.844 . . . . 0.0 106.022 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 69.6 m -132.11 142.77 49.62 Favored 'General case' 0 CA--C 1.493 -1.245 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 61.4 t -128.33 137.74 56.57 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.154 0 N-CA-C 105.298 -2.112 . . . . 0.0 105.298 179.285 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 10.5 t -150.15 153.77 36.9 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 -178.902 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -154.26 160.4 41.78 Favored 'General case' 0 N--CA 1.435 -1.204 0 N-CA-C 105.825 -1.917 . . . . 0.0 105.825 179.686 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -176.05 176.58 47.66 Favored Glycine 0 CA--C 1.494 -1.237 0 N-CA-C 108.764 -1.734 . . . . 0.0 108.764 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -79.8 160.54 24.56 Favored 'Trans proline' 0 C--N 1.312 -1.347 0 C-N-CA 122.907 2.405 . . . . 0.0 113.537 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.558 ' CG2' HG23 ' A' ' 44' ' ' ILE . 67.8 t -119.34 129.33 75.41 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.084 0 N-CA-C 106.936 -1.505 . . . . 0.0 106.936 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -112.97 137.28 51.61 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 44.5 ttm180 -111.67 130.26 55.83 Favored 'General case' 0 CA--C 1.5 -0.943 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 -179.579 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 49.0 mm -78.87 -65.92 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.359 1.003 0 N-CA-C 106.854 -1.536 . . . . 0.0 106.854 179.281 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 34.0 m120 -162.7 91.06 0.73 Allowed 'General case' 0 C--N 1.357 0.927 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 177.782 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 14.3 tt0 37.39 22.77 0.0 OUTLIER 'General case' 0 C--N 1.359 0.999 0 N-CA-C 114.313 1.227 . . . . 0.0 114.313 177.572 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -144.02 -41.31 0.27 Allowed 'General case' 0 CA--C 1.499 -0.996 0 CA-C-N 120.397 1.453 . . . . 0.0 110.477 -178.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 86.6 t -119.64 131.23 72.76 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.166 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 -177.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 69.0 m -119.71 145.52 46.45 Favored 'General case' 0 CA--C 1.499 -1.005 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 179.285 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.0 mp -116.34 146.02 42.76 Favored 'General case' 0 CA--C 1.496 -1.131 0 N-CA-C 106.7 -1.592 . . . . 0.0 106.7 179.769 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 33.0 m-85 -126.29 143.42 51.16 Favored 'General case' 0 CA--C 1.496 -1.1 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 -179.432 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -116.81 138.0 13.99 Favored Glycine 0 CA--C 1.493 -1.326 0 N-CA-C 105.216 -3.154 . . . . 0.0 105.216 177.792 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 87.5 mt -117.62 134.42 54.9 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 -178.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 4.4 tt -146.7 130.23 16.84 Favored 'General case' 0 N--CA 1.437 -1.078 0 N-CA-C 105.322 -2.103 . . . . 0.0 105.322 178.504 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -176.86 -160.51 24.02 Favored Glycine 0 CA--C 1.492 -1.387 0 N-CA-C 108.578 -1.809 . . . . 0.0 108.578 -179.373 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -149.91 161.99 41.21 Favored 'General case' 0 N--CA 1.434 -1.234 0 N-CA-C 107.346 -1.353 . . . . 0.0 107.346 -179.202 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -141.79 164.73 26.69 Favored Glycine 0 CA--C 1.493 -1.294 0 N-CA-C 107.304 -2.318 . . . . 0.0 107.304 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 72.6 t60 -151.89 150.14 29.75 Favored 'General case' 0 N--CA 1.438 -1.029 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 -179.721 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -99.79 143.51 16.48 Favored Glycine 0 C--N 1.352 1.468 0 N-CA-C 107.994 -2.042 . . . . 0.0 107.994 -179.532 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -119.82 148.44 43.45 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -147.82 154.12 40.06 Favored 'General case' 0 N--CA 1.436 -1.143 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 40.9 ttmt -92.99 119.72 32.55 Favored 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 -179.722 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 92.1 t80 -145.13 129.16 17.51 Favored 'General case' 0 N--CA 1.437 -1.088 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 179.608 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 37.6 t -146.63 125.47 12.69 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 106.956 -1.498 . . . . 0.0 106.956 179.741 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 1.7 m -175.6 -81.34 0.01 OUTLIER 'General case' 0 CA--C 1.498 -1.055 0 N-CA-C 106.497 -1.668 . . . . 0.0 106.497 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 85.4 mt -123.16 126.35 73.37 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.042 0 N-CA-C 106.299 -1.741 . . . . 0.0 106.299 179.595 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -113.91 124.09 51.34 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 -179.802 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 175.91 175.41 43.27 Favored Glycine 0 CA--C 1.491 -1.418 0 N-CA-C 106.855 -2.498 . . . . 0.0 106.855 179.629 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 3.7 mm-40 -151.61 156.31 40.18 Favored 'General case' 0 CA--C 1.495 -1.147 0 N-CA-C 107.159 -1.422 . . . . 0.0 107.159 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 10.4 t -128.29 2.32 5.73 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -154.77 163.79 39.74 Favored 'General case' 0 N--CA 1.437 -1.08 0 N-CA-C 107.108 -1.441 . . . . 0.0 107.108 -179.72 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 67.6 m -104.32 128.6 52.15 Favored 'General case' 0 CA--C 1.495 -1.147 0 N-CA-C 106.822 -1.547 . . . . 0.0 106.822 179.667 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 42.0 ptt180 -158.22 163.84 37.08 Favored 'General case' 0 N--CA 1.437 -1.105 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 -179.676 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 98.4 p -154.26 159.6 41.37 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 106.9 -1.519 . . . . 0.0 106.9 179.787 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 39.6 ttmt -148.07 127.12 12.83 Favored 'General case' 0 N--CA 1.438 -1.064 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 88.9 m -138.37 135.14 35.04 Favored 'General case' 0 CA--C 1.498 -1.037 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 46.7 t -95.14 124.59 39.27 Favored 'General case' 0 CA--C 1.498 -1.035 0 N-CA-C 106.672 -1.603 . . . . 0.0 106.672 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 90.9 mt -86.8 143.44 27.49 Favored 'General case' 0 CA--C 1.499 -0.994 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 -179.762 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -124.61 134.64 52.86 Favored 'General case' 0 N--CA 1.439 -1.025 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 -179.47 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -135.74 153.24 51.63 Favored 'General case' 0 CA--C 1.496 -1.134 0 N-CA-C 106.367 -1.716 . . . . 0.0 106.367 179.579 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -174.43 179.86 45.49 Favored Glycine 0 CA--C 1.491 -1.454 0 N-CA-C 108.65 -1.78 . . . . 0.0 108.65 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -155.99 160.65 40.24 Favored 'General case' 0 N--CA 1.435 -1.218 0 N-CA-C 106.174 -1.787 . . . . 0.0 106.174 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -162.39 -178.86 36.6 Favored Glycine 0 CA--C 1.49 -1.526 0 N-CA-C 108.209 -1.956 . . . . 0.0 108.209 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -151.16 164.58 36.2 Favored 'General case' 0 N--CA 1.436 -1.154 0 N-CA-C 107.297 -1.372 . . . . 0.0 107.297 -179.66 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 40.0 tt0 -142.84 139.5 30.91 Favored 'General case' 0 CA--C 1.496 -1.113 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 -179.303 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -106.18 139.47 40.65 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 178.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 75.4 m-20 -125.47 74.43 68.86 Favored Pre-proline 0 N--CA 1.443 -0.777 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 -179.401 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -71.64 -28.56 17.13 Favored 'Trans proline' 0 CA--C 1.501 -1.161 0 C-N-CA 121.794 1.663 . . . . 0.0 112.983 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 79.0 m80 -136.54 151.92 73.77 Favored Pre-proline 0 N--CA 1.439 -1.02 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -85.92 62.12 5.19 Favored 'Trans proline' 0 C--N 1.312 -1.345 0 C-N-CA 122.138 1.892 . . . . 0.0 112.654 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.87 -65.25 0.04 OUTLIER 'General case' 0 N--CA 1.44 -0.97 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -108.78 137.65 46.37 Favored 'General case' 0 CA--C 1.496 -1.124 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 32.7 m -130.52 156.92 42.85 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.0 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 86.0 mt -121.46 130.69 74.39 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.114 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 -179.701 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 14.7 p-10 -136.12 160.22 39.31 Favored 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 108.361 -0.978 . . . . 0.0 108.361 -179.126 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -151.51 151.66 31.91 Favored 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 105.92 -1.881 . . . . 0.0 105.92 179.263 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 94.2 p -155.77 164.12 38.97 Favored 'General case' 0 CA--C 1.495 -1.154 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -122.12 139.8 53.31 Favored 'General case' 0 CA--C 1.495 -1.135 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 -179.799 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -126.37 128.45 47.08 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 106.922 -1.51 . . . . 0.0 106.922 179.769 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 90.6 t80 -124.32 128.65 49.43 Favored 'General case' 0 N--CA 1.439 -1.008 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 70.3 m -114.16 136.96 52.37 Favored 'General case' 0 CA--C 1.495 -1.164 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 65.4 tttm -116.16 125.03 51.75 Favored 'General case' 0 CA--C 1.499 -1.008 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 -179.041 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 35.2 tp -150.15 140.9 22.69 Favored 'General case' 0 N--CA 1.436 -1.162 0 N-CA-C 105.459 -2.052 . . . . 0.0 105.459 179.046 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -62.72 -38.27 89.8 Favored 'General case' 0 CA--C 1.507 -0.682 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 -179.0 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -62.87 -41.84 99.54 Favored 'General case' 0 C--N 1.353 0.728 0 O-C-N 122.114 -0.366 . . . . 0.0 110.09 -178.578 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 14.6 p -162.64 142.1 2.48 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.879 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 -179.273 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 56.5 mtmt -110.0 137.44 47.76 Favored 'General case' 0 CA--C 1.497 -1.07 0 N-CA-C 105.899 -1.889 . . . . 0.0 105.899 179.196 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 13.3 p -150.57 145.8 16.73 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 -178.734 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -128.93 140.55 11.8 Favored Glycine 0 C--N 1.349 1.297 0 N-CA-C 105.953 -2.859 . . . . 0.0 105.953 178.921 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 68.4 p -128.35 152.18 48.46 Favored 'General case' 0 CA--C 1.498 -1.044 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 -179.209 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 52.5 m0 -108.88 139.22 44.03 Favored 'General case' 0 CA--C 1.497 -1.061 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 179.805 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 26.8 ttt -114.65 124.58 52.19 Favored 'General case' 0 CA--C 1.498 -1.053 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 -179.836 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 62.9 tp -130.68 129.99 43.3 Favored 'General case' 0 N--CA 1.438 -1.041 0 N-CA-C 105.744 -1.947 . . . . 0.0 105.744 179.005 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -168.89 -167.67 29.85 Favored Glycine 0 CA--C 1.492 -1.391 0 N-CA-C 108.648 -1.781 . . . . 0.0 108.648 -179.321 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -144.43 164.57 30.44 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 106.26 -1.756 . . . . 0.0 106.26 -179.443 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -139.41 168.33 24.94 Favored Glycine 0 CA--C 1.489 -1.559 0 N-CA-C 108.642 -1.783 . . . . 0.0 108.642 -179.167 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 56.5 t80 -123.32 128.48 49.99 Favored 'General case' 0 N--CA 1.437 -1.104 0 N-CA-C 106.063 -1.828 . . . . 0.0 106.063 179.808 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 6.6 tmm_? -107.51 129.83 54.92 Favored 'General case' 0 CA--C 1.499 -1.005 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 -178.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 19.1 t80 . . . . . 0 C--O 1.262 1.718 0 CA-C-O 117.806 -1.092 . . . . 0.0 108.448 179.309 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 120.998 0.428 . . . . 0.0 110.789 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.93 178.05 48.43 Favored Glycine 0 CA--C 1.492 -1.37 0 N-CA-C 106.805 -2.518 . . . . 0.0 106.805 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 99.7 mt-10 -130.22 145.65 51.76 Favored 'General case' 0 N--CA 1.438 -1.055 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 62.9 m -129.78 157.81 41.17 Favored 'General case' 0 CA--C 1.496 -1.131 0 N-CA-C 106.763 -1.569 . . . . 0.0 106.763 -179.848 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 35.6 t -136.37 141.46 43.71 Favored 'General case' 0 CA--C 1.497 -1.061 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 -179.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 85.5 mt -121.26 130.68 74.42 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.998 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.433 ' HA ' ' HA2' ' A' ' 153' ' ' GLY . 44.1 t -128.63 137.58 51.74 Favored 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 107.205 -1.405 . . . . 0.0 107.205 -179.73 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.583 HG22 ' HG ' ' A' ' 31' ' ' LEU . 47.4 pt -127.13 157.82 38.45 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.059 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -166.28 -179.55 39.73 Favored Glycine 0 CA--C 1.492 -1.371 0 N-CA-C 108.184 -1.966 . . . . 0.0 108.184 -179.71 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -127.85 149.05 50.46 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 -179.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -74.16 143.09 45.42 Favored 'General case' 0 N--CA 1.44 -0.967 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -122.28 152.11 40.41 Favored 'General case' 0 CA--C 1.499 -1.003 0 N-CA-C 106.877 -1.527 . . . . 0.0 106.877 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 37.8 t -144.63 150.39 37.33 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 106.567 -1.642 . . . . 0.0 106.567 -179.591 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -72.07 129.36 38.32 Favored 'General case' 0 N--CA 1.44 -0.945 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 -179.478 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 31.5 m -133.53 159.75 42.58 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.004 0 N-CA-C 106.604 -1.628 . . . . 0.0 106.604 179.412 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -111.93 138.01 49.13 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 107.273 -1.38 . . . . 0.0 107.273 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 79.4 mm-40 -124.78 125.14 43.56 Favored 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -109.58 20.65 17.92 Favored 'General case' 0 CA--C 1.503 -0.841 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.35 -6.44 71.63 Favored Glycine 0 C--N 1.352 1.463 0 N-CA-C 107.494 -2.242 . . . . 0.0 107.494 -179.14 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -128.31 152.03 48.62 Favored 'General case' 0 N--CA 1.436 -1.136 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 179.675 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 61.9 mtpt -81.6 63.09 5.73 Favored 'General case' 0 CA--C 1.504 -0.808 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -179.121 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 87.6 mt -70.26 -38.18 75.05 Favored 'General case' 0 N--CA 1.442 -0.845 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 179.23 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -98.58 137.96 36.47 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 107.602 -1.258 . . . . 0.0 107.602 -179.597 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -85.11 151.75 23.9 Favored 'General case' 0 N--CA 1.441 -0.902 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 179.246 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 97.2 m-20 -71.95 147.0 90.99 Favored Pre-proline 0 N--CA 1.443 -0.814 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 -179.276 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -78.37 160.94 28.95 Favored 'Trans proline' 0 CA--C 1.499 -1.233 0 C-N-CA 122.437 2.092 . . . . 0.0 112.632 179.403 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 95.2 mtm-85 -125.56 129.51 49.84 Favored 'General case' 0 CA--C 1.5 -0.971 0 N-CA-C 107.451 -1.314 . . . . 0.0 107.451 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -178.68 167.16 37.4 Favored Glycine 0 C--N 1.35 1.317 0 N-CA-C 106.995 -2.442 . . . . 0.0 106.995 179.597 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 54.9 p90 -157.23 164.57 37.58 Favored 'General case' 0 CA--C 1.5 -0.951 0 N-CA-C 107.418 -1.327 . . . . 0.0 107.418 -179.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 12.7 p30 -151.42 156.62 41.04 Favored 'General case' 0 N--CA 1.438 -1.07 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 179.613 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.583 ' HG ' HG22 ' A' ' 8' ' ' ILE . 0.8 OUTLIER -145.39 137.64 25.73 Favored 'General case' 0 N--CA 1.437 -1.087 0 N-CA-C 106.444 -1.687 . . . . 0.0 106.444 179.974 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.423 ' HZ1' HD21 ' A' ' 90' ' ' LEU . 68.2 mttm -128.82 144.36 51.15 Favored 'General case' 0 N--CA 1.44 -0.955 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 -179.65 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . 0.527 ' CZ ' HD22 ' A' ' 31' ' ' LEU . 96.4 m-85 -127.39 138.71 53.07 Favored 'General case' 0 CA--C 1.499 -1.003 0 N-CA-C 106.806 -1.553 . . . . 0.0 106.806 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . 0.536 ' HA ' HG22 ' A' ' 44' ' ' ILE . 48.3 ttp180 -112.36 128.16 56.21 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 107.069 -1.456 . . . . 0.0 107.069 179.661 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 10.7 t80 -117.95 129.43 55.61 Favored 'General case' 0 N--CA 1.439 -1.002 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 179.618 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -96.08 126.63 41.45 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 -178.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 74.8 m-85 -120.99 161.1 22.2 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 106.124 -1.806 . . . . 0.0 106.124 178.491 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 66.0 t30 -80.29 95.32 6.3 Favored 'General case' 0 N--CA 1.439 -1.006 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -165.32 -178.84 5.22 Favored 'General case' 0 N--CA 1.434 -1.267 0 N-CA-C 106.047 -1.835 . . . . 0.0 106.047 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -83.64 -16.76 43.9 Favored 'General case' 0 N--CA 1.441 -0.882 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 -179.311 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 53.3 m95 -133.95 151.24 51.41 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 -179.366 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -100.19 -175.59 30.3 Favored Glycine 0 C--N 1.354 1.551 0 N-CA-C 107.842 -2.103 . . . . 0.0 107.842 -179.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 10.1 p -143.11 146.14 21.93 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.895 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.619 HD13 ' CD2' ' A' ' 88' ' ' TYR . 43.4 pt -130.16 161.63 39.52 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.053 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 -179.592 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -125.15 137.44 10.39 Favored Glycine 0 CA--C 1.492 -1.375 0 N-CA-C 105.202 -3.159 . . . . 0.0 105.202 178.119 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 53.3 m -130.89 145.75 52.11 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 -178.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 88.6 t80 -131.77 132.19 43.59 Favored 'General case' 0 CA--C 1.498 -1.023 0 N-CA-C 105.695 -1.965 . . . . 0.0 105.695 178.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -138.44 143.98 39.93 Favored 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 -179.339 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 59.7 tt0 -142.01 136.3 30.13 Favored 'General case' 0 N--CA 1.437 -1.107 0 N-CA-C 106.278 -1.749 . . . . 0.0 106.278 179.428 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 15.2 t -145.42 152.22 39.48 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 79.2 ttt-85 -103.51 130.97 50.99 Favored 'General case' 0 N--CA 1.438 -1.036 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 4.7 tmt_? -112.77 130.38 56.09 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 -178.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -169.5 174.03 43.82 Favored Glycine 0 CA--C 1.491 -1.45 0 N-CA-C 106.486 -2.645 . . . . 0.0 106.486 179.756 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -88.03 96.14 10.4 Favored 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 106.352 -1.722 . . . . 0.0 106.352 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 72.9 mm-40 -95.79 2.59 53.91 Favored 'General case' 0 CA--C 1.504 -0.817 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 -178.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -91.16 149.81 21.64 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 -179.704 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 45.4 m -98.49 132.37 43.98 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 179.131 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 78.6 t -64.67 -47.41 88.96 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.754 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -179.662 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 62.4 m-20 -129.78 -51.45 1.14 Allowed 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 107.042 -1.466 . . . . 0.0 107.042 179.448 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 170.88 122.79 0.66 Allowed Glycine 0 CA--C 1.492 -1.398 0 N-CA-C 106.746 -2.542 . . . . 0.0 106.746 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 94.8 m-85 62.48 31.19 17.18 Favored 'General case' 0 C--N 1.356 0.85 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 17.3 tppt? -144.36 126.15 15.23 Favored 'General case' 0 CA--C 1.495 -1.151 0 N-CA-C 106.411 -1.7 . . . . 0.0 106.411 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -157.38 173.94 16.17 Favored 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 -179.101 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 83.7 mt -97.1 122.56 48.77 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.023 0 N-CA-C 106.558 -1.645 . . . . 0.0 106.558 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -82.19 132.45 35.24 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 -179.242 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -168.17 159.05 32.13 Favored Glycine 0 CA--C 1.491 -1.413 0 N-CA-C 106.253 -2.739 . . . . 0.0 106.253 179.373 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 63.7 m-20 -132.83 129.28 38.28 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 9.2 t80 -158.15 133.98 9.11 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 106.273 -1.751 . . . . 0.0 106.273 178.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 57.3 mtmt -127.95 142.96 51.1 Favored 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 107.602 -1.258 . . . . 0.0 107.602 -179.276 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -117.09 133.02 56.52 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 179.359 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -114.09 127.53 55.97 Favored 'General case' 0 CA--C 1.495 -1.146 0 N-CA-C 105.227 -2.138 . . . . 0.0 105.227 178.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 70.1 m -132.86 140.51 47.96 Favored 'General case' 0 CA--C 1.493 -1.231 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 -179.338 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 61.6 t -128.61 135.18 63.04 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.242 0 N-CA-C 105.097 -2.186 . . . . 0.0 105.097 178.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 68.0 p -140.26 160.66 39.46 Favored 'General case' 0 CA--C 1.495 -1.153 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 -179.425 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -153.7 155.69 36.44 Favored 'General case' 0 N--CA 1.433 -1.275 0 N-CA-C 106.108 -1.812 . . . . 0.0 106.108 179.272 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -178.83 171.64 43.81 Favored Glycine 0 N--CA 1.435 -1.388 0 N-CA-C 107.949 -2.06 . . . . 0.0 107.949 179.554 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_endo -81.8 165.18 17.88 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 122.734 2.289 . . . . 0.0 113.361 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 8.3 p -121.43 132.65 70.16 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.989 0 N-CA-C 106.181 -1.785 . . . . 0.0 106.181 178.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -115.41 124.81 52.13 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 -178.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 56.3 ttp180 -112.15 132.44 54.88 Favored 'General case' 0 CA--C 1.498 -1.04 0 N-CA-C 106.131 -1.803 . . . . 0.0 106.131 179.253 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 97.1 mt -71.97 -63.95 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.912 0 N-CA-C 106.981 -1.488 . . . . 0.0 106.981 179.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 65.8 t30 -175.25 93.89 0.07 Allowed 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 177.693 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 39.69 44.13 1.23 Allowed 'General case' 0 C--N 1.357 0.905 0 C-N-CA 123.103 0.561 . . . . 0.0 112.21 177.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -141.62 -46.26 0.37 Allowed 'General case' 0 CA--C 1.501 -0.93 0 C-N-CA 118.824 -1.15 . . . . 0.0 109.022 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 22.1 m -149.02 158.08 6.6 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.149 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 64.2 m -133.95 142.93 47.89 Favored 'General case' 0 CA--C 1.496 -1.109 0 N-CA-C 106.622 -1.622 . . . . 0.0 106.622 178.568 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 89.9 mt -117.05 139.72 50.36 Favored 'General case' 0 CA--C 1.497 -1.079 0 N-CA-C 107.16 -1.422 . . . . 0.0 107.16 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.619 ' CD2' HD13 ' A' ' 44' ' ' ILE . 64.3 m-85 -116.57 142.83 46.38 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 -179.775 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -114.66 138.35 14.75 Favored Glycine 0 C--N 1.35 1.341 0 N-CA-C 105.727 -2.949 . . . . 0.0 105.727 178.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.423 HD21 ' HZ1' ' A' ' 32' ' ' LYS . 8.7 mp -117.77 133.2 56.18 Favored 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 -179.136 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.3 tt -150.33 133.51 16.25 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 106.194 -1.78 . . . . 0.0 106.194 178.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 179.01 -151.24 10.09 Favored Glycine 0 CA--C 1.493 -1.332 0 N-CA-C 108.016 -2.034 . . . . 0.0 108.016 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -143.67 160.15 41.21 Favored 'General case' 0 N--CA 1.437 -1.124 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 -179.071 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -131.69 155.77 21.56 Favored Glycine 0 CA--C 1.493 -1.3 0 N-CA-C 107.751 -2.14 . . . . 0.0 107.751 -179.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 60.3 t-80 -151.57 141.67 22.2 Favored 'General case' 0 N--CA 1.437 -1.102 0 N-CA-C 106.952 -1.499 . . . . 0.0 106.952 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -147.44 140.5 8.56 Favored Glycine 0 CA--C 1.492 -1.39 0 N-CA-C 107.032 -2.427 . . . . 0.0 107.032 179.458 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -157.33 134.92 10.62 Favored 'General case' 0 N--CA 1.436 -1.126 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -143.68 52.54 1.32 Allowed 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 107.359 -1.348 . . . . 0.0 107.359 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -125.47 139.88 53.25 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 107.097 -1.445 . . . . 0.0 107.097 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -132.57 147.46 52.35 Favored 'General case' 0 CA--C 1.498 -1.056 0 N-CA-C 106.835 -1.543 . . . . 0.0 106.835 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 32.6 t -147.37 -72.19 0.22 Allowed 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 37.2 t -155.1 149.57 26.24 Favored 'General case' 0 N--CA 1.437 -1.103 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 45.5 pt -96.83 -3.19 10.19 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.869 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 88.5 t80 -138.57 124.2 19.65 Favored 'General case' 0 N--CA 1.439 -1.016 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 159.88 -175.52 36.7 Favored Glycine 0 CA--C 1.491 -1.414 0 N-CA-C 107.107 -2.397 . . . . 0.0 107.107 179.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 64.7 tt0 -135.42 120.31 18.55 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 106.666 -1.605 . . . . 0.0 106.666 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 36.7 t -160.31 151.24 18.92 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 63.0 mt-10 -74.22 141.15 45.44 Favored 'General case' 0 N--CA 1.44 -0.942 0 N-CA-C 107.022 -1.473 . . . . 0.0 107.022 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 68.0 m -129.77 151.14 50.68 Favored 'General case' 0 CA--C 1.494 -1.179 0 N-CA-C 107.577 -1.268 . . . . 0.0 107.577 -179.415 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -128.68 150.83 50.09 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 38.4 t -148.26 147.9 29.87 Favored 'General case' 0 CA--C 1.497 -1.096 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 -179.397 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 65.3 mttp -125.39 148.69 48.68 Favored 'General case' 0 CA--C 1.497 -1.061 0 N-CA-C 106.803 -1.555 . . . . 0.0 106.803 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 93.0 m -110.2 128.46 55.5 Favored 'General case' 0 CA--C 1.495 -1.148 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 -179.762 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 51.1 m -88.56 144.06 26.56 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 -179.575 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 63.6 tp -94.95 123.5 38.46 Favored 'General case' 0 CA--C 1.498 -1.044 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 179.671 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -114.9 130.57 56.93 Favored 'General case' 0 N--CA 1.438 -1.051 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -178.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 55.5 p90 -149.87 161.28 42.58 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 106.48 -1.674 . . . . 0.0 106.48 179.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 179.36 -169.43 40.56 Favored Glycine 0 CA--C 1.491 -1.423 0 N-CA-C 108.056 -2.018 . . . . 0.0 108.056 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -153.13 159.37 42.73 Favored 'General case' 0 CA--C 1.495 -1.158 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 -179.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -144.07 154.2 25.51 Favored Glycine 0 CA--C 1.491 -1.442 0 N-CA-C 108.496 -1.842 . . . . 0.0 108.496 -179.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 3.9 mp -121.63 140.59 52.07 Favored 'General case' 0 N--CA 1.437 -1.119 0 N-CA-C 106.543 -1.651 . . . . 0.0 106.543 179.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 38.5 tt0 -116.65 131.88 56.83 Favored 'General case' 0 CA--C 1.495 -1.167 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 -179.693 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -122.57 140.66 52.55 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 106.188 -1.782 . . . . 0.0 106.188 179.044 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 7.5 m120 -127.69 79.14 73.99 Favored Pre-proline 0 CA--C 1.502 -0.893 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 -179.054 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.08 -25.36 27.18 Favored 'Trans proline' 0 CA--C 1.499 -1.23 0 C-N-CA 121.665 1.577 . . . . 0.0 112.156 179.15 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 78.7 m80 -135.8 152.19 75.47 Favored Pre-proline 0 N--CA 1.437 -1.115 0 N-CA-C 105.849 -1.908 . . . . 0.0 105.849 179.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.11 -20.97 37.18 Favored 'Trans proline' 0 C--N 1.31 -1.477 0 C-N-CA 121.719 1.613 . . . . 0.0 113.637 -179.645 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -109.45 14.54 23.54 Favored 'General case' 0 N--CA 1.444 -0.766 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 -179.028 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 50.3 t80 -142.44 121.44 12.85 Favored 'General case' 0 CA--C 1.5 -0.967 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 59.7 t -119.39 129.49 75.22 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.972 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 -179.27 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 85.4 mt -101.61 126.2 55.54 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.026 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -119.59 112.78 19.76 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 -179.263 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -118.44 132.69 56.24 Favored 'General case' 0 CA--C 1.498 -1.054 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 178.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 97.7 p -156.2 170.81 21.36 Favored 'General case' 0 CA--C 1.497 -1.085 0 C-N-CA 119.384 -0.926 . . . . 0.0 108.683 -178.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 54.4 p90 -142.28 155.81 45.24 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 179.406 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -137.0 133.53 35.64 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 87.5 t80 -118.33 129.31 55.37 Favored 'General case' 0 N--CA 1.438 -1.043 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 47.9 t -103.98 121.8 43.91 Favored 'General case' 0 CA--C 1.497 -1.068 0 N-CA-C 106.14 -1.8 . . . . 0.0 106.14 179.501 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 60.3 tptt -93.38 119.79 32.91 Favored 'General case' 0 N--CA 1.439 -1.021 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 -178.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -152.97 126.87 8.95 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 105.282 -2.118 . . . . 0.0 105.282 178.623 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -64.76 -39.54 93.78 Favored 'General case' 0 N--CA 1.445 -0.694 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.129 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -63.17 -47.87 80.79 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 120.53 -0.468 . . . . 0.0 110.581 -178.268 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 58.6 t -142.21 128.2 18.23 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.004 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 -179.098 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -91.21 127.71 36.75 Favored 'General case' 0 CA--C 1.501 -0.937 0 N-CA-C 106.036 -1.839 . . . . 0.0 106.036 178.7 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 81.5 t -126.75 127.1 69.74 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.013 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -178.733 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -117.28 134.16 11.03 Favored Glycine 0 C--N 1.351 1.416 0 N-CA-C 105.671 -2.972 . . . . 0.0 105.671 178.341 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 88.8 m -129.87 135.3 48.22 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 -178.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 92.9 m95 -107.66 140.56 40.5 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 105.314 -2.106 . . . . 0.0 105.314 178.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 78.7 mtm -125.32 132.74 52.8 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 -178.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -133.53 138.4 46.05 Favored 'General case' 0 CA--C 1.495 -1.157 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 179.563 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -170.58 -168.75 32.81 Favored Glycine 0 N--CA 1.434 -1.436 0 N-CA-C 108.374 -1.89 . . . . 0.0 108.374 -179.55 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -139.19 160.86 38.81 Favored 'General case' 0 N--CA 1.435 -1.197 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 -179.293 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . 0.433 ' HA2' ' HA ' ' A' ' 7' ' ' SER . . . -133.78 165.26 24.27 Favored Glycine 0 CA--C 1.491 -1.447 0 N-CA-C 108.183 -1.967 . . . . 0.0 108.183 -179.311 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 88.2 t80 -132.21 135.18 46.13 Favored 'General case' 0 N--CA 1.435 -1.179 0 N-CA-C 106.49 -1.671 . . . . 0.0 106.49 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 6.8 tmm_? -136.94 139.68 41.7 Favored 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 -179.522 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 31.7 t80 . . . . . 0 C--O 1.263 1.815 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 179.826 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 80.3 mm-40 . . . . . 0 N--CA 1.488 1.461 0 CA-C-O 120.886 0.374 . . . . 0.0 110.549 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 179.41 -179.81 48.82 Favored Glycine 0 N--CA 1.436 -1.351 0 N-CA-C 107.224 -2.351 . . . . 0.0 107.224 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 24.1 pt-20 -154.59 156.04 35.84 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 55.8 m -116.05 -60.49 1.86 Allowed 'General case' 0 CA--C 1.498 -1.033 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 38.7 t -154.51 145.96 23.08 Favored 'General case' 0 CA--C 1.498 -1.037 0 N-CA-C 107.413 -1.329 . . . . 0.0 107.413 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 47.4 pt -129.01 149.5 33.75 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.097 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 179.278 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.418 ' HB2' ' HB2' ' A' ' 32' ' ' LYS . 63.6 m -138.75 149.32 44.91 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 -179.498 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 46.5 pt -131.94 157.09 43.06 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.057 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 179.216 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -176.83 -168.3 36.59 Favored Glycine 0 CA--C 1.492 -1.394 0 N-CA-C 108.19 -1.964 . . . . 0.0 108.19 -179.703 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -127.54 149.21 50.25 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 -179.492 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -111.68 134.06 53.51 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 107.375 -1.342 . . . . 0.0 107.375 -179.672 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 84.2 mt-30 -123.23 136.31 54.67 Favored 'General case' 0 CA--C 1.495 -1.149 0 N-CA-C 106.681 -1.599 . . . . 0.0 106.681 179.508 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 66.6 m -120.73 145.77 47.16 Favored 'General case' 0 CA--C 1.493 -1.226 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -142.05 153.19 44.03 Favored 'General case' 0 N--CA 1.437 -1.103 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 -179.761 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.2 p -143.81 142.7 24.56 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.166 0 N-CA-C 106.42 -1.696 . . . . 0.0 106.42 179.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 75.5 mmtt -109.19 124.89 51.57 Favored 'General case' 0 CA--C 1.497 -1.091 0 N-CA-C 106.984 -1.488 . . . . 0.0 106.984 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -153.27 140.56 19.56 Favored 'General case' 0 N--CA 1.435 -1.201 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 -179.882 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -65.01 136.99 57.43 Favored 'General case' 0 N--CA 1.442 -0.868 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 -179.765 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 104.35 -16.29 49.17 Favored Glycine 0 C--N 1.352 1.452 0 N-CA-C 108.365 -1.894 . . . . 0.0 108.365 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 88.8 m-85 -115.19 128.83 56.43 Favored 'General case' 0 CA--C 1.497 -1.065 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 179.446 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 60.8 tptt -110.49 -58.04 2.14 Favored 'General case' 0 CA--C 1.501 -0.915 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 -179.494 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.537 ' HG ' ' H ' ' A' ' 24' ' ' LYS . 58.3 tp -120.77 121.77 38.9 Favored 'General case' 0 N--CA 1.44 -0.954 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 -179.04 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 97.5 m-20 -98.3 6.33 47.46 Favored 'General case' 0 C--N 1.356 0.891 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 -179.474 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.537 ' H ' ' HG ' ' A' ' 22' ' ' LEU . 48.3 mmtm 69.98 -147.67 0.1 Allowed 'General case' 0 C--N 1.355 0.818 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 47.3 t30 -130.69 116.69 17.24 Favored Pre-proline 0 N--CA 1.439 -0.982 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 -179.751 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -74.05 156.43 47.34 Favored 'Trans proline' 0 CA--C 1.499 -1.253 0 C-N-CA 121.758 1.639 . . . . 0.0 112.495 179.583 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -94.78 122.04 37.0 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -152.1 156.2 26.56 Favored Glycine 0 C--N 1.351 1.399 0 N-CA-C 107.942 -2.063 . . . . 0.0 107.942 -179.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -131.82 151.72 51.48 Favored 'General case' 0 CA--C 1.498 -1.021 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 -179.668 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.524 HD22 ' HB2' ' A' ' 48' ' ' ALA . 10.8 t-20 -137.25 125.25 22.79 Favored 'General case' 0 N--CA 1.441 -0.909 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 -179.688 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 89.7 mt -119.64 135.47 54.8 Favored 'General case' 0 CA--C 1.499 -1.006 0 N-CA-C 106.153 -1.795 . . . . 0.0 106.153 178.714 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.418 ' HB2' ' HB2' ' A' ' 7' ' ' SER . 37.8 mtmm -133.36 144.68 49.76 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 107.859 -1.163 . . . . 0.0 107.859 -179.483 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 92.3 m-85 -132.19 136.78 47.29 Favored 'General case' 0 CA--C 1.498 -1.042 0 N-CA-C 106.764 -1.569 . . . . 0.0 106.764 179.577 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 79.2 ttt180 -119.22 132.33 55.92 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 98.4 m-85 -117.57 130.2 56.25 Favored 'General case' 0 N--CA 1.438 -1.061 0 N-CA-C 106.346 -1.724 . . . . 0.0 106.346 179.148 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -109.2 127.07 53.93 Favored 'General case' 0 CA--C 1.498 -1.036 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 -179.381 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 -127.99 147.68 50.5 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 179.646 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -86.65 72.92 10.14 Favored 'General case' 0 N--CA 1.441 -0.893 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 -179.375 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 31.9 m120 -124.13 -54.96 1.69 Allowed 'General case' 0 CA--C 1.499 -1.017 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 178.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -178.45 -55.22 0.01 OUTLIER 'General case' 0 N--CA 1.439 -0.987 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 35.7 m0 -125.25 149.47 47.98 Favored 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 -178.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -87.32 -179.48 48.29 Favored Glycine 0 C--N 1.351 1.41 0 N-CA-C 107.716 -2.154 . . . . 0.0 107.716 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.9 p -138.68 143.05 33.09 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.891 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.3 tt -131.96 141.19 46.17 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.951 0 N-CA-C 107.37 -1.344 . . . . 0.0 107.37 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -118.91 145.91 18.29 Favored Glycine 0 CA--C 1.492 -1.359 0 N-CA-C 106.459 -2.656 . . . . 0.0 106.459 179.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 45.3 t -138.66 136.67 36.11 Favored 'General case' 0 CA--C 1.499 -0.995 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 -179.205 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 91.2 t80 -131.02 130.42 43.3 Favored 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 105.765 -1.939 . . . . 0.0 105.765 179.248 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.524 ' HB2' HD22 ' A' ' 30' ' ' ASN . . . -146.86 152.89 39.46 Favored 'General case' 0 N--CA 1.436 -1.126 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 -179.314 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 20.6 pt20 -150.96 152.25 33.3 Favored 'General case' 0 N--CA 1.433 -1.287 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 179.398 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 10.1 t -146.38 152.11 38.55 Favored 'General case' 0 CA--C 1.499 -1.003 0 N-CA-C 107.215 -1.402 . . . . 0.0 107.215 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 5.6 tmm_? -132.84 129.62 38.7 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 107.004 -1.48 . . . . 0.0 107.004 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 72.3 ttp85 -133.71 127.02 31.98 Favored 'General case' 0 CA--C 1.495 -1.156 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 179.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -173.57 160.39 30.64 Favored Glycine 0 CA--C 1.489 -1.583 0 N-CA-C 108.1 -2.0 . . . . 0.0 108.1 179.795 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 95.7 m-85 -135.96 152.38 50.9 Favored 'General case' 0 N--CA 1.437 -1.106 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 179.723 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -63.93 -39.87 95.16 Favored 'General case' 0 CA--C 1.505 -0.787 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 -179.83 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -138.81 132.7 31.02 Favored 'General case' 0 N--CA 1.439 -0.999 0 N-CA-C 106.753 -1.573 . . . . 0.0 106.753 179.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 69.3 m -128.03 142.01 51.35 Favored 'General case' 0 CA--C 1.496 -1.113 0 N-CA-C 107.224 -1.398 . . . . 0.0 107.224 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 76.6 t -65.55 -45.57 92.16 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.826 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 179.294 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 61.2 t0 -152.36 100.98 2.64 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 106.302 -1.74 . . . . 0.0 106.302 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -150.6 43.95 0.7 Allowed Glycine 0 CA--C 1.491 -1.413 0 N-CA-C 107.427 -2.269 . . . . 0.0 107.427 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 6.5 t80 79.58 -54.43 0.41 Allowed 'General case' 0 C--N 1.358 0.966 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -117.31 137.33 52.5 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 179.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 87.8 mt -67.11 -40.09 86.79 Favored 'General case' 0 CA--C 1.505 -0.786 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 -179.628 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 45.5 pt -133.67 157.8 42.38 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.086 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 -179.517 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 59.04 41.42 20.8 Favored 'General case' 0 C--N 1.358 0.962 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 179.548 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -92.36 85.55 1.19 Allowed Glycine 0 C--N 1.35 1.36 0 N-CA-C 107.555 -2.218 . . . . 0.0 107.555 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -112.25 135.38 53.01 Favored 'General case' 0 CA--C 1.499 -0.996 0 N-CA-C 107.397 -1.335 . . . . 0.0 107.397 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -127.33 125.4 40.73 Favored 'General case' 0 N--CA 1.439 -0.986 0 N-CA-C 106.708 -1.59 . . . . 0.0 106.708 179.739 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 65.0 mttp -109.11 140.63 42.42 Favored 'General case' 0 CA--C 1.496 -1.1 0 N-CA-C 106.733 -1.58 . . . . 0.0 106.733 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 49.9 t80 -136.29 127.36 27.88 Favored 'General case' 0 N--CA 1.438 -1.058 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -120.29 140.76 50.76 Favored 'General case' 0 CA--C 1.495 -1.137 0 N-CA-C 106.813 -1.551 . . . . 0.0 106.813 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 67.9 m -132.33 136.15 46.68 Favored 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 108.015 -1.105 . . . . 0.0 108.015 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 61.1 t -129.12 136.39 59.71 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.211 0 N-CA-C 105.013 -2.217 . . . . 0.0 105.013 178.572 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 11.2 t -159.08 154.84 26.28 Favored 'General case' 0 N--CA 1.436 -1.137 0 C-N-CA 119.152 -1.019 . . . . 0.0 108.609 -179.086 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -156.52 159.43 38.58 Favored 'General case' 0 N--CA 1.435 -1.182 0 N-CA-C 106.119 -1.808 . . . . 0.0 106.119 179.447 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -174.33 175.46 46.7 Favored Glycine 0 C--N 1.348 1.233 0 N-CA-C 108.208 -1.957 . . . . 0.0 108.208 179.759 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -77.68 155.49 31.27 Favored 'Trans proline' 0 C--N 1.312 -1.394 0 C-N-CA 122.547 2.165 . . . . 0.0 113.239 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 65.8 t -115.26 128.31 72.5 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.995 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 94.8 m-85 -113.79 130.4 56.46 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 -179.191 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 54.2 ttp180 -112.64 134.58 54.09 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 179.163 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 51.2 mm -73.16 -64.26 0.85 Allowed 'Isoleucine or valine' 0 CA--C 1.503 -0.841 0 N-CA-C 106.972 -1.492 . . . . 0.0 106.972 179.779 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 65.7 t30 -176.75 93.59 0.04 OUTLIER 'General case' 0 N--CA 1.441 -0.911 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 177.655 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 70.8 tt0 36.48 46.72 0.45 Allowed 'General case' 0 C--N 1.359 0.984 0 C-N-CA 123.378 0.671 . . . . 0.0 111.365 178.337 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 18.2 t80 -142.57 -45.96 0.32 Allowed 'General case' 0 CA--C 1.501 -0.922 0 C-N-CA 118.823 -1.151 . . . . 0.0 108.641 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 16.6 m -148.85 157.89 6.97 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.159 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 179.618 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 66.3 m -132.09 145.96 51.74 Favored 'General case' 0 CA--C 1.497 -1.079 0 N-CA-C 106.52 -1.659 . . . . 0.0 106.52 178.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 1.1 pp -142.47 159.63 41.86 Favored 'General case' 0 CA--C 1.493 -1.226 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 23.7 p90 -152.64 158.76 42.88 Favored 'General case' 0 N--CA 1.435 -1.175 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 -179.566 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -109.05 151.22 17.15 Favored Glycine 0 CA--C 1.491 -1.447 0 N-CA-C 107.059 -2.416 . . . . 0.0 107.059 -179.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 92.0 mt -115.88 133.52 55.94 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 -179.473 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 64.5 tp -137.42 128.08 26.93 Favored 'General case' 0 N--CA 1.437 -1.092 0 N-CA-C 105.312 -2.107 . . . . 0.0 105.312 178.599 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -178.71 -158.26 20.9 Favored Glycine 0 CA--C 1.491 -1.431 0 N-CA-C 108.518 -1.833 . . . . 0.0 108.518 -179.319 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -146.66 158.37 43.89 Favored 'General case' 0 N--CA 1.434 -1.246 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 -179.206 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -117.49 150.67 18.33 Favored Glycine 0 CA--C 1.493 -1.342 0 N-CA-C 107.166 -2.374 . . . . 0.0 107.166 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 96.8 m-70 -126.56 137.36 53.33 Favored 'General case' 0 CA--C 1.497 -1.086 0 N-CA-C 107.164 -1.421 . . . . 0.0 107.164 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -113.15 141.28 16.84 Favored Glycine 0 C--N 1.35 1.358 0 N-CA-C 107.313 -2.315 . . . . 0.0 107.313 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 17.9 tppt? -137.6 128.91 27.9 Favored 'General case' 0 CA--C 1.5 -0.973 0 N-CA-C 107.443 -1.317 . . . . 0.0 107.443 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -155.04 33.02 0.39 Allowed 'General case' 0 N--CA 1.44 -0.97 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 179.58 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 40.0 ttpt -147.86 137.47 22.5 Favored 'General case' 0 N--CA 1.436 -1.131 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 -179.535 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -97.74 134.27 41.14 Favored 'General case' 0 CA--C 1.497 -1.072 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 31.2 t -152.82 153.92 34.09 Favored 'General case' 0 N--CA 1.438 -1.054 0 N-CA-C 106.666 -1.605 . . . . 0.0 106.666 -179.52 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 44.3 t -66.86 142.31 57.37 Favored 'General case' 0 CA--C 1.504 -0.823 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 93.8 mt -62.09 -44.58 99.19 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.828 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -102.63 115.46 30.63 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 106.53 -1.655 . . . . 0.0 106.53 179.54 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 166.58 -167.8 39.75 Favored Glycine 0 CA--C 1.492 -1.383 0 N-CA-C 106.782 -2.527 . . . . 0.0 106.782 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 54.3 tt0 -104.36 119.39 38.85 Favored 'General case' 0 N--CA 1.439 -0.992 0 N-CA-C 107.004 -1.48 . . . . 0.0 107.004 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 70.9 m -132.48 148.84 52.4 Favored 'General case' 0 CA--C 1.495 -1.149 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 179.643 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -131.93 144.28 50.72 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 107.154 -1.425 . . . . 0.0 107.154 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 66.4 m -133.21 139.83 47.21 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 179.599 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 60.8 ttp180 -84.18 -52.19 6.46 Favored 'General case' 0 CA--C 1.503 -0.863 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 4.2 m -168.29 80.27 0.16 Allowed 'General case' 0 CA--C 1.497 -1.068 0 N-CA-C 107.305 -1.368 . . . . 0.0 107.305 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -98.73 1.4 46.04 Favored 'General case' 0 CA--C 1.502 -0.88 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 89.2 m -115.09 129.08 56.6 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 106.83 -1.545 . . . . 0.0 106.83 -179.592 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 63.8 m -128.66 148.28 50.8 Favored 'General case' 0 CA--C 1.496 -1.098 0 N-CA-C 107.359 -1.349 . . . . 0.0 107.359 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 92.1 mt -79.72 149.62 31.11 Favored 'General case' 0 CA--C 1.499 -0.998 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -136.01 144.89 45.55 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 -179.548 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -134.04 152.05 51.68 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 106.396 -1.705 . . . . 0.0 106.396 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -174.39 -175.69 42.16 Favored Glycine 0 CA--C 1.491 -1.431 0 N-CA-C 108.612 -1.795 . . . . 0.0 108.612 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -154.78 159.98 40.99 Favored 'General case' 0 N--CA 1.435 -1.199 0 N-CA-C 106.129 -1.804 . . . . 0.0 106.129 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -142.65 152.68 24.04 Favored Glycine 0 CA--C 1.491 -1.427 0 N-CA-C 108.477 -1.849 . . . . 0.0 108.477 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 89.0 mt -120.36 142.62 48.99 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 106.384 -1.71 . . . . 0.0 106.384 179.76 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 51.8 tt0 -125.02 126.92 46.17 Favored 'General case' 0 N--CA 1.437 -1.112 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -114.77 120.27 39.49 Favored 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 106.467 -1.679 . . . . 0.0 106.467 179.651 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 12.7 p-10 -133.36 75.17 70.63 Favored Pre-proline 0 N--CA 1.439 -0.996 0 N-CA-C 108.401 -0.962 . . . . 0.0 108.401 -179.34 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -67.54 -22.49 44.6 Favored 'Trans proline' 0 CA--C 1.499 -1.274 0 C-N-CA 121.761 1.641 . . . . 0.0 111.914 179.202 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 4.3 p80 -152.51 152.8 29.61 Favored Pre-proline 0 N--CA 1.433 -1.282 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 179.037 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -72.05 -15.03 29.2 Favored 'Trans proline' 0 C--N 1.31 -1.456 0 C-N-CA 122.004 1.802 . . . . 0.0 114.074 -179.049 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 27.1 m120 -62.93 -41.83 99.61 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 -178.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -139.5 140.8 37.31 Favored 'General case' 0 CA--C 1.498 -1.04 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 -179.658 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 75.7 t -124.77 129.73 73.52 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.006 0 N-CA-C 106.16 -1.793 . . . . 0.0 106.16 179.21 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 84.6 mt -101.16 125.62 55.09 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.995 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 -179.064 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 45.3 m-20 -119.26 134.13 55.38 Favored 'General case' 0 N--CA 1.44 -0.931 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -139.7 128.68 23.57 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 106.089 -1.819 . . . . 0.0 106.089 178.721 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 63.6 m -136.46 150.1 48.55 Favored 'General case' 0 CA--C 1.494 -1.196 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -179.214 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -126.73 134.78 50.57 Favored 'General case' 0 N--CA 1.438 -1.055 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 179.348 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -137.06 133.27 35.24 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 -179.751 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -130.96 150.07 52.29 Favored 'General case' 0 CA--C 1.498 -1.053 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 -179.593 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 47.1 t -134.65 135.15 41.88 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 179.751 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -112.89 124.9 53.66 Favored 'General case' 0 CA--C 1.498 -1.037 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 -178.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 52.8 tp -138.81 142.74 38.7 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 104.946 -2.242 . . . . 0.0 104.946 178.861 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -61.46 -38.62 87.9 Favored 'General case' 0 CA--C 1.508 -0.658 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 -178.487 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -62.98 -41.87 99.68 Favored 'General case' 0 C--N 1.352 0.711 0 C-N-CA 120.604 -0.438 . . . . 0.0 110.113 -178.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 13.8 p -166.49 144.5 1.36 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.79 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 -179.461 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 57.5 mtmt -107.53 135.92 48.17 Favored 'General case' 0 CA--C 1.498 -1.038 0 N-CA-C 106.18 -1.785 . . . . 0.0 106.18 179.145 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 35.2 m -133.83 157.98 42.28 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.06 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 -179.019 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -128.17 140.07 11.52 Favored Glycine 0 C--N 1.352 1.423 0 N-CA-C 106.702 -2.559 . . . . 0.0 106.702 179.284 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 92.1 m -126.65 129.66 48.92 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 -179.614 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 54.1 m0 -113.64 138.84 49.63 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 106.216 -1.772 . . . . 0.0 106.216 179.519 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 64.5 mtt -126.37 126.48 43.94 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 -179.321 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 89.9 mt -126.88 142.66 51.49 Favored 'General case' 0 CA--C 1.494 -1.177 0 N-CA-C 105.998 -1.853 . . . . 0.0 105.998 179.293 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -172.72 -171.89 37.91 Favored Glycine 0 CA--C 1.492 -1.389 0 N-CA-C 108.737 -1.745 . . . . 0.0 108.737 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -143.67 160.18 41.16 Favored 'General case' 0 N--CA 1.434 -1.242 0 N-CA-C 106.508 -1.664 . . . . 0.0 106.508 -179.376 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -142.46 -178.16 18.18 Favored Glycine 0 CA--C 1.49 -1.481 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -179.116 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 93.5 t80 -143.2 143.4 31.76 Favored 'General case' 0 N--CA 1.436 -1.14 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 -179.579 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 17.7 ptm180 -145.67 159.85 42.56 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 36.1 t80 . . . . . 0 C--O 1.264 1.832 0 N-CA-C 108.134 -1.062 . . . . 0.0 108.134 -179.995 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 . . . . . 0 N--CA 1.489 1.501 0 CA-C-O 120.865 0.364 . . . . 0.0 110.564 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 179.67 -176.42 47.57 Favored Glycine 0 CA--C 1.492 -1.377 0 N-CA-C 107.162 -2.375 . . . . 0.0 107.162 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -129.38 146.35 51.26 Favored 'General case' 0 CA--C 1.497 -1.072 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 13.2 m -120.96 -88.28 0.63 Allowed 'General case' 0 CA--C 1.5 -0.946 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 -179.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 64.0 m -139.7 150.99 45.52 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 107.902 -1.148 . . . . 0.0 107.902 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 20.1 tt -133.43 138.96 50.08 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.996 0 N-CA-C 106.208 -1.775 . . . . 0.0 106.208 179.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.439 ' HB2' ' HB2' ' A' ' 32' ' ' LYS . 49.7 m -131.57 148.55 52.63 Favored 'General case' 0 CA--C 1.497 -1.079 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 -179.156 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 45.6 pt -131.6 158.24 43.27 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.106 0 N-CA-C 106.311 -1.737 . . . . 0.0 106.311 179.205 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -167.19 -176.05 37.74 Favored Glycine 0 CA--C 1.493 -1.329 0 N-CA-C 108.506 -1.837 . . . . 0.0 108.506 -179.547 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -125.38 150.77 46.93 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 106.849 -1.538 . . . . 0.0 106.849 -179.43 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -100.62 135.44 42.06 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 -179.469 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 7.5 tp-100 -117.69 129.17 55.56 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 179.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 43.8 m -122.04 -3.11 9.1 Favored 'General case' 0 CA--C 1.502 -0.892 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 -179.27 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 79.6 ttt180 -134.46 127.59 31.77 Favored 'General case' 0 CA--C 1.497 -1.072 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 -179.02 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 64.9 t -122.44 118.13 54.28 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.013 0 N-CA-C 106.174 -1.787 . . . . 0.0 106.174 178.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 65.8 tttm -161.49 141.42 10.5 Favored 'General case' 0 CA--C 1.497 -1.069 0 N-CA-C 106.803 -1.555 . . . . 0.0 106.803 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 89.1 tt0 -91.07 109.17 20.41 Favored 'General case' 0 N--CA 1.438 -1.035 0 N-CA-C 107.006 -1.479 . . . . 0.0 107.006 179.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -158.44 97.05 1.45 Allowed 'General case' 0 N--CA 1.436 -1.153 0 N-CA-C 106.667 -1.605 . . . . 0.0 106.667 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -102.1 1.17 51.07 Favored Glycine 0 C--N 1.35 1.361 0 N-CA-C 108.514 -1.834 . . . . 0.0 108.514 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -71.09 -40.06 71.77 Favored 'General case' 0 CA--C 1.503 -0.843 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 -179.493 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 39.9 ttmt -157.56 137.66 12.58 Favored 'General case' 0 N--CA 1.437 -1.083 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 88.9 mt -108.99 123.42 49.09 Favored 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 179.549 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 19.9 t0 -167.62 155.88 9.23 Favored 'General case' 0 N--CA 1.435 -1.192 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 57.0 mtmt 58.85 43.93 17.5 Favored 'General case' 0 C--N 1.357 0.932 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 179.503 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 36.2 m120 -106.42 147.53 35.1 Favored Pre-proline 0 N--CA 1.441 -0.916 0 N-CA-C 107.059 -1.459 . . . . 0.0 107.059 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -75.65 155.59 39.98 Favored 'Trans proline' 0 CA--C 1.497 -1.328 0 C-N-CA 122.224 1.95 . . . . 0.0 112.88 179.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 16.0 mtm180 -136.57 129.76 31.35 Favored 'General case' 0 N--CA 1.438 -1.039 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -159.21 160.03 30.91 Favored Glycine 0 CA--C 1.492 -1.367 0 N-CA-C 107.595 -2.202 . . . . 0.0 107.595 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -130.16 145.71 51.74 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 107.045 -1.465 . . . . 0.0 107.045 -179.499 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 85.0 m-20 -125.06 136.8 54.03 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 7.0 mp -124.69 129.85 51.29 Favored 'General case' 0 CA--C 1.497 -1.081 0 N-CA-C 105.682 -1.97 . . . . 0.0 105.682 178.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.439 ' HB2' ' HB2' ' A' ' 7' ' ' SER . 97.4 mttt -128.37 142.53 51.09 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 -179.044 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -127.13 137.28 52.95 Favored 'General case' 0 CA--C 1.495 -1.135 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 179.632 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 78.5 ttt180 -117.86 129.24 55.53 Favored 'General case' 0 CA--C 1.495 -1.147 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 -179.496 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -110.88 127.38 55.42 Favored 'General case' 0 N--CA 1.438 -1.048 0 N-CA-C 106.153 -1.795 . . . . 0.0 106.153 179.007 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 50.1 mt-10 -105.8 139.56 40.19 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 108.007 -1.108 . . . . 0.0 108.007 -179.167 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -132.18 164.82 25.49 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 66.9 t30 -79.62 77.79 6.21 Favored 'General case' 0 N--CA 1.443 -0.806 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 9.3 t-20 -165.94 175.98 8.18 Favored 'General case' 0 N--CA 1.433 -1.277 0 N-CA-C 106.056 -1.831 . . . . 0.0 106.056 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -91.11 -0.17 57.66 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 93.7 m95 -115.52 139.47 50.04 Favored 'General case' 0 CA--C 1.498 -1.036 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -124.85 174.43 17.19 Favored Glycine 0 C--N 1.35 1.307 0 N-CA-C 107.265 -2.334 . . . . 0.0 107.265 179.704 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 92.6 t -127.5 131.94 69.75 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.997 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 19.8 tt -127.24 138.05 55.97 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.878 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -120.76 140.03 13.93 Favored Glycine 0 CA--C 1.489 -1.532 0 N-CA-C 106.12 -2.792 . . . . 0.0 106.12 179.297 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 54.8 m -133.04 139.51 47.23 Favored 'General case' 0 CA--C 1.497 -1.071 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 -179.021 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -123.5 133.21 54.05 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 105.814 -1.921 . . . . 0.0 105.814 178.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -128.96 130.14 46.32 Favored 'General case' 0 CA--C 1.496 -1.099 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 -179.428 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 71.5 mt-30 -129.78 127.52 40.52 Favored 'General case' 0 CA--C 1.497 -1.085 0 N-CA-C 106.447 -1.686 . . . . 0.0 106.447 179.353 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 88.0 m -121.77 121.7 37.84 Favored 'General case' 0 CA--C 1.498 -1.051 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 71.7 ttp85 -70.12 -43.19 71.48 Favored 'General case' 0 CA--C 1.502 -0.889 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 -179.521 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 76.0 ttt180 -151.07 135.25 16.78 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -120.62 149.67 17.5 Favored Glycine 0 C--N 1.352 1.418 0 N-CA-C 107.04 -2.424 . . . . 0.0 107.04 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 89.9 t80 -137.94 130.17 29.01 Favored 'General case' 0 N--CA 1.438 -1.032 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 -179.653 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -98.47 139.25 34.49 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 106.851 -1.537 . . . . 0.0 106.851 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 36.3 mp0 -73.1 102.83 3.66 Favored 'General case' 0 CA--C 1.501 -0.91 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 -179.793 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 34.8 t -159.89 152.54 21.29 Favored 'General case' 0 N--CA 1.435 -1.18 0 N-CA-C 105.909 -1.886 . . . . 0.0 105.909 179.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 58.8 t -85.66 95.29 4.43 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.968 0 N-CA-C 106.827 -1.546 . . . . 0.0 106.827 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -158.74 110.76 2.2 Favored 'General case' 0 N--CA 1.434 -1.243 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -168.5 173.17 43.18 Favored Glycine 0 CA--C 1.492 -1.376 0 N-CA-C 107.429 -2.268 . . . . 0.0 107.429 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 18.8 t80 77.83 -70.31 0.12 Allowed 'General case' 0 C--N 1.356 0.864 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 179.492 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -66.14 -39.81 90.11 Favored 'General case' 0 CA--C 1.504 -0.813 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -124.87 144.52 50.27 Favored 'General case' 0 CA--C 1.497 -1.077 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 -179.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 46.6 mm -66.32 -45.1 90.48 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.759 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 179.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 33.7 t0 58.83 50.01 9.17 Favored 'General case' 0 C--N 1.359 1.02 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.556 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 176.58 -167.67 39.28 Favored Glycine 0 CA--C 1.491 -1.412 0 N-CA-C 107.131 -2.387 . . . . 0.0 107.131 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 33.3 t0 62.19 48.26 5.04 Favored 'General case' 0 C--N 1.355 0.83 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 33.9 t80 -135.86 125.82 25.92 Favored 'General case' 0 N--CA 1.438 -1.052 0 N-CA-C 106.034 -1.839 . . . . 0.0 106.034 179.718 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 8.0 mptt -89.69 141.9 28.18 Favored 'General case' 0 CA--C 1.501 -0.942 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 -179.096 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -126.34 134.66 51.03 Favored 'General case' 0 CA--C 1.499 -1.007 0 N-CA-C 106.957 -1.497 . . . . 0.0 106.957 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -130.64 136.49 48.89 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 179.228 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 70.9 m -145.02 142.76 30.04 Favored 'General case' 0 CA--C 1.493 -1.234 0 N-CA-C 108.106 -1.072 . . . . 0.0 108.106 179.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 71.2 t -128.7 135.55 62.05 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.246 0 N-CA-C 105.271 -2.122 . . . . 0.0 105.271 178.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 67.5 p -140.19 159.95 41.04 Favored 'General case' 0 CA--C 1.499 -1.007 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 -179.408 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -156.94 156.63 33.37 Favored 'General case' 0 N--CA 1.436 -1.17 0 N-CA-C 106.19 -1.781 . . . . 0.0 106.19 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -177.12 177.16 48.28 Favored Glycine 0 N--CA 1.436 -1.328 0 N-CA-C 108.355 -1.898 . . . . 0.0 108.355 179.618 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 69.5 Cg_endo -82.45 157.76 16.84 Favored 'Trans proline' 0 C--N 1.309 -1.501 0 C-N-CA 122.754 2.303 . . . . 0.0 113.836 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 66.4 t -119.74 130.09 74.57 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.017 0 N-CA-C 105.641 -1.985 . . . . 0.0 105.641 178.733 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 86.9 t80 -124.96 131.5 53.41 Favored 'General case' 0 N--CA 1.441 -0.917 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 -179.077 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 41.6 ptt180 -112.17 142.89 44.08 Favored 'General case' 0 CA--C 1.5 -0.969 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 179.689 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 49.1 mm -75.07 -63.28 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.502 -0.885 0 N-CA-C 106.787 -1.56 . . . . 0.0 106.787 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.2 p30 -174.8 92.82 0.07 Allowed 'General case' 0 N--CA 1.442 -0.865 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 177.508 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 38.93 41.45 0.54 Allowed 'General case' 0 C--N 1.357 0.898 0 CA-C-N 115.596 -0.729 . . . . 0.0 112.136 177.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 19.8 t80 -142.19 -45.62 0.34 Allowed 'General case' 0 CA--C 1.501 -0.93 0 C-N-CA 118.749 -1.18 . . . . 0.0 108.655 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 27.8 m -144.74 155.48 14.41 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.184 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 66.0 m -136.26 147.1 47.38 Favored 'General case' 0 CA--C 1.496 -1.132 0 N-CA-C 106.908 -1.516 . . . . 0.0 106.908 178.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 1.1 pp -134.54 158.79 43.05 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -151.46 158.93 44.31 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 -179.47 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -123.16 147.58 16.7 Favored Glycine 0 CA--C 1.489 -1.574 0 N-CA-C 106.356 -2.698 . . . . 0.0 106.356 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 94.8 mt -123.85 140.05 53.37 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 -179.36 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -148.72 149.01 30.68 Favored 'General case' 0 N--CA 1.436 -1.157 0 N-CA-C 106.078 -1.823 . . . . 0.0 106.078 178.602 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 175.6 -147.28 8.7 Favored Glycine 0 CA--C 1.491 -1.423 0 N-CA-C 107.704 -2.158 . . . . 0.0 107.704 -179.46 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -140.78 155.77 46.32 Favored 'General case' 0 N--CA 1.438 -1.052 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 -178.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -119.72 142.83 16.6 Favored Glycine 0 C--N 1.351 1.404 0 N-CA-C 107.118 -2.393 . . . . 0.0 107.118 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . 0.458 ' HE1' ' HE2' ' A' ' 97' ' ' LYS . 58.8 t-80 -151.67 136.45 17.15 Favored 'General case' 0 N--CA 1.438 -1.026 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 -179.504 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -154.82 152.83 24.34 Favored Glycine 0 CA--C 1.494 -1.274 0 N-CA-C 107.672 -2.171 . . . . 0.0 107.672 179.404 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.458 ' HE2' ' HE1' ' A' ' 95' ' ' HIS . 68.7 mttm -132.03 138.79 48.34 Favored 'General case' 0 CA--C 1.497 -1.065 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 178.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -66.83 -41.69 87.05 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 179.142 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 62.7 mtpt -136.43 151.3 49.35 Favored 'General case' 0 CA--C 1.497 -1.059 0 N-CA-C 106.882 -1.525 . . . . 0.0 106.882 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -112.39 140.76 46.84 Favored 'General case' 0 CA--C 1.497 -1.07 0 N-CA-C 107.031 -1.47 . . . . 0.0 107.031 179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 72.3 m -85.24 127.4 34.29 Favored 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 -179.776 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 73.2 m -67.0 -39.61 87.14 Favored 'General case' 0 CA--C 1.503 -0.844 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 85.1 mt -116.37 127.56 73.94 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.001 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 -179.326 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 93.1 m-85 -91.03 140.3 29.96 Favored 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -178.39 -170.34 40.36 Favored Glycine 0 CA--C 1.491 -1.424 0 N-CA-C 106.759 -2.536 . . . . 0.0 106.759 -179.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 64.4 tt0 -83.7 116.97 22.92 Favored 'General case' 0 N--CA 1.438 -1.027 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 5.6 t -169.33 -169.02 0.88 Allowed 'General case' 0 N--CA 1.437 -1.082 0 N-CA-C 106.208 -1.775 . . . . 0.0 106.208 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 50.0 mt-10 -83.45 133.03 34.93 Favored 'General case' 0 N--CA 1.44 -0.968 0 N-CA-C 107.03 -1.47 . . . . 0.0 107.03 179.628 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 34.8 t -155.86 150.33 25.89 Favored 'General case' 0 CA--C 1.498 -1.042 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 -179.58 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 86.0 mtp180 -127.19 145.85 50.62 Favored 'General case' 0 CA--C 1.496 -1.109 0 N-CA-C 106.813 -1.551 . . . . 0.0 106.813 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 36.5 t -149.58 140.0 22.39 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 -179.677 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -124.87 134.21 52.79 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 106.96 -1.496 . . . . 0.0 106.96 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 86.0 m -128.55 133.38 48.37 Favored 'General case' 0 CA--C 1.495 -1.149 0 N-CA-C 106.573 -1.64 . . . . 0.0 106.573 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 93.2 p -147.2 160.73 42.12 Favored 'General case' 0 CA--C 1.496 -1.119 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 89.4 mt -96.65 144.09 27.0 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -118.09 138.12 52.47 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 107.445 -1.316 . . . . 0.0 107.445 -179.288 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -132.65 149.38 52.31 Favored 'General case' 0 CA--C 1.494 -1.174 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 179.778 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -164.53 173.47 40.47 Favored Glycine 0 N--CA 1.433 -1.508 0 N-CA-C 107.925 -2.07 . . . . 0.0 107.925 179.745 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -150.72 157.63 43.19 Favored 'General case' 0 CA--C 1.492 -1.264 0 N-CA-C 106.001 -1.851 . . . . 0.0 106.001 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -159.08 167.44 34.89 Favored Glycine 0 N--CA 1.435 -1.432 0 N-CA-C 108.834 -1.706 . . . . 0.0 108.834 -179.477 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 88.9 mt -121.28 149.27 43.15 Favored 'General case' 0 CA--C 1.497 -1.069 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -117.18 127.62 54.29 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 179.588 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -112.77 138.82 49.02 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 107.088 -1.449 . . . . 0.0 107.088 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 67.0 m-20 -127.24 77.68 75.29 Favored Pre-proline 0 N--CA 1.442 -0.829 0 N-CA-C 107.004 -1.48 . . . . 0.0 107.004 -179.381 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -69.34 -28.62 27.04 Favored 'Trans proline' 0 CA--C 1.5 -1.207 0 C-N-CA 121.9 1.733 . . . . 0.0 113.326 -179.47 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -137.55 151.36 70.84 Favored Pre-proline 0 N--CA 1.438 -1.049 0 N-CA-C 106.86 -1.533 . . . . 0.0 106.86 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 92.6 Cg_endo -84.03 65.88 7.09 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 C-N-CA 122.003 1.802 . . . . 0.0 112.325 179.691 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.99 -33.66 0.04 OUTLIER 'General case' 0 N--CA 1.44 -0.97 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 -179.589 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -141.86 159.82 41.44 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 -179.468 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 32.7 m -130.06 158.0 42.56 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.009 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 -179.159 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 51.4 mm -116.63 125.06 73.42 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 106.352 -1.721 . . . . 0.0 106.352 179.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -114.2 136.03 53.4 Favored 'General case' 0 CA--C 1.5 -0.958 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 -179.147 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -137.67 139.95 40.54 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 105.428 -2.064 . . . . 0.0 105.428 178.487 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 34.1 t -157.99 153.01 25.39 Favored 'General case' 0 CA--C 1.501 -0.927 0 C-N-CA 119.326 -0.95 . . . . 0.0 108.527 -179.12 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 79.7 t80 -121.23 129.73 53.34 Favored 'General case' 0 N--CA 1.441 -0.896 0 N-CA-C 105.856 -1.905 . . . . 0.0 105.856 178.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -114.24 133.34 55.7 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 107.996 -1.112 . . . . 0.0 107.996 -179.128 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 86.3 t80 -116.51 126.15 52.94 Favored 'General case' 0 N--CA 1.439 -0.975 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 69.2 m -132.12 151.0 52.02 Favored 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 106.468 -1.678 . . . . 0.0 106.468 179.393 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -134.39 124.86 26.4 Favored 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 81.8 mt -120.65 113.9 20.9 Favored 'General case' 0 CA--C 1.495 -1.146 0 N-CA-C 106.939 -1.504 . . . . 0.0 106.939 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 65.2 m-20 60.64 -118.87 0.81 Allowed 'General case' 0 C--N 1.352 0.702 0 N-CA-C 108.131 -1.062 . . . . 0.0 108.131 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -108.99 16.55 22.53 Favored 'General case' 0 N--CA 1.443 -0.794 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 76.7 t -109.26 124.47 65.97 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.878 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 -179.037 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -94.78 134.01 37.86 Favored 'General case' 0 N--CA 1.439 -1.002 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 80.4 t -124.86 124.67 68.33 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.028 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 -179.633 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -123.72 133.73 8.99 Favored Glycine 0 CA--C 1.491 -1.445 0 N-CA-C 106.318 -2.713 . . . . 0.0 106.318 179.238 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 82.8 p -131.25 151.19 51.73 Favored 'General case' 0 CA--C 1.495 -1.159 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 -179.606 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 28.0 m-90 -113.29 138.05 50.59 Favored 'General case' 0 CA--C 1.495 -1.154 0 N-CA-C 106.472 -1.677 . . . . 0.0 106.472 179.39 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 2.5 mpp? -119.23 122.59 42.3 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -129.12 137.58 51.29 Favored 'General case' 0 CA--C 1.494 -1.201 0 N-CA-C 106.049 -1.834 . . . . 0.0 106.049 179.46 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -170.65 -175.39 39.3 Favored Glycine 0 N--CA 1.435 -1.398 0 N-CA-C 108.667 -1.773 . . . . 0.0 108.667 -179.668 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -145.67 161.3 40.18 Favored 'General case' 0 N--CA 1.436 -1.16 0 N-CA-C 106.346 -1.724 . . . . 0.0 106.346 -179.355 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -140.17 166.74 25.66 Favored Glycine 0 CA--C 1.487 -1.719 0 N-CA-C 108.641 -1.784 . . . . 0.0 108.641 -179.188 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 51.8 t80 -117.0 136.52 52.87 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 -179.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 58.7 ttp180 -86.6 127.13 34.89 Favored 'General case' 0 N--CA 1.441 -0.886 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 -179.311 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 . . . . . 0 C--O 1.262 1.747 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 -179.686 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 52.7 tp10 . . . . . 0 N--CA 1.489 1.501 0 CA-C-O 120.883 0.373 . . . . 0.0 110.491 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 179.5 177.84 48.04 Favored Glycine 0 CA--C 1.492 -1.383 0 N-CA-C 106.908 -2.477 . . . . 0.0 106.908 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 80.3 mm-40 -133.73 146.56 50.9 Favored 'General case' 0 CA--C 1.497 -1.069 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 66.9 m -132.85 146.84 52.16 Favored 'General case' 0 CA--C 1.496 -1.113 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 54.2 m -130.21 148.95 52.1 Favored 'General case' 0 CA--C 1.495 -1.135 0 N-CA-C 106.957 -1.498 . . . . 0.0 106.957 179.554 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 83.6 mt -117.15 126.93 74.77 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.072 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 -179.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 59.2 m -124.23 142.97 50.8 Favored 'General case' 0 CA--C 1.496 -1.113 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 -179.641 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 46.1 pt -132.65 157.96 43.16 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.103 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 179.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -173.23 -175.82 41.29 Favored Glycine 0 CA--C 1.491 -1.447 0 N-CA-C 107.682 -2.167 . . . . 0.0 107.682 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -125.46 151.36 46.35 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 107.088 -1.449 . . . . 0.0 107.088 -179.532 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -115.9 141.07 48.6 Favored 'General case' 0 N--CA 1.439 -0.979 0 N-CA-C 107.467 -1.308 . . . . 0.0 107.467 -179.575 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 85.9 mm-40 -129.09 148.5 51.04 Favored 'General case' 0 CA--C 1.497 -1.068 0 N-CA-C 107.198 -1.408 . . . . 0.0 107.198 179.745 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 31.9 m -137.32 21.66 2.97 Favored 'General case' 0 CA--C 1.499 -0.989 0 N-CA-C 108.196 -1.038 . . . . 0.0 108.196 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 79.7 ttt180 -131.02 124.94 31.99 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 -179.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 27.4 m -136.62 153.02 29.9 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.026 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 178.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 58.0 mtmt -137.04 146.47 45.26 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 106.951 -1.5 . . . . 0.0 106.951 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -66.92 -39.41 87.36 Favored 'General case' 0 CA--C 1.503 -0.839 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 179.399 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 18.0 t0 -161.63 161.08 29.48 Favored 'General case' 0 N--CA 1.434 -1.235 0 N-CA-C 106.391 -1.707 . . . . 0.0 106.391 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -168.18 169.1 41.27 Favored Glycine 0 CA--C 1.491 -1.413 0 N-CA-C 106.979 -2.448 . . . . 0.0 106.979 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -104.24 -22.17 13.42 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 64.5 pttt -159.46 162.69 35.67 Favored 'General case' 0 N--CA 1.436 -1.133 0 N-CA-C 107.351 -1.352 . . . . 0.0 107.351 -179.837 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 88.3 mt -116.91 137.58 52.11 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 106.546 -1.65 . . . . 0.0 106.546 179.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 22.3 t0 -160.99 150.06 16.66 Favored 'General case' 0 N--CA 1.435 -1.189 0 N-CA-C 106.906 -1.516 . . . . 0.0 106.906 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 99.3 mttt 58.28 46.4 15.66 Favored 'General case' 0 C--N 1.357 0.897 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 91.7 m-20 -74.28 151.33 87.79 Favored Pre-proline 0 N--CA 1.443 -0.822 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 179.483 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -70.65 152.46 64.71 Favored 'Trans proline' 0 CA--C 1.497 -1.368 0 C-N-CA 121.778 1.652 . . . . 0.0 112.442 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.436 HH21 ' HD3' ' A' ' 51' ' ' ARG . 72.7 mtm-85 -110.39 131.64 54.88 Favored 'General case' 0 CA--C 1.495 -1.138 0 N-CA-C 107.209 -1.404 . . . . 0.0 107.209 -179.336 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -153.39 148.59 19.51 Favored Glycine 0 CA--C 1.489 -1.536 0 N-CA-C 107.307 -2.317 . . . . 0.0 107.307 179.725 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -130.01 147.31 51.74 Favored 'General case' 0 CA--C 1.495 -1.153 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 50.2 t30 -128.45 114.6 17.0 Favored 'General case' 0 N--CA 1.44 -0.96 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 60.1 tp -111.38 122.11 46.98 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 105.879 -1.897 . . . . 0.0 105.879 179.534 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 39.2 ttpt -135.23 137.89 43.05 Favored 'General case' 0 CA--C 1.503 -0.863 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 -177.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -121.17 145.14 48.14 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 179.382 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . 0.443 ' HA ' HG22 ' A' ' 44' ' ' ILE . 53.2 ttp180 -115.67 129.32 56.44 Favored 'General case' 0 CA--C 1.496 -1.124 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 179.514 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -114.29 116.44 29.0 Favored 'General case' 0 CA--C 1.498 -1.055 0 N-CA-C 106.335 -1.728 . . . . 0.0 106.335 179.359 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -113.01 118.22 34.2 Favored 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 -179.222 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -105.06 -28.39 11.06 Favored 'General case' 0 CA--C 1.5 -0.968 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 179.632 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 32.4 m120 -130.57 146.68 52.14 Favored 'General case' 0 CA--C 1.496 -1.102 0 N-CA-C 106.231 -1.766 . . . . 0.0 106.231 179.575 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 65.2 t30 -83.97 69.66 10.34 Favored 'General case' 0 N--CA 1.443 -0.808 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 -179.64 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 19.9 t0 179.78 -33.74 0.01 OUTLIER 'General case' 0 N--CA 1.441 -0.915 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 -179.742 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 90.5 t90 -146.26 143.41 29.17 Favored 'General case' 0 CA--C 1.5 -0.967 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 -179.007 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -156.41 -177.41 29.55 Favored Glycine 0 C--N 1.351 1.381 0 N-CA-C 107.443 -2.263 . . . . 0.0 107.443 -179.62 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.7 m -131.55 158.06 43.25 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.027 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 -179.634 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.619 HD13 ' CD2' ' A' ' 88' ' ' TYR . 32.8 pt -130.68 159.27 42.83 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.115 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 -179.847 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -137.3 141.7 12.6 Favored Glycine 0 CA--C 1.49 -1.508 0 N-CA-C 104.716 -3.353 . . . . 0.0 104.716 177.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 33.8 t -145.2 144.22 30.72 Favored 'General case' 0 CA--C 1.498 -1.038 0 C-N-CA 118.966 -1.094 . . . . 0.0 108.858 -178.514 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 89.3 t80 -129.17 129.9 45.68 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 105.162 -2.162 . . . . 0.0 105.162 179.181 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -135.15 145.87 48.21 Favored 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 -178.773 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 64.1 tt0 -134.4 129.76 35.82 Favored 'General case' 0 CA--C 1.495 -1.171 0 N-CA-C 105.773 -1.936 . . . . 0.0 105.773 179.264 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 87.5 m -129.38 130.44 46.02 Favored 'General case' 0 CA--C 1.496 -1.112 0 N-CA-C 107.472 -1.306 . . . . 0.0 107.472 -179.519 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.436 ' HD3' HH21 ' A' ' 27' ' ' ARG . 80.2 ttt180 -106.03 126.88 52.72 Favored 'General case' 0 N--CA 1.438 -1.026 0 N-CA-C 106.736 -1.579 . . . . 0.0 106.736 179.602 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 42.6 ttm180 -89.28 124.46 34.43 Favored 'General case' 0 N--CA 1.44 -0.952 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 -179.482 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -96.23 -161.23 32.74 Favored Glycine 0 C--N 1.352 1.468 0 N-CA-C 107.646 -2.182 . . . . 0.0 107.646 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -103.4 133.91 47.67 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -98.57 127.67 44.59 Favored 'General case' 0 CA--C 1.5 -0.967 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 -179.375 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -142.17 156.01 45.32 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 179.582 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 46.1 t -146.76 146.79 30.4 Favored 'General case' 0 CA--C 1.497 -1.059 0 N-CA-C 106.218 -1.771 . . . . 0.0 106.218 179.526 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.2 m -73.2 -23.87 20.28 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.812 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 -179.47 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 98.3 m-20 -65.52 -39.62 92.02 Favored 'General case' 0 C--N 1.356 0.856 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 179.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 149.41 -179.14 26.44 Favored Glycine 0 CA--C 1.493 -1.319 0 N-CA-C 106.828 -2.509 . . . . 0.0 106.828 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 38.5 t80 75.84 114.87 0.06 Allowed 'General case' 0 C--N 1.356 0.875 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 179.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 30.0 mtpp -124.68 137.25 54.37 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 106.602 -1.629 . . . . 0.0 106.602 179.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 59.6 tp -110.59 120.9 43.92 Favored 'General case' 0 N--CA 1.438 -1.037 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 45.5 pt -96.78 -3.67 10.12 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.837 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 -179.232 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 38.3 t70 -87.8 107.89 18.88 Favored 'General case' 0 N--CA 1.439 -0.982 0 N-CA-C 106.773 -1.566 . . . . 0.0 106.773 179.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -173.04 -171.62 37.9 Favored Glycine 0 CA--C 1.491 -1.438 0 N-CA-C 107.085 -2.406 . . . . 0.0 107.085 -179.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 26.0 t0 66.29 45.78 2.16 Favored 'General case' 0 C--N 1.354 0.796 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 -179.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 45.2 t80 -131.72 131.94 43.47 Favored 'General case' 0 N--CA 1.439 -1.012 0 N-CA-C 106.096 -1.816 . . . . 0.0 106.096 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -99.48 130.28 45.72 Favored 'General case' 0 N--CA 1.44 -0.971 0 N-CA-C 107.829 -1.175 . . . . 0.0 107.829 -179.129 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -111.35 137.38 49.18 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 106.768 -1.567 . . . . 0.0 106.768 179.107 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -121.26 137.24 54.78 Favored 'General case' 0 CA--C 1.496 -1.122 0 N-CA-C 106.247 -1.76 . . . . 0.0 106.247 179.697 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 70.9 m -134.22 138.92 45.44 Favored 'General case' 0 CA--C 1.494 -1.201 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 61.5 t -128.5 136.99 58.59 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.265 0 N-CA-C 104.697 -2.334 . . . . 0.0 104.697 178.836 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.565 HG21 HD13 ' A' ' 90' ' ' LEU . 13.8 t -156.45 158.26 36.96 Favored 'General case' 0 N--CA 1.437 -1.075 0 C-N-CA 119.015 -1.074 . . . . 0.0 108.679 -178.663 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -157.09 159.84 38.29 Favored 'General case' 0 N--CA 1.435 -1.206 0 N-CA-C 106.24 -1.763 . . . . 0.0 106.24 179.68 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -176.47 173.99 46.68 Favored Glycine 0 C--N 1.349 1.259 0 N-CA-C 108.384 -1.886 . . . . 0.0 108.384 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -84.28 162.07 13.17 Favored 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.992 2.462 . . . . 0.0 113.829 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.476 ' CG2' HG23 ' A' ' 44' ' ' ILE . 97.8 t -122.61 126.85 74.61 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.029 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 178.679 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 99.5 m-85 -115.37 132.53 56.59 Favored 'General case' 0 CA--C 1.498 -1.037 0 N-CA-C 107.467 -1.309 . . . . 0.0 107.467 -179.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 44.3 ttm180 -111.6 132.89 54.24 Favored 'General case' 0 CA--C 1.498 -1.021 0 N-CA-C 106.835 -1.543 . . . . 0.0 106.835 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 97.0 mt -73.51 -64.24 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.896 0 N-CA-C 107.037 -1.468 . . . . 0.0 107.037 179.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 66.0 t30 -177.97 94.09 0.03 OUTLIER 'General case' 0 CA--C 1.502 -0.881 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 177.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 38.03 46.06 0.78 Allowed 'General case' 0 C--N 1.36 1.062 0 C-N-CA 123.094 0.558 . . . . 0.0 111.796 177.803 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 60.5 t80 -141.9 -43.34 0.35 Allowed 'General case' 0 CA--C 1.5 -0.959 0 C-N-CA 119.005 -1.078 . . . . 0.0 108.917 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 12.6 p -161.28 149.58 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.097 0 N-CA-C 106.977 -1.49 . . . . 0.0 106.977 -179.597 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 68.2 m -116.25 135.34 53.98 Favored 'General case' 0 N--CA 1.438 -1.044 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 179.341 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -97.56 128.46 44.31 Favored 'General case' 0 CA--C 1.496 -1.112 0 N-CA-C 106.508 -1.664 . . . . 0.0 106.508 -179.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.619 ' CD2' HD13 ' A' ' 44' ' ' ILE . 2.9 m-85 -107.61 141.22 39.41 Favored 'General case' 0 N--CA 1.437 -1.102 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 -179.538 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -135.86 151.42 20.67 Favored Glycine 0 CA--C 1.487 -1.702 0 N-CA-C 105.462 -3.055 . . . . 0.0 105.462 178.774 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.565 HD13 HG21 ' A' ' 74' ' ' THR . 0.5 OUTLIER -158.01 143.63 17.01 Favored 'General case' 0 N--CA 1.435 -1.188 0 C-N-CA 118.999 -1.08 . . . . 0.0 108.91 -179.193 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 5.0 tt -136.82 138.92 41.33 Favored 'General case' 0 CA--C 1.498 -1.053 0 N-CA-C 105.498 -2.038 . . . . 0.0 105.498 179.348 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -162.66 -154.87 7.78 Favored Glycine 0 CA--C 1.491 -1.424 0 N-CA-C 108.487 -1.845 . . . . 0.0 108.487 -179.052 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -145.47 156.1 43.53 Favored 'General case' 0 N--CA 1.435 -1.182 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 -179.148 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -101.91 143.7 16.09 Favored Glycine 0 C--N 1.35 1.35 0 N-CA-C 107.091 -2.403 . . . . 0.0 107.091 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -131.52 145.34 51.7 Favored 'General case' 0 CA--C 1.498 -1.026 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 -179.439 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -154.24 168.95 32.62 Favored Glycine 0 CA--C 1.491 -1.422 0 N-CA-C 106.457 -2.657 . . . . 0.0 106.457 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 59.1 mtmt -77.11 129.57 36.2 Favored 'General case' 0 CA--C 1.5 -0.947 0 N-CA-C 107.593 -1.262 . . . . 0.0 107.593 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -160.82 160.34 31.02 Favored 'General case' 0 N--CA 1.434 -1.273 0 N-CA-C 106.717 -1.586 . . . . 0.0 106.717 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -87.68 135.14 33.49 Favored 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 179.725 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -129.65 147.19 51.42 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 5.6 t -159.38 179.91 8.53 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 106.523 -1.658 . . . . 0.0 106.523 179.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 46.3 t -72.27 140.34 48.56 Favored 'General case' 0 CA--C 1.504 -0.804 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 96.4 mt -64.0 -44.58 97.88 Favored 'Isoleucine or valine' 0 C--N 1.354 0.769 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -109.28 135.9 49.62 Favored 'General case' 0 CA--C 1.499 -1.001 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 -179.566 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 170.12 -160.0 32.71 Favored Glycine 0 CA--C 1.491 -1.427 0 N-CA-C 106.778 -2.529 . . . . 0.0 106.778 -179.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 26.0 mp0 -64.1 -39.3 93.75 Favored 'General case' 0 CA--C 1.504 -0.81 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 179.634 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 46.4 t -121.48 130.03 53.31 Favored 'General case' 0 CA--C 1.496 -1.122 0 N-CA-C 106.236 -1.764 . . . . 0.0 106.236 179.402 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 99.7 mt-10 -80.2 151.35 29.73 Favored 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 107.764 -1.199 . . . . 0.0 107.764 -179.698 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 42.4 t -146.19 143.76 29.48 Favored 'General case' 0 CA--C 1.497 -1.07 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -82.45 152.24 26.2 Favored 'General case' 0 N--CA 1.438 -1.029 0 N-CA-C 107.7 -1.222 . . . . 0.0 107.7 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 46.7 t -98.05 137.03 37.45 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 106.746 -1.576 . . . . 0.0 106.746 179.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 8.5 mptt -119.22 141.61 48.75 Favored 'General case' 0 CA--C 1.499 -1.003 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 -179.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 14.1 t -152.91 161.23 42.8 Favored 'General case' 0 CA--C 1.498 -1.053 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 179.608 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 36.9 t -149.14 136.31 19.96 Favored 'General case' 0 CA--C 1.497 -1.064 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 89.8 mt -114.53 143.53 44.82 Favored 'General case' 0 CA--C 1.496 -1.128 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -123.15 140.29 53.18 Favored 'General case' 0 N--CA 1.438 -1.039 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 -179.418 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 89.6 t80 -145.85 141.29 27.73 Favored 'General case' 0 CA--C 1.497 -1.06 0 N-CA-C 106.291 -1.744 . . . . 0.0 106.291 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -159.2 178.92 35.15 Favored Glycine 0 CA--C 1.491 -1.415 0 N-CA-C 108.653 -1.779 . . . . 0.0 108.653 -179.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -154.48 163.08 40.74 Favored 'General case' 0 N--CA 1.436 -1.14 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -160.81 171.37 36.9 Favored Glycine 0 CA--C 1.489 -1.562 0 N-CA-C 108.669 -1.772 . . . . 0.0 108.669 -179.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 88.6 mt -127.04 143.43 51.29 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 54.5 tt0 -121.73 129.5 52.76 Favored 'General case' 0 CA--C 1.496 -1.115 0 N-CA-C 106.699 -1.593 . . . . 0.0 106.699 179.074 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 34.4 t80 -125.59 131.09 52.78 Favored 'General case' 0 N--CA 1.437 -1.101 0 N-CA-C 106.196 -1.779 . . . . 0.0 106.196 -179.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 11.8 p-10 -121.77 82.19 41.8 Favored Pre-proline 0 N--CA 1.443 -0.814 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 -178.51 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.24 -27.13 29.33 Favored 'Trans proline' 0 CA--C 1.498 -1.32 0 C-N-CA 121.667 1.578 . . . . 0.0 112.491 179.517 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -137.86 151.73 70.94 Favored Pre-proline 0 N--CA 1.436 -1.126 0 N-CA-C 106.287 -1.746 . . . . 0.0 106.287 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -74.62 -18.22 19.92 Favored 'Trans proline' 0 C--N 1.309 -1.533 0 C-N-CA 121.793 1.662 . . . . 0.0 113.031 179.312 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 27.7 m120 -64.82 -40.23 94.85 Favored 'General case' 0 C--N 1.353 0.72 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 -178.796 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 54.0 p90 -154.06 161.71 41.73 Favored 'General case' 0 CA--C 1.499 -1.015 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 -178.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 29.4 m -128.0 159.26 39.26 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.95 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 -179.56 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 50.9 mm -108.26 127.46 64.53 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.09 0 N-CA-C 106.57 -1.641 . . . . 0.0 106.57 -179.76 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -120.97 131.23 54.19 Favored 'General case' 0 N--CA 1.439 -1.015 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 -178.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -134.19 137.36 44.38 Favored 'General case' 0 CA--C 1.495 -1.165 0 N-CA-C 105.333 -2.099 . . . . 0.0 105.333 178.644 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 35.8 t -154.83 149.86 26.87 Favored 'General case' 0 CA--C 1.497 -1.086 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 -178.712 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 21.0 m-85 -123.18 138.71 54.58 Favored 'General case' 0 N--CA 1.436 -1.17 0 N-CA-C 105.292 -2.114 . . . . 0.0 105.292 179.117 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 88.2 tt0 -136.24 134.79 38.45 Favored 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 -178.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -123.39 140.97 52.47 Favored 'General case' 0 N--CA 1.436 -1.169 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 68.9 m -123.35 139.38 54.1 Favored 'General case' 0 CA--C 1.492 -1.252 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 64.7 tttm -113.48 126.14 54.99 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 107.341 -1.355 . . . . 0.0 107.341 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.14 159.47 20.85 Favored 'General case' 0 N--CA 1.437 -1.113 0 N-CA-C 105.595 -2.002 . . . . 0.0 105.595 178.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -62.2 -38.2 88.23 Favored 'General case' 0 N--CA 1.443 -0.802 0 O-C-N 122.131 -0.356 . . . . 0.0 110.361 -178.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -93.65 -38.72 11.18 Favored 'General case' 0 C--N 1.353 0.726 0 C-N-CA 119.862 -0.735 . . . . 0.0 111.642 -176.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 35.5 m -138.29 166.28 23.75 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.947 0 C-N-CA 119.44 -0.904 . . . . 0.0 109.604 -177.344 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -113.83 140.4 48.36 Favored 'General case' 0 CA--C 1.499 -0.986 0 N-CA-C 105.713 -1.958 . . . . 0.0 105.713 178.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 69.9 t -125.91 128.25 71.84 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.018 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 -178.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -114.43 134.87 11.99 Favored Glycine 0 CA--C 1.492 -1.397 0 N-CA-C 106.338 -2.705 . . . . 0.0 106.338 178.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 81.4 p -130.03 151.11 50.93 Favored 'General case' 0 CA--C 1.498 -1.04 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 -179.313 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 29.1 m-90 -124.83 138.54 54.26 Favored 'General case' 0 N--CA 1.437 -1.084 0 N-CA-C 105.692 -1.966 . . . . 0.0 105.692 179.236 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 3.5 mpp? -128.71 139.62 52.14 Favored 'General case' 0 CA--C 1.498 -1.033 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 -179.08 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 61.1 tp -142.11 134.12 27.39 Favored 'General case' 0 CA--C 1.497 -1.06 0 N-CA-C 105.698 -1.964 . . . . 0.0 105.698 179.304 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -168.93 -166.95 28.85 Favored Glycine 0 N--CA 1.436 -1.338 0 N-CA-C 108.966 -1.653 . . . . 0.0 108.966 -179.412 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -147.0 163.81 35.02 Favored 'General case' 0 N--CA 1.435 -1.185 0 N-CA-C 106.279 -1.749 . . . . 0.0 106.279 -179.332 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -144.24 173.43 24.95 Favored Glycine 0 CA--C 1.489 -1.539 0 N-CA-C 108.541 -1.824 . . . . 0.0 108.541 -179.114 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -124.66 143.39 50.76 Favored 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 -179.76 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 80.2 ttt180 -102.62 125.9 49.51 Favored 'General case' 0 CA--C 1.499 -0.984 0 N-CA-C 107.226 -1.398 . . . . 0.0 107.226 -179.386 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 43.6 t80 . . . . . 0 C--O 1.262 1.749 0 CA-C-O 117.764 -1.112 . . . . 0.0 108.3 179.835 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 . . . . . 0 N--CA 1.487 1.376 0 CA-C-O 121.347 0.594 . . . . 0.0 110.378 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -179.55 -179.4 48.76 Favored Glycine 0 CA--C 1.49 -1.487 0 N-CA-C 106.872 -2.491 . . . . 0.0 106.872 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -155.31 160.25 40.62 Favored 'General case' 0 N--CA 1.437 -1.107 0 N-CA-C 107.24 -1.392 . . . . 0.0 107.24 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 96.8 p -153.4 161.67 42.06 Favored 'General case' 0 CA--C 1.497 -1.087 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 63.0 m -131.62 154.74 48.59 Favored 'General case' 0 CA--C 1.496 -1.106 0 N-CA-C 107.208 -1.404 . . . . 0.0 107.208 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 20.6 tt -126.61 140.98 47.33 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.998 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.434 ' HA ' ' HA2' ' A' ' 153' ' ' GLY . 51.0 m -127.58 142.42 51.37 Favored 'General case' 0 CA--C 1.497 -1.095 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 85.6 mt -123.61 129.99 74.3 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.061 0 N-CA-C 106.644 -1.613 . . . . 0.0 106.644 -179.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -146.72 177.95 24.7 Favored Glycine 0 C--N 1.35 1.322 0 N-CA-C 107.905 -2.078 . . . . 0.0 107.905 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -126.31 147.29 49.75 Favored 'General case' 0 CA--C 1.495 -1.168 0 N-CA-C 106.844 -1.539 . . . . 0.0 106.844 -179.759 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -100.99 129.04 46.76 Favored 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 -179.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 83.5 mm-40 -129.62 149.79 51.23 Favored 'General case' 0 CA--C 1.496 -1.122 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 35.9 t -145.94 115.71 7.28 Favored 'General case' 0 CA--C 1.498 -1.056 0 N-CA-C 106.41 -1.7 . . . . 0.0 106.41 179.311 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 73.1 ttt180 -160.91 142.58 12.1 Favored 'General case' 0 N--CA 1.436 -1.172 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 179.731 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 14.4 p -136.61 143.32 35.7 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.0 0 N-CA-C 106.812 -1.551 . . . . 0.0 106.812 -179.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -90.91 120.48 31.96 Favored 'General case' 0 N--CA 1.439 -1.013 0 N-CA-C 107.252 -1.388 . . . . 0.0 107.252 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -159.72 -55.7 0.06 Allowed 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -133.06 105.55 7.12 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 179.726 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -87.5 67.84 3.21 Favored Glycine 0 C--N 1.352 1.433 0 N-CA-C 108.035 -2.026 . . . . 0.0 108.035 -179.541 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 35.2 t80 -158.05 -64.71 0.09 Allowed 'General case' 0 N--CA 1.438 -1.039 0 N-CA-C 106.432 -1.692 . . . . 0.0 106.432 179.688 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 62.4 mtpt -67.26 -38.7 85.54 Favored 'General case' 0 C--N 1.355 0.823 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.467 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 62.7 tp -102.39 127.09 49.55 Favored 'General case' 0 CA--C 1.499 -1.001 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -154.8 164.56 38.64 Favored 'General case' 0 N--CA 1.437 -1.109 0 N-CA-C 106.514 -1.661 . . . . 0.0 106.514 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 34.5 mmtp 68.91 -173.28 0.19 Allowed 'General case' 0 C--N 1.358 0.952 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 -179.724 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 5.9 m120 -134.74 150.33 73.17 Favored Pre-proline 0 N--CA 1.441 -0.9 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 -179.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -80.31 161.01 22.96 Favored 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.31 2.007 . . . . 0.0 112.406 179.026 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -99.99 125.84 46.08 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 179.592 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -148.9 148.15 19.29 Favored Glycine 0 CA--C 1.492 -1.399 0 N-CA-C 108.085 -2.006 . . . . 0.0 108.085 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 93.6 m-85 -131.24 147.48 52.6 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 24.4 t-20 -142.73 120.69 12.05 Favored 'General case' 0 N--CA 1.438 -1.05 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -179.823 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 89.8 mt -110.62 135.46 51.21 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 106.261 -1.755 . . . . 0.0 106.261 179.072 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 28.4 ttpp -130.41 133.54 46.43 Favored 'General case' 0 CA--C 1.498 -1.037 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 -179.31 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -117.62 139.35 51.11 Favored 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 107.067 -1.456 . . . . 0.0 107.067 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . 0.55 ' HA ' HG22 ' A' ' 44' ' ' ILE . 60.5 ttp180 -119.26 129.08 54.73 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 107.141 -1.429 . . . . 0.0 107.141 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -120.51 139.6 52.67 Favored 'General case' 0 N--CA 1.438 -1.035 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -107.78 126.51 52.72 Favored 'General case' 0 N--CA 1.438 -1.073 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 -179.521 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -129.42 160.86 31.81 Favored 'General case' 0 CA--C 1.495 -1.139 0 N-CA-C 106.26 -1.755 . . . . 0.0 106.26 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 52.6 t30 -80.11 99.57 7.8 Favored 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 106.877 -1.527 . . . . 0.0 106.877 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 9.5 t-20 -164.72 -176.28 4.19 Favored 'General case' 0 N--CA 1.434 -1.24 0 N-CA-C 106.207 -1.775 . . . . 0.0 106.207 -179.455 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -87.54 -2.0 58.32 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 -179.431 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 46.3 p90 -150.37 157.91 43.58 Favored 'General case' 0 CA--C 1.5 -0.975 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 179.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -97.55 176.05 30.88 Favored Glycine 0 C--N 1.353 1.485 0 N-CA-C 107.421 -2.272 . . . . 0.0 107.421 179.708 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 71.8 t -130.23 130.97 65.89 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.95 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 -179.79 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.55 HG22 ' HA ' ' A' ' 34' ' ' ARG . 36.8 pt -127.63 159.02 38.83 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.072 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 179.323 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -139.06 141.72 12.16 Favored Glycine 0 CA--C 1.49 -1.473 0 N-CA-C 105.943 -2.863 . . . . 0.0 105.943 178.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 61.4 m -132.55 145.65 51.3 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 -179.281 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.42 ' CD1' HG22 ' A' ' 73' ' ' VAL . 72.0 t80 -127.63 123.95 36.85 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 105.242 -2.133 . . . . 0.0 105.242 179.448 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -119.87 140.28 51.08 Favored 'General case' 0 CA--C 1.499 -1.002 0 CA-C-O 121.588 0.708 . . . . 0.0 109.209 -177.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 67.0 mt-30 -128.75 133.13 48.01 Favored 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 105.999 -1.852 . . . . 0.0 105.999 178.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 85.3 m -133.2 131.12 40.0 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 179.578 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 -140.28 133.22 29.28 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 107.008 -1.478 . . . . 0.0 107.008 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 44.3 ttm180 -117.53 124.02 47.69 Favored 'General case' 0 CA--C 1.497 -1.069 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 179.719 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -129.24 134.53 8.01 Favored Glycine 0 CA--C 1.492 -1.383 0 N-CA-C 107.142 -2.383 . . . . 0.0 107.142 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 87.3 t80 -147.57 123.55 10.7 Favored 'General case' 0 N--CA 1.436 -1.148 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -149.21 105.35 3.49 Favored 'General case' 0 N--CA 1.436 -1.145 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 179.426 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -142.87 149.0 37.95 Favored 'General case' 0 CA--C 1.495 -1.159 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 44.7 t -107.74 109.4 20.97 Favored 'General case' 0 CA--C 1.496 -1.112 0 N-CA-C 106.17 -1.789 . . . . 0.0 106.17 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 31.5 m -135.03 156.85 40.25 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.017 0 N-CA-C 107.639 -1.245 . . . . 0.0 107.639 -179.434 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -110.01 20.29 18.1 Favored 'General case' 0 CA--C 1.502 -0.879 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 179.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -172.23 -159.75 19.31 Favored Glycine 0 CA--C 1.493 -1.341 0 N-CA-C 107.429 -2.268 . . . . 0.0 107.429 -179.322 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 92.2 m-85 70.79 -135.58 0.05 OUTLIER 'General case' 0 C--N 1.355 0.809 0 N-CA-C 107.859 -1.163 . . . . 0.0 107.859 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 29.6 tptp -149.71 137.01 19.84 Favored 'General case' 0 N--CA 1.436 -1.13 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 -179.634 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 7.9 mp -88.04 145.22 26.09 Favored 'General case' 0 CA--C 1.5 -0.96 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 179.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 83.8 mt -104.8 124.63 59.55 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.986 0 N-CA-C 107.211 -1.403 . . . . 0.0 107.211 -179.359 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -70.74 144.85 50.79 Favored 'General case' 0 CA--C 1.504 -0.801 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 179.742 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -173.69 -140.54 3.24 Favored Glycine 0 CA--C 1.492 -1.368 0 N-CA-C 107.147 -2.381 . . . . 0.0 107.147 -179.425 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 65.47 50.59 1.66 Allowed 'General case' 0 C--N 1.355 0.831 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 52.9 p90 -145.52 160.22 41.94 Favored 'General case' 0 CA--C 1.499 -1.001 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 179.19 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -123.27 143.9 49.77 Favored 'General case' 0 CA--C 1.498 -1.048 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 -179.525 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -135.93 132.01 35.9 Favored 'General case' 0 N--CA 1.438 -1.028 0 N-CA-C 106.603 -1.628 . . . . 0.0 106.603 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -127.48 145.79 50.72 Favored 'General case' 0 CA--C 1.496 -1.128 0 N-CA-C 107.289 -1.375 . . . . 0.0 107.289 -179.576 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 39.3 t -150.59 144.14 25.08 Favored 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.42 HG22 ' CD1' ' A' ' 47' ' ' PHE . 57.7 t -128.03 135.94 61.54 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.168 0 N-CA-C 105.802 -1.925 . . . . 0.0 105.802 179.752 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 67.6 p -137.85 159.09 42.93 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -157.97 160.44 37.52 Favored 'General case' 0 CA--C 1.494 -1.185 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 179.544 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 178.82 176.91 47.05 Favored Glycine 0 N--CA 1.436 -1.363 0 N-CA-C 108.392 -1.883 . . . . 0.0 108.392 179.509 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -83.01 163.45 15.59 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.818 2.345 . . . . 0.0 113.548 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.472 ' CG2' HG23 ' A' ' 44' ' ' ILE . 67.1 t -113.69 124.62 70.51 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.092 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 178.775 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 89.8 t80 -107.55 117.52 34.31 Favored 'General case' 0 CA--C 1.5 -0.963 0 N-CA-C 107.443 -1.317 . . . . 0.0 107.443 -179.287 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 82.2 mtp180 -112.84 137.45 51.17 Favored 'General case' 0 CA--C 1.497 -1.058 0 N-CA-C 106.503 -1.665 . . . . 0.0 106.503 179.579 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 97.2 mt -79.79 -64.59 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.502 -0.89 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 179.452 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 66.9 t30 179.64 94.73 0.02 OUTLIER 'General case' 0 CA--C 1.502 -0.885 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 178.204 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 77.6 mm-40 40.85 46.03 2.26 Favored 'General case' 0 C--N 1.359 1.005 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.122 178.252 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 51.5 t80 -141.59 -43.35 0.36 Allowed 'General case' 0 CA--C 1.501 -0.916 0 C-N-CA 118.985 -1.086 . . . . 0.0 109.023 -179.373 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 14.9 p -159.98 147.47 6.44 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.053 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 -179.259 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 52.0 m -119.33 137.37 53.75 Favored 'General case' 0 CA--C 1.496 -1.101 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 179.214 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 90.2 mt -115.35 142.6 46.46 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 106.69 -1.596 . . . . 0.0 106.69 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 24.2 m-85 -118.29 142.46 47.48 Favored 'General case' 0 CA--C 1.496 -1.134 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -116.25 133.1 10.57 Favored Glycine 0 CA--C 1.493 -1.342 0 N-CA-C 105.314 -3.114 . . . . 0.0 105.314 177.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 90.3 mt -122.65 134.88 54.48 Favored 'General case' 0 CA--C 1.497 -1.075 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 -178.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -153.43 148.39 26.62 Favored 'General case' 0 N--CA 1.437 -1.119 0 N-CA-C 105.92 -1.882 . . . . 0.0 105.92 178.375 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 171.16 -148.69 11.41 Favored Glycine 0 CA--C 1.492 -1.363 0 N-CA-C 108.04 -2.024 . . . . 0.0 108.04 -179.569 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -144.66 162.8 35.77 Favored 'General case' 0 N--CA 1.438 -1.036 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 -179.005 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -141.43 162.64 26.89 Favored Glycine 0 CA--C 1.493 -1.322 0 N-CA-C 108.02 -2.032 . . . . 0.0 108.02 -179.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 32.0 p80 -151.81 159.94 43.73 Favored 'General case' 0 N--CA 1.436 -1.129 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -141.07 160.38 26.73 Favored Glycine 0 CA--C 1.491 -1.452 0 N-CA-C 107.366 -2.294 . . . . 0.0 107.366 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 63.2 mtpt -87.89 64.48 7.9 Favored 'General case' 0 N--CA 1.441 -0.893 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 -179.669 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -65.04 -40.4 94.74 Favored 'General case' 0 N--CA 1.443 -0.82 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 15.0 ptmm? -157.41 167.55 29.93 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 -179.741 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -106.65 143.44 34.74 Favored 'General case' 0 CA--C 1.498 -1.019 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 96.1 p -155.37 160.71 40.91 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 179.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 99.1 p -157.12 160.67 39.05 Favored 'General case' 0 CA--C 1.497 -1.094 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 44.6 pt -132.21 154.89 40.88 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.037 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 179.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 90.1 t80 -62.73 -47.99 81.17 Favored 'General case' 0 C--N 1.355 0.808 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -163.68 -48.37 0.02 OUTLIER Glycine 0 CA--C 1.493 -1.32 0 N-CA-C 107.402 -2.279 . . . . 0.0 107.402 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 25.8 pt20 -149.17 152.54 36.24 Favored 'General case' 0 N--CA 1.436 -1.129 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 179.439 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 35.3 t -159.05 148.33 18.69 Favored 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 106.565 -1.643 . . . . 0.0 106.565 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -94.48 120.14 34.26 Favored 'General case' 0 N--CA 1.439 -1.015 0 N-CA-C 106.93 -1.507 . . . . 0.0 106.93 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 4.9 t -164.45 -165.97 1.03 Allowed 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 -179.672 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -127.63 148.81 50.38 Favored 'General case' 0 CA--C 1.498 -1.051 0 N-CA-C 106.78 -1.563 . . . . 0.0 106.78 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 36.8 t -149.32 147.05 27.87 Favored 'General case' 0 N--CA 1.438 -1.053 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 -179.693 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 65.3 mttp -129.1 151.24 50.0 Favored 'General case' 0 CA--C 1.498 -1.04 0 N-CA-C 107.081 -1.452 . . . . 0.0 107.081 -179.629 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 68.0 p -124.18 157.9 33.65 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 36.1 t -94.1 130.72 40.17 Favored 'General case' 0 CA--C 1.499 -1.019 0 N-CA-C 107.356 -1.35 . . . . 0.0 107.356 -179.533 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 91.1 mt -95.89 143.71 26.85 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 179.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -113.78 137.64 51.37 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 -179.451 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -145.37 139.02 26.68 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 106.375 -1.713 . . . . 0.0 106.375 179.758 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -167.69 -176.32 38.25 Favored Glycine 0 N--CA 1.436 -1.354 0 N-CA-C 108.313 -1.915 . . . . 0.0 108.313 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -152.83 165.82 34.22 Favored 'General case' 0 N--CA 1.435 -1.203 0 N-CA-C 106.367 -1.716 . . . . 0.0 106.367 -179.753 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -155.79 175.03 33.73 Favored Glycine 0 CA--C 1.491 -1.458 0 N-CA-C 108.423 -1.871 . . . . 0.0 108.423 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.558 HD13 ' CE1' ' A' ' 123' ' ' PHE . 3.1 pp -141.7 159.42 42.26 Favored 'General case' 0 CA--C 1.497 -1.068 0 N-CA-C 106.941 -1.504 . . . . 0.0 106.941 -179.698 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 3.6 tm0? -147.41 134.55 20.46 Favored 'General case' 0 N--CA 1.437 -1.092 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 -179.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.558 ' CE1' HD13 ' A' ' 121' ' ' LEU . 97.4 m-85 -124.45 146.88 48.67 Favored 'General case' 0 CA--C 1.499 -1.006 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 179.479 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -130.01 76.6 77.87 Favored Pre-proline 0 N--CA 1.442 -0.832 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -72.06 -32.59 10.72 Favored 'Trans proline' 0 CA--C 1.498 -1.3 0 C-N-CA 121.706 1.604 . . . . 0.0 112.524 179.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 79.4 m80 -139.75 151.34 65.7 Favored Pre-proline 0 N--CA 1.436 -1.147 0 N-CA-C 106.194 -1.78 . . . . 0.0 106.194 179.576 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -75.82 -9.21 19.57 Favored 'Trans proline' 0 C--N 1.311 -1.399 0 C-N-CA 122.004 1.802 . . . . 0.0 112.762 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 27.7 m120 -63.68 -39.66 94.87 Favored 'General case' 0 N--CA 1.443 -0.782 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.197 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 55.1 p90 -154.01 160.86 42.21 Favored 'General case' 0 CA--C 1.5 -0.978 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 74.2 t -121.48 131.4 73.15 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.981 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 179.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 19.5 tt -99.31 133.45 42.0 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.843 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 -179.456 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 50.2 m-20 -127.61 138.85 52.97 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 -179.404 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -140.1 129.91 24.57 Favored 'General case' 0 CA--C 1.495 -1.137 0 N-CA-C 105.851 -1.907 . . . . 0.0 105.851 178.586 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 53.5 m -146.53 163.44 35.73 Favored 'General case' 0 CA--C 1.495 -1.139 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 -179.365 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -143.41 148.9 36.88 Favored 'General case' 0 N--CA 1.438 -1.048 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 178.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 62.1 mt-10 -138.22 149.51 45.85 Favored 'General case' 0 CA--C 1.498 -1.045 0 N-CA-C 107.964 -1.125 . . . . 0.0 107.964 -179.675 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -127.58 143.79 51.14 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 178.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 67.2 m -127.43 141.17 51.75 Favored 'General case' 0 CA--C 1.495 -1.158 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 179.465 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 40.2 ttpt -104.43 120.85 42.16 Favored 'General case' 0 N--CA 1.438 -1.026 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 -179.502 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 87.4 mt -120.76 158.34 27.74 Favored 'General case' 0 CA--C 1.496 -1.1 0 N-CA-C 105.884 -1.895 . . . . 0.0 105.884 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 44.5 p-10 -86.47 4.15 40.96 Favored 'General case' 0 N--CA 1.442 -0.87 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 -179.379 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -103.68 -66.25 0.96 Allowed 'General case' 0 N--CA 1.441 -0.885 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 179.826 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 34.8 m -139.76 161.15 26.96 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.985 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 -179.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 23.4 tptm -82.75 129.61 35.0 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 106.597 -1.631 . . . . 0.0 106.597 179.275 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 94.1 t -119.66 127.14 75.86 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.949 0 N-CA-C 108.42 -0.955 . . . . 0.0 108.42 -178.6 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -127.27 140.22 11.72 Favored Glycine 0 CA--C 1.492 -1.403 0 N-CA-C 105.879 -2.889 . . . . 0.0 105.879 178.66 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 82.8 p -129.9 151.13 50.8 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -179.166 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 29.1 m-90 -118.71 139.66 51.19 Favored 'General case' 0 CA--C 1.497 -1.086 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 178.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 1.8 tmt? -119.94 124.13 45.23 Favored 'General case' 0 CA--C 1.497 -1.059 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -178.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 89.9 mt -124.38 140.13 53.25 Favored 'General case' 0 CA--C 1.497 -1.096 0 N-CA-C 105.571 -2.011 . . . . 0.0 105.571 178.429 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -175.47 -170.11 37.98 Favored Glycine 0 CA--C 1.491 -1.452 0 N-CA-C 108.489 -1.844 . . . . 0.0 108.489 -179.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -135.15 154.06 51.76 Favored 'General case' 0 N--CA 1.437 -1.106 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 -179.339 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . 0.434 ' HA2' ' HA ' ' A' ' 7' ' ' SER . . . -109.97 146.41 17.13 Favored Glycine 0 CA--C 1.491 -1.45 0 N-CA-C 108.114 -1.994 . . . . 0.0 108.114 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 92.5 t80 -115.11 134.43 55.17 Favored 'General case' 0 N--CA 1.439 -1.011 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 179.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 17.6 ptm180 -143.38 160.65 40.14 Favored 'General case' 0 N--CA 1.435 -1.201 0 N-CA-C 106.788 -1.56 . . . . 0.0 106.788 -179.675 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 35.0 t80 . . . . . 0 C--O 1.262 1.714 0 CA-C-O 117.638 -1.172 . . . . 0.0 108.089 -179.99 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 120.826 0.346 . . . . 0.0 110.702 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -178.67 -179.97 48.61 Favored Glycine 0 CA--C 1.491 -1.44 0 N-CA-C 107.106 -2.398 . . . . 0.0 107.106 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -136.7 136.25 38.88 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 106.892 -1.521 . . . . 0.0 106.892 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 63.3 m -122.22 142.24 50.64 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 107.035 -1.468 . . . . 0.0 107.035 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 68.0 m -127.25 151.01 49.28 Favored 'General case' 0 CA--C 1.497 -1.074 0 N-CA-C 107.119 -1.438 . . . . 0.0 107.119 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 85.0 mt -115.53 129.46 71.78 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 -179.368 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.474 ' HB2' ' HB3' ' A' ' 32' ' ' LYS . 69.0 m -124.09 144.72 49.71 Favored 'General case' 0 CA--C 1.499 -0.996 0 N-CA-C 107.716 -1.216 . . . . 0.0 107.716 -179.788 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 85.5 mt -122.34 131.05 73.99 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.053 0 N-CA-C 106.398 -1.704 . . . . 0.0 106.398 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -137.85 164.12 25.52 Favored Glycine 0 C--N 1.354 1.539 0 N-CA-C 108.237 -1.945 . . . . 0.0 108.237 -179.314 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -127.66 147.24 50.37 Favored 'General case' 0 CA--C 1.499 -1.014 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.94 138.85 41.26 Favored 'General case' 0 CA--C 1.5 -0.975 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 97.0 mm-40 -111.51 122.4 47.73 Favored 'General case' 0 N--CA 1.438 -1.064 0 N-CA-C 107.173 -1.418 . . . . 0.0 107.173 179.653 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 73.4 m -162.03 -177.98 6.13 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 105.708 -1.96 . . . . 0.0 105.708 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 17.6 ptm180 -140.45 144.91 36.35 Favored 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 107.405 -1.331 . . . . 0.0 107.405 179.317 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 27.1 m -140.06 158.93 26.32 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.989 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -145.52 129.38 17.31 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 179.1 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -136.14 147.86 47.93 Favored 'General case' 0 CA--C 1.498 -1.019 0 N-CA-C 107.051 -1.462 . . . . 0.0 107.051 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 63.4 t0 -90.56 100.09 13.0 Favored 'General case' 0 N--CA 1.44 -0.937 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 167.98 -169.28 41.28 Favored Glycine 0 CA--C 1.491 -1.431 0 N-CA-C 107.001 -2.44 . . . . 0.0 107.001 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -90.31 70.83 7.13 Favored 'General case' 0 CA--C 1.501 -0.924 0 N-CA-C 107.011 -1.478 . . . . 0.0 107.011 179.713 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -135.44 158.04 45.37 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 106.69 -1.596 . . . . 0.0 106.69 -179.628 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 92.9 mt -73.41 135.91 44.25 Favored 'General case' 0 N--CA 1.441 -0.907 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 -179.517 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -114.61 149.87 35.93 Favored 'General case' 0 CA--C 1.499 -1.007 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 97.7 mttt 62.77 34.15 14.82 Favored 'General case' 0 C--N 1.356 0.879 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 45.3 m-80 -138.56 113.16 8.57 Favored Pre-proline 0 N--CA 1.441 -0.907 0 N-CA-C 106.658 -1.608 . . . . 0.0 106.658 179.115 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -75.73 153.08 38.13 Favored 'Trans proline' 0 CA--C 1.497 -1.357 0 C-N-CA 121.901 1.734 . . . . 0.0 113.113 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -129.66 109.27 10.85 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 179.463 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -170.9 167.87 41.02 Favored Glycine 0 CA--C 1.492 -1.389 0 N-CA-C 107.371 -2.291 . . . . 0.0 107.371 179.709 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 72.5 t80 -146.78 131.68 18.1 Favored 'General case' 0 CA--C 1.499 -1.007 0 N-CA-C 106.037 -1.838 . . . . 0.0 106.037 -179.806 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 80.3 m-20 -126.89 144.13 51.08 Favored 'General case' 0 CA--C 1.501 -0.933 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 -178.649 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 83.2 mt -119.77 139.12 52.8 Favored 'General case' 0 CA--C 1.495 -1.155 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 178.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.474 ' HB3' ' HB2' ' A' ' 7' ' ' SER . 86.6 tttt -137.22 133.84 35.57 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -124.36 139.13 54.19 Favored 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 106.671 -1.603 . . . . 0.0 106.671 179.529 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . 0.581 ' HA ' HG22 ' A' ' 44' ' ' ILE . 7.9 tmm_? -120.18 129.57 54.18 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 -179.371 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -115.19 126.87 55.09 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 106.803 -1.554 . . . . 0.0 106.803 179.624 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -116.56 130.6 56.84 Favored 'General case' 0 CA--C 1.497 -1.065 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 -179.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -119.94 176.45 5.41 Favored 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 67.0 t30 -79.89 78.25 6.5 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 -166.31 172.01 11.51 Favored 'General case' 0 N--CA 1.434 -1.226 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -89.71 -3.24 58.3 Favored 'General case' 0 N--CA 1.443 -0.793 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 54.3 m0 -113.73 140.14 48.51 Favored 'General case' 0 CA--C 1.499 -0.993 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 -179.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -129.17 178.46 17.31 Favored Glycine 0 C--N 1.349 1.262 0 N-CA-C 107.016 -2.434 . . . . 0.0 107.016 179.696 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.8 p -142.66 142.72 26.42 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.9 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.581 HG22 ' HA ' ' A' ' 34' ' ' ARG . 32.2 pt -129.88 157.88 42.44 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.052 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -137.62 139.87 10.81 Favored Glycine 0 CA--C 1.491 -1.454 0 N-CA-C 105.828 -2.909 . . . . 0.0 105.828 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 56.2 m -138.45 149.36 45.38 Favored 'General case' 0 CA--C 1.496 -1.107 0 C-N-CA 119.674 -0.81 . . . . 0.0 108.9 -179.242 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -125.93 139.96 53.03 Favored 'General case' 0 CA--C 1.496 -1.122 0 N-CA-C 105.06 -2.2 . . . . 0.0 105.06 178.746 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -134.18 138.98 45.53 Favored 'General case' 0 CA--C 1.498 -1.043 0 C-N-CA 119.575 -0.85 . . . . 0.0 108.902 -178.624 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 64.7 tt0 -137.83 123.54 19.87 Favored 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 106.109 -1.812 . . . . 0.0 106.109 178.561 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 11.4 t -147.53 174.66 11.51 Favored 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 107.137 -1.431 . . . . 0.0 107.137 -179.67 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 83.5 mtp180 -126.74 145.66 50.52 Favored 'General case' 0 CA--C 1.495 -1.155 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 179.594 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 31.8 tpt180 -97.26 121.46 39.18 Favored 'General case' 0 CA--C 1.499 -1.0 0 N-CA-C 106.746 -1.576 . . . . 0.0 106.746 -179.726 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -105.71 -139.43 9.68 Favored Glycine 0 C--N 1.349 1.276 0 N-CA-C 107.934 -2.066 . . . . 0.0 107.934 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -125.65 149.32 48.53 Favored 'General case' 0 N--CA 1.438 -1.065 0 N-CA-C 106.845 -1.539 . . . . 0.0 106.845 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.415 ' H ' HD12 ' A' ' 64' ' ' ILE . 97.8 mt-10 -129.4 148.4 51.31 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -136.33 128.97 30.66 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 106.77 -1.567 . . . . 0.0 106.77 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 11.5 p -157.51 -48.72 0.07 Allowed 'General case' 0 CA--C 1.498 -1.052 0 N-CA-C 107.362 -1.347 . . . . 0.0 107.362 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 73.4 t -119.68 128.84 75.9 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.053 0 N-CA-C 106.63 -1.619 . . . . 0.0 106.63 179.683 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -83.75 82.03 8.5 Favored 'General case' 0 N--CA 1.441 -0.898 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 -179.752 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -92.59 1.8 72.59 Favored Glycine 0 C--N 1.353 1.494 0 N-CA-C 108.332 -1.907 . . . . 0.0 108.332 179.694 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 64.93 38.71 6.26 Favored 'General case' 0 C--N 1.356 0.856 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -127.98 147.06 50.48 Favored 'General case' 0 CA--C 1.497 -1.07 0 N-CA-C 106.677 -1.601 . . . . 0.0 106.677 179.6 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 90.3 mt -112.46 134.38 54.03 Favored 'General case' 0 CA--C 1.497 -1.085 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.415 HD12 ' H ' ' A' ' 55' ' ' GLU . 96.8 mt -65.53 -42.41 93.03 Favored 'Isoleucine or valine' 0 C--N 1.354 0.769 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.66 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 32.9 t0 64.86 53.86 1.4 Allowed 'General case' 0 C--N 1.359 0.988 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -93.66 -117.01 2.67 Favored Glycine 0 C--N 1.352 1.456 0 N-CA-C 107.661 -2.176 . . . . 0.0 107.661 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 34.8 t0 66.75 52.05 1.0 Allowed 'General case' 0 C--N 1.355 0.807 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 53.6 p90 -148.42 159.89 43.58 Favored 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 107.307 -1.368 . . . . 0.0 107.307 179.364 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 65.0 mttp -91.59 137.8 32.07 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 -179.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 86.3 t80 -117.22 125.79 51.72 Favored 'General case' 0 N--CA 1.44 -0.952 0 N-CA-C 107.297 -1.372 . . . . 0.0 107.297 -178.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -116.47 140.64 49.15 Favored 'General case' 0 CA--C 1.494 -1.189 0 N-CA-C 106.148 -1.797 . . . . 0.0 106.148 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 34.8 t -150.12 145.98 26.64 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 -179.554 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 35.3 m -128.79 149.2 33.32 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.152 0 N-CA-C 105.678 -1.971 . . . . 0.0 105.678 179.025 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 12.9 t -156.75 154.58 30.2 Favored 'General case' 0 N--CA 1.437 -1.121 0 C-N-CA 119.205 -0.998 . . . . 0.0 108.37 -178.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -157.04 159.39 37.92 Favored 'General case' 0 N--CA 1.436 -1.171 0 N-CA-C 105.841 -1.911 . . . . 0.0 105.841 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -174.68 170.2 43.28 Favored Glycine 0 N--CA 1.437 -1.241 0 N-CA-C 108.365 -1.894 . . . . 0.0 108.365 179.714 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo -80.17 155.0 22.35 Favored 'Trans proline' 0 C--N 1.312 -1.371 0 C-N-CA 122.596 2.197 . . . . 0.0 113.255 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.491 HG21 HG23 ' A' ' 44' ' ' ILE . 65.9 t -123.98 128.71 74.29 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.062 0 N-CA-C 106.695 -1.594 . . . . 0.0 106.695 179.511 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -113.18 124.91 53.65 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 107.06 -1.459 . . . . 0.0 107.06 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 45.1 ttm180 -111.73 132.73 54.43 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 49.7 mm -74.58 -64.68 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.937 0 N-CA-C 107.033 -1.469 . . . . 0.0 107.033 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 66.4 t30 -179.24 94.54 0.03 OUTLIER 'General case' 0 CA--C 1.502 -0.892 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 178.127 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 58.7 mt-10 39.63 45.88 1.45 Allowed 'General case' 0 C--N 1.359 0.996 0 C-N-CA 122.972 0.509 . . . . 0.0 111.647 177.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 85.3 t80 -141.46 -43.52 0.36 Allowed 'General case' 0 CA--C 1.501 -0.905 0 C-N-CA 118.942 -1.103 . . . . 0.0 108.785 -179.737 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 9.9 p -162.69 150.34 3.77 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.055 0 N-CA-C 107.127 -1.434 . . . . 0.0 107.127 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 70.1 m -123.38 136.98 54.91 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 179.199 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 65.4 tp -117.38 130.76 56.7 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 106.429 -1.693 . . . . 0.0 106.429 -179.724 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.426 ' HB3' HG22 ' A' ' 78' ' ' VAL . 48.2 p90 -141.67 158.05 44.31 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 -179.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -124.46 154.35 17.92 Favored Glycine 0 CA--C 1.49 -1.472 0 N-CA-C 106.968 -2.453 . . . . 0.0 106.968 -179.457 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 93.6 mt -123.25 139.64 53.84 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 -179.12 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -148.84 146.57 28.03 Favored 'General case' 0 N--CA 1.437 -1.083 0 N-CA-C 105.962 -1.866 . . . . 0.0 105.962 178.494 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 175.01 -155.53 20.79 Favored Glycine 0 CA--C 1.492 -1.352 0 N-CA-C 108.217 -1.953 . . . . 0.0 108.217 -179.468 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -148.31 159.49 43.94 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -144.9 167.48 27.2 Favored Glycine 0 CA--C 1.493 -1.338 0 N-CA-C 107.901 -2.08 . . . . 0.0 107.901 -179.291 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 31.3 p80 -149.61 159.64 44.16 Favored 'General case' 0 N--CA 1.439 -1.005 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -124.79 138.06 10.87 Favored Glycine 0 C--N 1.351 1.368 0 N-CA-C 108.059 -2.016 . . . . 0.0 108.059 -179.456 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 75.2 mmtt -133.17 142.12 48.47 Favored 'General case' 0 CA--C 1.497 -1.06 0 N-CA-C 107.064 -1.458 . . . . 0.0 107.064 179.73 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -105.74 -57.23 2.07 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 179.573 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 38.7 mtmm -135.4 150.15 49.82 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 106.679 -1.6 . . . . 0.0 106.679 179.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -107.02 126.47 52.37 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 75.1 m -143.11 36.29 1.37 Allowed 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 -179.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 80.9 p -96.97 1.84 50.81 Favored 'General case' 0 CA--C 1.504 -0.818 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 46.1 pt -83.35 -15.09 11.63 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.805 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 -179.192 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 -69.97 -39.0 76.25 Favored 'General case' 0 CA--C 1.503 -0.853 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 104.09 110.32 3.47 Favored Glycine 0 C--N 1.351 1.388 0 N-CA-C 107.456 -2.258 . . . . 0.0 107.456 179.773 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 13.5 pm0 -153.82 154.83 34.69 Favored 'General case' 0 N--CA 1.436 -1.157 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 85.5 p -94.06 -16.52 23.75 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 -179.088 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -110.33 118.14 35.52 Favored 'General case' 0 CA--C 1.497 -1.075 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 -179.647 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 70.4 m -130.78 150.04 52.14 Favored 'General case' 0 CA--C 1.495 -1.156 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 30.8 mmm180 -118.95 139.51 51.54 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 106.667 -1.605 . . . . 0.0 106.667 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 35.5 t -154.19 146.28 23.68 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -128.51 145.56 51.08 Favored 'General case' 0 CA--C 1.497 -1.074 0 N-CA-C 106.765 -1.569 . . . . 0.0 106.765 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 71.9 p -128.93 156.09 44.27 Favored 'General case' 0 CA--C 1.497 -1.091 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 54.5 m -129.58 151.11 50.55 Favored 'General case' 0 CA--C 1.496 -1.133 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 89.5 mt -92.86 141.37 28.5 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -119.25 129.35 54.88 Favored 'General case' 0 N--CA 1.438 -1.059 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -178.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -135.49 150.04 49.68 Favored 'General case' 0 CA--C 1.494 -1.175 0 N-CA-C 105.985 -1.857 . . . . 0.0 105.985 178.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -173.95 -179.31 44.51 Favored Glycine 0 CA--C 1.491 -1.432 0 N-CA-C 108.796 -1.722 . . . . 0.0 108.796 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -157.27 163.36 38.82 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 105.748 -1.945 . . . . 0.0 105.748 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -161.05 167.37 36.0 Favored Glycine 0 N--CA 1.436 -1.365 0 N-CA-C 108.618 -1.793 . . . . 0.0 108.618 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 87.9 mt -123.09 147.41 46.78 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 -179.714 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 6.5 mt-30 -121.86 127.16 50.19 Favored 'General case' 0 CA--C 1.498 -1.052 0 N-CA-C 106.96 -1.496 . . . . 0.0 106.96 179.168 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 83.9 t80 -133.71 135.7 44.18 Favored 'General case' 0 N--CA 1.439 -1.013 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . 0.412 ' OD1' HG13 ' A' ' 130' ' ' VAL . 61.8 m-20 -116.0 96.92 48.3 Favored Pre-proline 0 N--CA 1.442 -0.838 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 -179.111 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -71.45 -24.06 22.93 Favored 'Trans proline' 0 CA--C 1.496 -1.393 0 C-N-CA 121.746 1.63 . . . . 0.0 112.058 178.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -135.45 153.3 77.7 Favored Pre-proline 0 N--CA 1.434 -1.245 0 N-CA-C 105.73 -1.952 . . . . 0.0 105.73 179.687 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -67.0 -19.7 51.57 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 121.81 1.673 . . . . 0.0 113.566 -179.57 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -112.52 19.0 17.94 Favored 'General case' 0 N--CA 1.443 -0.783 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 -179.146 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 47.8 t80 -143.85 127.34 16.92 Favored 'General case' 0 CA--C 1.503 -0.864 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 -179.658 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . 0.412 HG13 ' OD1' ' A' ' 124' ' ' ASN . 96.4 t -120.79 129.65 75.43 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.93 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -179.353 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 89.4 mt -100.14 124.01 53.35 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.04 0 N-CA-C 106.719 -1.585 . . . . 0.0 106.719 179.293 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 51.1 m-20 -114.63 123.6 49.72 Favored 'General case' 0 N--CA 1.439 -0.998 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 -179.549 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -129.07 126.42 39.36 Favored 'General case' 0 CA--C 1.496 -1.115 0 N-CA-C 105.754 -1.943 . . . . 0.0 105.754 178.425 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 63.7 m -139.81 150.66 44.98 Favored 'General case' 0 CA--C 1.493 -1.237 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 -179.028 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 90.0 t80 -124.24 126.6 46.36 Favored 'General case' 0 CA--C 1.496 -1.106 0 N-CA-C 105.555 -2.017 . . . . 0.0 105.555 178.158 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -118.51 130.26 55.82 Favored 'General case' 0 CA--C 1.497 -1.096 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 -179.056 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 82.8 t80 -118.49 126.11 51.32 Favored 'General case' 0 N--CA 1.436 -1.173 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 42.7 t -91.99 121.61 33.72 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 105.82 -1.919 . . . . 0.0 105.82 179.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 60.1 tptt -108.77 119.96 41.07 Favored 'General case' 0 N--CA 1.438 -1.027 0 CA-C-O 121.74 0.781 . . . . 0.0 109.021 -178.156 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 43.2 tp -158.08 144.47 17.49 Favored 'General case' 0 N--CA 1.431 -1.391 0 N-CA-C 104.526 -2.398 . . . . 0.0 104.526 177.754 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -62.44 -38.44 89.76 Favored 'General case' 0 N--CA 1.446 -0.656 0 O-C-N 121.958 -0.464 . . . . 0.0 110.262 -178.36 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -89.52 -28.4 19.65 Favored 'General case' 0 N--CA 1.444 -0.767 0 C-N-CA 120.255 -0.578 . . . . 0.0 111.129 -177.399 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 67.6 t -126.28 125.59 67.88 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.789 0 C-N-CA 119.547 -0.861 . . . . 0.0 109.637 -177.461 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 65.4 mttp -125.6 111.39 14.94 Favored 'General case' 0 CA--C 1.5 -0.966 0 N-CA-C 105.845 -1.909 . . . . 0.0 105.845 178.367 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 86.4 t -133.76 131.16 56.53 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.98 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -178.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -109.06 130.21 9.9 Favored Glycine 0 C--N 1.353 1.493 0 N-CA-C 105.809 -2.916 . . . . 0.0 105.809 178.086 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 89.2 m -130.2 134.89 47.6 Favored 'General case' 0 CA--C 1.498 -1.053 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 -178.794 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 25.4 t90 -107.63 137.36 45.8 Favored 'General case' 0 CA--C 1.5 -0.967 0 N-CA-C 105.665 -1.976 . . . . 0.0 105.665 179.21 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 2.7 mpp? -118.22 131.66 56.36 Favored 'General case' 0 CA--C 1.496 -1.112 0 N-CA-C 108.026 -1.102 . . . . 0.0 108.026 -179.106 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 62.1 tp -128.18 130.62 48.33 Favored 'General case' 0 N--CA 1.437 -1.084 0 N-CA-C 105.833 -1.914 . . . . 0.0 105.833 179.299 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -159.72 -179.06 34.26 Favored Glycine 0 CA--C 1.492 -1.373 0 N-CA-C 108.426 -1.869 . . . . 0.0 108.426 -179.554 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -135.04 153.32 52.1 Favored 'General case' 0 N--CA 1.437 -1.111 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 -179.486 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -116.07 156.04 15.88 Favored Glycine 0 CA--C 1.49 -1.521 0 N-CA-C 108.154 -1.979 . . . . 0.0 108.154 -179.309 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 55.3 p90 -145.35 160.73 41.09 Favored 'General case' 0 N--CA 1.435 -1.194 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 34.5 ptt180 -151.86 159.07 43.98 Favored 'General case' 0 N--CA 1.436 -1.136 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 -179.503 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 72.0 m-85 . . . . . 0 C--O 1.262 1.749 0 CA-C-O 117.906 -1.045 . . . . 0.0 108.637 -179.869 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 . . . . . 0 N--CA 1.489 1.499 0 CA-C-O 120.944 0.402 . . . . 0.0 110.76 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 176.08 -170.55 43.47 Favored Glycine 0 CA--C 1.491 -1.422 0 N-CA-C 107.002 -2.439 . . . . 0.0 107.002 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 49.3 mp0 -120.51 143.24 48.66 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 106.729 -1.582 . . . . 0.0 106.729 179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 63.8 m -129.53 143.44 50.83 Favored 'General case' 0 CA--C 1.495 -1.172 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 51.6 m -132.96 144.51 50.17 Favored 'General case' 0 CA--C 1.496 -1.119 0 N-CA-C 106.559 -1.645 . . . . 0.0 106.559 179.404 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 50.4 mm -119.34 126.39 75.29 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.152 0 N-CA-C 106.648 -1.612 . . . . 0.0 106.648 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 64.4 m -122.58 142.03 51.06 Favored 'General case' 0 CA--C 1.495 -1.158 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 46.6 pt -133.12 155.86 41.45 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.148 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 179.593 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -166.36 176.45 41.59 Favored Glycine 0 CA--C 1.491 -1.419 0 N-CA-C 107.949 -2.06 . . . . 0.0 107.949 -179.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -104.05 144.96 30.85 Favored 'General case' 0 CA--C 1.496 -1.115 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 -179.421 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -109.42 135.17 50.9 Favored 'General case' 0 N--CA 1.437 -1.08 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 94.5 mm-40 -129.39 158.62 38.65 Favored 'General case' 0 CA--C 1.498 -1.028 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 6.1 t -125.61 -165.89 1.48 Allowed 'General case' 0 CA--C 1.501 -0.94 0 N-CA-C 106.884 -1.524 . . . . 0.0 106.884 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 85.4 mtp180 -74.02 140.81 45.69 Favored 'General case' 0 N--CA 1.441 -0.902 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 -179.285 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 72.6 t -125.09 129.1 73.34 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.028 0 N-CA-C 106.23 -1.767 . . . . 0.0 106.23 179.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 17.5 tptp -84.73 124.31 31.38 Favored 'General case' 0 N--CA 1.441 -0.911 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 -179.412 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -145.01 121.62 11.11 Favored 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 107.022 -1.473 . . . . 0.0 107.022 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 48.5 m-20 -144.58 81.82 1.67 Allowed 'General case' 0 CA--C 1.503 -0.861 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 79.61 22.84 63.58 Favored Glycine 0 C--N 1.352 1.472 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 178.724 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -126.01 154.1 43.44 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 107.19 -1.411 . . . . 0.0 107.19 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 59.7 mtmt -70.91 149.15 47.01 Favored 'General case' 0 CA--C 1.502 -0.898 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 58.1 tp -76.23 121.97 23.69 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -179.399 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 12.9 t0 -161.01 165.21 30.22 Favored 'General case' 0 N--CA 1.435 -1.222 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 99.5 mttt 60.82 49.63 5.94 Favored 'General case' 0 C--N 1.358 0.948 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 179.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 95.4 m-20 -72.02 149.15 92.18 Favored Pre-proline 0 N--CA 1.442 -0.844 0 N-CA-C 107.094 -1.446 . . . . 0.0 107.094 179.367 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -70.57 149.64 62.06 Favored 'Trans proline' 0 CA--C 1.497 -1.357 0 C-N-CA 121.792 1.661 . . . . 0.0 112.756 -179.753 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 2.0 mpp_? -101.26 125.57 47.9 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -156.88 158.83 29.12 Favored Glycine 0 CA--C 1.49 -1.482 0 N-CA-C 106.941 -2.464 . . . . 0.0 106.941 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -146.94 146.34 30.09 Favored 'General case' 0 N--CA 1.437 -1.108 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 -179.652 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 27.9 t-20 -126.87 129.91 49.15 Favored 'General case' 0 N--CA 1.44 -0.956 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 -179.092 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 87.6 mt -114.16 138.47 50.4 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 179.062 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 37.8 ttpt -133.98 131.19 38.67 Favored 'General case' 0 CA--C 1.498 -1.038 0 N-CA-C 107.294 -1.372 . . . . 0.0 107.294 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -111.59 128.85 56.17 Favored 'General case' 0 N--CA 1.437 -1.093 0 N-CA-C 106.263 -1.754 . . . . 0.0 106.263 179.574 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . 0.572 ' HA ' HG22 ' A' ' 44' ' ' ILE . 79.2 ttt-85 -119.14 127.55 53.44 Favored 'General case' 0 CA--C 1.494 -1.176 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 -179.498 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -124.73 131.81 53.43 Favored 'General case' 0 N--CA 1.435 -1.184 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -116.91 126.49 53.06 Favored 'General case' 0 N--CA 1.436 -1.139 0 N-CA-C 106.917 -1.512 . . . . 0.0 106.917 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 94.0 m-85 -122.95 176.25 6.12 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 106.279 -1.749 . . . . 0.0 106.279 -179.646 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 66.1 t30 -80.53 70.43 7.24 Favored 'General case' 0 N--CA 1.442 -0.86 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 -179.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 33.9 m120 -139.73 169.17 18.23 Favored 'General case' 0 N--CA 1.437 -1.107 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 179.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -85.71 -5.3 59.28 Favored 'General case' 0 N--CA 1.441 -0.892 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 -179.305 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 55.1 m95 -130.49 149.12 52.31 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 -179.51 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.04 159.84 17.11 Favored Glycine 0 C--N 1.354 1.533 0 N-CA-C 107.629 -2.189 . . . . 0.0 107.629 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 81.2 t -123.74 126.93 73.53 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.965 0 N-CA-C 107.051 -1.462 . . . . 0.0 107.051 -179.657 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.572 HG22 ' HA ' ' A' ' 34' ' ' ARG . 41.0 pt -129.71 162.69 36.83 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.974 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -142.61 152.73 24.06 Favored Glycine 0 CA--C 1.492 -1.347 0 N-CA-C 105.558 -3.017 . . . . 0.0 105.558 178.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 40.9 t -145.38 147.05 31.84 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 -179.019 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 93.2 t80 -127.87 129.54 47.08 Favored 'General case' 0 N--CA 1.439 -1.008 0 N-CA-C 106.09 -1.818 . . . . 0.0 106.09 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -124.59 137.49 54.38 Favored 'General case' 0 CA--C 1.499 -0.985 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 -179.617 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 63.0 tt0 -136.84 128.23 28.32 Favored 'General case' 0 CA--C 1.499 -1.015 0 N-CA-C 107.47 -1.307 . . . . 0.0 107.47 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 91.5 m -127.75 127.97 44.54 Favored 'General case' 0 CA--C 1.496 -1.099 0 N-CA-C 106.313 -1.736 . . . . 0.0 106.313 179.018 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 4.7 tmt_? -149.09 129.11 13.49 Favored 'General case' 0 CA--C 1.498 -1.035 0 N-CA-C 107.32 -1.363 . . . . 0.0 107.32 -179.559 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 4.0 tmt_? -106.13 -67.67 0.92 Allowed 'General case' 0 CA--C 1.502 -0.881 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 155.51 -167.96 33.12 Favored Glycine 0 CA--C 1.493 -1.33 0 N-CA-C 106.832 -2.507 . . . . 0.0 106.832 -179.779 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 88.6 t80 -140.14 115.42 9.87 Favored 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 179.744 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -140.49 140.98 35.42 Favored 'General case' 0 CA--C 1.501 -0.921 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 78.7 mm-40 -109.79 4.77 22.09 Favored 'General case' 0 CA--C 1.503 -0.864 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 179.691 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 70.6 m -120.51 131.73 54.85 Favored 'General case' 0 CA--C 1.496 -1.106 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 -179.708 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 67.2 t -128.69 125.92 64.25 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.014 0 N-CA-C 106.514 -1.662 . . . . 0.0 106.514 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 68.4 m-20 -88.51 -31.68 18.59 Favored 'General case' 0 CA--C 1.502 -0.886 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 179.88 176.0 47.01 Favored Glycine 0 CA--C 1.491 -1.434 0 N-CA-C 106.615 -2.594 . . . . 0.0 106.615 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 60.64 52.13 4.64 Favored 'General case' 0 C--N 1.356 0.851 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 39.8 ttpt -70.43 129.54 39.53 Favored 'General case' 0 N--CA 1.441 -0.909 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 -179.661 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 90.6 mt -116.56 157.78 24.73 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 45.7 pt -111.94 161.23 10.79 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.047 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 61.2 39.43 15.84 Favored 'General case' 0 C--N 1.358 0.938 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 -179.183 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -117.77 -175.99 17.09 Favored Glycine 0 C--N 1.352 1.431 0 N-CA-C 107.223 -2.351 . . . . 0.0 107.223 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 59.48 41.57 19.04 Favored 'General case' 0 C--N 1.357 0.906 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 -179.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 85.0 t80 -139.23 138.57 36.95 Favored 'General case' 0 N--CA 1.436 -1.142 0 N-CA-C 106.435 -1.691 . . . . 0.0 106.435 -179.677 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 18.6 ptpt -128.6 153.45 47.23 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 -179.648 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 49.6 p90 -157.97 160.29 37.38 Favored 'General case' 0 N--CA 1.437 -1.103 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 -179.489 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -127.93 140.18 52.15 Favored 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 105.991 -1.855 . . . . 0.0 105.991 179.83 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 58.6 m -139.28 140.37 37.61 Favored 'General case' 0 CA--C 1.497 -1.091 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 58.7 t -129.09 136.14 60.32 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.125 0 N-CA-C 105.545 -2.021 . . . . 0.0 105.545 179.01 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 80.4 p -139.85 160.37 40.05 Favored 'General case' 0 CA--C 1.499 -1.008 0 N-CA-C 108.747 -0.835 . . . . 0.0 108.747 -179.479 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -156.47 155.29 31.78 Favored 'General case' 0 CA--C 1.497 -1.075 0 N-CA-C 105.772 -1.936 . . . . 0.0 105.772 178.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -178.57 173.16 45.56 Favored Glycine 0 C--N 1.349 1.253 0 N-CA-C 108.711 -1.756 . . . . 0.0 108.711 179.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_endo -82.81 160.46 16.23 Favored 'Trans proline' 0 C--N 1.311 -1.437 0 C-N-CA 122.996 2.464 . . . . 0.0 113.369 179.735 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 66.7 t -115.0 125.86 72.43 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.958 0 N-CA-C 106.876 -1.528 . . . . 0.0 106.876 179.554 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 70.7 t80 -102.31 121.74 42.87 Favored 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 -179.753 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 93.2 mtm-85 -111.83 137.21 50.09 Favored 'General case' 0 CA--C 1.497 -1.085 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 83.7 mt -83.17 -64.03 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.833 0 N-CA-C 106.49 -1.67 . . . . 0.0 106.49 179.418 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.2 p30 179.93 93.61 0.02 OUTLIER 'General case' 0 C--N 1.355 0.82 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 177.51 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 69.4 tt0 36.67 48.46 0.64 Allowed 'General case' 0 C--N 1.362 1.137 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.213 178.397 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 63.9 t80 -141.97 -43.52 0.34 Allowed 'General case' 0 CA--C 1.499 -0.992 0 C-N-CA 119.27 -0.972 . . . . 0.0 108.57 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 11.0 p -161.65 151.08 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.144 0 N-CA-C 106.933 -1.506 . . . . 0.0 106.933 -179.675 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 67.6 m -124.92 140.94 52.46 Favored 'General case' 0 CA--C 1.498 -1.056 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 179.611 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 6.6 tt -129.72 134.92 47.91 Favored 'General case' 0 CA--C 1.494 -1.2 0 N-CA-C 105.801 -1.926 . . . . 0.0 105.801 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 26.9 p90 -134.56 157.45 46.52 Favored 'General case' 0 CA--C 1.494 -1.181 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 -179.403 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -115.07 150.08 18.77 Favored Glycine 0 CA--C 1.491 -1.417 0 N-CA-C 107.167 -2.373 . . . . 0.0 107.167 -179.423 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 88.1 mt -114.12 133.99 55.19 Favored 'General case' 0 CA--C 1.497 -1.058 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 63.1 tp -137.19 132.41 33.86 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 179.489 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -178.47 -152.98 10.81 Favored Glycine 0 CA--C 1.491 -1.423 0 N-CA-C 108.239 -1.944 . . . . 0.0 108.239 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -145.43 156.91 44.04 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 -179.297 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -142.85 142.37 11.44 Favored Glycine 0 CA--C 1.491 -1.457 0 N-CA-C 107.526 -2.23 . . . . 0.0 107.526 -179.837 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . 0.411 ' CE1' ' H ' ' A' ' 114' ' ' SER . 98.6 m-70 -142.76 151.74 41.57 Favored 'General case' 0 CA--C 1.497 -1.079 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 -179.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -149.65 145.13 12.97 Favored Glycine 0 CA--C 1.492 -1.4 0 N-CA-C 106.972 -2.451 . . . . 0.0 106.972 179.449 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 21.9 ptmt -163.99 164.07 23.23 Favored 'General case' 0 N--CA 1.436 -1.155 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -104.89 128.26 53.05 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 106.906 -1.516 . . . . 0.0 106.906 179.598 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 60.8 tptt -126.56 123.46 37.76 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -120.29 -51.59 2.19 Favored 'General case' 0 CA--C 1.499 -1.003 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 179.727 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 3.6 p -169.9 -68.58 0.02 OUTLIER 'General case' 0 CA--C 1.5 -0.973 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 36.9 t -151.58 145.83 25.41 Favored 'General case' 0 CA--C 1.497 -1.096 0 N-CA-C 106.578 -1.638 . . . . 0.0 106.578 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 46.3 pt -129.81 160.25 41.02 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.068 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -125.13 137.84 54.17 Favored 'General case' 0 CA--C 1.497 -1.077 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 -179.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 172.8 -179.24 44.41 Favored Glycine 0 CA--C 1.491 -1.448 0 N-CA-C 106.763 -2.535 . . . . 0.0 106.763 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 78.9 mt-30 -131.81 135.54 46.82 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 179.704 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 37.0 t -158.95 145.81 17.19 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 106.49 -1.67 . . . . 0.0 106.49 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -120.33 117.07 26.83 Favored 'General case' 0 CA--C 1.497 -1.059 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 179.677 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 70.6 m -141.75 148.06 38.38 Favored 'General case' 0 CA--C 1.494 -1.177 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 179.617 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -105.64 -66.93 0.95 Allowed 'General case' 0 CA--C 1.5 -0.961 0 N-CA-C 107.111 -1.44 . . . . 0.0 107.111 179.553 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 70.6 m -143.24 140.75 30.82 Favored 'General case' 0 CA--C 1.496 -1.131 0 N-CA-C 106.764 -1.569 . . . . 0.0 106.764 179.316 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 39.7 ttmt -157.11 136.68 12.23 Favored 'General case' 0 CA--C 1.496 -1.106 0 N-CA-C 107.116 -1.439 . . . . 0.0 107.116 179.691 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 15.2 t -152.6 153.67 33.83 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 106.456 -1.683 . . . . 0.0 106.456 179.608 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.411 ' H ' ' CE1' ' A' ' 95' ' ' HIS . 58.2 m -117.94 129.22 55.48 Favored 'General case' 0 CA--C 1.496 -1.133 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 91.6 mt -97.74 147.58 24.22 Favored 'General case' 0 CA--C 1.497 -1.065 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 -179.775 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -116.36 138.54 51.25 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 107.551 -1.277 . . . . 0.0 107.551 -179.312 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -130.4 148.93 52.27 Favored 'General case' 0 CA--C 1.497 -1.081 0 N-CA-C 106.695 -1.595 . . . . 0.0 106.695 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -170.86 178.98 43.07 Favored Glycine 0 N--CA 1.436 -1.331 0 N-CA-C 108.106 -1.998 . . . . 0.0 108.106 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -156.55 163.57 39.21 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 106.169 -1.789 . . . . 0.0 106.169 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -153.0 160.61 29.17 Favored Glycine 0 CA--C 1.491 -1.412 0 N-CA-C 108.847 -1.701 . . . . 0.0 108.847 -179.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 88.3 mt -117.44 144.4 45.05 Favored 'General case' 0 CA--C 1.497 -1.076 0 N-CA-C 106.364 -1.717 . . . . 0.0 106.364 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 46.6 tt0 -130.28 131.38 45.43 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -125.28 146.51 49.52 Favored 'General case' 0 CA--C 1.497 -1.096 0 N-CA-C 106.541 -1.651 . . . . 0.0 106.541 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 29.4 t30 -128.43 79.5 74.05 Favored Pre-proline 0 N--CA 1.439 -1.007 0 N-CA-C 107.424 -1.324 . . . . 0.0 107.424 -179.18 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.79 -28.43 16.83 Favored 'Trans proline' 0 CA--C 1.497 -1.33 0 C-N-CA 121.869 1.713 . . . . 0.0 112.612 179.457 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -137.58 150.48 68.42 Favored Pre-proline 0 N--CA 1.437 -1.115 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -70.14 -18.55 35.14 Favored 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 121.761 1.64 . . . . 0.0 113.501 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 34.8 m120 -108.68 15.35 23.76 Favored 'General case' 0 N--CA 1.442 -0.868 0 N-CA-C 109.157 -0.682 . . . . 0.0 109.157 -179.068 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -152.16 117.94 5.43 Favored 'General case' 0 CA--C 1.502 -0.878 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 67.5 t -112.43 129.55 67.77 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.97 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 -179.552 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 84.9 mt -113.86 127.8 71.08 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.029 0 N-CA-C 107.032 -1.469 . . . . 0.0 107.032 -179.534 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -141.5 160.43 40.17 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -147.79 146.42 29.15 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 105.382 -2.081 . . . . 0.0 105.382 179.122 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 55.4 m -150.27 164.02 36.8 Favored 'General case' 0 CA--C 1.494 -1.182 0 C-N-CA 119.207 -0.997 . . . . 0.0 109.107 -178.741 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 51.7 p90 -139.59 148.84 43.08 Favored 'General case' 0 N--CA 1.435 -1.21 0 N-CA-C 106.23 -1.767 . . . . 0.0 106.23 178.453 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -139.22 135.65 34.16 Favored 'General case' 0 N--CA 1.438 -1.051 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 -179.465 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -126.51 138.46 53.49 Favored 'General case' 0 CA--C 1.496 -1.114 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 178.898 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 66.8 m -130.02 143.93 51.06 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 179.72 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 30.2 mtpp -101.96 118.11 36.22 Favored 'General case' 0 CA--C 1.498 -1.044 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 -179.561 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 5.0 mp -126.18 140.28 52.68 Favored 'General case' 0 N--CA 1.438 -1.031 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 179.237 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -65.48 -39.59 92.13 Favored 'General case' 0 N--CA 1.444 -0.733 0 C-N-CA 120.74 -0.384 . . . . 0.0 110.015 -179.024 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -63.55 -50.01 71.19 Favored 'General case' 0 C--N 1.355 0.804 0 C-N-CA 120.461 -0.496 . . . . 0.0 110.734 -177.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 15.6 m -151.54 160.44 3.67 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.018 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 -178.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 40.0 ttpt -84.36 128.96 34.89 Favored 'General case' 0 CA--C 1.501 -0.935 0 N-CA-C 105.786 -1.931 . . . . 0.0 105.786 178.244 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 71.1 t -111.94 122.11 65.65 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.0 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 -178.115 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -125.53 131.21 7.54 Favored Glycine 0 C--N 1.351 1.37 0 N-CA-C 105.701 -2.959 . . . . 0.0 105.701 178.498 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 87.0 m -127.48 130.53 49.39 Favored 'General case' 0 CA--C 1.496 -1.125 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 -178.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 28.3 m-90 -120.85 140.44 51.76 Favored 'General case' 0 CA--C 1.495 -1.15 0 N-CA-C 105.31 -2.107 . . . . 0.0 105.31 178.225 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -144.86 151.24 38.43 Favored 'General case' 0 N--CA 1.438 -1.05 0 C-N-CA 119.183 -1.007 . . . . 0.0 108.86 -179.127 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 2.3 tt -146.86 143.76 28.8 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 105.874 -1.899 . . . . 0.0 105.874 179.81 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -168.33 -164.32 23.82 Favored Glycine 0 CA--C 1.491 -1.408 0 N-CA-C 108.77 -1.732 . . . . 0.0 108.77 -179.242 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -146.2 163.83 34.19 Favored 'General case' 0 N--CA 1.435 -1.218 0 N-CA-C 106.571 -1.641 . . . . 0.0 106.571 -179.35 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -144.6 171.97 25.72 Favored Glycine 0 CA--C 1.49 -1.502 0 N-CA-C 108.544 -1.822 . . . . 0.0 108.544 -179.235 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 92.3 m-85 -130.88 149.51 52.48 Favored 'General case' 0 N--CA 1.437 -1.084 0 N-CA-C 107.03 -1.47 . . . . 0.0 107.03 -179.608 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 58.9 ttp180 -89.25 129.08 35.87 Favored 'General case' 0 CA--C 1.501 -0.916 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 58.0 m-85 . . . . . 0 C--O 1.262 1.73 0 CA-C-O 117.992 -1.004 . . . . 0.0 108.317 -179.555 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 49.8 tt0 . . . . . 0 N--CA 1.487 1.399 0 CA-C-O 121.452 0.644 . . . . 0.0 110.385 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -179.5 179.43 48.86 Favored Glycine 0 CA--C 1.492 -1.399 0 N-CA-C 106.943 -2.463 . . . . 0.0 106.943 179.834 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -115.32 126.88 55.0 Favored 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 107.274 -1.38 . . . . 0.0 107.274 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 71.1 m -129.27 152.12 49.19 Favored 'General case' 0 CA--C 1.494 -1.199 0 N-CA-C 106.646 -1.613 . . . . 0.0 106.646 179.592 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 61.7 m -125.37 142.38 51.53 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 85.7 mt -119.46 130.69 73.7 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.107 0 N-CA-C 106.285 -1.746 . . . . 0.0 106.285 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 47.7 t -130.69 137.34 49.5 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 -179.608 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 47.1 pt -128.65 157.65 41.22 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.093 0 N-CA-C 106.784 -1.562 . . . . 0.0 106.784 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -173.01 -161.73 23.9 Favored Glycine 0 CA--C 1.491 -1.435 0 N-CA-C 107.618 -2.193 . . . . 0.0 107.618 -179.655 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 41.2 p90 -138.38 158.39 44.38 Favored 'General case' 0 N--CA 1.438 -1.062 0 N-CA-C 106.784 -1.561 . . . . 0.0 106.784 -179.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -112.4 138.37 49.23 Favored 'General case' 0 N--CA 1.44 -0.938 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 -179.128 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 21.0 pt20 -131.29 163.38 27.93 Favored 'General case' 0 CA--C 1.502 -0.886 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 179.494 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 6.7 t -134.45 -157.05 0.78 Allowed 'General case' 0 CA--C 1.503 -0.845 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 -179.706 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -82.66 107.93 15.65 Favored 'General case' 0 CA--C 1.501 -0.929 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 -179.302 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 75.5 t -127.6 128.01 69.2 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.068 0 N-CA-C 106.386 -1.709 . . . . 0.0 106.386 179.333 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -152.18 160.92 43.29 Favored 'General case' 0 N--CA 1.437 -1.117 0 N-CA-C 107.47 -1.307 . . . . 0.0 107.47 -179.707 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -137.81 165.54 26.2 Favored 'General case' 0 N--CA 1.438 -1.027 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 44.7 p-10 -91.86 11.93 23.23 Favored 'General case' 0 N--CA 1.444 -0.74 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 -179.573 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -154.42 171.39 32.91 Favored Glycine 0 CA--C 1.492 -1.374 0 N-CA-C 106.666 -2.574 . . . . 0.0 106.666 179.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -103.91 102.62 12.41 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 -179.592 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 54.2 tptt -160.43 140.81 11.58 Favored 'General case' 0 N--CA 1.436 -1.164 0 N-CA-C 106.107 -1.812 . . . . 0.0 106.107 179.521 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 91.8 mt -88.63 66.17 8.04 Favored 'General case' 0 CA--C 1.502 -0.882 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -179.683 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -65.63 -39.77 91.81 Favored 'General case' 0 C--N 1.355 0.847 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 179.409 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 26.6 pttm -158.58 165.7 33.86 Favored 'General case' 0 N--CA 1.435 -1.188 0 N-CA-C 106.92 -1.511 . . . . 0.0 106.92 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 69.0 m-80 -129.52 153.86 80.73 Favored Pre-proline 0 N--CA 1.438 -1.047 0 N-CA-C 106.291 -1.744 . . . . 0.0 106.291 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -59.29 141.72 98.16 Favored 'Trans proline' 0 CA--C 1.501 -1.174 0 C-N-CA 122.158 1.906 . . . . 0.0 112.832 179.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -119.12 127.04 52.98 Favored 'General case' 0 CA--C 1.497 -1.087 0 N-CA-C 107.37 -1.345 . . . . 0.0 107.37 -179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -171.48 160.84 33.04 Favored Glycine 0 N--CA 1.435 -1.424 0 N-CA-C 107.103 -2.399 . . . . 0.0 107.103 179.521 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 -135.65 148.81 49.11 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 23.3 t-20 -143.51 121.03 11.73 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 179.47 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 67.2 tp -123.65 126.26 46.28 Favored 'General case' 0 CA--C 1.499 -0.998 0 N-CA-C 106.997 -1.482 . . . . 0.0 106.997 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 17.1 mtpp -125.95 148.33 49.27 Favored 'General case' 0 CA--C 1.501 -0.925 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 40.3 t80 -137.44 130.47 30.54 Favored 'General case' 0 N--CA 1.441 -0.905 0 N-CA-C 106.285 -1.746 . . . . 0.0 106.285 179.343 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . 0.649 ' HA ' HG22 ' A' ' 44' ' ' ILE . 7.7 tmm_? -102.28 127.86 49.07 Favored 'General case' 0 CA--C 1.5 -0.952 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 -179.427 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -108.4 137.63 46.03 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 106.679 -1.601 . . . . 0.0 106.679 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -88.98 75.48 8.0 Favored 'General case' 0 N--CA 1.442 -0.868 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 91.7 t80 -63.51 -48.1 78.99 Favored 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 179.077 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 -154.76 162.49 41.1 Favored 'General case' 0 N--CA 1.436 -1.164 0 N-CA-C 105.719 -1.956 . . . . 0.0 105.719 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 9.5 p-10 -79.0 -30.09 44.08 Favored 'General case' 0 N--CA 1.44 -0.933 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 -179.633 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -71.08 -41.94 70.01 Favored 'General case' 0 C--N 1.356 0.887 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 -179.327 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 23.0 m-90 -140.14 139.22 35.72 Favored 'General case' 0 CA--C 1.495 -1.144 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -110.52 169.25 13.34 Favored Glycine 0 C--N 1.349 1.258 0 N-CA-C 107.466 -2.254 . . . . 0.0 107.466 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 99.6 t -130.76 131.56 64.53 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.028 0 N-CA-C 106.777 -1.564 . . . . 0.0 106.777 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.649 HG22 ' HA ' ' A' ' 34' ' ' ARG . 38.5 pt -124.9 158.86 32.2 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.152 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -140.03 142.23 12.36 Favored Glycine 0 CA--C 1.489 -1.548 0 N-CA-C 105.267 -3.133 . . . . 0.0 105.267 178.453 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 89.6 p -146.29 151.1 37.0 Favored 'General case' 0 CA--C 1.497 -1.077 0 C-N-CA 119.112 -1.035 . . . . 0.0 109.187 -179.3 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -121.4 141.45 50.96 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 105.745 -1.946 . . . . 0.0 105.745 179.271 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -135.91 141.35 44.53 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 -179.53 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 72.4 mt-30 -131.73 138.37 48.61 Favored 'General case' 0 CA--C 1.495 -1.15 0 N-CA-C 106.402 -1.703 . . . . 0.0 106.402 179.327 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 84.7 m -132.67 129.91 39.43 Favored 'General case' 0 CA--C 1.497 -1.076 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 179.634 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 79.8 ttt180 -126.15 129.94 50.04 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.192 -1.411 . . . . 0.0 107.192 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 85.4 mtp180 -129.34 140.5 51.36 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 106.706 -1.59 . . . . 0.0 106.706 179.409 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -179.94 172.29 43.85 Favored Glycine 0 CA--C 1.491 -1.467 0 N-CA-C 107.326 -2.31 . . . . 0.0 107.326 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 90.5 t80 -137.42 129.94 29.81 Favored 'General case' 0 N--CA 1.438 -1.067 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 -179.8 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -94.09 123.3 37.38 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 -179.67 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -95.23 94.05 7.66 Favored 'General case' 0 N--CA 1.439 -1.002 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 69.5 m -93.55 -5.8 48.13 Favored 'General case' 0 CA--C 1.501 -0.933 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 179.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 35.2 m -132.77 159.68 43.03 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.097 0 N-CA-C 106.943 -1.502 . . . . 0.0 106.943 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 67.6 t0 -89.84 102.26 14.96 Favored 'General case' 0 N--CA 1.439 -0.976 0 N-CA-C 106.774 -1.565 . . . . 0.0 106.774 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -133.79 41.06 1.51 Allowed Glycine 0 CA--C 1.491 -1.434 0 N-CA-C 106.992 -2.443 . . . . 0.0 106.992 179.626 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 5.3 t80 76.51 -171.61 0.09 Allowed 'General case' 0 C--N 1.357 0.923 0 N-CA-C 107.289 -1.375 . . . . 0.0 107.289 -179.672 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 18.0 tppt? -91.51 118.55 30.68 Favored 'General case' 0 CA--C 1.499 -0.998 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 88.9 mt -119.63 139.25 52.49 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 45.8 pt -130.53 153.61 39.32 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.055 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 53.3 t0 -164.92 88.62 0.47 Allowed 'General case' 0 N--CA 1.436 -1.151 0 N-CA-C 106.158 -1.793 . . . . 0.0 106.158 179.718 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 85.66 -91.97 1.74 Allowed Glycine 0 C--N 1.349 1.3 0 N-CA-C 107.531 -2.228 . . . . 0.0 107.531 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 59.24 43.0 17.56 Favored 'General case' 0 C--N 1.359 0.98 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -149.66 141.67 23.88 Favored 'General case' 0 N--CA 1.434 -1.251 0 N-CA-C 106.25 -1.759 . . . . 0.0 106.25 -179.311 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -102.16 139.37 37.87 Favored 'General case' 0 CA--C 1.496 -1.121 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 -179.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -126.88 139.97 52.69 Favored 'General case' 0 CA--C 1.497 -1.06 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -128.82 143.18 50.84 Favored 'General case' 0 CA--C 1.495 -1.148 0 N-CA-C 105.877 -1.897 . . . . 0.0 105.877 179.627 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 40.0 t -149.93 145.15 26.33 Favored 'General case' 0 CA--C 1.496 -1.098 0 N-CA-C 107.9 -1.148 . . . . 0.0 107.9 -179.346 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.4 p -136.64 137.47 47.5 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.116 0 N-CA-C 105.694 -1.965 . . . . 0.0 105.694 178.663 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 74.4 p -142.09 160.88 39.35 Favored 'General case' 0 CA--C 1.497 -1.076 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 -179.235 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -155.09 157.93 38.27 Favored 'General case' 0 N--CA 1.433 -1.318 0 N-CA-C 105.539 -2.023 . . . . 0.0 105.539 178.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -179.96 177.0 47.82 Favored Glycine 0 N--CA 1.437 -1.268 0 N-CA-C 108.909 -1.676 . . . . 0.0 108.909 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 68.5 Cg_endo -81.86 162.05 18.57 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 123.101 2.534 . . . . 0.0 114.012 -179.488 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.432 HG22 ' CD2' ' A' ' 88' ' ' TYR . 60.1 t -115.52 127.12 73.21 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.045 0 N-CA-C 106.079 -1.823 . . . . 0.0 106.079 179.264 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 83.9 t80 -128.75 121.99 29.63 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 -179.317 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 90.9 mtm180 -112.06 141.93 45.12 Favored 'General case' 0 CA--C 1.497 -1.058 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 49.3 mm -74.35 -64.23 0.87 Allowed 'Isoleucine or valine' 0 CA--C 1.503 -0.839 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 179.764 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 66.5 t30 179.86 94.92 0.02 OUTLIER 'General case' 0 CA--C 1.501 -0.93 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 178.258 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 23.0 tt0 37.57 48.47 0.91 Allowed 'General case' 0 C--N 1.36 1.051 0 C-N-CA 122.973 0.509 . . . . 0.0 110.976 178.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 73.7 t80 -141.8 -43.3 0.35 Allowed 'General case' 0 CA--C 1.5 -0.973 0 C-N-CA 119.427 -0.909 . . . . 0.0 108.574 -179.631 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 11.1 p -159.17 149.55 7.19 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.138 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 -179.591 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 42.4 t -117.89 129.28 55.54 Favored 'General case' 0 N--CA 1.438 -1.044 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 87.8 mt -109.63 140.14 43.81 Favored 'General case' 0 CA--C 1.497 -1.068 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 -179.412 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.432 ' CD2' HG22 ' A' ' 78' ' ' VAL . 86.6 m-85 -128.01 142.4 51.24 Favored 'General case' 0 CA--C 1.493 -1.23 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 -179.712 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -111.86 134.48 12.1 Favored Glycine 0 CA--C 1.489 -1.559 0 N-CA-C 105.683 -2.967 . . . . 0.0 105.683 178.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 89.8 mt -120.6 134.67 55.26 Favored 'General case' 0 CA--C 1.497 -1.085 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 -179.071 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -150.78 149.44 29.75 Favored 'General case' 0 N--CA 1.436 -1.17 0 N-CA-C 105.875 -1.898 . . . . 0.0 105.875 178.69 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 171.89 -146.36 9.31 Favored Glycine 0 CA--C 1.49 -1.511 0 N-CA-C 107.782 -2.127 . . . . 0.0 107.782 -179.48 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -141.54 157.21 45.41 Favored 'General case' 0 N--CA 1.435 -1.206 0 N-CA-C 107.57 -1.271 . . . . 0.0 107.57 -178.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -130.72 154.04 20.53 Favored Glycine 0 CA--C 1.493 -1.294 0 N-CA-C 107.35 -2.3 . . . . 0.0 107.35 -179.71 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 79.4 m80 -136.62 152.64 50.66 Favored 'General case' 0 N--CA 1.437 -1.111 0 N-CA-C 107.164 -1.421 . . . . 0.0 107.164 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -121.8 146.68 17.12 Favored Glycine 0 CA--C 1.491 -1.423 0 N-CA-C 106.899 -2.481 . . . . 0.0 106.899 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 28.9 tptp -138.19 131.96 31.13 Favored 'General case' 0 N--CA 1.438 -1.031 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 -179.367 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -85.4 155.93 21.07 Favored 'General case' 0 N--CA 1.439 -0.979 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 179.564 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 62.8 mtpt -72.9 150.66 42.41 Favored 'General case' 0 CA--C 1.503 -0.857 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -86.44 119.79 27.08 Favored 'General case' 0 CA--C 1.499 -1.007 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 39.1 t -169.71 -80.11 0.02 OUTLIER 'General case' 0 N--CA 1.438 -1.055 0 N-CA-C 106.772 -1.566 . . . . 0.0 106.772 179.589 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 37.1 t -155.71 145.05 20.9 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 20.5 tt -146.93 138.07 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.057 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 88.4 t80 -143.36 122.15 12.66 Favored 'General case' 0 N--CA 1.436 -1.129 0 N-CA-C 106.367 -1.716 . . . . 0.0 106.367 179.581 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 155.96 -168.76 33.5 Favored Glycine 0 CA--C 1.491 -1.407 0 N-CA-C 107.119 -2.393 . . . . 0.0 107.119 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 99.0 mt-30 -131.35 147.77 52.6 Favored 'General case' 0 CA--C 1.497 -1.064 0 N-CA-C 106.695 -1.594 . . . . 0.0 106.695 179.753 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 38.5 t -150.29 143.2 24.77 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -144.9 132.84 21.3 Favored 'General case' 0 N--CA 1.436 -1.142 0 N-CA-C 106.679 -1.6 . . . . 0.0 106.679 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 34.8 t -149.79 148.41 29.17 Favored 'General case' 0 CA--C 1.496 -1.122 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 96.3 mtm-85 -89.06 -5.44 57.86 Favored 'General case' 0 N--CA 1.442 -0.871 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 -179.334 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 42.7 t -151.01 140.32 21.35 Favored 'General case' 0 CA--C 1.498 -1.026 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -100.87 1.79 40.33 Favored 'General case' 0 CA--C 1.502 -0.891 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 179.141 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 92.3 m -118.16 130.97 56.42 Favored 'General case' 0 CA--C 1.497 -1.072 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 -179.344 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 67.8 m -107.2 147.27 30.35 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -83.67 150.16 26.04 Favored 'General case' 0 N--CA 1.442 -0.838 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 -179.596 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -130.07 139.29 50.98 Favored 'General case' 0 N--CA 1.439 -0.993 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 179.696 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 90.7 t80 -145.12 141.95 29.22 Favored 'General case' 0 CA--C 1.499 -1.018 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -166.66 -171.46 32.81 Favored Glycine 0 N--CA 1.437 -1.293 0 N-CA-C 108.363 -1.895 . . . . 0.0 108.363 -179.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -149.56 161.49 42.05 Favored 'General case' 0 N--CA 1.436 -1.126 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -133.1 148.41 19.31 Favored Glycine 0 C--N 1.35 1.345 0 N-CA-C 108.221 -1.952 . . . . 0.0 108.221 -179.633 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -124.22 143.9 50.26 Favored 'General case' 0 CA--C 1.498 -1.021 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 179.663 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 40.4 tt0 -143.04 139.05 30.38 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 -179.322 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -126.11 141.49 51.92 Favored 'General case' 0 N--CA 1.436 -1.131 0 N-CA-C 106.139 -1.801 . . . . 0.0 106.139 178.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -128.81 74.76 80.59 Favored Pre-proline 0 CA--C 1.503 -0.855 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 -179.087 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.22 -30.35 20.28 Favored 'Trans proline' 0 CA--C 1.499 -1.246 0 C-N-CA 121.496 1.464 . . . . 0.0 112.344 179.265 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 79.3 m80 -139.78 151.52 66.04 Favored Pre-proline 0 N--CA 1.437 -1.083 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 179.483 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 94.4 Cg_endo -78.82 -12.07 15.01 Favored 'Trans proline' 0 C--N 1.312 -1.366 0 C-N-CA 121.943 1.762 . . . . 0.0 112.84 179.203 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 24.2 m120 -64.5 -38.68 91.88 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.118 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 50.6 p90 -149.41 158.56 44.28 Favored 'General case' 0 CA--C 1.5 -0.953 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 -178.752 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 62.1 t -125.75 131.9 71.41 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.897 0 N-CA-C 107.424 -1.324 . . . . 0.0 107.424 -179.063 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 86.1 mt -109.43 129.05 64.91 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.986 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -140.52 160.54 39.78 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 -179.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -146.99 147.12 30.38 Favored 'General case' 0 N--CA 1.436 -1.126 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 69.1 m -142.88 159.85 41.45 Favored 'General case' 0 CA--C 1.492 -1.262 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 -179.391 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 51.2 p90 -146.37 149.46 33.81 Favored 'General case' 0 N--CA 1.435 -1.176 0 N-CA-C 106.9 -1.519 . . . . 0.0 106.9 179.033 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -138.05 145.8 42.22 Favored 'General case' 0 CA--C 1.498 -1.052 0 N-CA-C 107.274 -1.38 . . . . 0.0 107.274 179.616 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 78.5 m-85 -129.72 144.37 51.26 Favored 'General case' 0 CA--C 1.496 -1.111 0 N-CA-C 107.494 -1.299 . . . . 0.0 107.494 179.09 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 34.7 t -140.79 137.92 33.71 Favored 'General case' 0 N--CA 1.437 -1.087 0 N-CA-C 105.388 -2.079 . . . . 0.0 105.388 178.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 59.9 mtpt -115.89 131.15 57.02 Favored 'General case' 0 CA--C 1.496 -1.134 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 -178.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 5.0 mp -125.05 154.87 40.65 Favored 'General case' 0 N--CA 1.435 -1.206 0 N-CA-C 105.312 -2.107 . . . . 0.0 105.312 178.21 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -63.18 -38.1 89.83 Favored 'General case' 0 N--CA 1.445 -0.722 0 C-N-CA 120.602 -0.439 . . . . 0.0 110.036 -178.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 69.0 m-20 -76.71 -47.81 20.77 Favored 'General case' 0 C--N 1.352 0.702 0 C-N-CA 119.998 -0.681 . . . . 0.0 111.136 -177.623 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 31.0 m -143.56 166.49 13.91 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.91 0 C-N-CA 119.818 -0.753 . . . . 0.0 109.282 -177.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 35.5 mmtp -106.73 140.45 39.57 Favored 'General case' 0 CA--C 1.5 -0.944 0 N-CA-C 105.585 -2.006 . . . . 0.0 105.585 178.479 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 99.1 t -124.2 127.74 73.51 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.956 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -178.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -123.78 132.99 8.64 Favored Glycine 0 C--N 1.352 1.427 0 N-CA-C 105.972 -2.851 . . . . 0.0 105.972 178.529 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 86.3 m -127.05 130.75 50.56 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 -179.029 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 91.6 m95 -114.65 138.93 50.08 Favored 'General case' 0 CA--C 1.497 -1.076 0 N-CA-C 106.136 -1.801 . . . . 0.0 106.136 179.12 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 2.1 mpt? -127.68 139.83 52.46 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -179.292 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 63.1 tp -133.6 132.78 41.22 Favored 'General case' 0 CA--C 1.497 -1.059 0 N-CA-C 105.707 -1.96 . . . . 0.0 105.707 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -163.15 -172.23 30.38 Favored Glycine 0 C--N 1.35 1.354 0 N-CA-C 108.807 -1.717 . . . . 0.0 108.807 -179.241 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -135.54 154.25 51.44 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 -179.581 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -115.74 149.88 18.75 Favored Glycine 0 CA--C 1.492 -1.372 0 N-CA-C 108.411 -1.876 . . . . 0.0 108.411 -179.013 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 85.9 t80 -129.78 128.77 43.06 Favored 'General case' 0 N--CA 1.437 -1.08 0 N-CA-C 106.16 -1.792 . . . . 0.0 106.16 179.476 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 82.7 mtp180 -80.47 137.58 36.48 Favored 'General case' 0 CA--C 1.501 -0.938 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 -179.413 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 . . . . . 0 C--O 1.262 1.733 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.586 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 . . . . . 0 N--CA 1.489 1.487 0 CA-C-O 120.887 0.375 . . . . 0.0 110.648 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -179.74 178.71 48.72 Favored Glycine 0 CA--C 1.493 -1.32 0 N-CA-C 106.879 -2.488 . . . . 0.0 106.879 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -133.04 142.98 49.08 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 65.6 m -139.52 143.63 37.52 Favored 'General case' 0 CA--C 1.495 -1.146 0 N-CA-C 106.572 -1.64 . . . . 0.0 106.572 179.037 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 64.2 m -129.95 147.95 51.76 Favored 'General case' 0 CA--C 1.497 -1.058 0 N-CA-C 107.37 -1.344 . . . . 0.0 107.37 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 85.4 mt -118.41 130.33 73.41 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.015 0 N-CA-C 106.498 -1.667 . . . . 0.0 106.498 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.43 ' HA ' ' HA2' ' A' ' 153' ' ' GLY . 48.4 t -135.32 140.71 45.31 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 -179.533 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 46.6 pt -130.77 155.58 41.98 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.124 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 179.487 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -164.63 179.67 39.22 Favored Glycine 0 CA--C 1.49 -1.489 0 N-CA-C 107.924 -2.07 . . . . 0.0 107.924 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -126.31 147.0 49.8 Favored 'General case' 0 CA--C 1.494 -1.174 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 -179.609 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -99.26 129.86 45.51 Favored 'General case' 0 N--CA 1.438 -1.075 0 N-CA-C 106.844 -1.539 . . . . 0.0 106.844 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 75.5 mt-30 -129.36 147.94 51.24 Favored 'General case' 0 CA--C 1.498 -1.021 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 -179.435 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.43 ' HB2' HG22 ' A' ' 147' ' ' THR . 35.3 t -154.45 141.98 19.76 Favored 'General case' 0 CA--C 1.497 -1.058 0 N-CA-C 106.577 -1.638 . . . . 0.0 106.577 179.552 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 30.6 tpt180 -154.51 137.88 15.82 Favored 'General case' 0 N--CA 1.436 -1.138 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 70.3 t -108.67 119.55 58.45 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.061 0 N-CA-C 106.005 -1.85 . . . . 0.0 106.005 179.319 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -82.56 136.84 34.74 Favored 'General case' 0 CA--C 1.498 -1.027 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 -179.088 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -133.6 -67.36 0.61 Allowed 'General case' 0 CA--C 1.498 -1.037 0 N-CA-C 106.786 -1.561 . . . . 0.0 106.786 179.33 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 -94.19 -29.52 15.07 Favored 'General case' 0 N--CA 1.441 -0.885 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 179.482 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 174.92 -171.22 44.41 Favored Glycine 0 CA--C 1.492 -1.358 0 N-CA-C 106.912 -2.475 . . . . 0.0 106.912 -179.836 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 87.2 t80 -105.07 119.92 40.22 Favored 'General case' 0 CA--C 1.501 -0.941 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 32.2 mmmt -131.85 149.38 52.47 Favored 'General case' 0 CA--C 1.498 -1.028 0 N-CA-C 107.341 -1.355 . . . . 0.0 107.341 -179.614 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 87.2 mt -103.19 76.63 1.46 Allowed 'General case' 0 CA--C 1.5 -0.975 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 45.7 t0 -154.96 111.54 3.25 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 -179.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 31.1 ttpt 70.71 73.45 0.2 Allowed 'General case' 0 C--N 1.357 0.903 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 179.347 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -127.23 149.62 70.12 Favored Pre-proline 0 CA--C 1.5 -0.956 0 N-CA-C 106.487 -1.671 . . . . 0.0 106.487 179.761 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_endo -73.04 153.91 52.39 Favored 'Trans proline' 0 CA--C 1.499 -1.258 0 C-N-CA 121.825 1.683 . . . . 0.0 112.522 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 22.7 tpt180 -136.33 135.36 38.82 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 106.25 -1.759 . . . . 0.0 106.25 -179.75 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -135.35 156.29 22.58 Favored Glycine 0 CA--C 1.493 -1.334 0 N-CA-C 107.621 -2.192 . . . . 0.0 107.621 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -111.18 141.53 44.57 Favored 'General case' 0 CA--C 1.496 -1.122 0 N-CA-C 106.574 -1.639 . . . . 0.0 106.574 -179.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.457 HD22 ' HB2' ' A' ' 48' ' ' ALA . 28.7 t-20 -136.6 126.47 25.8 Favored 'General case' 0 N--CA 1.439 -1.016 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 88.6 mt -114.51 139.0 49.92 Favored 'General case' 0 CA--C 1.496 -1.102 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 178.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 40.5 ttpt -136.7 132.86 35.47 Favored 'General case' 0 CA--C 1.5 -0.967 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 -179.292 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -123.5 140.38 53.07 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 106.697 -1.594 . . . . 0.0 106.697 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . 0.462 ' HA ' HG22 ' A' ' 44' ' ' ILE . 2.6 tmt_? -121.97 132.42 54.52 Favored 'General case' 0 CA--C 1.498 -1.051 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 -179.233 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -125.91 138.37 53.78 Favored 'General case' 0 N--CA 1.437 -1.094 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 179.597 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -90.97 102.4 15.17 Favored 'General case' 0 N--CA 1.439 -1.001 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 -179.441 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 89.8 t80 -63.7 -47.44 81.15 Favored 'General case' 0 CA--C 1.505 -0.756 0 N-CA-C 108.204 -1.036 . . . . 0.0 108.204 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.9 t-20 -156.06 175.15 14.34 Favored 'General case' 0 N--CA 1.436 -1.141 0 N-CA-C 106.574 -1.639 . . . . 0.0 106.574 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -83.23 68.69 9.72 Favored 'General case' 0 N--CA 1.443 -0.822 0 N-CA-C 107.845 -1.168 . . . . 0.0 107.845 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -171.32 -62.33 0.02 OUTLIER 'General case' 0 N--CA 1.439 -1.025 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 179.745 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 41.8 m0 -126.28 147.58 49.68 Favored 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 -179.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -123.27 172.05 15.99 Favored Glycine 0 CA--C 1.492 -1.372 0 N-CA-C 107.076 -2.41 . . . . 0.0 107.076 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.8 m -130.88 152.5 37.66 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.148 0 N-CA-C 107.049 -1.463 . . . . 0.0 107.049 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.559 HG21 ' CE2' ' A' ' 88' ' ' TYR . 33.1 pt -133.12 160.24 42.65 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.151 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 -179.791 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -136.68 139.86 10.98 Favored Glycine 0 CA--C 1.489 -1.553 0 N-CA-C 104.658 -3.377 . . . . 0.0 104.658 177.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 44.9 t -145.38 144.61 30.77 Favored 'General case' 0 CA--C 1.498 -1.045 0 C-N-CA 119.257 -0.977 . . . . 0.0 108.431 -178.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -127.1 142.36 51.54 Favored 'General case' 0 N--CA 1.437 -1.104 0 N-CA-C 106.057 -1.831 . . . . 0.0 106.057 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.457 ' HB2' HD22 ' A' ' 30' ' ' ASN . . . -137.77 143.17 40.98 Favored 'General case' 0 CA--C 1.497 -1.069 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 -179.829 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 76.3 mt-30 -132.24 137.11 47.42 Favored 'General case' 0 CA--C 1.498 -1.038 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 179.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 71.8 p -135.3 159.04 42.81 Favored 'General case' 0 CA--C 1.501 -0.938 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 179.667 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 78.9 ttt180 -142.31 135.63 28.9 Favored 'General case' 0 N--CA 1.439 -0.998 0 N-CA-C 106.665 -1.605 . . . . 0.0 106.665 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 82.3 mtp180 -119.39 129.3 54.74 Favored 'General case' 0 CA--C 1.499 -0.995 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -174.83 164.76 35.67 Favored Glycine 0 CA--C 1.492 -1.364 0 N-CA-C 106.618 -2.593 . . . . 0.0 106.618 179.477 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 94.8 m-85 -110.49 -5.38 15.15 Favored 'General case' 0 CA--C 1.5 -0.958 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 81.2 mm-40 -136.48 146.23 46.04 Favored 'General case' 0 CA--C 1.497 -1.076 0 N-CA-C 107.354 -1.351 . . . . 0.0 107.354 -179.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -101.91 7.44 41.5 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 107.816 -1.179 . . . . 0.0 107.816 179.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 34.6 t -147.5 150.91 35.45 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 -179.461 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 34.9 m -126.85 158.56 37.47 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.002 0 N-CA-C 107.292 -1.373 . . . . 0.0 107.292 -179.463 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 13.9 t0 -159.87 166.18 30.75 Favored 'General case' 0 N--CA 1.435 -1.177 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 -179.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -78.35 164.72 51.22 Favored Glycine 0 C--N 1.35 1.356 0 N-CA-C 108.059 -2.016 . . . . 0.0 108.059 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 63.86 32.28 13.44 Favored 'General case' 0 C--N 1.356 0.883 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 29.6 tptp -148.66 133.08 17.59 Favored 'General case' 0 N--CA 1.437 -1.122 0 N-CA-C 106.917 -1.512 . . . . 0.0 106.917 179.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 7.6 mp -103.8 118.97 37.94 Favored 'General case' 0 CA--C 1.498 -1.042 0 N-CA-C 106.656 -1.609 . . . . 0.0 106.656 179.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 82.7 mt -124.73 125.58 70.14 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.01 0 N-CA-C 107.137 -1.431 . . . . 0.0 107.137 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -100.4 116.85 33.34 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 179.169 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 149.53 -142.91 10.2 Favored Glycine 0 CA--C 1.492 -1.391 0 N-CA-C 106.965 -2.454 . . . . 0.0 106.965 -179.539 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 26.2 t0 71.11 47.49 0.4 Allowed 'General case' 0 C--N 1.355 0.828 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.509 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -113.12 136.75 52.38 Favored 'General case' 0 CA--C 1.498 -1.033 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 38.3 mtmm -119.53 141.3 49.34 Favored 'General case' 0 CA--C 1.495 -1.137 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -129.45 144.01 51.07 Favored 'General case' 0 CA--C 1.496 -1.114 0 N-CA-C 107.332 -1.358 . . . . 0.0 107.332 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 90.3 m-85 -125.5 135.54 52.4 Favored 'General case' 0 N--CA 1.437 -1.102 0 N-CA-C 106.162 -1.792 . . . . 0.0 106.162 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 69.6 m -133.06 142.63 48.87 Favored 'General case' 0 CA--C 1.493 -1.249 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 60.0 t -128.78 136.05 60.78 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.155 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 179.033 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 70.3 p -139.19 159.54 41.92 Favored 'General case' 0 CA--C 1.5 -0.973 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 -179.701 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -157.78 159.86 37.22 Favored 'General case' 0 N--CA 1.436 -1.149 0 N-CA-C 105.768 -1.938 . . . . 0.0 105.768 179.211 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -179.63 175.65 47.05 Favored Glycine 0 N--CA 1.437 -1.274 0 N-CA-C 108.613 -1.795 . . . . 0.0 108.613 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -85.19 162.01 11.45 Favored 'Trans proline' 0 C--N 1.311 -1.433 0 C-N-CA 122.99 2.46 . . . . 0.0 113.771 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.469 ' CG2' HG23 ' A' ' 44' ' ' ILE . 69.7 t -124.2 126.83 72.82 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.023 0 N-CA-C 106.371 -1.715 . . . . 0.0 106.371 178.733 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -118.65 125.05 48.88 Favored 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 10.8 ptm180 -112.71 142.4 45.37 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 107.32 -1.363 . . . . 0.0 107.32 179.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 50.9 mm -77.71 -64.58 0.87 Allowed 'Isoleucine or valine' 0 CA--C 1.501 -0.94 0 N-CA-C 106.347 -1.723 . . . . 0.0 106.347 179.126 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 65.2 t30 178.66 94.72 0.02 OUTLIER 'General case' 0 N--CA 1.44 -0.952 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 177.679 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 60.8 mt-10 41.57 44.92 2.73 Favored 'General case' 0 C--N 1.358 0.959 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.278 178.121 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 48.6 t80 -141.47 -43.76 0.36 Allowed 'General case' 0 CA--C 1.5 -0.96 0 C-N-CA 119.056 -1.058 . . . . 0.0 108.772 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 9.7 p -163.47 150.18 3.24 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.095 0 N-CA-C 106.957 -1.498 . . . . 0.0 106.957 -179.675 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 64.0 m -126.28 140.65 52.36 Favored 'General case' 0 CA--C 1.496 -1.104 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 179.476 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 66.0 tp -103.86 125.73 50.48 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.559 ' CE2' HG21 ' A' ' 44' ' ' ILE . 4.6 m-85 -108.7 141.2 41.01 Favored 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 -179.286 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -128.53 138.18 10.17 Favored Glycine 0 CA--C 1.491 -1.468 0 N-CA-C 106.343 -2.703 . . . . 0.0 106.343 178.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.2 mp -128.71 138.53 52.18 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 -179.681 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -150.91 149.9 30.21 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 106.08 -1.822 . . . . 0.0 106.08 178.56 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 174.78 -150.46 11.3 Favored Glycine 0 CA--C 1.492 -1.374 0 N-CA-C 108.128 -1.989 . . . . 0.0 108.128 -179.627 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -144.16 162.18 36.97 Favored 'General case' 0 N--CA 1.437 -1.112 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -178.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -119.34 160.03 14.45 Favored Glycine 0 C--N 1.35 1.331 0 N-CA-C 107.555 -2.218 . . . . 0.0 107.555 -179.708 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 86.3 t60 -147.32 142.23 26.91 Favored 'General case' 0 N--CA 1.438 -1.05 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -133.47 161.93 24.29 Favored Glycine 0 CA--C 1.49 -1.475 0 N-CA-C 107.173 -2.371 . . . . 0.0 107.173 -179.681 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 29.0 ttpp -80.69 124.43 29.01 Favored 'General case' 0 N--CA 1.439 -0.977 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 -179.609 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.438 ' HB3' ' CE1' ' A' ' 100' ' ' PHE . . . -155.78 157.8 37.09 Favored 'General case' 0 N--CA 1.435 -1.175 0 N-CA-C 106.516 -1.661 . . . . 0.0 106.516 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -94.49 124.25 38.4 Favored 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 -179.805 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . 0.438 ' CE1' ' HB3' ' A' ' 98' ' ' ALA . 98.5 m-85 -125.77 138.09 53.83 Favored 'General case' 0 CA--C 1.496 -1.1 0 N-CA-C 106.64 -1.615 . . . . 0.0 106.64 179.557 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 96.3 p -158.51 161.19 37.34 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 35.0 t -156.12 145.72 20.97 Favored 'General case' 0 N--CA 1.437 -1.087 0 N-CA-C 106.401 -1.703 . . . . 0.0 106.401 179.683 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 96.6 mt -66.35 -44.42 90.89 Favored 'Isoleucine or valine' 0 C--N 1.354 0.792 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 -179.764 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 -126.18 147.09 49.72 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -63.73 -39.96 98.03 Favored Glycine 0 C--N 1.352 1.433 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 19.7 mp0 -86.87 74.88 9.68 Favored 'General case' 0 N--CA 1.44 -0.93 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 -179.332 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 68.0 m -132.08 149.95 52.28 Favored 'General case' 0 CA--C 1.496 -1.114 0 N-CA-C 107.091 -1.448 . . . . 0.0 107.091 179.506 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -136.03 128.23 29.94 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 179.674 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 16.9 m -157.8 -67.48 0.09 Allowed 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 179.741 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 85.1 mtp180 -134.72 148.07 50.21 Favored 'General case' 0 CA--C 1.496 -1.114 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 70.0 m -134.95 149.13 50.19 Favored 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 179.434 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 41.2 ttmt -130.34 124.31 31.97 Favored 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 88.2 m -130.67 130.94 44.53 Favored 'General case' 0 CA--C 1.496 -1.119 0 N-CA-C 106.889 -1.522 . . . . 0.0 106.889 179.695 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 69.8 m -110.36 119.66 39.94 Favored 'General case' 0 CA--C 1.497 -1.081 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 179.629 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 64.4 tp -110.48 128.92 55.84 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 -178.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -111.88 132.87 54.44 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 107.34 -1.355 . . . . 0.0 107.34 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 91.3 t80 -147.6 140.89 25.23 Favored 'General case' 0 CA--C 1.498 -1.036 0 N-CA-C 106.549 -1.649 . . . . 0.0 106.549 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -157.16 169.93 34.31 Favored Glycine 0 N--CA 1.436 -1.329 0 N-CA-C 108.288 -1.925 . . . . 0.0 108.288 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -154.0 157.08 38.56 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 106.122 -1.807 . . . . 0.0 106.122 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -164.35 173.56 40.33 Favored Glycine 0 CA--C 1.49 -1.51 0 N-CA-C 108.469 -1.853 . . . . 0.0 108.469 -179.68 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 6.6 mp -126.98 146.57 50.29 Favored 'General case' 0 N--CA 1.436 -1.131 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 -179.734 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 34.6 tt0 -117.61 133.26 56.14 Favored 'General case' 0 CA--C 1.496 -1.123 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 179.678 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -121.44 138.57 54.22 Favored 'General case' 0 N--CA 1.437 -1.084 0 N-CA-C 106.77 -1.567 . . . . 0.0 106.77 179.558 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 8.8 m120 -128.6 77.68 77.03 Favored Pre-proline 0 CA--C 1.502 -0.87 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 -179.456 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -69.72 -25.95 28.29 Favored 'Trans proline' 0 CA--C 1.5 -1.203 0 C-N-CA 121.685 1.59 . . . . 0.0 112.688 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 78.7 m80 -136.52 151.86 73.68 Favored Pre-proline 0 N--CA 1.439 -1.012 0 N-CA-C 106.49 -1.67 . . . . 0.0 106.49 179.602 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -83.96 62.09 6.84 Favored 'Trans proline' 0 C--N 1.313 -1.329 0 C-N-CA 121.941 1.761 . . . . 0.0 112.44 179.704 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -166.66 -54.9 0.03 OUTLIER 'General case' 0 CA--C 1.499 -0.995 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 -179.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -100.67 135.58 41.89 Favored 'General case' 0 CA--C 1.497 -1.069 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 -179.481 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 57.8 t -118.05 129.52 74.29 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.023 0 N-CA-C 106.964 -1.495 . . . . 0.0 106.964 -179.671 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 85.3 mt -97.07 122.33 48.49 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.975 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 -179.777 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 56.0 m-20 -123.2 131.11 53.56 Favored 'General case' 0 N--CA 1.439 -0.982 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 -178.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -136.64 126.67 26.04 Favored 'General case' 0 CA--C 1.496 -1.119 0 N-CA-C 105.338 -2.097 . . . . 0.0 105.338 178.144 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 53.3 m -142.61 153.43 43.48 Favored 'General case' 0 CA--C 1.493 -1.226 0 C-N-CA 119.487 -0.885 . . . . 0.0 108.726 -178.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -114.61 136.66 52.79 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 105.514 -2.032 . . . . 0.0 105.514 178.624 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 49.7 mt-10 -121.83 136.02 54.92 Favored 'General case' 0 CA--C 1.495 -1.136 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 -179.303 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -129.53 126.58 38.91 Favored 'General case' 0 N--CA 1.433 -1.282 0 N-CA-C 107.052 -1.462 . . . . 0.0 107.052 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 67.2 m -116.94 126.43 52.93 Favored 'General case' 0 CA--C 1.492 -1.265 0 N-CA-C 106.236 -1.764 . . . . 0.0 106.236 179.374 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 65.2 tttm -106.92 118.71 37.42 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 -179.225 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 4.0 mp -120.8 151.23 39.85 Favored 'General case' 0 N--CA 1.436 -1.167 0 N-CA-C 105.266 -2.124 . . . . 0.0 105.266 178.434 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -64.19 -39.48 94.07 Favored 'General case' 0 N--CA 1.441 -0.882 0 C-N-CA 120.36 -0.536 . . . . 0.0 109.873 -179.027 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -71.85 -44.13 64.35 Favored 'General case' 0 C--N 1.354 0.763 0 C-N-CA 120.136 -0.626 . . . . 0.0 111.321 -177.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 31.6 m -147.51 164.93 6.33 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.934 0 C-N-CA 119.738 -0.785 . . . . 0.0 109.367 -177.837 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -108.74 133.16 53.19 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 105.576 -2.009 . . . . 0.0 105.576 178.43 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 75.5 t -127.84 128.61 69.41 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.976 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 -178.715 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -125.25 133.58 8.49 Favored Glycine 0 C--N 1.351 1.412 0 N-CA-C 106.097 -2.801 . . . . 0.0 106.097 178.627 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . 0.43 HG22 ' HB2' ' A' ' 13' ' ' SER . 80.9 p -134.21 152.23 51.72 Favored 'General case' 0 CA--C 1.501 -0.936 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 -179.263 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 25.8 t90 -109.06 136.91 47.8 Favored 'General case' 0 N--CA 1.439 -0.99 0 N-CA-C 105.862 -1.903 . . . . 0.0 105.862 179.003 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 16.5 tmm? -113.3 122.86 48.7 Favored 'General case' 0 CA--C 1.498 -1.056 0 N-CA-C 107.631 -1.248 . . . . 0.0 107.631 -179.324 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 64.1 tp -122.77 129.14 51.38 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 105.772 -1.936 . . . . 0.0 105.772 179.22 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -166.73 -170.83 32.13 Favored Glycine 0 CA--C 1.491 -1.458 0 N-CA-C 108.514 -1.834 . . . . 0.0 108.514 -179.385 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -145.05 156.54 43.99 Favored 'General case' 0 N--CA 1.433 -1.282 0 N-CA-C 106.773 -1.565 . . . . 0.0 106.773 -179.373 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . 0.43 ' HA2' ' HA ' ' A' ' 7' ' ' SER . . . -124.09 167.88 16.32 Favored Glycine 0 CA--C 1.49 -1.505 0 N-CA-C 108.218 -1.953 . . . . 0.0 108.218 -179.314 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 91.5 t80 -131.63 138.57 48.83 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 -179.734 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 17.4 ptm180 -145.07 160.74 40.92 Favored 'General case' 0 N--CA 1.437 -1.089 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 34.6 t80 . . . . . 0 C--O 1.262 1.742 0 CA-C-O 117.673 -1.156 . . . . 0.0 108.146 179.934 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 . . . . . 0 N--CA 1.489 1.515 0 CA-C-O 120.915 0.388 . . . . 0.0 110.583 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -179.73 176.81 47.81 Favored Glycine 0 CA--C 1.492 -1.375 0 N-CA-C 106.803 -2.519 . . . . 0.0 106.803 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -136.25 147.49 47.58 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 107.414 -1.328 . . . . 0.0 107.414 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 97.1 p -154.94 161.25 41.47 Favored 'General case' 0 N--CA 1.436 -1.139 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 179.63 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 54.8 m -135.97 146.1 46.88 Favored 'General case' 0 CA--C 1.496 -1.113 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 85.3 mt -119.64 129.31 75.5 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.083 0 N-CA-C 105.322 -2.103 . . . . 0.0 105.322 179.026 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 48.2 t -135.33 142.08 45.73 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 -178.609 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 46.9 pt -130.79 157.4 43.1 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.14 0 N-CA-C 106.001 -1.851 . . . . 0.0 106.001 179.047 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -163.66 178.53 39.13 Favored Glycine 0 CA--C 1.49 -1.486 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -179.669 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -117.51 149.44 40.61 Favored 'General case' 0 CA--C 1.495 -1.148 0 N-CA-C 106.854 -1.536 . . . . 0.0 106.854 -179.394 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -96.31 133.25 40.9 Favored 'General case' 0 N--CA 1.437 -1.088 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 -179.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 98.6 mm-40 -110.16 139.72 45.01 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 179.421 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 35.8 t -151.59 150.18 30.02 Favored 'General case' 0 CA--C 1.498 -1.036 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 -179.339 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 77.1 ttt180 -85.64 118.58 25.24 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 83.6 t -105.98 -56.37 4.99 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.016 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.4 tttm -156.75 141.71 17.11 Favored 'General case' 0 N--CA 1.437 -1.123 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 99.3 mt-10 -127.1 147.24 50.17 Favored 'General case' 0 CA--C 1.497 -1.074 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 179.478 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -159.96 170.83 20.52 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -88.8 64.26 3.43 Favored Glycine 0 C--N 1.351 1.391 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -178.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 44.1 m-85 -132.59 148.77 52.37 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 178.69 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 40.2 ttpt -62.51 -44.44 96.37 Favored 'General case' 0 CA--C 1.505 -0.777 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 89.2 mt -114.91 137.71 51.66 Favored 'General case' 0 CA--C 1.497 -1.076 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -149.6 67.93 1.01 Allowed 'General case' 0 N--CA 1.437 -1.104 0 N-CA-C 106.59 -1.633 . . . . 0.0 106.59 179.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 68.0 mttm 65.04 -168.15 0.21 Allowed 'General case' 0 C--N 1.357 0.914 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 69.1 m-80 -138.49 151.45 69.14 Favored Pre-proline 0 N--CA 1.44 -0.932 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -74.89 160.09 40.9 Favored 'Trans proline' 0 C--N 1.314 -1.251 0 C-N-CA 122.116 1.877 . . . . 0.0 112.282 179.051 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 36.3 ptt-85 -149.42 157.04 42.96 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 -179.678 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 141.65 136.49 3.27 Favored Glycine 0 C--N 1.349 1.301 0 N-CA-C 106.6 -2.6 . . . . 0.0 106.6 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 -127.24 138.61 53.13 Favored 'General case' 0 CA--C 1.496 -1.111 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 -179.238 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 84.4 m-20 -131.54 135.81 47.34 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 179.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 88.5 mt -117.25 141.12 48.69 Favored 'General case' 0 CA--C 1.498 -1.055 0 N-CA-C 106.328 -1.73 . . . . 0.0 106.328 179.303 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 41.1 ttmt -141.17 135.7 31.09 Favored 'General case' 0 CA--C 1.502 -0.9 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 -179.552 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -127.31 143.65 51.19 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.208 -1.405 . . . . 0.0 107.208 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . 0.486 ' HA ' HG22 ' A' ' 44' ' ' ILE . 75.7 ttt180 -124.9 130.37 52.23 Favored 'General case' 0 CA--C 1.499 -0.995 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 -179.598 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . . . . . . . . . 64.7 t80 -121.35 126.49 49.58 Favored 'General case' 0 N--CA 1.44 -0.964 0 N-CA-C 106.156 -1.794 . . . . 0.0 106.156 179.249 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -99.13 112.05 24.28 Favored 'General case' 0 CA--C 1.5 -0.956 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 -179.032 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 78.7 m-85 -80.8 -35.58 32.84 Favored 'General case' 0 CA--C 1.503 -0.856 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 178.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 12.1 t-20 -164.1 172.57 13.58 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 106.565 -1.643 . . . . 0.0 106.565 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 54.3 m-80 -86.2 73.21 10.26 Favored 'General case' 0 CA--C 1.502 -0.884 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 -179.751 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -162.2 -66.65 0.05 Allowed 'General case' 0 N--CA 1.437 -1.1 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 179.645 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 42.1 m0 -126.59 146.49 50.14 Favored 'General case' 0 CA--C 1.499 -1.005 0 N-CA-C 106.806 -1.553 . . . . 0.0 106.806 -179.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -128.78 163.69 22.12 Favored Glycine 0 CA--C 1.494 -1.277 0 N-CA-C 107.259 -2.336 . . . . 0.0 107.259 179.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 70.8 t -129.09 132.8 66.85 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.009 0 N-CA-C 106.977 -1.49 . . . . 0.0 106.977 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.558 HG23 ' CG2' ' A' ' 78' ' ' VAL . 35.5 pt -123.21 159.65 27.11 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.129 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 179.793 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -137.99 147.31 19.15 Favored Glycine 0 CA--C 1.491 -1.451 0 N-CA-C 105.563 -3.015 . . . . 0.0 105.563 178.631 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 39.7 t -145.38 146.7 31.66 Favored 'General case' 0 N--CA 1.438 -1.065 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 -179.231 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 87.6 t80 -126.79 131.61 51.23 Favored 'General case' 0 N--CA 1.439 -1.002 0 N-CA-C 106.01 -1.848 . . . . 0.0 106.01 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -127.67 143.23 51.17 Favored 'General case' 0 CA--C 1.501 -0.932 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 -179.102 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 63.4 tt0 -136.57 133.57 36.52 Favored 'General case' 0 CA--C 1.5 -0.943 0 N-CA-C 106.772 -1.566 . . . . 0.0 106.772 179.768 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 15.2 t -146.12 156.16 43.24 Favored 'General case' 0 N--CA 1.443 -0.809 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 -179.753 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 61.7 ttp180 -114.05 129.31 56.62 Favored 'General case' 0 CA--C 1.498 -1.036 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ARG . . . . . . . . . . . . . 32.2 tpt180 -102.52 123.87 47.05 Favored 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -173.91 169.88 42.96 Favored Glycine 0 CA--C 1.491 -1.442 0 N-CA-C 107.163 -2.375 . . . . 0.0 107.163 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 84.6 t80 -140.29 125.84 19.1 Favored 'General case' 0 N--CA 1.436 -1.131 0 N-CA-C 106.021 -1.844 . . . . 0.0 106.021 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 48.8 mp0 -95.95 132.72 40.96 Favored 'General case' 0 N--CA 1.439 -1.005 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 -179.43 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -144.86 136.47 25.47 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 106.416 -1.698 . . . . 0.0 106.416 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 47.3 t -87.83 117.65 26.81 Favored 'General case' 0 CA--C 1.499 -0.991 0 N-CA-C 107.105 -1.443 . . . . 0.0 107.105 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 32.1 m -135.2 159.08 41.12 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.086 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . . . . . . . . . 36.1 t70 -65.55 -44.57 86.39 Favored 'General case' 0 C--N 1.354 0.787 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 179.692 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 150.69 -178.92 27.83 Favored Glycine 0 CA--C 1.493 -1.329 0 N-CA-C 107.254 -2.338 . . . . 0.0 107.254 179.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 63.45 36.16 11.54 Favored 'General case' 0 C--N 1.354 0.786 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.521 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 32.7 mmmt -128.7 146.19 50.95 Favored 'General case' 0 CA--C 1.496 -1.127 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 179.582 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 89.6 mt -117.18 138.73 51.48 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 106.708 -1.59 . . . . 0.0 106.708 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 46.0 pt -131.6 156.85 42.98 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.055 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 -179.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 37.8 t70 -100.86 108.8 20.67 Favored 'General case' 0 N--CA 1.438 -1.059 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 179.768 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -179.98 -167.35 36.96 Favored Glycine 0 CA--C 1.493 -1.311 0 N-CA-C 107.456 -2.258 . . . . 0.0 107.456 -179.603 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 30.2 t0 73.38 49.25 0.14 Allowed 'General case' 0 C--N 1.356 0.874 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -121.4 141.65 50.77 Favored 'General case' 0 CA--C 1.497 -1.058 0 N-CA-C 107.065 -1.457 . . . . 0.0 107.065 179.492 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -101.8 130.1 48.15 Favored 'General case' 0 CA--C 1.498 -1.051 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -119.02 136.63 54.03 Favored 'General case' 0 CA--C 1.495 -1.156 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 179.687 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 90.3 m-85 -127.21 137.6 52.94 Favored 'General case' 0 CA--C 1.494 -1.181 0 N-CA-C 106.022 -1.844 . . . . 0.0 106.022 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 69.6 m -132.11 142.77 49.62 Favored 'General case' 0 CA--C 1.493 -1.245 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 61.4 t -128.33 137.74 56.57 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.154 0 N-CA-C 105.298 -2.112 . . . . 0.0 105.298 179.285 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 10.5 t -150.15 153.77 36.9 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 -178.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . -154.26 160.4 41.78 Favored 'General case' 0 N--CA 1.435 -1.204 0 N-CA-C 105.825 -1.917 . . . . 0.0 105.825 179.686 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -176.05 176.58 47.66 Favored Glycine 0 CA--C 1.494 -1.237 0 N-CA-C 108.764 -1.734 . . . . 0.0 108.764 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -79.8 160.54 24.56 Favored 'Trans proline' 0 C--N 1.312 -1.347 0 C-N-CA 122.907 2.405 . . . . 0.0 113.537 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.558 ' CG2' HG23 ' A' ' 44' ' ' ILE . 67.8 t -119.34 129.33 75.41 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.084 0 N-CA-C 106.936 -1.505 . . . . 0.0 106.936 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -112.97 137.28 51.61 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 44.5 ttm180 -111.67 130.26 55.83 Favored 'General case' 0 CA--C 1.5 -0.943 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 -179.579 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 49.0 mm -78.87 -65.92 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.359 1.003 0 N-CA-C 106.854 -1.536 . . . . 0.0 106.854 179.281 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 34.0 m120 -162.7 91.06 0.73 Allowed 'General case' 0 C--N 1.357 0.927 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 177.782 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 14.3 tt0 37.39 22.77 0.0 OUTLIER 'General case' 0 C--N 1.359 0.999 0 N-CA-C 114.313 1.227 . . . . 0.0 114.313 177.572 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -144.02 -41.31 0.27 Allowed 'General case' 0 CA--C 1.499 -0.996 0 CA-C-N 120.397 1.453 . . . . 0.0 110.477 -178.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 86.6 t -119.64 131.23 72.76 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.166 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 -177.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 69.0 m -119.71 145.52 46.45 Favored 'General case' 0 CA--C 1.499 -1.005 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 179.285 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.0 mp -116.34 146.02 42.76 Favored 'General case' 0 CA--C 1.496 -1.131 0 N-CA-C 106.7 -1.592 . . . . 0.0 106.7 179.769 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 33.0 m-85 -126.29 143.42 51.16 Favored 'General case' 0 CA--C 1.496 -1.1 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 -179.432 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -116.81 138.0 13.99 Favored Glycine 0 CA--C 1.493 -1.326 0 N-CA-C 105.216 -3.154 . . . . 0.0 105.216 177.792 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 87.5 mt -117.62 134.42 54.9 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 -178.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 4.4 tt -146.7 130.23 16.84 Favored 'General case' 0 N--CA 1.437 -1.078 0 N-CA-C 105.322 -2.103 . . . . 0.0 105.322 178.504 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -176.86 -160.51 24.02 Favored Glycine 0 CA--C 1.492 -1.387 0 N-CA-C 108.578 -1.809 . . . . 0.0 108.578 -179.373 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -149.91 161.99 41.21 Favored 'General case' 0 N--CA 1.434 -1.234 0 N-CA-C 107.346 -1.353 . . . . 0.0 107.346 -179.202 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -141.79 164.73 26.69 Favored Glycine 0 CA--C 1.493 -1.294 0 N-CA-C 107.304 -2.318 . . . . 0.0 107.304 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 72.6 t60 -151.89 150.14 29.75 Favored 'General case' 0 N--CA 1.438 -1.029 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 -179.721 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -99.79 143.51 16.48 Favored Glycine 0 C--N 1.352 1.468 0 N-CA-C 107.994 -2.042 . . . . 0.0 107.994 -179.532 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -119.82 148.44 43.45 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -147.82 154.12 40.06 Favored 'General case' 0 N--CA 1.436 -1.143 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 40.9 ttmt -92.99 119.72 32.55 Favored 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 -179.722 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' PHE . . . . . . . . . . . . . 92.1 t80 -145.13 129.16 17.51 Favored 'General case' 0 N--CA 1.437 -1.088 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 179.608 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 37.6 t -146.63 125.47 12.69 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 106.956 -1.498 . . . . 0.0 106.956 179.741 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 1.7 m -175.6 -81.34 0.01 OUTLIER 'General case' 0 CA--C 1.498 -1.055 0 N-CA-C 106.497 -1.668 . . . . 0.0 106.497 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 85.4 mt -123.16 126.35 73.37 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.042 0 N-CA-C 106.299 -1.741 . . . . 0.0 106.299 179.595 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -113.91 124.09 51.34 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 -179.802 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 175.91 175.41 43.27 Favored Glycine 0 CA--C 1.491 -1.418 0 N-CA-C 106.855 -2.498 . . . . 0.0 106.855 179.629 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 3.7 mm-40 -151.61 156.31 40.18 Favored 'General case' 0 CA--C 1.495 -1.147 0 N-CA-C 107.159 -1.422 . . . . 0.0 107.159 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 10.4 t -128.29 2.32 5.73 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -154.77 163.79 39.74 Favored 'General case' 0 N--CA 1.437 -1.08 0 N-CA-C 107.108 -1.441 . . . . 0.0 107.108 -179.72 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 67.6 m -104.32 128.6 52.15 Favored 'General case' 0 CA--C 1.495 -1.147 0 N-CA-C 106.822 -1.547 . . . . 0.0 106.822 179.667 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 42.0 ptt180 -158.22 163.84 37.08 Favored 'General case' 0 N--CA 1.437 -1.105 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 -179.676 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 98.4 p -154.26 159.6 41.37 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 106.9 -1.519 . . . . 0.0 106.9 179.787 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 39.6 ttmt -148.07 127.12 12.83 Favored 'General case' 0 N--CA 1.438 -1.064 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 88.9 m -138.37 135.14 35.04 Favored 'General case' 0 CA--C 1.498 -1.037 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 46.7 t -95.14 124.59 39.27 Favored 'General case' 0 CA--C 1.498 -1.035 0 N-CA-C 106.672 -1.603 . . . . 0.0 106.672 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 90.9 mt -86.8 143.44 27.49 Favored 'General case' 0 CA--C 1.499 -0.994 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 -179.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -124.61 134.64 52.86 Favored 'General case' 0 N--CA 1.439 -1.025 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 -179.47 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -135.74 153.24 51.63 Favored 'General case' 0 CA--C 1.496 -1.134 0 N-CA-C 106.367 -1.716 . . . . 0.0 106.367 179.579 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -174.43 179.86 45.49 Favored Glycine 0 CA--C 1.491 -1.454 0 N-CA-C 108.65 -1.78 . . . . 0.0 108.65 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -155.99 160.65 40.24 Favored 'General case' 0 N--CA 1.435 -1.218 0 N-CA-C 106.174 -1.787 . . . . 0.0 106.174 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -162.39 -178.86 36.6 Favored Glycine 0 CA--C 1.49 -1.526 0 N-CA-C 108.209 -1.956 . . . . 0.0 108.209 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -151.16 164.58 36.2 Favored 'General case' 0 N--CA 1.436 -1.154 0 N-CA-C 107.297 -1.372 . . . . 0.0 107.297 -179.66 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 40.0 tt0 -142.84 139.5 30.91 Favored 'General case' 0 CA--C 1.496 -1.113 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 -179.303 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -106.18 139.47 40.65 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 178.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 75.4 m-20 -125.47 74.43 68.86 Favored Pre-proline 0 N--CA 1.443 -0.777 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 -179.401 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -71.64 -28.56 17.13 Favored 'Trans proline' 0 CA--C 1.501 -1.161 0 C-N-CA 121.794 1.663 . . . . 0.0 112.983 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' HIS . . . . . . . . . . . . . 79.0 m80 -136.54 151.92 73.77 Favored Pre-proline 0 N--CA 1.439 -1.02 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -85.92 62.12 5.19 Favored 'Trans proline' 0 C--N 1.312 -1.345 0 C-N-CA 122.138 1.892 . . . . 0.0 112.654 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.87 -65.25 0.04 OUTLIER 'General case' 0 N--CA 1.44 -0.97 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -108.78 137.65 46.37 Favored 'General case' 0 CA--C 1.496 -1.124 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 32.7 m -130.52 156.92 42.85 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.0 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 86.0 mt -121.46 130.69 74.39 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.114 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 -179.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 14.7 p-10 -136.12 160.22 39.31 Favored 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 108.361 -0.978 . . . . 0.0 108.361 -179.126 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -151.51 151.66 31.91 Favored 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 105.92 -1.881 . . . . 0.0 105.92 179.263 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 94.2 p -155.77 164.12 38.97 Favored 'General case' 0 CA--C 1.495 -1.154 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -122.12 139.8 53.31 Favored 'General case' 0 CA--C 1.495 -1.135 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 -179.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -126.37 128.45 47.08 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 106.922 -1.51 . . . . 0.0 106.922 179.769 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 90.6 t80 -124.32 128.65 49.43 Favored 'General case' 0 N--CA 1.439 -1.008 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 70.3 m -114.16 136.96 52.37 Favored 'General case' 0 CA--C 1.495 -1.164 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' LYS . . . . . . . . . . . . . 65.4 tttm -116.16 125.03 51.75 Favored 'General case' 0 CA--C 1.499 -1.008 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 -179.041 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . . . . . . . . . 35.2 tp -150.15 140.9 22.69 Favored 'General case' 0 N--CA 1.436 -1.162 0 N-CA-C 105.459 -2.052 . . . . 0.0 105.459 179.046 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -62.72 -38.27 89.8 Favored 'General case' 0 CA--C 1.507 -0.682 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 -179.0 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -62.87 -41.84 99.54 Favored 'General case' 0 C--N 1.353 0.728 0 O-C-N 122.114 -0.366 . . . . 0.0 110.09 -178.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 14.6 p -162.64 142.1 2.48 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.879 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 -179.273 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 56.5 mtmt -110.0 137.44 47.76 Favored 'General case' 0 CA--C 1.497 -1.07 0 N-CA-C 105.899 -1.889 . . . . 0.0 105.899 179.196 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 13.3 p -150.57 145.8 16.73 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 -178.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -128.93 140.55 11.8 Favored Glycine 0 C--N 1.349 1.297 0 N-CA-C 105.953 -2.859 . . . . 0.0 105.953 178.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' THR . . . . . . . . . . . . . 68.4 p -128.35 152.18 48.46 Favored 'General case' 0 CA--C 1.498 -1.044 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 -179.209 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' TRP . . . . . . . . . . . . . 52.5 m0 -108.88 139.22 44.03 Favored 'General case' 0 CA--C 1.497 -1.061 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 179.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 26.8 ttt -114.65 124.58 52.19 Favored 'General case' 0 CA--C 1.498 -1.053 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 -179.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' LEU . . . . . . . . . . . . . 62.9 tp -130.68 129.99 43.3 Favored 'General case' 0 N--CA 1.438 -1.041 0 N-CA-C 105.744 -1.947 . . . . 0.0 105.744 179.005 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -168.89 -167.67 29.85 Favored Glycine 0 CA--C 1.492 -1.391 0 N-CA-C 108.648 -1.781 . . . . 0.0 108.648 -179.321 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -144.43 164.57 30.44 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 106.26 -1.756 . . . . 0.0 106.26 -179.443 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -139.41 168.33 24.94 Favored Glycine 0 CA--C 1.489 -1.559 0 N-CA-C 108.642 -1.783 . . . . 0.0 108.642 -179.167 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' TYR . . . . . . . . . . . . . 56.5 t80 -123.32 128.48 49.99 Favored 'General case' 0 N--CA 1.437 -1.104 0 N-CA-C 106.063 -1.828 . . . . 0.0 106.063 179.808 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 6.6 tmm_? -107.51 129.83 54.92 Favored 'General case' 0 CA--C 1.499 -1.005 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 -178.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 19.1 t80 . . . . . 0 C--O 1.262 1.718 0 CA-C-O 117.806 -1.092 . . . . 0.0 108.448 179.309 . . . . . . . . 0 0 . 1 stop_ save_